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ABSTRACT 
 
Biliary atresia is a common form of paediatric liver disease, with progressive, inflammatory 
obliteration of the biliary tree, leading to liver failure early in life.  Mutations in PKHD1, 
encoding the ciliary protein fibrocystin, are associated with autosomal recessive polycystic 
kidney disease (ARPKD), a ciliopathy with clinical features that resemble biliary atresia.  The 
hepatic developmental defects detectable in a significant number of infants with ARPKD are 
thought to be caused by dysfunction in the structure and function of primary cilia.  The 
pathogenetic mechanism of both disorders is thought to be dysregulation of epithelial cell 
growth and tubulomorphogenesis.  Preliminary investigations uncovered an association of 
PKHD1 sequence variants in a subset of biliary atresia patients with renal cysts, promoting 
further investigation to determine the functional role of fibrocystin in epithelial cells from 
renal and biliary tubules.  Immunohistochemical studies, using a monoclonal antibody raised 
against wildtype fibrocystin, showed that it localises specifically to intrahepatic bile ducts.  
Absence of fibrocystin staining in end-stage liver tissue reflects ongoing damage to the 
intrahepatic biliary tree, rather than a phenomenon specific to biliary atresia.  Studies utilising 
the Pkhd1del2/del2 mouse model of ARPKD revealed 17β-estradiol sensitive centrosomal 
overduplication underlies the dysregulation of epithelial cell growth in renal tubules, however 
this does not appear to be in synergy with Pkhd1 knockdown.  Therefore, it remains uncertain 
whether sequence variants of PKHD1 are associated with biliary atresia. 
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CHAPTER  1 INTRODUCTION 
 
1.1 BILIARY ATRESIA 
Extrahepatic biliary atresia (EHBA) is an idiopathic congenital obliterative panductular 
cholangiopathy.  It results from a progressive localized inflammatory and fibrosclerosing 
destruction of the extrahepatic bile ducts (EHBDs) accompanied by a characteristic 
intrahepatic portal lesion.  The resulting obstruction to bile flow leads to cholestasis, 
progressive fibrosis and ultimately cirrhosis [Balistreri et al., 1996].  As fibrotic obliteration 
may involve the entire extrahepatic biliary system or any part of the system, with concomitant 
injury and fibrosis of intrahepatic bile ducts (IHBDs), consequently the term extrahepatic has 
been dropped from the name of this disorder in recent years [Sokol et al., 2003] and will 
therefore be referred to only as biliary atresia (BA) throughout this thesis. 
 
Despite being relatively rare, BA is the most common cholestatic disorder in neonates [Sokol 
et al., 2003].  Approximate incidence figures are available from France (1 in 19,500 live 
births), the UK and Eire (1 in 16,700 live births), the USA and Sweden (1 in 14,000 live 
births) and Asian countries  (1 in 18,000 live births) [Chardot et al., 1999; Fischler et al., 
2002; McKiernan et al., 2000; Yoon et al., 1997], with large studies reporting a 1.4:1 
female:male predominance [Lipsett et al., 1997].  The overall clinical presentation is of 
persisting jaundice from the second day of life.  Other features include hypopigmented or 
noticeably acholic (white or gray) stools, dark urine, failure to thrive, and hepatosplenomegaly 
[Kelly and Davenport, 2007; Sokol et al., 2003].  Most infants with BA are full term with a 
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normal birth weight [Kelly and Davenport, 2007].  However, upon careful anthropometric 
evaluation it has been stated that infants with BA have significantly decreased body fat stores 
and lean body mass.  The added mass of an enlarged liver and spleen, and the occasional 
finding of subclinical ascites may account for the appearance of a well-nourished infant (i.e. a 
relatively normal birth weight) [Sokol and Stall, 1990]. 
 
Attempts to characterise BA on the basis of differential phenotypes have led to the 
description of anatomical and clinical subtypes.  Three broad anatomical forms based on the 
patency of the hepatic bile duct and the extent of biliary damage are recognised [Lipsett et al., 
1997].  Type I affects the common bile duct and proximal cystic biliary duct; type II affects 
the common hepatic duct; and type III, which is the most common, affects the entire 
extrahepatic biliary tree.  Each of the anatomical subtypes presents a unique surgical challenge.  
Type I BA referred to as “correctable” is characterised by a patent hepatic duct, up to the porta 
hepatis, without duodenal communication, and may allow for a direct extrahepatic biliary 
duct-intestinal anastomosis.  This “correctable” subtype is less frequent compared with types 
II and III, accounting for only 10% to 15% of BA patients.  No lumen is available for bile 
duct-intestinal anastomosis in types II and III, referred to as “uncorrectable”.  However, in the 
late 1950s, Dr Morio Kasai reported the presence of patent microscopic biliary channels at the 
porta hepatis in young infants with “uncorrectable” BA.  Exposure of these remnants by 
radical excision to the jejunum allows the microscopic biliary structures to drain bile into the 
intestinal conduit, thus relieving the obstruction to bile flow [Kobayashi and Stringer, 2003; 
Lipsett et al., 1997].  The Kasai hepatic portoenterostomy (HPE) operation is now accepted 
as the standard operation for the condition [Kobayashi and Stringer, 2003].  However, with 
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the HPE procedure many factors can affect the success of the surgery [Balistreri et al., 1996].  
If diagnosed in the first 2-3 months of life, HPE can restore bile flow from the liver into the 
intestinal tract in 30% to 80% of patients [Ohi, 2000; Schweizer, 1986; Sokol et al., 2003].  
Even if the outcome of surgery is an initial success, progressive inflammation and fibrosis of 
IHBDs develops to varying degrees in all patients.  Consequently, 70% to 80% of BA patients 
will eventually require liver transplantation, approximately half in the first two years of life 
[Chardot et al., 1999; Karrer and Bensard, 2000; Karrer et al., 1996].  Approximately another 
third of patients with BA will require transplantation by their teens, and the rest will live with 
some degree of liver disease [Balistreri et al., 1996].  Hence, BA remains the foremost 
indication for liver transplantation in infants and children, accounting for almost 50% of all 
paediatric liver transplants [Mack and Sokol, 2005; Whitington and Balistreri, 1991].  The 
natural history of BA without medical or surgical management is reasonably well documented.  
In the absence of orthotopic liver transplantation, patients with BA are subject to progressive 
and rapid development of end-stage liver disease due to the persistent intrahepatic 
inflammatory process.  Therefore, survival beyond 24 or 36 months of age is very unusual 
[Adelman, 1978; Hays and Synder, 1963; Karrer et al., 1990; Karrer et al., 1996; Kelly and 
Davenport, 2007]. 
 
The concept of two distinct clinical forms of BA was described by Desmet [1992a] and 
Schweizer [1986], (Table 1.1).  The embryonal or foetal type occurs in approximately 35% of 
patients, characterised by early onset cholestasis, absence of a jaundice-free period after 
physiological jaundice, and absence of bile duct remnants in the hepatoduodenal ligament.  
Stereotypical coexisting congenital anomalies of laterality complicate this foetal type in 10-
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20% of cases [Lipsett et al., 1997].  Coincidental congenital anomalies could include intestinal 
malrotation, asplenia or polysplenia, portal vein anomalies (preduodenal, absence, cavernous 
transformation), situs inversus (complete), situs ambiguous (partial), congenital heart defects, 
annular pancreas, Kartagener’s syndrome, duodenal, oesophageal, or jejunal atresia, polycystic 
kidneys, and cleft palate [Carmi et al., 1993; Silveira et al., 1991; Tanano et al., 1999].  In 
particular, polysplenia syndrome (polysplenia, midline liver, interrupted inferior vena cava, 
situs inversus, preduodenal portal vein, and malrotation of the intestine) is present to some 
degree in 8% to 12% of all children with BA [M. Davenport et al., 1993; Karrer et al., 1991].  
The perinatal or acquired form of BA is more common and represents 80% to 90% of cases.  
In contrast to the foetal form, the perinatal type of BA usually presents with cholestatic 
jaundice between one and two months of age, such that a jaundice-free interval may even be 
present between physiological jaundice and onset of cholestasis.  Perinatal BA is not associated 
with congenital abnormalities, and remnants of bile duct structures can typically be seen in 
histological sections of the hepatoduodenal ligament [Bassett and Murray, 2008; Lipsett et al., 
1997; Sokol et al., 2003]. 
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TABLE 1.1 Two clinical forms of biliary atresia 
EMBRYONIC OR FOETAL TYPE (35%) 
 
1. Early onset of neonatal cholestasis 
2. No jaundice-free period after physiological jaundice 
3. No bile duct remnants in hepatoduodenal ligament 
4. Associated congenital anomalies (10-20% of cases) 
 
PERINATAL TYPE (65%)  
 
1. “Later onset” of neonatal cholestasis 
2. Jaundice-free interval may be present after physiological jaundice 
3. Remnants of bile duct structures found in hepatoduodenal ligament 
4. No associated congenital anomalies 
NOTE.  According to Schweizer [1986] and Desmet [1992a] 
 
The cause of BA is not known.  Our understanding of the aetiology and pathogenesis of liver 
and bile duct injury in patients has remained essentially unchanged until recent years.  
Multiple theories regarding the pathogenesis of BA differ in the proposed primary mechanism 
of injury, but they are often similar in their dependence on secondary or coexisting factors.  
Currently, BA is believed to be a common phenotypic response of the neonatal liver and bile 
ducts to a variety of prenatal insults (viral, metabolic, vascular) that perturbs the normal 
development or maturation of the biliary tree that occurs during a specific period (perinatally 
to up to three months of age) amid the milieu of genetic or immunologic susceptibilities to 
this disease.  Currently, research efforts designed to address the pathogenesis of BA are 
centred on five major mechanisms that have been proposed in the literature (Table 1.2).  
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TABLE 1.2 Potential mechanisms involved in the pathogenesis of biliary atresia 
MECHANISM SUPPORTING DATA 
1. Defect in morphogenesis Coexistence of non-hepatic embryologic abnormalities 
Abnormal remodelling of the “ductal plate”  
HGF (c-met oncogene, adhesion molecules, differentiation of biliary epithelial cells) 
Mutations in hepatic developmental genes (HNF6, Jagged1) 
Mutations in laterality genes (CFC1, ZIC3) in patients with biliary atresia and laterality defects 
Epigenetic factors: overexpression of regulatory genes in children with the embryonic form of biliary 
atresia 
Inv mouse: model of biliary obstruction and situs inversus 
2. Defect in prenatal circulation Intrauterine devascularisation results in abnormal extrahepatic bile ducts 
3. Immunologic dysregulation Altered class I and II major histocompatibility complex expression 
Increased expression of intracellular adhesion molecules: ICAM-1 
Increased frequency of the HLA-B12, B8 or DR3 alleles 
Hepatic profile displaying a predominant Th1-like phenotype 
Prevention of inflammatory obstruction of bile ducts in IFN-γ deficient mice  
4. Viral infection CMV, reovirus, rotavirus, retrovirus, human papilloma virus, and other viral agents detected in infants 
with biliary atresia 
Biliary obstruction in newborn mice infected with rotavirus 
5. Environmental toxin exposure Time-space clustering of cases 
Phytotoxin or mycotoxin in Australian lambs 
NOTE: Adapted from Balistreri [1996] and Bezerra [2006] 
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It has been suggested by many that the trigger for the inflammatory cascade may be a 
hepatotropic viral infection [Bassett and Murray, 2008].  Several reports of time-space 
clustering of cases tends to support an infectious aetiology [Danks and Bodian, 1963; 
Strickland and Shannon, 1982].  A hepatotropic viral infection may lead to an initial bile duct 
injury that triggers a persistent immune mediated sclerosing process and results in obstruction 
of EHBDs [Leifeld et al., 2001].  There have been many hypotheses and studies to identify the 
aetiologic virus.  Potential candidates have included Epstein-Barr virus (EBV) [Fjaer et al., 
2005; Kobayashi and Stringer, 2003], cytomegalovirus (CMV) [Domiati-Saad et al., 2000; 
Fischler et al., 1998], human herpes virus [Domiati-Saad et al., 2000], human papilloma virus 
[Drut et al., 1998], group C rotavirus [Riepenhoff-Talty et al., 1996], and reovirus type 3 
[Steele et al., 1995; Tyler et al., 1998].  However, these suggestive results have been largely 
inconsistent and underpowered, with many other studies having disputed the role of these 
viruses in the pathogenesis of BA. However the main criticism of the hypothesis, of a viral 
infection as the primary trigger for BA, is the inability to document the presence of any virus 
in many patients with the disease [Bassett and Murray, 2008; Rauschenfels et al., 2009].  
Although congenital infections with CMV, EBV, or rubella virus have been found 
occasionally, the presence of these common agents may be coincidental [Balistreri, 1985; Hays 
and Kimura, 1980; Howard, 1983; Landing, 1974; Smith et al., 1991].   
 
The exposure of pregnant women to hepatotoxic substances has been considered in studies on 
the pathogenesis of BA.  Time and space clustering of cases has led to the proposal that an 
environmental toxin could be involved in its pathogenesis [Perlmutter and Shepherd, 2002].  
Currently, other than infectious agents, no environmental agent has been clearly associated 
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with BA in humans.  The possible toxic and inflammatory effects of bile that has extravasated 
through the injured bile duct epithelial layer into the submucosa of the damaged EHBDs 
could also be considered as a secondary factor in the pathogenesis of BA [Balistreri et al., 
1996; Sokol et al., 2003]. 
 
Vascular insults during foetal hepatobiliary development have also been implicated in the 
pathogenesis of BA.  Studies by Ho et al [1993] identified thickened, tortuous and dilated 
arteries in the biliary remnants of infants with BA.  These observations were taken as evidence 
for an arteriopathy accompanying the disorder, however the causative or consequential nature 
of these lesions remains unclear [Balistreri et al., 1996; Sokol et al., 2003].  However, this 
pathologic mechanism in BA does not appear to be a current research priority. 
 
An abnormality in the immune and/or inflammatory response as a pathologic mechanism in 
BA is a plausible theory.  The presence of lymphocytic infiltration in the portal tracts in liver 
biopsy specimens of infants with BA suggests a primary inflammatory process leading to bile 
duct obstruction.  The role of the immune system in bile duct injury in BA is poorly 
understood, but does appear to be highly complex.  Several studies have investigated whether 
bile duct epithelial cells are susceptible to immune/inflammatory attack because of abnormal 
expression of human leukocyte antigen (HLA) or intercellular adhesion molecules on their 
surface [Dillon et al., 1994; Seidman et al., 1991].   
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The progressive nature of BA, despite initial reestablishment of bile flow with HPE, suggests 
that a persistent autoimmune attack directed at bile ducts may play a role [Schreiber and 
Kleinman, 1993; Sokol and Mack, 2001].  BA shares features with several autoimmune 
diseases, such as female predominance, apparent triggering by viral infection, and aberrant 
major histocompatibility complex (MHC) expression in bile duct epithelium.  Consequently, 
it has been proposed that tissue injury in patients with BA may represent an autoimmune-
mediated process.  It is possible that the initiator of bile duct injury is a cholangiotropic virus, 
leading to the exposure of altered self-cholangiocyte epithelial antigens or previously 
sequestered self-cholangiocyte antigens that would then be recognized as “non-self” and elicit 
a persistent autoimmune-mediated bile duct injury [Eagar et al., 2001; Sokol and Mack, 
2001].  To date, there have been no studies addressing the frequency of other autoimmune 
diseases in BA patients or in other family members.  Interestingly, children with BA who 
undergo liver transplantation have a 2.5% risk of developing de novo autoimmune hepatitis 
after transplantation, perhaps indicating a genetic predisposition to autoimmune disease 
[Hernandez et al., 2001; Kerkar et al., 1998].   
 
Another proposed theory as to the pathogenesis of BA, of specific relevance to this project, is 
the hypothesis that there could be a genetic component resulting in defective morphogenesis 
of the biliary tree.  Generally, BA is not considered to be an inherited disorder, for example 
HLA-identical twins discordant for the disease have been described, and recurrence of BA 
within the same family is exceedingly rare [Gunasekaran et al., 1992; Hyams et al., 1985; 
Smith et al., 1991].  However, the presence of congenital non-hepatic malformations in the 
subset of infants with the embryonic (syndromic) form of BA points to a potential role of 
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genetic defects that result in defective embryogenesis and asymmetric left-right determination 
of visceral organs [Carmi et al., 1993].  The initial animal model that suggested the class of 
genes involved in axis determination was that of a recessive insertional mutation in the 
proximal region of mouse chromosome 4 or complete deletion of the inversin (inv) gene in the 
mouse.  The inv mouse model, with laterality defects in abdominal organ placement, also 
included anomalous development of the hepatobiliary system, and extrahepatic biliary 
obstruction [Mazziotti et al., 1999; Yokoyama et al., 1993].  Therefore, the human INV gene, 
mapped by Schön and colleagues [2002] was examined in 64 patients with heterotaxia.  No 
mutations were found in seven patients with BA and various congenital laterality defects, 
making it unlikely that the INV gene is responsible for the majority of embryonic cases of BA.  
Perhaps more subtle alterations in the human inversin orthologue accounts for some of the 
cases of BA without other situs anomalies, especially if it is true that the action of inversin has 
specific effects on morphogenesis of the biliary duct system [Perlmutter and Shepherd, 2002].  
Interestingly, recessive mutations in INV are responsible for infantile nephronophthisis type 
2, a disease in which abnormal biliary development with or without situs inversus has been 
described [Otto et al., 2003].  Furthermore, inversin the protein encoded by the INV gene was 
found to interact with nephrocystin, the gene mutated in nephronophthisis type 1.  Both 
inversin and nephrocystin are located in the primary cilia of renal tubular cells [Otto et al., 
2003].  Thus, gene products with localisation to the mechanosensory primary cilium of renal 
tubular cells and cholangiocytes may produce aberrant biliary development with 
predominance of ductal plate malformation (DPM) [Mack and Sokol, 2005].   Further 
supportive evidence for such gene products is the subset of patients with BA who display the 
DPM on liver biopsy [Low et al., 2001].  It remains to be seen whether mutations or 
  11 
polymorphisms in genes that code for proteins regulating functions of the primary cilia, will 
play a role in the pathogenesis of BA.  One of the primary aims in this project is to try to shed 
some light on this possible mechanism of pathogenesis. 
 
More than thirty other mammalian proteins have now been described that are involved in 
establishment of right-left patterning during embryogenesis, although few have been 
examined in BA.  The CFC1 gene, encoding the human cryptic protein, is associated with 
familial and sporadic cases of laterality defects.  In 2008 Davit-Spraul et al. [2008] identified a 
mutation in the CFC1 gene in five of ten patients with biliary atresia splenic malformation 
syndrome (BASM).  A loss-of-function mutation identified in the CFC1 gene in patients with 
heterotaxy and BA provides yet further evidence supporting the potential role of laterality 
genes in contributing to the phenotypic determination of BA [Bamford et al., 2000; 
Jacquemin et al., 2002].  Therefore, in the case of CFC1, it can be concluded that mutations 
are probably not responsible for the development of BA, but may represent a genetic 
predisposition requiring secondary genetic or environmental factors to produce the BA 
phenotype [Davit-Spraul et al., 2008].  Other human genes that determine laterality, such as 
ZIC3 have been shown to be associated with human situs defects and BA [Ware et al., 2004].  
It is certain however further investigations of such genes will be required in the coming years 
to help clarify whether inherited or somatic, mutations or deletions are responsible for 
individual cases of BA. 
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Tied into the hypothesis that BA has a possible genetic component, is the proposed 
pathogenic mechanism of defective morphogenesis of the extrahepatic biliary tract.  This 
hypothesis is also supported by the coexistence of anomalies of visceral organ symmetry in the 
syndromic form of the disease, especially when considered together with the evidence of DPM 
in infants with BA [Low et al., 2001].  Abnormal remodelling of the ductal plate leads to the 
DPM that is present in congenital hepatic fibrosis (CHF) and other bile duct dysplasias.  
Polymorphisms in HNF6, HNF1-β, JAGGED1, PKHD1 or other related genes that regulate 
remodelling of the ductal plate [Clotman et al., 2002; Clotman et al., 2003; Coffinier et al., 
2002] could act as susceptibility factors or modifier genes necessary, but not sufficient, for the 
development of BA.  The roles of JAGGED1, which is expressed in ductal plate epithelia 
[Kohsaka et al., 2002], and HNF6, a nuclear transcription factor expressed in the developing 
EHBD and gall bladder [Clotman et al., 2002], are being studied in patients with BA.   
 
Irrespective of the cause, the histopathologic appearance of liver biopsy samples from patients 
with BA appear the same [C.E. Tan et al., 1994a].  Histologically BA is characterised by portal 
tract fibrosis, widening of portal tracts with infiltration of inflammatory cells, portal oedema, 
intrahepatic cholestasis, canalicular and cellular bile stasis, presence of bile plugs in portal tract 
bile ducts, ductular proliferation, and hepatic giant cell transformation observable under light 
microscopy, and degenerate biliary ductular cells containing bile pigment and the loss of bile 
canalicular microvilli seen under electron microscopy [Park et al., 1996] (Fig. 1.1).  The portal 
tract fibrosis varies from portal expansion to cirrhosis. 
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FIGURE 1.1 Histology of liver and bile ducts in biliary atresia.  (A) Hepatocellular and 
canalicular cholestasis, swollen hepatocytes, multinucleated giant cells (arrow), and portal 
tract inflammation (hematoxylin and eosin, x400).  (B) Expanded portal tracts with increased 
fibrosis, bile duct proliferation (line arrows), and bile plug in portal tract bile duct (block 
arrow) Trichrome, x250).  (C) Proximal common hepatic duct, and increased concentric 
sclerosis (hematoxylin and eosin, x100).  (D) Remnant of common bile duct with absent 
lumen (arrow) and concentric sclerosis (hematoxylin and eosin, x40).  Taken from [Sokol et 
al., 2003]. 
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Comparisons of the histological features of the livers from infants suffering from BA with and 
without congenital anomalies show no difference.  There are no statistically significant 
differences in the presence or absence of DPM, bile duct injury/destruction, degree of giant 
cell transformation, or fibrosis [M. Davenport et al., 2006].  It is important to note that the 
liver histology in patients with alpha-1-antitrypsin (α1AT) deficiency, occasionally in those 
with Alagille’s syndrome [Deutsch et al., 2001], cystic fibrosis, and total parenteral nutrition 
(TPN)-related cholestasis, can resemble all the features of BA.  Infants with chromosomal 
anomalies (e.g. trisomy 18) and BA have been reported [Carmi et al., 1993; Silveira et al., 
1991], associated with unusual anomalies, such as diaphragmatic hernia [D-Y. Zhang et al., 
2004a], and oesophageal atresia [Pameijer et al., 2000].  Other genetic diseases, such as cat-eye 
syndrome (trisomy or tetrasomy 22qter q11), have also been noted [Schinzel et al., 1981].  
This evidence supports the recent observations suggesting that BA is not a single disease 
entity, but rather a phenotype of several underlying specific disorders to which the infant liver 
responds in a stereotypic manner by a complex and dynamic series of processes, including 
inflammation, bile duct proliferation, apoptosis, and fibrogenesis [Perlmutter and Shepherd, 
2002].  Furthermore, these multiple different insults and potentially divergent mechanisms 
may be occurring not only simultaneously but also both antenatally and perinatally.  There are 
an abundance of studies implicating different primary triggers for the biliary tract obstruction 
underlying BA, suggesting that the pathogenesis is multifactorial.  Thus genetic, 
inflammatory, and infectious factors likely all play a role, but the timing and characterisation 
of the interplay between these factors remains unclear. 
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1.2 MICROSTRUCTURE AND DEVELOPMENT OF THE BILIARY TRACT 
Understanding the development of the biliary system and its cell types is crucial to 
interpreting the proposed aetiopathologic mechanisms of BA.  The biliary tract is an excretory 
system with two secretary units: hepatocytes and biliary epithelial cells (BEC), including the 
peribiliary glands.  This tract drains bile, produced by the hepatocytes, from the liver to the 
duodenum.  The biliary tract is grossly divided into the intra- and extrahepatic biliary tract 
according to their anatomical locations relative to the liver.  The extrahepatic biliary tract is 
grossly divided into the common hepatic duct, common bile duct, cystic duct, and gallbladder 
(Fig. 1.2).  The intrahepatic biliary tract is grossly defined as the biliary tract proximal to the 
hepatic duct, it is subdivided into the right and left hepatic ducts, segmental ducts, area ducts, 
and their finer branches such as septal and interlobular bile ducts and bile ductules.  The right 
and left hepatic, segmental and area ducts, and their finer branches are collectively termed the 
“intrahepatic large bile ducts”. These are grossly recognisable and characterised by association 
with intrahepatic peribiliary glands.  By contrast, the septal and interlobular bile ducts and 
bile ductules, which are only identifiable under light microscopy are generally called “small 
bile ducts” or “peripheral bile ducts”, and are not associated with peribiliary glands.  On liver 
wedge biopsies, these small bile ducts can be studied, whereas on needle biopsies only 
interlobular bile ducts and ductules are present for histological examination [Nakanuma et al., 
1997].  The glandular elements of the biliary tract are usually not visible on wedge or needle 
liver biopsy specimens, and are of no interest to this study.   
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FIGURE 1.2 The human biliary system.  Bile is secreted from each lobe of the liver through 
the right and left hepatic ducts, which join to form the common hepatic duct. The latter 
meets the cystic duct from the gallbladder to form the common bile duct. After reaching the 
gallbladder, bile is concentrated and re-enters the common bile duct through the cystic duct, 
which usually enters the duodenum after combining with the pancreatic duct to form the 
ampulla of Vater. The ampullary opening into the duodenum is controlled through the 
muscular sphincter of Oddi.  [Wistuba and Gazdar, 2004]. 
  17 
The intrahepatic and extrahepatic biliary tract is supplied and nourished by a network of fine 
vessels called the peribiliary vascular (or capillary) plexus (PVP).  The hepatic arterial branches 
supply blood to this plexus, and the PVP drains into the sinusoids through “radicular portal 
veins” or communicate with portal venous branches through internal roots (Fig 1.3). 
 
Within the liver, the three anatomical elements, bile ducts, portal venous, and hepatic arterial 
branches, run parallel to each other in the portal connective tissue, termed the portal tract 
(Fig. 1.4).  There are usually one or two bile ducts in each portal tract, with the bile duct and 
hepatic arterial branch running parallel in the same portal tract being roughly of equal size 
(Fig. 1.4).  Bile ductules are not associated with or accompanied by hepatic arterial branches.   
 
FIGURE 1.3 Blood supply of the extrahepatic and intrahepatic biliary system.  The common bile duct is 
vascularised by the parabiliary arteries, which run adjacent to the bile duct.  The majority of their blood is 
supplied via the inferior retroduodenal artery, while the right hepatic artery supplies a minor portion.  By 
contrast, the intrahepatic bile ducts are supplied by a rich, nonaxial network of small arteries that are solely 
derived from the right and left hepatic arteries, known as the peribiliary vascular plexus.  [Ruemmele et al., 2009]. 
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FIGURE 1.4 Hepatic portal tract. Consisting of branches of a portal vein, hepatic artery, bile 
duct, and lymphatic vessels.  These four vessels lie within a network of connective tissue, and 
are surrounded on all sides by hepatocytes.  The ring of hepatocytes abutting the connective 
tissue of the tract is called the limiting plate.  [Hansen, 2001]. 
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The development of the hepatic biliary system in humans begins at the third post-ovulation 
week.  The distal foregut (duodenum) endodermal epithelium gives rise to a ventral 
outgrowth known as the liver primordium [Lipsett et al., 1997; Sergi et al., 2000].  The liver 
primordium, a collection of rapidly proliferating liver precursor cells, forms the hepatic 
diverticulum.  As the hepatic diverticulum grows towards and penetrates the adjacent 
mesodermal tissue (the septum transversum), the hepatic diverticulum separates from the 
distal foregut [Lipsett et al., 1997].  Two parts emerge: the pars hepatica (cranial), which gives 
rise to the liver, common hepatic duct and the IHBDs; and the pars cystica (caudal), from 
which the gallbladder, cystic duct and extrahepatic biliary tree originate [Lipsett et al., 1997].  
The development of the intrahepatic biliary system begins around the eighth week of 
gestation and proceeds centrifugally from the porta hepatis to the periphery.  This process 
may not be completed at birth, and the intrahepatic biliary tract completes its maturation 
during the first years of life [Strazzabosco et al., 2005].  Histologically, three stages in the 
development of the intrahepatic biliary tree can be distinguished.  In the first step, occurring 
during the period from 6 to 9 weeks of gestation, a subset of periportal hepatoblasts 
(progenitor cells), in contact with the mesenchyme surrounding a portal vein branch, switch 
their phenotype and begin to strongly express biliary specific cytokeratins.  These cells are 
located at the site where ducts form, and are therefore considered as biliary precursor cells.  At 
that stage, hepatoblasts expressing much lower levels of the same cytokeratins are also found 
throughout the parenchyma (Fig. 1.5) [Lemaigre, 2003].  In the next step, the biliary 
precursor cells form a continuous single-layered ring around the portal mesenchyme (ductal 
plate stage) [Nakanuma et al., 1997].  The ductal plate, which is composed of small flat 
epithelial cells, is recognised at 7 weeks [Lemaigre, 2003; Nakanuma et al., 1997].  Over the 
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following weeks a second layer of cells duplicates the ductal plate over some segments of its 
perimeter (double-layered ductal plate) (Fig. 1.5).    At around ten weeks of gestation, the 
ductal plate enters a phase of profound remodelling.  During this phase, the ductal plate is in 
the process of forming immature tubules; focal dilatations appear between the two cell layers, 
giving rise to immature tubules (Fig. 1.5) [Lemaigre, 2003; Nakanuma et al., 1997].  A few of 
these dilated primitive intrahepatic biliary structures migrate towards the centre of the portal 
tract (peripheral tubular or ductular structures) and become incorporated into the 
mesenchyme of the nascent portal space (migratory stage) [Sergi et al., 2000; Strazzabosco et 
al., 2005].  The part of the ductal plate not involved in the formation of the ducts 
progressively regresses and is gradually deleted by apoptosis [Strazzabosco et al., 2005].  At 30 
weeks of gestation, the migratory BEC are almost completely transformed into tubules and, 
concurrently, the ductal plate at the hepatic hilum disappears by 25 weeks of gestation 
[Nakanuma et al., 1997].   
 
  
21 
 
FIGURE 1.5 Morphogenesis of the intrahepatic biliary system.   At 6 to 9 weeks of gestation, the biliary precursor cells, which express biliary-
specific cytokeratins, are located close to the portal mesenchyme, and some hepatoblasts expressing low levels of biliary specific cytokeratins are 
found throughout the parenchyma.  By week 7, the biliary precursor cells form a continuous single-layered ring called the ductal plate.  Over the 
following weeks the ductal plate becomes partly bilayered.  At around 10 weeks of gestation, focal dilatations appear between the two cell layers.  
These dilatations give rise to the bile ducts, while the rest of the ductal plate progressively regresses.  Around birth, the ducts become incorporated 
into the portal mesenchyme.  Adapted from [Lemaigre, 2003]. 
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The timing of IHBD morphogenesis described above corresponds to that of the most 
advanced biliary structures found near the hilum.  The development of small bile ducts 
(peripheral bile duct development), which proceeds from deep within and moves towards the 
periphery of the liver, is essentially similar to that of the large IHBDs with three identifiable 
stages.  This development occurs later than that of large IHBDs.  In the period from 15 to 19 
weeks of gestation, the development of small (peripheral) bile ducts is at the stage of the ductal 
plate.  From 20 weeks of gestation, remodelling of the ductal plate involving biliary cell 
migration into the mesenchyme occurs and bile duct formation, which begins at 27 weeks of 
gestation, is completed by 35 weeks of gestation [Nakanuma et al., 1997].  The ductal plate at 
the peripheral portion of the liver becomes unrecognisable by two weeks after birth [Terada 
and Nakanuma, 1994].  The EHBDs develop from the caudal part of the hepatic 
diverticulum.  The biliary epithelium lining the EHBDs is continuous at its caudal end with 
the duodenal epithelium and at the cranial end with the proliferating precursor liver cells.  
The caudal segment develops into the gallbladder, part of the cystic duct, and the common 
bile duct.  The extrahepatic segments of the right and left hepatic ducts, which are 
recognisable from 12 weeks of gestation are continuous with the common hepatic duct, and 
part of the diverticulum [Nakanuma et al., 1997]. 
 
Impaired remodelling or persistence of the ductal plate during foetal and postnatal 
development (DPM) (Fig. 1.6) [Desmet, 1992a] is pathogenetically related to a number of 
developmental diseases termed the cholangiopathies.  The presence of ductal plate remnants, 
von Meyenburg complexes (excessive bile ducts or ductules with variable degrees of ectasia), 
biliary cysts, and in some cases intense fibrosis are the pathologic features of this group of 
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diseases [Desmet, 1992a].  Among them, BA, the autosomal dominant polycystic kidney 
disease with liver involvement, the polycystic liver disease with renal involvement, and the 
hepatorenal fibrocystic diseases (autosomal recessive polycystic kidney disease, Caroli’s 
disease, and CHF), all possess distinct features from a genetic, pathophysiologic, and clinical 
point of view (Appendix 1, Table 1.1) [Strazzabosco et al., 2005].  However, just how a defect 
in the ductal plate could lead to the phenotypic features shared by the cholangiopathies, and 
particularly BA, is not intuitively obvious. 
 
 
FIGURE 1.6 Ductal plate malformation.  Any interruption in the remodelling of the ductal 
plate can result in the persistence of embryonic duct structures, termed the ductal plate 
malformation.  The ductal plate (red biliary epithelial cells) is in the form of either an 
interrupted circle or peripheral tubular structures.  The ductal plate malformation is a 
characteristic manifestation of a number of congenital fibrocystic syndromes that are 
inherited in an autosomal recessive manner.  The ductal plate malformation can also result in 
subsequent liver damage, and inflammation can induce the formation of fibrosis, and in some 
cases, cirrhosis. 
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It is well known that bile begins to flow at about twelve weeks, so that the union of the 
extrahepatic segments of the right and left hepatic ducts with the common hepatic duct, and 
part of the cystic duct should be completed before twelve weeks of gestation [Nakanuma et al., 
1997; C.E.L. Tan and Moscoso, 1994b].  Two groups have demonstrated the presence of 
extravasated bile in the bile ducts of patients with BA, they proposed that this originated from 
breaks in the biliary mucosa at the porta hepatis [Park et al., 1996; C.E. Tan and Moscoso, 
1994a].  The hypothesis drawn on these findings is that there is a vulnerable stage of human 
biliary development between 11 and 13 weeks of gestation, when failure of remodelling of the 
ductal plate structures could lead to disturbances in the normal development of the 
mesenchymal cuff that surrounds the hepatic hilar bile ducts.  Alternatively, connections of 
the hepatic ducts with the EHBDs could be perturbed; either of these alterations could 
potentially cause hilar bile ducts to rupture at the initiation of bile flow.  Extravasated bile, 
with its detergent properties, in adjacent periductal tissues would then lead to protracting 
secondary obliteration and obstruction of more distal EHBDs [Sokol et al., 2003].  First 
described by Rolleston and Hayne in 1901, this hypothetical mechanism for ductular damage 
was termed “descending cholangitis” [Rolleston and Hayne, 1901].      
 
It is the very complex nature of BA that makes it challenging to uncover the possible 
aetiopathologic mechanisms that could result in this phenotype.  However, as with many 
other complex diseases it is the study of less complex genetic and inherited diseases with 
common clinical features that can help increase our understanding of the disease process.  In 
the case of BA, the group of diseases termed the cholangiopathies may provide insight into its 
pathogenesis. 
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1.3 CHOLANGIOCYTES AND THE CHOLANGIOPATHIES 
Chronic cholestatic liver diseases which target the biliary system at any site along the 
intrahepatic and extrahepatic bile ducts represent a large group of potentially evolutive 
congenital and acquired liver disorders affecting both the adult and paediatric populations.  
These diseases are collectively called “cholangiopathies” to recognise that cholangiocytes are 
the primary cell target in the pathogenetic sequence [Strazzabosco et al., 2005].  
Cholangiopathies are liver diseases resulting from a failure in cholangiocyte function or from 
the reaction of cholangiocytes to acute or chronic liver damage.  The spectrum of 
cholangiopathies ranges from genetically transmitted developmental diseases arising from an 
abnormal bile duct biology, such as cystic fibrosis, Alagille syndrome, and fibropolycystic liver 
diseases; to conditions in which the biliary epithelium is damaged by disordered immunity, 
infectious agents, ischemia, toxic compounds, or by an extrahepatic obstruction to bile efflux 
[Strazzabosco et al., 2005].  However, there are those that remain idiopathic in their cause, 
and despite their obvious heterogeneity, cholangiopathies share a number of basic 
pathogenetic mechanisms.   The cholangiopathies are typically characterised by coexistence of 
cholangiocyte growth and apoptosis, inflammation, and fibrosis, differentially targeting the 
biliary epithelium with heterogeneous proliferative and apoptotic responses of different sized 
ducts [Alpini et al., 2001; Strazzabosco et al., 2005].  Therefore, to gain a greater 
understanding of these disorders significant effort has been devoted to understanding the 
normal physiology of cholangiocytes and their pathophysiology in diseased states.  To aid the 
unravelling of the complexity of BA a basic understanding of cholangiocyte function is vital, 
and so follows. 
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Two kinds of epithelial cell, hepatocytes and cholangiocytes, are present in the liver [Alpini et 
al., 2001], with BEC accounting for 3-5% of the hepatic cell population [Roberts et al., 1997].  
While hepatocytes initially secrete bile into the bile canaliculi, cholangiocytes in addition to 
funnelling bile into the intestine are also actively involved in bile-secretory processes and in 
liver regenerative/reparative processes [Nathanson and Boyer, 1991; Strazzabosco, 1997].  
Cholangiocytes possess both absorptive and secretory properties, modifying bile of canalicular 
origin by a series of coordinated, spontaneous, and hormone/peptide regulated 
secretion/reabsorption of water and electrolytes before it reaches the intestine.  In humans, 
around 40% of total bile production is of ductal origin [Alpini et al., 2001; Kanno et al., 2001; 
Strazzabosco et al., 2005].  Such secretory functions are mainly performed by cholangiocytes 
lining the interlobular and major ducts, which express the appropriate ion transporters and 
hormone receptors in polarised domains of the plasma membrane (Fig. 1.7) [Strazzabosco, 
1997].   
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FIGURE 1.7 Biliary tree, cholangiocytes and ductal bile formation.   Bile is originated by 
hepatocytes (i.e., primary or hepatic bile) and is subsequently delivered into bile ducts. The 
canals of Hering provide the continuum between the hepatocyte canaliculus and the ductules 
or cholangioles (<15 µm), the small size bile ducts (15 µm to 300 µm), and the large bile 
ducts (300 µm to 800 µm) in which hepatic bile is modified by large size cholangiocytes (i.e., 
ductal bile). Active biliary epithelial transport of electrolytes and solutes occurs mainly in large 
bile ducts and determines the vectorial water movement (i.e., absorption or secretion) across 
cholangiocytes, thus altering ductal bile composition and flow. To achieve this notable task, 
biliary epithelia express an array of flux molecules located on their apical (i.e., luminal) and/or 
basolateral plasma membrane domains. The periductular capillary plexus (not shown) located 
under the basolateral cholangiocyte domain facilitates the communication of bile ducts with 
the systemic circulation (i.e., the cholehepatic shunt). NHE1 or SLC9A, Na+/H+ exchanger; 
NCB1 or SLC4A4, Na+/HCO3- cotransporter; KC, K+ channel; NCHE, Na+-dependent, 
Cl-/HCO3- exchanger; NHE2 or SLC9A2, Na+/H+ exchanger-2; AE2 or SLC4A2, Cl-
/HCO3- exchanger; P2U, purinergic receptors; CCC, Ca2+-activated Cl- channel; MDR1a or 
ABCB1, multidrug resistance protein 1a; AQP, aquaporins (i.e., water channels); GT, 
glutamate transporter; CFTR or ABCC7, cystic fibrosis transmembrane conductance 
regulator; SGLT1 or SLC5A1, Na+-dependent glucose cotransporter-1; ASBT or SLC10A2, 
apical Na+-dependent bile acid cotransporter; NKCC1 or SLC12A2, Na+/K+/2Cl- 
cotransporter; MRP3 or cMOAT2, or ABCC3, multidrug resistance protein 3; GLUT1 or 
SLC2A1, facilitated glucose transporter-1; t-ASBT, truncated ASBT; GLT, glutathiome; 
Glu, glucose; TCA, taurocholate.  Adapted from [Lazaridis et al., 2004]. 
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Other biological properties such as plasticity (the ability to undergo limited phenotypic 
change), reactivity (the ability to participate in the inflammatory reaction to liver damage), 
and the ability to behave as liver progenitor cells appears to be restricted to the smaller bile 
duct branches [Strazzabosco et al., 2005].  This functional heterogeneity of cholangiocytes is 
also accompanied by a morphological diversity.  Under light microscopy small ductules are 
lined by small cuboidal cells, whereas in larger bile ducts cholangiocytes become progressively 
larger and more columnar in shape, ranging from 6 to 15 µm in height (Fig. 1.8 A & B) 
[Roberts et al., 1997].  Ultrastructurally no difference exists among cholangiocytes lining 
small or large bile ducts [Alpini et al., 1988].  Cholangiocytes lining a typical bile duct show 
apical and basolateral domains easily distinguished by features such as apically oriented vesicles 
and tight junctions and numerous apical microvilli (Fig. 1.8 C & D) [Roberts et al., 1997].  
Cholangiocytes also have primary cilia extending from the apical plasma membrane into the 
ductal lumen [Bogert and LaRusso, 2007].  Studies have confirmed a mechano-sensory 
function of cholangiocyte cilia linking ductal bile flow to intracellular signalling via Ca2+ and 
cAMP, and will be discussed in later chapters. 
   29 
 
 
FIGURE 1.8 Normal human bile duct morphology.  (A) Interlobular bile duct lined by 
cuboidal cholangiocytes.  The accompanying hepatic artery (a) and portal vein (v) radicles are 
not visible in this particular frame (H&E).  (B) Septal bile ducts lined by columnar 
cholangiocytes (H&E).  These ducts are fed by two or more interlobular bile ducts as is shown 
in (A).  Note that in both frames the ducts appear empty.  (C) Transmission electron 
micrograph of interlobular bile duct.  Note microvilli in the lumen of the duct (arrow).  
(Inset) Close-up view of microvilli.  (D) Scanning electron micrograph of cholangiocytes 
lining the common bile duct.  Each cell is delineated by a groove.  Note the uniformly 
distributed microvilli on the surface of each cholangiocyte.  (Inset) View into a choledochal 
lacuna showing mucus secretion (arrowheads) by cholangiocytes.  (E) Schematic drawing of 
the peribiliary vascular plexus (PBVP).  DV, drainage vein for PBVP; FA, feeder artery for 
peribiliary vascular plexus; PB, portal branch (original magnification: A, 400x; B, 100x; C, 
1400x; inset, 6300x; D, 3000x; and inset, 700x).  [Ludwig et al., 1989]. 
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1.3.1 Cholangiocytes in health 
In terms of bile production, the function of cholangiocytes is finely tuned to that of 
hepatocytes.  The biliary epithelium is thus the site of rapid hormone-mediated regulation of 
the fluidity and alkalinity of the primary canalicular bile secreted by the hepatocytes.  The net 
amount of fluid and bicarbonate secreted is determined by integration of pro-secretory 
(secretin, glucagon, VIP, acetylcholine, bombesin) and anti-secretory signals (somatostatin, 
insulin, gastrin, endothelin 1) [Strazzabosco et al., 2005].  The secretory functions of the 
biliary epithelium are also regulated paracrinally via molecules (such as bile salts, glutathione, 
and purigenic nucleotides) secreted by hepatocytes into the canalicular bile, and delivered to 
receptors and transporters located on the apical aspect of cholangiocytes [Strazzabosco, 1997].  
The biliary epithelium is also involved in the reabsorption of biliary constituents, such as 
glucose and glutathione and in the cholehepatic circulation of bile salts [Strazzabosco et al., 
2005].  In addition, bile acids can stimulate proliferation of BEC [Alpini et al., 1997; Barone 
et al., 2004].  On the other hand, the overflow of bile acids, as found in BA [Park et al., 1996; 
C.E. Tan and Moscoso, 1994a], may alter the epithelial barrier function and cause portal 
inflammation [Fickert et al., 2004]. 
 
Finally, cholangiocytes synthesise and secrete a number of cytokines, chemokines, growth 
factors, and angiogenetic factors, that likely enable the bile duct epithelium to communicate 
extensively with other liver cells, including hepatocytes, endothelial cells, hepatic stellate cells, 
portal fibroblasts, and inflammatory cells (Fig. 1.9) [Strazzabosco et al., 2000].   
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FIGURE 1.9 Theoretical scheme for paracrine communications between cholangiocytes 
and non-epithelial cells in the liver.  Cholangiocytes synthesize and secrete a number of 
peptides and mediators that are likely to enable the biliary epithelium to communicate 
extensively with other liver cells, such as hepatic stellate cells, portal fibroblasts and 
inflammatory cells, by stimulating the fibrogenic response.  However, peptides and mediators, 
either released in the portal spaces by immune cells, macrophages (Mφ) and mesenchymal cells 
or produced by the epithelium itself, may have profound effects on epithelial cell function, 
inducing expression of molecules of MHC class II antigen expression or affecting transport 
properties.  MCP-1, monocyte chemotactic protein-1; NO, nitric oxide; ET-1, endothelin-1; 
FGF, fibroblast growth factor; TGF-β1, transforming growth factor-β1; PDGF, platelet-
derived growth factor; HGF, hepatocyte growth factor, IFN-γ, interferon-gamma; CIV, 
collagen IV; CXVII: collagen XVII; IL, interleukin; TNF-α, tumour necrosis factor-α; 
MMP-1, matrix metalloproteinase-1; PMN, polymorphonuclear cell.  Modified and adapted 
from Strazzabosco et al [2000]. 
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1.3.2 Cholangiocyte function in liver disease 
A derangement in the physiological processes outlined above constitutes the 
pathophysiological basis for cholangiopathies.  From a pathophysiological perspective, 
common to all cholangiopathies is the coexistence of cholangiocyte death (lytic and 
apoptotic), cholangiolar proliferation, various degrees of portal inflammation and fibrosis, and 
qualitative/quantitative changes in bile production (cholestasis) [Strazzabosco et al., 2000].  
These basic disease mechanisms are present, albeit to a different extent, in all kinds of 
cholangiopathies.  Cytokines and other proinflammatory mediators released in close 
proximity to the biliary epithelium contribute to these processes through (a) stimulation of 
cholangiocyte apoptotic and proliferative responses [Sakamoto et al., 1999]; (b) activation of 
fibrogenic processes [Friedman, 1999]; (c) induction of damage to the peribiliary circulation, 
and (d) induction of histocompatibility antigen expression transport function [Strazzabosco 
et al., 2000]. 
 
1.3.2.1 Inflammation 
Most cholangiopathies are associated with significant amounts of inflammatory infiltrates 
into the portal space [Strazzabosco et al., 2005].  Current views of the pathogenesis of 
cholangiopathies implicate the instrumental role of inflammatory mediators, cytokines and 
chemokines in determining most of the pathophysiological changes occurring in the biliary 
epithelium, from proliferation to apoptosis, cytotoxicity, cholestasis, fibrosis, and 
inflammation-related carcinogenesis [Marra, 2002; Spirli et al., 2003].   For example the 
inflammatory mediators TNF-α, IL-2, IL-4, IL-5, IL-6, and INF-γ, released into the portal 
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spaces by immune cells, macrophages, or mesenchymal cells have profound effects on 
epithelial cell function [Ayres et al., 1993; Vos et al., 1997]. 
 
However, beyond being a target for inflammatory mediators, cholangiocytes actively 
contribute to liver inflammation and the ensuing reparative/fibrogenic processes by secreting 
proinflammatory and chemotactic cytokines, and growth factors [Lazaridis et al., 2004; 
Strazzabosco et al., 2000].  Interestingly, these factors are not produced by normal epithelium, 
but by “reactive cholangiocytes”.  Reactive cholangiocytes are not present in “normal livers”, 
but their presence is common in many forms of liver injury, especially the cholangiopathies 
[Strazzabosco et al., 2005].  The presence of an increased number of cholangioles (i.e. the 
smallest of bile ducts) at the periphery of portal spaces and parenchymal areas marked by the 
presence of an inflammatory infiltrate are commonly seen in many forms of liver injury and is 
called the “ductular reaction” [Lazaridis et al., 2004; Strazzabosco et al., 2005].  These newly 
formed bile ducts are composed of reactive cholangiocytes, which have abandoned their 
differentiated secretory epithelial phenotype.  These so-called “reactive” cholangiocytes 
express adhesion molecules that are transiently present during ontogenesis, turn on 
antiapoptotic genes, and acquire the ability to produce proinflammatory and chemotactic 
mediators.  Thus, activated cholangiocytes are likely to play an important role, not only in 
liver damage, but also in the progression of liver damage in chronic cholestatic syndromes 
[Strazzabosco et al., 2000].  As discussed below, the inflammatory reaction is central to most 
manifestations of the cholangiopathies, from cholestasis, fibrosis, and proliferation, to 
ductopenia. 
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1.3.2.2 Apoptosis 
Ductopenia (i.e. a decrease in the number of bile ducts per portal tract) is the end result of 
most cholangiopathies.  With the progressive disappearance of bile ducts in conjunction with 
portal fibrosis accounting for the majority of complications seen in cholangiopathies.  
Ductopenia results from a continuous immune-mediated assault to the biliary epithelium, 
from the combination of alloimmune and ischemic damage, or from genetic changes in 
mechanisms signalling lateral specification [Lazaridis et al., 2004; Strazzabosco et al., 2005].  
The exact mechanisms by which cholangiocytes die are not well known, but may be due to 
lytic or apoptotic cell death [Alpini et al., 2002b]. 
 
Cholangiocyte apoptosis does occur physiologically and has a role in ontogenesis during 
ductal plate regression, as previously described [Strazzabosco et al., 2005].  Apoptotic 
mechanisms also contribute to tissue regression after induced biliary hyperplasia (e.g. 
disappearance of proliferating ducts following the relief of biliary obstruction) [Bhathal and 
Gall, 1985].  It is currently believed, that under normal homeostatic conditions there is a 
balance between apoptosis of senescent and damaged/abnormal cholangiocytes, and the 
proliferation of new cholangiocytes [Lazaridis et al., 2004].  In light of this, ductopenia could 
be considered to result primarily from excessive apoptosis that dominates over cholangiocyte 
proliferation [Celli and Que, 1998].  However, this remains a difficult question to address, 
because apoptosis is a transient phenomenon and apoptotic cells may be eliminated by 
shedding into the bile duct lumen [Strazzabosco et al., 2000].   
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1.3.2.3 Proliferation 
Cholangiocytes maintain latent mitotic capabilities throughout adult life, and actively 
proliferate following a number of liver injuries resulting in what is referred to as “ductular 
reaction” [Strazzabosco et al., 2000].  Proliferation of cholangiocytes and subsequent 
distortion of the biliary tree architecture is an important step in the development of chronic 
liver damage, as ductular reaction is considered to be the pacemaker of portal fibrosis [Desmet 
et al., 1995; Lazaridis et al., 2004].  In the early stages of many cholangiopathies, destruction 
of interlobular bile ducts is associated with a vigorous proliferation of bile ductules in a variety 
of patterns at the periphery of portal spaces.  Elucidation of the mechanisms responsible for 
cholangiocyte proliferation has been the subject of extensive investigation [Alvaro et al., 
2000b; Melero et al., 2002].  In general, any stimuli increasing intracellular cAMP content 
facilitates cholangiolar proliferation [Alvaro et al., 2000b].  A number of growth factors, such 
as epidermal growth factor (EGF), hepatocyte growth factor (HGF), and 3-iodo-thyronine 
(T3) have been shown to stimulate cholangiocyte growth in vitro (Table1.3) [Lazaridis et al., 
2004; Matsumoto et al., 1994].  The list of stimulators of cholangiocyte proliferation also 
includes some bile salts [Alpini et al., 2002a], cytokines such as IL-6 [Yokomuro et al., 2000], 
and hormones such as oestrogens (Table 1.3) [Alvaro et al., 2002a; Alvaro et al., 2000a].  The 
ability of oestrogens to stimulate cholangiocyte proliferation has many important 
pathophysiologic implications for a number of cholangiopathies from PBC and primary 
sclerosing cholangitis (PSC), to liver cyst growth in autosomal dominant polycystic kidney 
disease (ADPKD) [Alvaro et al., 2002b; Chapman, 2003]. 
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TABLE 1.3 Regulation of cholangiocyte proliferation 
 STIMULATION INHIBITION 
Cytokines/growth factors IL-1α, IL-6α,  
TNF-α, EGF, HGF, IGF-1 
TGF-β1, TGF-β2 
Hormones/neuropeptides Oestrogens, Ach, PTHrP Somatostatin, Gastrin 
Bile salts LCA, TLCA, TCA UDCA, TUDCA 
IL=interleukin; TGF=transforming growth factor; TNF=tumour necrosis factor; EGF=epidermal growth 
factor; HGF=hepatocyte growth factor; IGF=insulin-like growth factor; ACh=acetylcholine; 
PTHrP=parathyroid hormone-related peptide; LCA=lithocholate; TLCA=taurolithocholate; 
TCA=taurocholate; UDCA=ursodeoxycholate; TUDCA=tauroursodeoxycholate.  Table taken from Alvaro et 
al [2000b]. 
 
 
1.3.2.4 Portal fibrosis 
A complex interplay of signals between reactive cholangiocytes, inflammatory cells, 
mesenchymal cells and extracellular matrix components, polypeptide growth factors, 
cytokines, and other soluble mediators regulates portal fibrosis.  Progressive disappearance of 
bile ducts, in conjunction with extensive portal fibrosis, contributes to most of the 
pathophysiologic implications of cholangiopathies.  Fibrogenesis is a dynamic process that 
depends on the extent and duration of cholangiocyte damage.  Several lines of evidence 
indicate that reactive cholangiocytes play an important role in initiating and modulating the 
response of a multiplicity of mesenchymal cells, as well as hepatic stellate cells (HSCs), the 
main connective tissue producing cells in the liver.  During tissue repair HSCs undergo 
activation from a quiescent to a highly proliferative myofibroblastic phenotype resulting in 
increased synthesis of collagen types I and III [Lazaridis et al., 2004; Pinzani et al., 1998]. 
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These mechanisms have mostly been studied in experimental models of obstructive cholestasis 
(such as ligation of the common bile duct in rat) [Alpini et al., 1998].  Indeed, chronic 
obstructive cholangiopathies are characterised by rapid appearance of an important portal 
fibrosis, as in BA [Perlmutter and Shepherd, 2002].  However, it remains unclear whether the 
changing epithelial phenotype directly induces an alteration of the mesenchymal cells or if the 
changes in the extracellular matrix induces the phenotypic shift in the biliary epithelium 
[Strazzabosco et al., 2000]. 
 
1.3.2.5 Cholestasis 
Consistent with the role of cholangiocytes in bile production, cholestasis is a prominent 
clinical manifestation in cholangiopathies.  Most frequently, cholestasis is the effect of 
immune-mediated toxic, or inflammatory damage to the biliary epithelium resulting in fibro-
inflammatory obliteration of bile ducts.  In other cases, cholangiocyte cholestasis may 
originate from an impaired fluid secretion caused by mutations in transport proteins, or by 
inflammatory mediators as the primary event that exposes the biliary epithelium to further 
damage [Strazzabosco et al., 2005].  Extrahepatic obstructions to bile outflow, as in BA, 
induces the retention of biliary constituents and triggers important pathophysiologic changes 
in cholangiocytes that promote the rapid appearance of significant liver fibrosis [Strazzabosco 
et al., 2000].  Retention of bile salts is another mechanism able to cause dramatic changes in 
biliary epithelial barrier function, also able to promote hepatocyte apoptosis and necrosis 
resulting in hepatocellular cholestasis [Lazaridis et al., 2004; Trauner et al., 1998]. 
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1.3.2.6 Altered development 
A number of cholangiopathies are caused by an altered development of the biliary tree.  The 
common pathological features of this group of diseases are the presence of ductal plate 
remnants, von Meyenburg complexes, biliary cysts, and in some cases intense fibrosis.   
Disorders characterised by abnormalities of the biliary tree that can be interpreted as sequelae 
of persistence of the ductal plate beyond embryonic and foetal life are not limited to the 
cholangiopathies.  Classed together as the DPM [Desmet, 1992a; Desmet, 1992b; 1998], at 
least ten heritable disorders, some of which are defined only phenotypically are recognised 
(Appendix 1, Table 1.1).  As seen in the cholangiopathies, they include circumferentially 
disposed bile ducts at the margin of the portal tract (that is, not separated from hepatocytes by 
connective tissue), increased numbers of bile duct profiles with connective contours, ecstasia 
of bile duct lumina, and lack of bile ducts or portal venules within portal tracts.  It must be 
noted, not all features are present in every disorder, nor need to be present in every portal tract 
[Knisely, 2003]. 
 
1.4 THE CILIOPATHIES 
Cystic diseases of the liver and kidney are a clinically important and genetically diverse group 
of disorders that share in common altered regulation of tubular morphology.  Among them 
can be listed the hepatorenal fibrocystic syndromes, and disorders associated with altered 
development of the ductal plate (Appendix 1, Table 1.1).  The hepatorenal fibrocystic 
(HRFC) syndromes are a heterogeneous group of severe monogenic conditions that may be 
detected before birth.  Commonly presenting in the neonatal and paediatric age, HRFC 
syndromes consistently include developmental abnormalities mostly involving the liver and 
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kidneys.  The changes include the proliferation and dilatation of epithelial ducts in these 
tissues with abnormal deposition of extracellular matrix.  Included within this group of 
syndromes are autosomal recessive polycystic kidney disease, nephronophthisis (NPHP), 
Meckel-Gruber syndrome (MKS), Bardet-Biedl syndrome (BBS), and Jeune asphyxiating 
thoracic dystrophy.  Despite their clinical and pathological heterogeneity, the fact that these 
disorders result in a similar outcome – dilated tubules or cysts – led to the naïve assumption 
that the gene defect in each of these disorders must somehow disrupt a common pathway 
[Watnick and Germino, 2003].  However, the observation that many of the genes responsible 
for various cystic diseases encode proteins that localise to subcellular compartments including 
focal adhesions, adherens junctions, cilia, basal bodies, centrosomes, and the mitotic spindle 
has resulted in many hypotheses on the mechanisms of cystogenesis based upon these 
subcellular localisations.  Among them are (i) the mechanosensory hypothesis of renal cilia 
function, (ii) participation in signalling at focal adhesions and adherens junctions, (iii) a role 
in the maintenance of planar cell polarity (PCP) within the noncanonical Wnt signalling 
pathway, and (iv) a role in centrosome-related functions of cell cycle regulation [Hildebrandt 
and Zhou, 2007].  The ciliary hypothesis has however evolved as the unifying concept of 
cystogenesis and revolutionised studies into the pathogenesis of many apparently unrelated 
genetic disorders.  The “ciliary/centrosome” hypothesis of renal cystic disease and related 
disorders states that virtually all proteins that are mutated in renal cystic disease in humans, 
mice, or zebrafish (“cystoproteins”) are part of a functional module, as defined by their 
subcellular localisations to primary cilia, basal bodies, or centrosomes [Igarashi and Somlo, 
2003; Watnick and Germino, 2003].  This applies to polycystin-1 and -2; 
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fibrocystin/polyductin; nephrocystin-1, -2 (inversin), -3, -4, and, -5; Bardet-Biedl associated 
proteins; cystin; polaris; ALMS1; and many others (Fig. 1.10) [Hildebrandt and Zhou, 2007]. 
 
 
 
FIGURE 1.10 Cystoproteins are proteins of genes that are mutated in cystic kidney diseases 
of humans, mice, or zebrafish.  They share the common feature of expression in primary cilia, 
basal bodies, or centrosomes.  Depending on cell-cycle stage, some cystoproteins localise to 
adherens junctions or focal adhesions.  Many cystoproteins have been localised to more than 
one intracellular domain.  AJ, adherens junction; BB, basal body; Cen, centriole; ER, 
endoplasmic reticulum; FAP, focal adhesion plaque; TJ, tight junction; PC-1, polycystin-1; 
PC-2, polycystin-2.  Taken from Hildebrandt and Zhou [2007]. 
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Disorders caused by mutations in genes encoding ‘cystoproteins’ are collectively termed 
“ciliopathies”.  Ciliopathies can either involve single organs or can occur as multisystemic 
disorders with phenotypically variable and overlapping disease manifestations [Fliegauf et al., 
2007].  A non-exhaustive list of ‘classical’ ciliopathies includes polycystic kidney disease 
(PKD), retinal degeneration, laterality defects, chronic respiratory problems, situs inversus, 
hydrocephalus, and infertility.  More recently, the discovery of other syndromes such as BBS 
and MKS, has extended the list of cilia related phenotpyes to include obesity, diabetes, liver 
fibrosis, hypertension, heart malformations, sensory deficits (anosmia, hearing impairment), 
skeletal, neurological and developmental anomalies [Inglis et al., 2006]. 
 
To appreciate how a single organelle, and its associated proteins can result in such a vast array 
of phenotypes, a basic understanding of this fascinating structure is invaluable. 
 
1.4.1 An overview of the cilium 
Cilia are ancient, evolutionarily conserved microtubule-based hair-like organelles that 
typically project from the apical surface of almost all cell types in the human body [Badano et 
al., 2006; Fliegauf et al., 2007].  Although these highly conserved structures are found across a 
broad range of species, a nearly ubiquitous appearance is observed only in vertebrates [Fliegauf 
et al., 2007].  Cilia can be structurally divided into subcompartments that include a basal 
body, transition zone, axoneme, matrix, ciliary membrane, and the ciliary tip (Box 1). 
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Box 1 Ciliary subcompartments 
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The basal body (Box 1) is a specialised centriole that serves as the foundation upon which the 
cilium is constructed.  Consisting of nine sets of helically arrayed tubulin-based triplet 
microtubules (MTs) (9x3 structure), this hollow cylinder lies embedded within pericentriolar 
material.  In most quiescent cells, the two centrioles that together constitute the centrosome 
move to the apical plasma membrane, and the mother (inherited) centriole functions as the 
microtubule organising centre (MTOC) to nucleate the axonemal MTs.  The daughter 
(newly synthesised) centriole remains perpendicular to the mother centriole [Fliegauf et al., 
2007].   
 
The transition zone (Box 1) refers to the junction of the basal body and the ciliary axoneme, 
where the triplet microtubular structure of the basal body converts into the characteristic 
doublet microtubular structure of the axoneme.  Demarcated by Y-shaped transition fibres 
connecting each MT doublet to the ciliary membrane.  The transition zone is proposed to 
contain a ciliary-pore complex that marks the compartment border at which access, import 
and export of cilia-specific proteins from the cytoplasmic compartment to the ciliary 
compartment, is controlled [Fliegauf and Omran, 2006]. 
 
The axoneme (Box 1) is the underlying structural scaffold of the cilium, comprised of a 
cylindrical array of nine peripheral MT doublets nucleated directly by the MTs found in the 
basal body.  In 9+2 cilia, the nine doublet MTs surround a central pair of singlet MTs; 9+0 
cilia lack this central pair of MTs.  Protein complexes known as radical spokes run inwards 
from the outer doublets to interact with the central pair, when present.  Inner and outer 
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dynein motors that power ciliary movement are attached to the outer doublets in a precise 
geometry that allows them to generate a bending force [Marshall and Nonaka, 2006]. 
 
Another component is the matrix, the fluid phase between the axoneme and the membrane 
that contains the intraflagellar transport machinery necessary to assemble and maintain cilia, 
as well as axonemal subunits being transported by this machinery.  The matrix may also 
contain factors involved in signal transduction via second messenger systems [Marshall and 
Nonaka, 2006]. 
 
The ciliary membrane, although continuous with the cell membrane, is both structurally and 
functionally distinct [Eley et al., 2005].  Containing many receptors and channels that are 
essential for the function of cilia as sensory antennae.   
 
The ciliary tip complex (Box 1) harbours the MT plus ends, which are bound to the ciliary 
membrane by capping structures.  The tip of the cilium is thought to also contain a set of 
unique proteins related to intraflagellar transport (IFT) function, as many IFT-related 
processes are restricted to the cilium tip, and the switch between the anterograde (kinesin) 
and retrograde (dynein) IFT motors [Fliegauf et al., 2007; Sloboda, 2005]. 
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1.4.1.1 Constructing the cilium 
In contrast to other cell organelles, cilia are only assembled when cells exit the cell cycle from 
mitosis into a stationary or quiescent and/or differentiated state.  Formation of most cilia 
begins when the basal body docks to the plasma membrane and serves as the template for MT 
nucleation and axoneme assembly.  The axoneme and the surrounding ciliary membrane 
projects out of the cell body, elongates and forms a compartment, the boundary of which is 
marked by the transition fibres, in a process referred to as compartmentalised ciliogenesis 
[Fliegauf and Omran, 2006].  The ciliary axoneme elongates by adding new material at the 
distal tip [K. A. Johnson and Rosenbaum, 1992; Rosenbaum and Child, 1967], this assembly 
at the tip does not cease when the cilium reaches its final length, but continues to occur.  The 
fixed length is maintained by continuous turnover at the tip [Marshall and Rosenbaum, 2001; 
Stephens, 1997].  Because the cilium lacks ribosomes, all proteins required for axoneme 
assembly, maintenance, and function must be transported from their site of synthesis in the 
cell body [Marshall and Nonaka, 2006].  This is achieved by the targeting of these specific 
proteins to the basal body area where pre-assembly of axonemal substructures (such as outer 
dynein arms) occurs [Fowkes and Mitchell, 1998].  The transport of proteins and 
multiprotein precursors across the ciliary compartment border and along the length of the 
axoneme to their functional site is dependent on IFT, the bidirectional movement of particles 
along the ciliary axoneme on raft-like transport structures [Rosenbaum and Witman, 2002].   
 
Because cilia are devoid of protein synthesis, IFT is thought to be the sole mechanism of 
protein transportation to the axoneme for, cilia assembly, maintenance and function.  Recent 
studies at the Mayo clinic [Hogan et al., 2009] have however uncovered a possible additional 
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mechanism for the delivery of proteins to the ciliary axoneme involving the multivesicular 
body (MVB) sorting pathway.  Urinary exosomes are thought to be end products of the MVB-
sorting pathway in which membrane proteins are uniquely packaged into intraluminal vesicles 
within the MVB, some of which are secreted as exosomes when MVBs fuse with the apical 
plasma membrane [Hyams et al., 1985].  MVBs and exosomes are thought to have a role in 
left/right axis determination in the embryonic node, released from the floor of the node and 
swept by nodal flow to the left side where they interact with the “picket-fence” immotile cilia 
[Tanaka et al., 2005].  This unifies the disparate localisation of many proteins implicated in 
ciliopathies, those not having a ciliary or centrosomal localisation.  Thus, raising the 
possibility of a novel form of “urocrine” and perhaps “bilocrine” signalling, fostering IFT 
independent communication along the length of the nephron/biliary tree [Hogan et al., 
2009].  
 
1.4.1.2 Classification of cilia 
Cilia can either be motile or immotile.  Based on whether the axoneme has a 9+0 or a 9+2 
structure, cilia have previously been referred to as primary cilia (immotile monocilia) or motile 
cilia, respectively [Fliegauf and Omran, 2006].  However, owing to numerous exceptions to 
this definition, the distinction of cilia into four subtypes is more appropriate, although at least 
eight categories of cilia or cilia-derived organelles exist in the human body upon more 
stringent categorisation (Fig. 1.11) [Afzelius, 2004].  All of which have been associated with 
human disease [Fliegauf et al., 2007]. 
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FIGURE 1.11 Ciliary categories.  A monociliated cell is shown in the centre.  Motile monocilia (9+0 axoneme, 
middle left panels) are found at the embryonic node and generate the nodal flow that is essential for 
determination of left-right body asymmetry.  Multiple motile cilia (9+2 axonemal structure, top panels) that 
transport extracellular fluid along the epithelial surface are located on respiratory epithelial cells, brain 
ependymal cells and epithelial cells lining the fallopian tubes.  The sperm flagellum (top right panel; co-stained 
with antibodies against the dynein heavy chain DNAH5, red) represents a specialised, elongated motile cilium 
(9+2) that confers motility.  Non-motile monocilia (9+0, bottom panels) extend from the surface of most 
quiescent cells of the body and sense environmental signals such as fluid flow and/or fluid composition.  Well-
known examples are the monocilia of the tubular epithelia of the kidney, and the epithelia of the bile duct and 
pancreatic ducts.  The chondrocyte and osteocyte monocilia probably function to sense the amount of strain on 
bones.  The connecting cilia of photoreceptor cells are specialised non-motile cilia (9+0) that connect the inner 
and outer segments.  Non-motile 9+2 cilia (middle right panel) are found in the inner ear (kinocilium, red, 
arrowhead; stereocilia, green).  Besides the four cilia types shown, there might be a high variability of the 
axonemal structures within vertebrates.  In all panels, axonemes were stained (red or green) by indirect 
immunofluorescence using an antibody against the cilia-specific acetylated α-tubulin isoform.  Nuclei were 
stained using Hoechst or 4’,6-diamidino-2-phenylindole (DAPI).  Figure taken from [Fliegauf et al., 2007] 
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Histologically, motile 9+2 cilia have been the most studied of all cilia.  Normally concentrated 
on the cell surface in large bundles that consist of 200-300 individual organelles (multiple 
cilia), motile cilia beat in an orchestrated wave like fashion. And are involved in fluid and cell 
movement such as mucociliary clearance in the lung, cerebrospinal fluid movement in the 
brain, and ovum and sperm transport along the respective reproductive tracts [J. R. 
Davenport and Yoder, 2005].  The primary or immotile 9+0 cilium is generally considered to 
be immotile because it lacks the central microtubule pairs, radical spokes, and the dynein 
apparatus needed to generate force.  When visualised by video microscopy, the cilium shows 
only Brownian movements, i.e. small fast movements induced by thermal energy.  An 
exception to the lack of motility of the 9+0 cilium is the specialised motile 9+0 primary 
cilium, the nodal cilium in the blastocyst, which does have radical spokes and dynein arms but 
lacks the central pair of MTs [Praetorius and Spring, 2005].  Instead of beating from side to 
side as does the motile 9+2 cilia, nodal cilia exhibit a characteristic propeller-like movement 
that is responsible for the nodal flow crucial for the development of left-right sidedness in the 
developing embryo [Nonaka et al., 1998]. 
 
1.4.1.3 The primary cilium 
The primary cilium is a solitary, nearly ubiquitous organelle in vertebrates [Pazour and 
Witman, 2003].  It has been found on most vertebrate cells that have been carefully examined; 
epithelial cells such as the kidney tubule, the bile duct, the endocrine pancreas, and the 
thyroid but also on nonepithelial cells such as chondrocytes, fibroblasts, smooth muscle cells, 
neurons, and Schwann cells (Fig. 1.11) [Satir and Christensen, 2007].  The most important 
exceptions are cells of myeloid and lymphoid origin, and the intercalated cells of the kidney 
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collecting duct [Praetorius and Spring, 2005; Wheatley, 1995].  The near ubiquity of cilia in 
human tissues and through eukaryotic biodiversity suggests that they must perform important 
functions that have been subject to evolutionary selection [Marshall and Nonaka, 2006].  
However, in spite of this near ubiquity, the function(s) of vertebrate primary cilia are very 
poorly understood.  Since the discovery of these organelles in 1898 [Zimmerman, 1898], three 
major hypotheses for their function have been put forward.  The first is that they are merely 
vestigial organelles inherited from an evolutionary ancestor whose cells had motile cilia, and 
that they now have no purpose [Sorokin, 1962].  However, the enormously complicated 
structure, and complexity of its protein composition, which has been shown to comprise of 
roughly 250 distinct proteins, argues against this hypothesis.  It would not be evolutionarily or 
biologically efficient to invest such high-energy expenditure into a vestigial organelle.  A 
second hypothesis is that they are involved in controlling the cell cycle [Tucker et al., 1979a].  
Primary cilia are intimately connected to the same centrioles that serve to organise the mitotic 
spindle.  Furthermore, although not required for a cell cycle the presence of the primary cilia is 
coordinated with the cell cycle [Pazour and Witman, 2003; Tucker et al., 1979a].  The third 
hypothesis implies cilia are sensory organelles [Poole et al., 1985; Wheatley et al., 1996].  This 
hypothesis is based on the fact that cilia are clearly used as sensory organelles in lower 
eukaryotes, and that the sensory structures of the vertebrate visual and olfactory systems are 
modified cilia.  This is a hypothesis that is not incompatible with a role in cell cycle control 
[Pazour and Witman, 2003]. 
 
This poses the question: why use a cilium as a sensory organelle?  A surprisingly large number 
of receptor proteins are localised mainly within cilia.  Clearly, cells benefit by projecting a 
   50 
sensory compartment like a probe into the surrounding fluid.  It is a well-known principle of 
fluid mechanics that any fluid immediately adjacent to a surface, such as the cell membrane, 
will be immobile and thus poorly mixed even when the surrounding media is flowing by the 
surface.  Moreover, many cells are encrusted with a glycocalyx that extends beyond the reach 
of a membrane-embedded receptor, thus producing a microenvironment around the receptors 
that differs from the true chemical environment of the media [Marshall and Nonaka, 2006].  
Cells may therefore obtain a more accurate reading of chemical composition and fluid velocity 
by extending receptors away from the cell surface.  The high flexural rigidity of the axoneme 
makes the primary cilium an ideal choice for such a whisker-like probe [Marshall and Nonaka, 
2006]. 
 
Another rationale for the evolutionary use of primary cilia for sensing may be signal 
processing.  The high surface to volume ratio of the cilium makes it an ideal compartment for 
signal transduction by second messenger generation.  A relatively small number of active 
receptors on the surface would produce an extremely high concentration of second messengers 
in the ciliary matrix, compared with the same number of receptors acting in the much more 
voluminous cytoplasm [Marshall and Nonaka, 2006].   
 
1.4.2 Pathogenetic mechanisms relevant to the ciliopathies 
While the existence of primary cilia has been known for more than a century, the interest of 
biomedical scientists in these organelles has increased only recently, providing the 
experimental evidence to support the hypothesis that primary cilia have an important sensory 
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role.  Three critical observations have been made in only the last six years: (i) that primary cilia 
in the node of gastrulation-stage embryos are essential for the determination of left-right 
asymmetry of the body [Marshall and Nonaka, 2006; McGrath et al., 2003]; (ii) that the two 
most frequent lethal genetic disorders (i.e. ADPKD and ARPKD), both characterised by 
progressive cyst development in the kidney, liver, and pancreas, are cilia-related diseases [T. V. 
Masyuk et al., 2004a; Tahvanainen et al., 2005]; and (iii) that Bardet-Biedl syndrome 
(patients with this syndrome have kidney failure,  lose their eyesight, are obese, and develop 
diabetes) is a ciliary-related disease caused by mutations in genes that determine ciliary 
structure and functions [Pan et al., 2005; Vogel, 2005].  It has therefore become apparent that 
primary cilia are functionally important organelles that are involved in both normal 
developmental and pathologic processes.  Primary cilia themselves may have a different 
composition or ultrastructure in different cell types thus potentially accounting for the array 
of phenotypes representing the ciliopathies when ciliary structures are mutated.  The most 
relevant established and emerging functions of the single, immotile primary cilia in relation to 
this project are described below, along with their potential pathophysiological role in the 
“classical” ciliopathies. 
 
1.4.2.1 The renal phenotype of ciliary dysfunction 
In considering a role for the primary cilia in the renal cystic phenotype, the exact nature of a 
cyst must be considered.  It is now well accepted that cell proliferation is an essential 
component of cyst formation; however, it is not clear what drives this proliferation.  It seems 
likely that for fully functional patent tubules to form, renal tubules need to undergo a highly 
regulated morphologic structuring that coordinates tubular elongation with tubular 
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expansion.  It is therefore a certainty that there is an ideal diameter for the tubule to perform 
optimally, and that this is a regulated process in the developing and adult kidney, perhaps 
allowing the tubule to adapt to varying luminal flow rates and pressure gradients.  If the cues 
for regulating tubular diameter are lost by mutation, the tubule may begin to lose morphology, 
transforming into a cyst.  It is theoretically acceptable that cystic epithelial cells do not 
dedifferentiate completely; instead they lose their sense of being a tubule and revert to what is 
essentially an epithelial sheet at first.  It has therefore been speculated that the primary cilia 
functions to measure luminal flow rates, or a lack thereof, and thus regulate tubule diameter 
by generating signals that the cells interpret as morphologic cues. 
 
The concept that defective cilia are the principal cause of PKD, originated with the discovery 
that the causative gene mutated in the Oak Ridge polycystic kidney (orpk) ARPKD mouse 
model, encoding polaris, is homologous to an IFT gene essential for ciliary assembly in 
Chlamydomonas, IFT88 [Pazour et al., 2000].  IFT mutant Tg737orpk mice develop progressive 
kidney and pancreatic cysts as well as abnormalities involving the hepatic bile ducts [Cano et 
al., 2004; Q. Zhang et al., 2005].  Indeed, scanning electron microscopy of the kidneys 
revealed that the renal epithelia was unable to assemble normal primary cilia [Pazour et al., 
2000].  Taken together, this strongly suggested that ciliary dysfunction affects the 
morphogenesis and integrity of kidney, liver, and pancreas.  All three organs contain similar 
functional units, tubular systems that transport urine, bile fluid, or pancreatic secretions 
respectively; monocilia extend into the lumen of each.  A clear interpretation from these 
studies is that mechanotransduction via the primary cilium is necessary for continued normal 
   53 
function, and cellular differentiation of the tubule epithelium, and that loss of the cilium leads 
to abnormal function, abnormal cell division, and PKD. 
 
Interestingly, many mutations that cause PKD are not found in genes that encode IFT 
proteins or the molecular motors involved in constructing the cilium.  In humans, all cases of 
ADPKD are caused by mutations in PKD1 and PKD2, which encode integral membrane 
proteins polycystin-1 (PC-1) and polycystin-2 (PC-2), respectively [Nauli et al., 2003].  PC-1 
and PC-2 are known to heterodimerise and normally also localise to the primary cilium of 
human renal epithelial cells [Hanaoka et al., 2008; A. I. Masyuk et al., 2006].  PC-1, a cell 
surface receptor activates a G-protein signalling pathway, which in turn, modulates the 
functions of the calcium-permeable cation channel PC-2 [Nauli et al., 2003].   
 
1.4.2.2 The mechanosensory hypothesis 
In 1997, Bowser and co-workers [Schwartz et al., 1997] provided the evidence that the 
structural properties of the primary cilium were appropriate for the detection of a range of 
bending forces present in renal tubule lumen.  Using a cultured renal cell line (PtK1) they 
showed that the primary cilium of these cultured cells was able to bend when the cells were 
superfused to flow rates comparable to those seen in renal tubules (Fig. 1.12). 
 
In 2001, Praetorius and Spring [2001], devised an elegant experimental procedure to test 
whether bending of the cilium itself was able to produce an intracellular response.  Using the 
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Madin Darby canine kidney (MDCK) cell line and a suction pipette to bend the cilium to 
avoid disturbing putative cell membrane flow sensors they were able to show bending of the 
cilium causes a substantial increase in intracellular calcium levels (Fig. 1.13).  They were also 
able to show that the calcium signal was able to spread as a wave from intracellular calcium 
stores from the perturbed cell to its neighbours by diffusion of a second messenger through 
gap junctions.  Pointing towards flow sensing as a coordinated event within the tissue, such as 
the renal tubule lumen, rather than an isolated phenomenon in a single cell.  The flow 
response observed was also proven by Praetorius and Spring [2002] to be absolutely 
dependent on the presence of a primary cilium, because immature cells that do not present a 
primary cilium or cells from which the cilium was removed by chloral hydrate treatment did 
not respond to increasing flow rates by increasing their intracellular calcium levels [Praetorius 
and Spring, 2002]. 
 
 
 
FIGURE 1.12 Representative time sequence of primary cilia bending in response to fluid 
shear.  Under conditions of zero flow primary cilia of the rat kangaroo kidney epithelial cells 
were perpendicular and straight (A).  Upon exposure to low levels of shear, the cilia passively 
bent in the direction of flow (B).  As flow increased, the degree of cilium bending increased 
considerably (C).  When flow stopped, the cilia returned to their original, straight, 
perpendicular position (D).  [Schwartz et al., 1997]. 
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FIGURE 1.13 The intracellular Ca2+ increase induced by bending of the primary cilium in 
MDCK cells.  (A) Bending of a single primary cilium with a micropipette.  The pipette was 
positioned ~4µm above the apical membrane and the primary cilium was bent toward the 
micropipette (arrow) by application of negative pressure in the pipette. The MDCK cells were 
grown to confluency on cover slips and loaded with the fluorescent probe fluo-4.  (B) Bending 
primary cilia by flow.  The traces represent increments of the intracellular Ca2+ concentration 
after changing the perfusate flow rate from 0 to 8 µl/s.  [Praetorius and Spring, 2001]. 
 
 
Evidence connecting primary ciliary mechanosensation and PKD was provided by Nauli et al 
[2004].  They found epithelial cells isolated from the kidney of transgenic mice that lack 
functional PC-1 formed cilia but did not produce a Ca2+ influx in response to physiological 
fluid flow.  Blocking antibodies directed against PC-2 similarly abolished the flow response in 
wildtype cells.  They concluded that their data suggested that PC-1 and PC-2 contribute to 
fluid-flow sensation by the primary cilium in renal epithelium and that they both function in 
the same mechanotransduction pathway [Nauli et al., 2003].  Defects due to mutant 
polycystin proteins might generate false signals that indicate a “lack of flow” and might result 
in a compensatory growth of the tubular cells and subsequent cyst formation [Fliegauf et al., 
2007]. 
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Interestingly, studies have shown that cessation of flow in kidney tubules of adult mice 
induces a proteolytic cleavage resulting in a cytoplasmic fragment of PC-1.  This is followed by 
translocation of the fragment to the nucleus where it directly initiates signalling processes that 
regulate branching morphogenesis of kidney tubule cells, suggesting that the protein is 
involved in early embryonic development of the nephron or in maintenance of its normal 
tubular structure [Nickel et al., 2002].  Such a pathway could regulate cellular proliferation; it 
is also likely that polycystin-mediated, flow-regulated calcium signalling also influences other 
epithelial properties within the tubule lumen, such as ion and/or fluid movement across the 
epithelium altering the composition of the luminal contents [Pan et al., 2005].  Additionally, 
considering the mechanisms involved in the NVP model, it is also feasible that molecules 
within the fluid flow might activate chemosensory or receptor-based signalling events to 
induce the subsequent intracellular calcium-release response.  Hence, chemical as well as 
mechanical fluid-flow sensing might provide morphogenic cues that regulate tubule diameters 
[Fliegauf et al., 2007].  However, the physiological consequences of ciliary mechanosensory 
and chemosensory dependent calcium signalling in the functioning of the normal renal 
epithelium remains to be fully uncovered. 
 
1.4.2.3 Hepatic disease in association with ciliary dysfunction 
Hepatic disease is one of the most common extrarenal features of the ciliopathies.  The 
hepatic involvement varies from cystic disease to fibrosis, with a combination of both present 
in some disorders.  The severity of hepatic involvement can also vary from serious impact on a 
patient’s quality of life whilst retaining normal liver function, to a significant impairment in 
liver morphology and function becoming a major cause of morbidity and mortality. 
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Development of cysts in the liver originally from the bile ducts is the most frequent extrarenal 
manifestation in both ADPKD (75% of patients) and ARPKD [Everson et al., 2004; 
Tahvanainen et al., 2005].  Liver involvement in ADPKD is characterised by altered 
remodelling of the embryonic ductal plate with presence of biliary cysts and aberrant portal 
vasculature [Bogert and LaRusso, 2007].  In stark contrast, ARPKD is invariably associated 
with biliary dysgenesis, a DPM characterised by aberrant IHBDs and portal fibrosis.  Gross 
cystic dilatation of the bile ducts is unusual except in the 6 to 12% of patients with Caroli’s 
disease [Igarashi and Somlo, 2003; Zerres et al., 1996].  In those who survive the renal disease, 
hepatic lesions become progressively more severe with age, and polycystic liver then becomes 
the major cause of morbidity and mortality [Everson et al., 2004; Tahvanainen et al., 2005]. 
 
Cholangiocytes have primary cilia extending from the apical membrane into the ductal lumen, 
heterogeneous in length along the biliary tree axis (i.e. longer in large vs. small ducts) [Huang 
et al., 2006].  Currently, nothing is known about the physiologic and pathophysiologic 
functions of primary cilia in cholangiocytes, the cells from which the liver cysts originate, as a 
potential result of an increased cholangiocyte proliferation and abnormal fluid secretion.  In 
contrast, considerable information has been generated within the last few years regarding the 
physiologic functions of primary cilia in renal epithelia providing an invaluable insight into 
the possible roles of cholangiocyte primary cilia in health and disease.  In light of these 
findings, Masyuk et al proposed that cholangiocyte primary cilia might function as a 
mechanosensor that monitors and transmits luminal bile flow stimuli into integrated 
intracellular calcium and cAMP signalling, as shown in renal tubules. 
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The mechanosensory function of cholangiocyte cilia was addressed directly by using 
microfused rat intrahepatic bile duct units (IBDUs) allowing controlled manipulation of 
luminal fluid flow rates, detection of both intracellular calcium and cAMP levels, and effective 
utilisation of gene silencing by small interfering RNA (siRNA) [A. I. Masyuk et al., 2006].  In 
microperfused IBDUs, luminal fluid flow induced an increase in intracellular calcium and 
caused suppression of the forskolin-stimulated cAMP increase.  In contrast, the fluid flow 
induced changes in intracellular calcium levels and cAMP levels were significantly reduced or 
abolished when cilia were chemically removed.  Furthermore, they were able to show that 
changes in intracellular calcium levels and cAMP are dependent on extracellular calcium, and 
expression of PC-1 and PC-2, as the changes were also abolished upon removal of extracellular 
calcium, and when PC-1 and PC-2 were individually down-regulated by siRNA [A. I. Masyuk 
et al., 2006].  Collectively, these data support the concept that cholangiocyte cilia function as 
sensory organelles that transmit luminal fluid flow stimuli into integrated intracellular 
calcium and cAMP signalling, as in the renal tubules, monitoring changes in bile flow within 
IHBDs and adjusting cholangiocyte functional response (i.e. ductal bile secretion) to such 
changes. 
 
Moreover, recent data from Masyuk et al [T. V. Masyuk et al., 2004a; 2004b] have revealed a 
strong connection between cholangiocyte cilia and hepatic cystogenesis.  Specifically, in an 
animal model of ARPKD, the PCK rat, cilia are functionally and structurally abnormal; in 
contrast to normal, they are shorter, have bulbous extensions on the axonemal membrane, and 
do not express fibrocystin, the protein mutated in ARPKD [2004a; T. V. Masyuk et al., 
2004b].  Therefore, it is feasible that defects in cholangiocyte primary cilia may result in the 
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hepatic phenotypes observed in the ciliopathies.  However, as is the case for renal tubule 
primary cilia, the precise mechanisms of a mechanosensory function of cholangiocyte cilia and 
the physiologic and pathophysiologic implications remain to be fully characterised. 
 
1.4.2.4 Lateralisation defects in association with ciliary dysfunction 
Abnormalities of left-right body patterning (or situs) is the third most likely relevant feature 
predicted to be a characteristic of disorders with ciliary involvement [Badano et al., 2006].   
Determination of left-right axis is a precocious embryonic event.  During embryonic 
development in vertebrates, the earliest organ lateralisation process is the looping of the heart 
tube to the right side.  This phenomenon represents only part of the lateralisation that 
corresponds to the asymmetric positioning of all internal organs along the left-right axis 
[Schön et al., 2002].  For example, the normal arrangement of asymmetrical organs (situs 
solitus) is characterised by the major lobe of the liver lying on the right side of the abdomen, 
whereas the spleen and the stomach are on the left side.  All phenotypic anomalies resulting 
from disruption of the normal lateralisation process are collectively referred to as the 
lateralisation defects [Schön et al., 2002]. 
 
Evidence to support a role for primary cilia in lateralisation defects is the infantile form of 
nephronophthisis (NPHP2).  Infantile NPHP with and without situs inversus is caused by 
mutations in the gene encoding the protein inversin (INVS).  Inversin has been shown to 
interact and co-localise with nephrocystin-1 and β-tubulin, which constitute the MT 
axoneme of primary cilia [Otto et al., 2003], not motile cilia [Pan et al., 2005].  In particular, 
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inversin/NPHP2 function is not implicated in ciliary assembly or motility, but in signalling 
mechanisms of PCP [Pan et al., 2005].  Thus, the co-localisation to primary cilia of 
nephrocystin-1, inversin, and β-tubulin provide a functional link between primary cilia 
function and left-right axis determination in humans [Pan et al., 2005]. 
 
1.4.2.5 Nodal hypothesis 
In early development of mammalian embryos a small triangular indentation, termed the 
“node”, forms transiently [Pazour and Witman, 2003].  Involved in the development of 
normal left-right asymmetry the node possess a specific cluster of primary cilia that play a 
crucial role in body axis determination [Nauli and Zhou, 2004].  Although these so-called 
intermediate primary cilia structurally show a “9+0” microtubule arrangement [Takeda et al., 
1999], careful observations showed that they also possess radical spokes and dynein arms, and 
are motile [Nonaka et al., 1998; Takeda et al., 1999].  Nodal cilia exhibit a characteristic 
clockwise twirling movement, generating a leftward flow of fluid across the node [Nonaka et 
al., 1998]. 
 
However, directional information of nodal flow must be converted to asymmetric gene 
expressions.  Theoretically, there are three independent questions in this process.  One is 
whether the information is chemically or mechanically sensed.  Another is whether the sensor 
is localised on the cilia or other non-ciliary cell membranes.  Finally, if the information is 
sensed on the cilia, are the necessary receptors situated on the nodal cilia themselves or on the 
non-motile sensory primary cilia [Marshall and Nonaka, 2006]? 
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The earliest model hypothesised that the nodal flow creates a gradient of a putative 
morphogen across the left-right axis of the node (Fig. 1.14), and that this gradient is 
responsible for the development of normal left-right asymmetry [Nonaka et al., 1998; Okada 
et al., 1999].  However, in a study carried out by Nonaka et al [2002], where superimposed 
flow from left to right over wt mouse embryos in vitro could reverse left-right asymmetry 
argues against that.  The relatively large volumes of fluid pumped over the nodes to achieve 
this makes it difficult to envision a gradient of a morphogen developing under such 
experimental conditions [Pazour and Witman, 2003].  
 
 
FIGURE 1.14 Classic morphogen accumulation model for nodal flow sensing.  A secreted 
molecule (X) makes a concentration gradient by leftward flow (red arrow).  Okada et al  
estimated the molecular weight of X to be 15-50 kDa considering effects of diffusion (green 
arrows) and returning flow (blue arrow).  Taken from [Marshall and Nonaka, 2006]. 
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An alternative hypothesis was proposed by Brueckner and colleagues [McGrath et al., 2003; 
Tabin and Vogan, 2003]; the “two cilia model” in which mechanical stress of the flow is 
sensed by a population of non-motile cilia at the periphery of the node (Fig. 1.15c), and in 
response generate a morphogenetic signal within the cell.  This model encompasses a 
functional role for the non-motile primary cilium in the determination of lateralisation 
providing a possible explanation for the presence of situs inversus in disorders caused by 
mutations in genes not encoding proteins involved in ciliary structure or IFT.   
 
Currently nodal flow hypotheses cannot efficiently explain the complex laterality defects that 
are observed in humans and mice with inborn ciliary defects (Fig. 1.15a) [Fliegauf et al., 
2007].  Partial laterality defects such as situs abdominalis and situs thoracalis indicate that 
reversal of left-right body asymmetry can independently occur along the anterior-posterior 
axis (corresponding to the upper and lower part of the human body) and is controlled by the 
nodal cilia function [Fliegauf et al., 2007].  It has been postulated that functional differences 
of the anterior and posterior part of the node, distinct signalling molecules for determining 
upper-lower body asymmetry and/or a temporal difference of left-right determination might 
explain partial laterality defects as seen in some cases of syndromic BA [Carmi et al., 1993]. 
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FIGURE 1.15 Human laterality disorders and current models for establishing left-right asymmetry.  (a) 
Schematic illustration of normal left-right body asymmetry (situs solitus) and five laterality defects that affect the 
lungs, heart, liver, stomach and spleen.  By their vigorous circular movements, motile monocilia at the embryonic 
node generate a leftward flow of extra-embryonic fluid (nodal flow).  (b) The nodal vesicular parcel (NVP) 
model predicts that vesicles filled with morphogens (such as sonic hedgehog and retinoic acid) are secreted from 
the right side of the embryonic node and transported to the left side by nodal flow, where they are smashed open 
by force.  The released contents probably bind to specific transmembrane receptors in the axonemal membrane 
of the cilia on the left side.  The consequent initiation of left-sided intracellular Ca2+ release induces downstream 
signalling events that break bilaterality.  In this model, the flow of extra-embryonic fluid is not detected by cilia-
based mechanosensation.  (c) In the two-cilia model, non-sensing motile cilia in the centre of the node create a 
leftward nodal flow that is mechanically sensed through passive bending of non-motile sensory cilia at the 
periphery of the node.  Bending of the cilia on the left side leads to a left-sided release of Ca2+ that initiates the 
establishment of body asymmetry.  Taken from [Fliegauf et al., 2007]. 
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1.4.2.6 Cilia and the cell cycle 
As previously touched upon, a balance between hyperproliferation and apoptosis may play an 
important role in the pathogenesis of cystic kidney diseases.  For example, whereas in PKD 
kidneys are grossly enlarged, in NPHP and BBS kidney size remains normal and cysts grow at 
the expense of normal tissue [Hildebrandt and Zhou, 2007]. This hypothesis could also be 
applied to the liver in these disorders, in PKD the liver shows significant cystic enlargement 
[Everson et al., 2004; Tahvanainen et al., 2005], whereas NPHP and BBS are associated with 
hepatic fibrosis [Boichis et al., 1973; Pagon et al., 1982].  It is therefore speculated that 
hyperproliferation may be the predominant mechanism in PKD-like diseases [A. C. Ong and 
Harris, 2005], whereas apoptosis is predominant in diseases of the NPHP and BBS group.  
Thus, defects in cell-cycle regulation may be ultimately responsible for the derangement of the 
balance between cellular proliferation and apoptosis in the ciliopathies. 
 
The cilium is nucleated from the elder centriole of the centrosome, the basal body.  Given the 
complex involvement of the centrosome in cell-cycle control, it is likely that the cilia may also 
play a role in cell cycle control.  Supportive of this possible role, the expression of cilia in most 
mammalian cells is coordinated with the cell cycle.  The presence of a cilium is associated with 
the establishment of polarity and differentiation of the cell; ciliated cell lines grown in vitro 
often grow a primary cilium as they approach confluence, and most ciliated cells are probably 
in the stationary or G0 phase of the cell cycle [Avidor-Reiss et al., 2004].  In many cells, entry 
into mitosis is preceded by ciliary resorption.  Following the absorption, the basal body 
converts back into a centriole.  After centriole duplication, the two centrosomes (i.e. four 
centrioles) form the poles of the spindle apparatus.  Shortly after mitosis, the centrosome 
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containing two centrioles migrates towards the apical membrane, where the elder centriole 
gives rise to the basal body, providing the base for the ciliary axoneme [Quarmby and Parker, 
2005; Wheatley et al., 1996].  If cilia provide information that serves to retain cells in their 
functioning differentiated G0 state, then defects in this pathway are predicted to cause 
proliferative disorders: cystic diseases, and fibrosis of various types.  Multiple signalling 
pathways are localised to cilia in mammalian cells, and some proteins have been shown to act 
both in the cilium and in cell cycle regulation [Quarmby and Parker, 2005].  It is interesting 
to consider that if cilia are indeed sending signals that regulate cell cycle progression; by 
physical necessity these signals must pass near or through the centrosome.  Proteomic analyses 
of centrosomes reveal that apart from structural components, several kinases and 
phosphatases involved in cell cycle progression and cytokinesis localise to the centrosome 
[Anderson et al., 2003; Hinchcliffe et al., 1999].  The cell cycle is an important aspect of 
cystoprotein biology that might help in the understanding of how ciliary defects can result in 
the extensive pleiotropy seen in the ciliopathies at a molecular level, as cystoproteins change 
their subcellular localisation according to the cell-cycle stage [Hildebrandt and Otto, 2005; 
Mollet et al., 2005]. 
 
In support of a role for primary cilia in cell cycle regulation, it has been observed that when 
cholangiocyte cell lines derived from the Tg737orpk mouse were transfected with the wildtype 
Tg737 gene, they proliferated at a slower rate than those transfected by a control vector alone 
[Richards et al., 1997].  As it is known the IFT-particle protein Tg737 is involved in primary 
cilia assembly, it is reasonable to conclude that the difference in the rates of cellular 
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proliferation in these cells reflected the presence or absence, respectively, of a functional 
primary cilium [Pazour et al., 2000; Pazour and Witman, 2003]. 
 
The polycystins have been reported to participate in a confusing plethora of signalling 
pathways.  PC-2 regulates cell proliferation and differentiation by directly interacting with 
and influencing the nuclear translocation of ID2 (inhibitor of DNA binding-2).  
Overexpressing PC-2 blocks cell-cycle progression through PC-1 dependent upregulation of 
the cyclin-dependent kinase inhibitor p21 [X. Li et al., 2005].  Overexpression of PC-1 
directly activates signalling through Janus Kinase (JAK)-signal transducer and activator of 
transcription (STAT) to regulate the cell cycle [Bhunia et al., 2002].  Furthermore, the 
cytoplasmic C-terminal of PC-1 undergoes proteolytic cleavage in response to fluid flow, 
enters the nucleus and directly initiates signalling processes (such as Wnt and the activating 
protein-1 (AP1) mediated pathways) that are modulated by PC-2.  As the transcription factor 
AP1 is involved in various processes, including proliferation, transformation, and apoptosis, 
this provides further evidence that ciliary mechanosensation in tubular regulation might be 
directly linked to cell-cycle regulation [Chauvet et al., 2004]. 
 
1.4.2.7 Centrosomes 
Named for its location near the centre of the cell, the centrosome first described by Boveri in 
the early 1900s can be recognised under a light microscope as a densely staining structure that 
is adjacent to the eukaryotic nucleus, and comprises two centrioles that are surrounded by an 
amorphous, proteinaceous matrix termed the pericentriolar material (PCM) [Badano et al., 
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2005].  In addition to its already established role in cilia assembly, the centrosome serves as the 
MTOC in interphase cells, is important for organising the mitotic spindle during mitosis, and 
organises regulatory aspects of cell physiology. 
 
The MTOC activity of the centrosome includes the nucleation and organisation of those 
MTs that form the interphase cytoplasmic microtubular array and the mitotic spindle, as well 
as cilia.  However, recent data indicate that centrosomes are not essential for spindle assembly 
in mammalian cells, suggesting that most, if not all, cells can assemble spindles by non-
centrosomal pathways [Hinchcliffe and Sluder, 2001; Khodjakov et al., 2000].  However, 
given its complexity and conservation, the centrosome must perform essential functions as 
otherwise it would have been eliminated during evolution by random mutations.   
 
Positioning of the spindle within cells is important for several fundamental processes, 
including, accurate segregation of chromosomes, asymmetric distribution of cell-fate 
determinants during development, normal and asymmetric cell divisions, and defining the 
plane of cytokinesis.  Thus centrosome-mediated spindle assembly could provide a redundant 
pathway to ensure that centrosomes are inherited during each cell division so they can 
complete other essential cellular functions [Doxsey, 2001].  One such role emerging from 
studies into centrosome function is in defining cell polarity.  One very interesting aspect of 
acentrosomal spindles is the lack of astral MTs (MTs that link centrosomes to the cell cortex). 
Astral MTs are important for the correct positioning of the spindle during mitosis, and for 
the establishment of the spindle axis [Rieder et al., 2001].  Thus, the centrosome seems to be 
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involved in either establishing or maintaining cell polarity, which relies on the directionality 
of MTs (which are inherently polar structures) [Badano et al., 2005].  As the centrosome 
represents a cellular organelle shared by the mitotic-spindle and cilia, it is tempting to 
speculate that cilia-sensed signals integrate into cellular programs that provide a vectorial cue 
for the positioning of the centrosome after mitosis and thus cellular polarity [Badano et al., 
2005].  Mutations in genes affecting the structure and/or function of cilia may result in 
impairment of the organelles to sense and transduce signals relating to cellular orientation 
onto the centrosome, perhaps explaining in part, the observation that almost all cell types 
affected in the ciliopathies are polarised. 
 
Another area of centrosome biology of relevance to the ciliopathies is the role of centrosomes 
in generating genetic instability [Doxsey, 2001].  Much like chromosomes, centrosomes 
duplicate precisely once every cell cycle.  The fidelity and timing of centrosome duplication is 
essential for ensuring that this process is effectively coupled to other events, such as cell-cycle 
progression and DNA replication [Hinchcliffe and Sluder, 2001].  Uncoupling of these events 
can lead to excess centrosomes that can organise multipolar spindles or single centrosomes 
with associated monopolar spindles [Doxsey, 2001].  As centrosomes act dominantly when 
present in somatic cells, abnormal centrosome numbers contribute to spindle abnormalities, 
chromosome misregulation and genetic instability, either alone or in combination with 
alterations in other cellular pathways [Doxsey, 2001; Heald et al., 1997].  The observation of a 
high frequency of chromosome anomalies and genetic aberrations in the cystic cells from 
patients with ADPKD [Gogusev et al., 2003], prompted investigation into the mechanisms 
underlying this observation.  Increased centrosome numbers and centrosome defects have 
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been observed and analysed in most aggressive tumours, in some low-grade tumours, and pre-
cancerous lesions [Marx, 2001; Pihan et al., 2001].  Although there is no correlation between 
ADPKD and renal carcinoma, various observations liken ADPKD to a benign neoplasia 
[Brasier and Henske, 1997; Harris and Watson, 1997].  Cystic cells are hyperproliferative, 
display abnormal expression of cell adhesion molecules, and show resistance to anoikis 
[Battini et al., 2006; Roitbak et al., 2004].  Recent studies have established that amplification 
of centrosomes, as well as formation of micronuclei and defects in DNA segregation, leads to 
genetic instability [Burtey et al., 2008; Fukasawa, 2005].  It is therefore speculated that this 
may either cause the cell to die, or survive a cycle through asymmetric division with the 
generation of viable, yet aneuploid cells in which cell death may ensue as a consequence of 
extensive loss of genetic material.  However, while mitotic catastrophe does occur within such 
cell populations, the observed disappearance of remarkable polyploidism over time suggests 
that cells are able to converge genomically towards a chromosomal composition adaptive to 
growth [Battini et al., 2008].  Thus, renal and hepatic phenotypes observed in the ciliopathies, 
cysts and fibrosis could be explained by chromosomal instability, with a balance between the 
rates of apoptosis and adaptive growth. 
 
Recently, the loss of oriented cell division consequent to alteration of mitotic spindle 
orientation has been suggested as an early mechanism of the cystogenic process in a mouse 
model of PKD [Fischer et al., 2006].  Therefore it is also conceivable centrosomal 
amplification may play a role in cystogenesis and fibrosis by causing the loss of normal mitotic 
orientation when multiple centrosomes are present [Burtey et al., 2008]. 
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1.4.2.8 Primary cilia in tubulomorphogenesis, and planar cell polarity 
Tubulogenesis involves many cellular processes, including differentiation, polarisation, shape 
change, proteolysis, growth, mitosis, death, motility, adhesion, signalling, ion fluxes, 
cytoskeletal organisation and membrane trafficking [Zegers et al., 2003].  Although each of 
these processes has been well studied, less is known about the complete temporal-spatial 
picture of how things are coordinated, and especially how the behaviours of many individual 
cells are linked together to form patent functional tubules.  Tubulogenesis is the most 
complex of several classically described alterations in epithelial tissue architecture, including 
convergent extension, epiboly, sheet closure, and epithelial-mesenchymal transition, and may 
share some features with these other types of morphogenic movement [Zegers et al., 2003]. 
 
Tubular epithelial cells are polarised along their apical-basal axis, allowing specialisation of 
function of their apical and basolateral surfaces [Drubin and Nelson, 1996; Shulman and St 
Johnston, 1999].  Cues for polarisation along the axis are derived from direct contacts with 
other cells and the substratum [Müller, 2000].  Many epithelia such as those lining tubules are 
also polarised along an axis orthogonal to the apical-basal axis, resulting in asymmetry within 
the plane of the epithelium (referred to as PCP) [Shulman et al., 1998; Shulman and St 
Johnston, 1999].  Polarisation along this axis requires signals to reach across vast expanses of 
cells [Axelrod and McNeill, 2002]. 
 
It is clear that the function of the tubular cells of the nephron and biliary system require a 
precisely defined structure not only at the single cell level but also at the tissue level. 
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Therefore, one of the main developmental challenges of the kidney and liver is to assemble a 
perfect architecture of the nephron and biliary system.  Morphogenesis involves coordinated 
proliferation, differentiation, and spatial distribution of cells, notably the massive 
proliferation lengthens tubules without substantial increase in their diameter.  Studies by 
Fischer et al [2006] were able to demonstrate that lengthening of renal tubules is associated 
with mitotic orientation of cells along the tubule axis, demonstrating intrinsic planar cell 
polarisation.  Their study also demonstrated that mitotic orientations are significantly 
distorted in rodent polycystic kidney models [Fischer et al., 2006].  Thus, it was suggested that 
oriented cell division dictates the maintenance of constant tubule diameter during tubular 
lengthening, and that defects in this process trigger abnormal tubule growth and formation. 
 
Oriented cell division is the result of a correctly positioned spindle axis.  A number of studies 
in different model organisms have placed the spindle axis orientation under the control of the 
PCP pathway, also known as the non-canonical Wnt pathway [Klein and Mlodzik, 2005; 
Simons and Walz, 2006].  Wnt signalling regulates a diverse set of developmental processes 
[Logan and Nusse, 2004; Veeman et al., 2003].  In vertebrates, processes requiring precise 
PCP signalling include; regulation of convergent extension movements during embryo 
gastrulation, body hair orientation and skin development, neural tube closure, as well as the 
organisation of the stereocilia bundles of the inner ear epithelium [Simons and Walz, 2006].  
The central elements of the Wnt signalling pathway include a family of ligands and receptors 
that together regulate activity of the cytoplasmic protein dishevelled (Dvl).  The Wnt 
pathway then branches into two pathways, the β-catenin dependent (canonical) and the β-
catenin independent (non-canonical).  During early kidney development, canonical Wnt 
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signalling is necessary for the induction of metanephric mesenchyme and cell proliferation in 
branching morphogenesis [Perantoni, 2003].  At later developmental stages however the non-
canonical Wnt pathway is required for oriented cell division to allow proper elongation of the 
renal tubules.    
 
Several groups have been able to show that a number of cystoproteins may be directly involved 
in switching between the canonical and non-canonical Wnt Pathways [Guo et al., 2004; 
Schwarz-Romond et al., 2002; Simons et al., 2005].  Most convincingly Simons et al [2005] 
were able to show that fluid flow detected by primary cilia regulates a crucial inversin-
dependent switch between Wnt signalling pathways during renal development.  On the basis 
of these findings, Simons et al [2005] propose a model in which urinary flow terminates 
canonical Wnt signalling to facilitate β-catenin-independent Wnt pathways, perhaps to 
endow tubular epithelial cells with the spatial information important to maintain the 
genetically determined tubular geometry (Fig.1.16).   
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FIGURE 1.16 Flow-based model of Wnt regulation in the kidney.  In the model proposed by 
Simons et al. [2005], Wnt signalling occurs primarily through β-catenin-dependent pathways 
in the absence of flow.  Ligand binding by the Frizzled-LRP complex results in inactivation of 
the β-catenin destruction complex, increased cytoplasmic and nuclear β-catenin levels, and 
upregulation of effector gene expression (left).  Stimulation of the primary cilium by flow is 
postulated to result in increased expression of inversin (Inv), which then reduces levels of 
cytoplasmic dishevelled (Dvl) by increasing its proteasomal degradation.  This process is 
thought to switch off the canonical pathway by allowing reassembly and activation of the β-
catenin destruction complex.  Inversin might also enhance trafficking of Dvl to the plasma 
membrane, where it could activate noncanonical Wnt pathway components.  The question 
marks indicate uncertainty as to whether the inversin-Dvl or Frizzled-LRP complexes are 
present in the primary cilia-basal body-centrosomal complex.  Taken from [Germino, 2005]. 
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According to this model, any process that impairs this switch would result in compromised 
canonical Wnt signalling and abnormal tubulomorphogenesis (Fig. 1.17).  Interestingly, urine 
and bile production begins remarkably early in embryogenesis.  Long before fluid and 
electrolyte balance is required for homeostasis [Nakanuma et al., 1997; Simons and Walz, 
2006].  It is therefore tempting to speculate that urine and bile flow terminates canonical Wnt 
signalling.  Given that primary cilia are now believed to function as mechanosensors to flow 
[Praetorius and Spring, 2001], this model provides a mechanistic link between the primary 
cilia-basal body-centrosomal (CBC) complex and a pathway regulating tubular morphology. 
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FIGURE 1.17 Noncanonical Wnt signalling and tubular morphogenesis.  Proper apical-
basolateral polarity is essential for normal solute and water transport, and tubular epithelial 
cells must also be correctly oriented with respect to the longitudinal axis of the tubule.  This is 
especially true during renal and biliary development when newly formed tubules undergo 
progressive lengthening.  The default structure that would result from disruption of this 
planar orientation is predicted to be a dilated tubule or cyst.  Noncanonical Wnt signalling 
regulates a number of processes that could help orient cells properly along the longitudinal 
axis.  Tubular flow could be one of these signals that provide information about cellular 
orientation.  Adapted from [Germino, 2005]. 
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Taken together, these findings and this model support the emerging link between PCP and 
the CBC complex.  The monocilium appears to provide the spatial cues (by sensing tubular 
fluid flow, for example) to position the centrosome and the mitotic spindle before the next 
cell division [Benzing and Walz, 2006].  Defective cilia function or PCP signalling might 
cause the tubular epithelial cells to lose spatial orientation and apical-basolateral polarity, to 
proliferate abnormally and to form defective tubules [Fliegauf et al., 2007]. 
 
Although Wnts are known to play a role in PCP and hepatic development, another 
developmental pathway shown to interact with Wnt signalling in organogenesis is the Notch 
pathway.  Experimental studies in mutant mice and zebrafish, and human genetic studies have 
shown that Notch signalling is required for biliary tree development during ductal plate 
remodelling [Flynn et al., 2004; Kodama et al., 2004].  Notch signalling seems to control 
hepatoblast and mature hepatocyte transdifferentiation into cholangiocytes, by altering the 
expression of liver-enriched transcription factors [Nishikawa et al., 2005; Tanimizu and 
Miyajima, 2004].  Interestingly, changes in Jagged1 and Notch expression have been reported 
also in the course of chronic liver diseases [Nijjar et al., 2001].  Most notably, mutations in 
Jagged1, a notch Ligand, have been shown to result in the cholangiopathy Alagille syndrome.  
Alagille syndrome (OMIM #118450) is a pleiotropic developmental disorder characterised by 
neonatal jaundice and impaired differentiation of IHBDs [Alagille et al., 1987; Emerick et al., 
1999].  Much like syndromic BA, features including congenital heart defects, and kidney 
abnormalities also accompany Alagille syndrome [Bassett and Murray, 2008; Krantz et al., 
1997]. 
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The notch-signalling pathway plays an important role in cell-to-cell communication and cell 
fate determination in a wide range of organisms [Gridley, 1997; Hadchouel, 1992], and has 
been shown to have a role during tubulogenesis [McCright et al., 2001; 2002].  Notch 
signalling leads to amplification and consolidation of molecular differences between 
neighbouring cells, apparently via various mechanisms depending on the cellular context and 
integration with other factors [Artavanis-Tsakonas et al., 1999].  Studies in Drosophila 
indicate an interplay between Frizzled and Dvl, of the Wnt pathway, and Notch, indicating 
that polarity is established through local comparisons between cells, and explains how a signal 
from one position (for example, a proximally located cell relative to bile flow) could be 
interpreted by distal cells in the tubule. 
 
Importantly, the hypothesis that the renal cystic disease phenotype of the ciliopathies, and 
possibly their accompanying features is linked to the maintenance of PCP seems plausible for 
multiple reasons: (i) it would reconcile previous functional hypotheses, because focal 
adhesions, adherens junctions, cilia, centrosomes, basal bodies, and regulation of the cell cycle 
all play a pivotal role in the regulation and maintenance of PCP [Keller, 2002]; (ii) because 
PCP plays an important role in developmental morphogenesis, tubulogenesis, and also in the 
regeneration of differentiated tissue, a defect in PCP may explain both the occurrence of cysts 
during organogenesis in certain ciliopathies and degenerative cystogenesis and fibrosis as it 
occurs in NPHP, and (iii) the mechanism of convergent extension, which may be central to 
renal and hepatic tubular morphology, was shown to be disturbed in many ciliopathies with a 
renal cystic phenotype [Ross et al., 2005]. 
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Thus, when all the above evidence is considered the possibility of CBC dysfunction, as a 
pathogenetic mechanism in BA cannot be dismissed.  The interaction of multiple 
developmental pathways shown to be important in hepatic development and tubulogenesis, 
two of which are clearly linked to primary cilia mechanosensation, provides evidence of a 
relationship between hepatic development and tubulomorphogenesis, PCP, and the CBC 
complex. 
 
1.5 AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE AND PKHD1 
Despite the evidence presented here so far, it is still unclear how mutations in a cystoprotein 
could contribute to the syndromic BA phenotype.  To clarify this link the notable features of 
syndromic BA must be considered in relation to the other ciliopathies.  Like many of the 
other cholangiopathies BA displays an assortment of associated abnormalities that have been 
proven to be caused by mutations in cystoproteins, and abnormalities in PCP and the CBC 
complex.  These features include the occasional association of renal cysts in patients with BA 
(unpublished observation) [Franchi-Abella et al., 2007], anomalies of situs determination, and 
evidence of DPM in a number of infants with BA [Strazzabosco et al., 2005].  The compelling 
overlap of the clinical features of syndromic BA with the ciliopathies suggests a common 
aetiology. 
 
Of the many disorders classified as both cholangiopathy and ciliopathy, fewer also display 
DPM; these include ADPKD, ARPKD, Caroli’s disease, and CHF [J. R. Davenport and 
Yoder, 2005; Strazzabosco et al., 2005].  However, of these four ARPKD stands out in 
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relation to BA for several specific reasons.  Autosomal recessive polycystic kidney disease is 
one of the most important paediatric nephropathies associated with significant neonatal 
mortality and childhood morbidity [Guay-Woodford, 1996; MacRae Dell and Avner, 2001; 
Zerres et al., 1998b].  Estimates of the disease prevalence vary widely, with a proposed 
incidence of 1:20,000 to 1:40,000 [Guay-Woodford, 1996; Guay-Woodford and Desmond, 
2003; Zerres et al., 1998b]. 
 
The renal cystic disease typically begins in utero and manifests as fusiform dilatation of the 
collecting ducts (CDs) that radiate from the medulla to the cortex [Blyth and Ockenden, 
1971].  During foetal development, cysts also appear transiently in proximal tubules (PTs) 
[Nakanishi et al., 2000].  This results in a typical neonatal presentation of bilaterally enlarged, 
echogenic kidneys [Harris and Rossetti, 2004].  However, the clinical spectrum is highly 
variable, ARPKD can present as perinatal, neonatal, infantile, or juvenile – onset disease 
[Blyth and Ockenden, 1971].  This variability in the age of onset is due to variable expression 
of mutations within the same gene, as well as the effects of modifier genes and environmental 
factors, rather than mutations of different genes [Guay-Woodford et al., 1995; Kaplan et al., 
1988].  ARPKD is also characterised by liver disease, which is detectable in approximately 
45% of infants and is often a major feature in older patients [Onuchic et al., 2002; Roy et al., 
1997].  The liver disease in ARPKD is primarily manifest by two major types of 
pathophysiology; biliary disease and portal hypertension, due to biliary dysgenesis and portal 
tract fibrosis [D'Agata et al., 1994; Shneider and Magid, 2005].  The hepatic histopathology 
of ARPKD is characterised by DPM [Desmet, 1992a], portal spaces enlarged by portal 
fibrosis, and proliferation of biliary ducts, which can become dilated.  Abnormal multiple bile 
   80 
ductules can lose connection with the biliary system and dilate to form large cysts [Sherlock 
and Dooley, 1997].  When larger biliary ducts are also dilated, the disorder is called Caroli’s 
disease [Menezes and Onuchic, 2006].  In some cases, cholestasis leads to a gradual 
replacement of the immature ducts by fibrosis, resulting in a condition known as hepatic 
fibrosis.  Thus, patients with ARPKD tend to present with CHF and Caroli’s disease, known 
as Caroli’s syndrome [C. A. Johnson et al., 2003]. 
 
There is a remarkable parallelism in the type and evolution of both the renal and hepatic 
lesions of ARPKD, illustrated in table 1.4.  The renal lesion consists of a fusiform dilatation of 
the CDs and the hepatic lesions of DPM of the interlobular bile ducts.  Atrophy of tubules 
and ducts occurs in BA.  It appears that the early lesions of ARPKD, in the kidneys and in the 
liver can be conceived as a malformation, i.e. a disturbance in normal development.  Both 
fusiform ecstasia of the CDs in the kidney and DPM in the liver seem to result from a faulty 
epithelial-mesenchymal inductive interaction [Desmet, 1992b].  In ARPKD, both tubular 
systems seem to be subject to a slowly progressive, destructive process of epithelial involution, 
resulting in the disappearance of increasing numbers of patent tubules (both renal and 
hepatic) and associated with increasing amounts of interstitial fibrosis.  Thus, the 
morphological similarities of the destructive cholangiopathy caused by CHF in ARPKD and 
the basic disease process of BA may suggest shared aetiology and pathogenesis [Desmet, 
1992b]. 
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TABLE 1.4 Autosomal recessive polycystic kidney disease 
 Hepatic lesions Renal lesions 
Early stage Ductal plate malformation of 
interlobular ducts (‘cystic’ form of 
cholangiodysplastic pseudo-
cirrhosis) 
 
 Fusiform dilation of 
collecting ducts (+ tubules) 
(Neonatal form of 
ARPKD) 
 
Progression ‘Destructive cholangiopathy’ 
 
 
 
(Rapid variant: 
‘early severe 
EHBDA’) 
Destructive tubulopathy 
(Rapid variant: 
‘nephronophthisis’) 
Later stage CHF (non-cystic form of 
cholangiodysplastic pseudo-
cirrhosis) 
 
 
 
Biliary cirrhosis 
+ liver fibrosis 
Renal cysts, tubular 
atrophy, interstitial fibrosis 
(later infantile and juvenile 
form of ARPKD) 
Renal failure 
CHF = congenital hepatic fibrosis; EHBDA = extrahepatic bile duct atresia; ARPKD = autosomal recessive polycystic 
kidney disease 
Taken from [Desmet, 1992b] 
 
All typical forms of ARPKD are caused by mutations in a single gene PKHD1 (polycystic 
kidney and hepatic disease 1) [Menezes and Onuchic, 2006].  PKHD1 was cloned and 
sequenced in 2002 independently by three different groups.  Identification of PKHD1 as the 
gene defective in ARPKD was dependent upon the analysis of patients with ARPKD and a 
relevant rat model of the disease, the pck rat [Onuchic et al., 2002; Ward et al., 2002; Xiong et 
al., 2002].  While Xiong et al. [2002] also identified and mapped the mouse orthologue 
(Pkhd1) on mouse chromosome 1.  Taken together, the work of these three groups provided 
evidence that the gene responsible for ARPKD had been identified. 
 
PKHD1 is a very large and complex gene consisting of at least 86 exons extending over 
approximately 472kb of genomic DNA [Onuchic et al., 2002; Ward et al., 2002].  The gene 
undergoes a complex pattern of alternative splicing to generate a large number of mRNA 
transcripts ranging in size from 8.5kb to 13kb [Igarashi and Somlo, 2003; Onuchic et al., 
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2002].  These predicted translation products are novel proteins that share homology to a 
superfamily of proteins involved in the regulation of cell proliferation, and cellular adhesion 
and repulsion.  The longest transcript in humans is 16,235bp encoded by 67 exons, spanning a 
genomic region of approximately 472kb [Ward et al., 2002].  The open reading frame starting 
within exon 2 is 12,222bp, and is predicted to encode a protein of 4,074 amino acids 
[Onuchic et al., 2002; Ward et al., 2002; Xiong et al., 2002].  The encoded protein, designated 
fibrocystin/polyductin, is a large protein with a calculated unglycosylated molecular mass of 
447kDa.  Fibrocystin is predicted to be a highly glycosylated, novel single transmembrane 
protein with a 192 amino acid intracellular carboxyl-terminus, and a very large extracellular 
amino-terminus, with a total molecular mass greater than 500kDa (Fig. 1.18) [Kaimori et al., 
2007; Ward et al., 2002]. 
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FIGURE 1.18 Model of fibrocystin.  Structure of the fibrocystin protein showing conserved 
domains and regions of homology with other proteins.  Taken from [Ward et al., 2002] 
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Although the overall predicted structure of the protein is new, it contains significant 
homologies to several other proteins, which may provide a clue to its function.  The 
extracellular domain contains 6-8 of the recognised TIG/IPT domains (Fig. 1.18), 
immunoglobulin like folds that have been identified in cell surface receptors, such as the HGF 
receptor and plexins, as well as in the Rel family of transcription factors [Igarashi and Somlo, 
2003; Ward et al., 2002].  Between the TIG/IPT domains and the transmembrane domain, 
there are between nine and ten PbH1 repeats, found in polysaccharidases and are essential for 
enzyme function forming both the ligand-binding and catalytic sites necessary for degradation 
of cell-wall polysaccharides [Onuchic et al., 2002].  The predicted external region is also 
predicted to contain a single arginine-glycine-aspartate (RGD) domain.  This motif is found 
in fibronectin and numerous other proteins, where it has been shown to play a role in cell 
adhesion.  Three putative cAMP/cGMP-dependent protein kinase phosphorylation sites have 
been identified within the cytoplasmic carboxyl terminus [Onuchic et al., 2002].  In addition, 
there are potential phosphorylation sites for Protein kinase A (PKA), and protein kinase C 
(PKC) in the C-terminal tail that are conserved in mouse [Ward et al., 2002].  Significant 
homologies are present for two expressed sequences TMEM2, and PKHD1L.  However, the 
sequence homology to TMEM2 or PKHD1L also provides little insight into structure or the 
biological role of fibrocystin, as the role of these proteins is also unknown [Hogan et al., 
2003].   
 
Analysis of the N-terminal region of fibrocystin showed the presence of a hydrophobic signal 
peptide [Ward et al., 2002].  The C-terminal cytoplasmic domain has also been found to 
harbour a nuclear localisation signal (NLS) [Hiesberger et al., 2006].  However, despite the 
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identification of these multiple domains shared by a multitude of protein families the 
function of fibrocystin remains elusive.  While containing domains from many full and part 
characterised protein super-families, fibrocystin also lacks key structural elements of these 
protein classes, suggesting that its mechanism of action will differ from that observed in the 
other classes. 
 
It is notable that mouse fibrocystin presents the same general domain structure as the human 
product.  In fact, these proteins share 73% identity over their complete length, though there 
are segments with considerably higher (87%) and lower (40%) identity values [Nagasawa et 
al., 2002], this level of evolutionary conservation suggests fibrocystin to be of functional 
importance. 
 
As previously mentioned, the PKHD1 gene encodes a complex and extensive array of splice 
variants [Onuchic et al., 2002].  Although it is presently unknown how many of the 
transcripts are actually translated into protein, the complicated pattern of splicing has been 
shown to be conserved in the mouse orthologue, indicating a functional role for this property 
[Nagasawa et al., 2002].  In the event that various mRNAs are translated, it could mean that 
this single gene might encode numerous distinct polypeptides differing in size and amino acid 
sequence, that are predicted to fall into two broad categories [Bergmann et al., 2004; Onuchic 
et al., 2002].  One group, which includes the longest continuous open reading frame (ORF), 
but which may also include molecules lacking some middle domains, has a single 
transmembrane (TM) element and are likely to be associated with the plasma membrane.  
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The other group lacks the TM domain and, thus, its members may be secreted [Bergmann et 
al., 2004]. 
 
When taken all together, the structural features of the deduced protein and the human 
ARPKD phenotype, fibrocystin might be involved in cellular adhesion, repulsion, and 
proliferation.  In addition, the domain and structural analyses suggest that the potential 
PKHD1 products may be involved in intercellular signalling and function as receptors, 
ligands, and/or membrane-associated enzymes [Bergmann et al., 2004]. 
 
1.5.1 Expression features of PKHD1 
The tissue expression profile of PKHD1 by northern blot analyses suggests that the gene is 
predominantly expressed in the kidney, consistent with the observed phenotype in ARPKD.  
Strong staining is observed in human adult kidney, with moderate expression in foetal kidney 
[Menezes et al., 2004; Ward et al., 2002].  Much lower transcript expression is detected in 
whole adult and foetal liver [Onuchic et al., 2002].  The human foetal expression pattern of 
PKHD1 is consistent with both the observation that renal and hepatic abnormalities develop 
in utero and the hypothesis that disease pathogenesis involves a defect in terminal epithelial 
differentiation [Calvet, 1993].  Continued expression of PKHD1 in adult human tissue 
suggests an additional undefined role for fibrocystin in mature, terminally differentiated 
organs [Onuchic et al., 2002].  PKHD1 expression slightly greater than that observed in the 
liver is also reported in the pancreas, although in this organ it may be an underappreciated 
manifestation [Lu et al., 1997; Wu et al., 1998].  Additionally, loss of protein expression in 
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the kidney and liver samples taken from ARPKD patients has also been shown [Ward et al., 
2003]. 
 
Several studies to determine the localisation of fibrocystin at the subcellular level have shown 
fibrocystin to be expressed in the primary cilia and basal body in renal epithelial cells and 
cholangiocytes [Menezes et al., 2004; Wang et al., 2004].  Providing further evidence to 
support the cystoprotein hypothesis of defects in tubulomorphogenesis.  Fibrocystin has also 
been shown to localise to the apical membrane and cytoplasm of epithelial cells lining the CDs 
in human tissue stained for the protein [Ward et al., 2003].  Cytoplasmic staining is also 
reported in inner medullary collecting duct (IMCD) and MDCK cell lines grown in culture 
[Menezes et al., 2004; Ward et al., 2003].  This may reflect protein that is being processed for 
ciliary and/or plasma membrane localisation, or recycling from the surface of the cell, as is the 
case for the ADPKD associated protein PC-1 [Ward et al., 2003].  However, this also raises 
the possibility of multiple functional roles for fibrocystin, and thus by extension, the 
generation of pathologies differing to ARPKD involving disruptions in other subcellular 
domains. 
 
1.5.2 Functional insights 
Although the exact function of fibrocystin remains elusive, efforts remain ongoing to uncover 
its role in health and disease pathogenesis.  Studies have uncovered a number of interesting 
observations, all providing clues to the exact function(s) of this protein.  Multiple studies do 
confirm a ciliary role for fibrocystin.  The simple fact that the protein structure is conserved in 
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Chlamydomonas but not in nonciliated organisms such as Saccharomyces and Arabidopsis is 
consistent with a ciliary function [Pazour, 2004].  This was further confirmed when Masyuk 
et al [2003], were able to show the cholangiocyte cilia of the pck rat were abnormal with 
bulbous extensions and diminished length, and were devoid of fibrocystin.  They further 
supported this finding by silencing Pkhd1 in cholangiocytes of normal isolated IBDUs, this 
resulted in significant shortening of cilia, and reduced fibrocystin ciliary expression to an 
undetectable level.  This is yet further supported by the work of Mai et al [2005], who were 
able to show that stable knockdown of Pkhd1 in IMCD cells in culture resulted in aberrant 
ciliogenesis, suggesting that fibrocystin plays a role in this event.  However, the mechanism by 
which this occurs is not clear.  Fibrocystin is not a known subunit of the IFT particle.  
Interestingly, an ARPKD mouse model with an exon 40 deletion of Pkhd1 which causes 
distinct liver cysts, does not show any ciliary abnormality in cholangiocytes, suggesting that a 
lack of fully functional fibrocystin may not affect normal ciliogenesis in vivo [Moser et al., 
2005]. 
 
Indeed, extra-ciliary roles for fibrocystin have also been suggested.  In the same study where 
Mai et al [2005] demonstrated silencing of Pkhd1 results in aberrant ciliogenesis, they also 
discovered that the down-regulation of Pkhd1 also resulted in: (i) inhibition of 
tubulomorphogenesis; (ii) impairment of cell-cell interactions and inducement of 
spontaneous cell scattering; (iii) disorganisation of the actin cytoskeleton and induction of 
endothelial-mesenchymal transformation (EMT); (iv) reduction of integrin-dependent 
adhesion; (v) increased apoptosis and decreased cell proliferation; and (vi) decreased 
extracellular signal-regulated kinase (ERK) and focal adhesion kinase (FAK) activation [Mai 
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et al., 2005].  Implicating fibrocystin in a complex network of cellular polarity, cell-cell/matrix 
contact, cell cycle control, and ciliary/cytoskeleton assembly, all of which is vital for normal 
tubule formation. 
 
Studies are now beginning to uncover features of the protein fibrocystin that may explain the 
diversity of cellular alterations observed by Mai et al [2005].  In order to better understand the 
function of fibrocystin, Nagano et al [2005] utilised the yeast two-hybrid system to identify 
proteins that interact with the intracellular C-terminus of fibrocystin.  From the screening 
they identified calcium modulating cyclophilin ligand (CAML), a protein involved in calcium 
signalling by regulating cytosolic calcium pools with an intracellular distribution that is 
similar to that of PC-2 [Feng et al., 2002; Tovey et al., 2000].  The study was able to show that 
these two proteins co-localise in cilia, the basal body, and the plasma membrane in cells from 
the distal nephron, bile ducts, and pancreatic ducts, and that expression constructs of the two 
proteins co-immunoprecipitate from mammalian cells.  Thus supporting the possibility that 
fibrocystin may participate in calcium signalling like PC-1 and PC-2 [Nagano et al., 2005].  
Further evidence for a role in calcium signalling came from studies by Hiesberger et al [2006].  
In their study Hiesberger and colleagues were able to show that fibrocystin undergoes a 
calcium-dependent proteolysis, similar to that of PC-1.  While they found fibrocystin 
undergoes several proteolytic cleavages within the predicted ectodomain, at least one was 
found to occur within the cytoplasmic portion.  This cleavage generates a C-terminal 
intracellular fragment that was found to harbour a NLS and translocates to the nucleus 
[Hiesberger et al., 2006].  It was also determined that this cleavage event is regulated by 
activation of PKC and release of intracellular calcium, in what they suggest is a cilia-
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dependent event, much like that of PC-1.  Similar to other proteins that are subjected to 
regulated proteolysis, only a small fraction of fibrocystin was found to be cleaved.  In 
particular, the pattern of proteolytic cleavage observed (close proximity to the transmembrane 
fragment) resembles regulated intramembrane proteolysis (RIP) of other type 1 membrane 
proteins.  Nuclear signalling of cytoplasmic fragments generated by RIP is most extensively 
described for Notch, the pathway involved in PCP and bile duct development, as previously 
discussed [Flynn et al., 2004; Kodama et al., 2004; Landman and Kim, 2004; Lorent et al., 
2004]. 
 
Evidence to further support the importance of calcium in the function of fibrocystin is the 
observation that fibrocystin can be found in the same complex as the calcium channel PC-2, 
suggesting these two proteins may function in a common molecular pathway [Kim et al., 
2008; Wang et al., 2007].  Kim et al [2008] found that the C-terminus of fibrocystin and the 
N-terminus of PC-2 interact, and that a lack of fibrocystin reduced PC-2 expression, but not 
vice versa, suggesting that PC-2 may function immediately downstream of fibrocystin in vivo.  
PC-2 channel activities were also found to be dysregulated in cultured renal epithelial cells 
derived from Pkhd1 mutant mice.  Furthermore, Wang et al [2007] determined that the 
extracellular domains of fibrocystin may be responsible for the flow induced cellular calcium 
response.  Thus, the work of these groups suggests that both cystoproteins function, at least in 
some part, in a common mechanotransduction pathway. 
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Hogan et al [2009] proposed that fibrocystin acts as a bi-directional signalling molecule with 
the ectodomain acting as a ‘urocrine’ and perhaps ‘bilocrine’ signalling molecule fostering 
communication along the length of the nephron/biliary tree [Hogan et al., 2009; Kaimori et 
al., 2007].  Hogan et al observed an accumulation of PC-1 positive exosome-like vesicles 
around renal cilia in Pkhd1 knockdown mice and ARPKD patients [Hogan et al., 2009].  
Upon further examination, they were able to determine these vesicles resembled the exosomes 
thought to be the end product of the MVB-sorting pathway.  The MVB-sorting pathway 
involves the unique packaging of membrane proteins into intraluminal vesicles within multi-
vesicular bodies, some of which are secreted as exosomes when MVBs fuse with the apical 
plasma membrane.  The unique way in which these vesicles are formed results in the 
ectodomain of the packaged proteins to be facing outwards into the lumen upon release.  
MVBs and exosomes have been shown to have a role in left/right axis determination in the 
embryonic node.  The observation of PC-1 rich exosome-like vesicles and of abnormal 
exosome-like vesicle (ELV) accumulation in fibrocystin-deficient mice led the group to 
examine whether these vesicles have a functional role in the urinary and biliary systems 
analogous to NVPs in the node, and if fibrocystin plays a role in their interactions with the 
primary ciliary axoneme.  Using a plethora of techniques they were able to produce results 
suggesting that urinary ELVs interact with the primary cilia in vivo, analogous to the 
‘smashing’ events described by Tanaka et al [2005].  From these results and observations they 
postulated that because fibrocystin contains multiple domains similar to those involved in 
host invasion (PA14 and PBH domains [de Groot and Klis, 2008; Onuchic et al., 2002; 
Rigden et al., 2004]), it is possible that this molecule behaves as an invasin and the 
accumulation of ELVs on the ciliary axoneme in fibrocystin (Pkhd1) deficient mice may 
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represent a failure of the invasion process, with fibrocystin itself not being responsible for the 
initial adhesion event [Hogan et al., 2009]. 
 
Not only do all the mentioned studies and observations unify the apparently disparate and 
transitory localisations of fibrocystin and its cleaved products, they also raise the possibility of 
fibrocystin being a highly complex bi-directional signalling molecule, fostering 
communication along the length of the biliary tree that is vital to its development.  It is for 
these reasons fibrocystin and its encoding gene PKHD1 are candidates in the pathogenesis of 
the complex disorder BA, especially as a definite function remains elusive. 
 
1.6 UNRAVELLING THE PATHOGENESIS OF BILIARY ATRESIA: INSIGHTS 
PROVIDED BY ANIMAL MODELS 
 
There is no ideal animal model of BA, and this has slowed understanding of its pathogenesis.  
During the past forty years, several groups have tried to create an animal model of EHBA, but 
failed to simulate the real pattern of liver damage [Bangaru et al., 1980; Papadimitriou, 1968; 
P. A. Phillips et al., 1969; Schmeling et al., 1991; G. A. Wilson et al., 1994].  Basic research in 
animal models of EHBA has often showed fibrosing inflammation of the bile ducts, but 
without complete and definitive atresia [Bangaru et al., 1980; Parashar et al., 1992].  This 
could only be obtained by direct manipulation either by injection of chemically defined 
substances into the gall bladder [Schmeling et al., 1991], or by operative intervention [Spitz, 
1980].  In this way, the expected consequences of mechanically caused cholestasis were seen, 
but without simulating the clinical entity of BA [Petersen et al., 1997a].  In 1993, Riepenhoff-
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Talty et al [1993] observed a temporary biliary obstruction after rota virus inoculation in 
newborn mice, similar to BA.  This was the initial step in the development of the first animal 
model for BA.  Consecutive studies confirmed these observations, and focused on the 
immunological aspect [Petersen et al., 1997b]. 
 
In brief, the intraperitoneal inoculation of newborn Balb/c mice in the first 24 hours of life 
with rhesus rotavirus (RRV) group A leads to a generalised jaundice, acholic stools, and 
bilirubinemia by the end of the first week of life.  Progressive inflammation and obstruction of 
the EHBD is observed by two weeks of age, resembling human BA [Czech-Schmidt et al., 
2001; Riepenhoff-Talty et al., 1993].  The histological appearance of the liver and biliary tree 
in late stages of biliary obstruction shows similarity with the histological features of BA, 
although no definitive atresia of the common bile duct is described in this model [Petersen et 
al., 1997a].  Analysis of the EHBDs before and after onset of jaundice shows inflammation 
and oedema of the duct wall, progression to sloughing of the biliary epithelium, closure of the 
duct lumen by inflammatory cells and other cellular debris, and finally concentric fibrosis of 
the EHBDs.  These processes result in a segmental or continuous obstruction of the 
extrahepatic lumen [Bezerra, 2006].  The intrahepatic changes are as those described in the 
EHBDs, including reactive necrosis and proliferation of the small bile ducts [Petersen et al., 
1997a]. 
This infectious model does comply with two conditions to qualify it as a model for BA.  
Firstly, the changes in the EHBDs develop progressively without direct manipulation, and the 
atresia is irreversible.  Secondly, all described observations occur in an infection model, and 
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varying changes can be observed in different mice simultaneously [Petersen et al., 1997a].  
However, despite all these findings, the evidence in humans remains inconclusive [Petersen et 
al., 1997a; Petersen et al., 1997b; Riepenhoff-Talty et al., 1993].  The similarity between the 
immune response seen in human BA and the rota virus-simulated animal model, does 
however demonstrate the potential for use of this model as a powerful tool to hopefully 
further elucidate the pathogenesis of BA [Bassett and Murray, 2008]. 
A transgenic mouse strain currently under investigation as a possible experimental model for 
BA is the inv mouse, created by insertional mutagenesis.  Yokoyama et al [1993] first reported 
the inv transgenic mouse in 1993, when they described situs inversus and severe jaundice in 
homozygous mutants, carrying  partial deletion of the inversin gene.  Anomalies included 
mirror-image left-right inversions of stomach, spleen, and liver.  Some had asplenia, 
preduodenal portal vein, intestinal malrotation, and dextrocardia in various combinations 
[Shimadera et al., 2007].  Inv mice became progressively jaundiced soon after birth, had cystic 
changes in their kidneys, grew poorly, and rarely lived beyond one week of age [Yokoyama et 
al., 1993].  Detailed morphological studies of the hepatobiliary system in the inv/inv mouse to 
determine the aetiology of the jaundice identified a defect in the patency of the extrahepatic 
ductular system.  The results from several groups show that these mice have cholestasis with 
conjugated hyperbilirubinemia, failure to excrete technetium-labelled mebrofenin from the 
liver into the small intestine, lack of continuity between the extrahepatic biliary tree and the 
small intestine as demonstrated by Trypan blue cholangiography, and a liver histologic picture 
indicative of extrahepatic biliary obstruction with the presence of microscopic EHBD 
remnants [Perlmutter and Shepherd, 2002; Shimadera et al., 2007]. 
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One of the most interesting characteristics of the inv mouse is the histology of the liver (Fig. 
1.19).  There is very little, if any, hepatocellular injury, inflammation, or necrosis within the 
hepatic parenchyma or portal tracts, but a marked abnormality in the IHBDs and ductules.  
Instead, persistence of the biliary plate is associated with marked BEC proliferation as defined 
by a marked increase in lectin-positive epithelial cells surrounding the portal vein and/or 
portal mesenchyme, corresponding to an arrest on ductal plate maturation (Fig 1.19) 
[Perlmutter and Shepherd, 2002].  With respect to the EHBDs the histology appears to vary 
widely between studies.  A marked lack of evidence of ischemia or inflammation is consistent 
between independent studies in the inv mouse, however other observations differ 
significantly.  While some groups describe a fully patent common bile duct and normal 
extrahepatic duct anatomy, others show distant anatomic variations in the extrahepatic biliary 
system such as anatomic and cystic changes [Mazziotti et al., 1999; Shimadera et al., 2007].  
Thus, a number of characteristics of the inv mouse are identical to those of human infants 
with BA and situs inversus.  There is a similar spectrum of situs anomalies. There is conjugated 
hyperbilirubinemia and progressive cholestasis.  There is marked IHBD proliferation in the 
ductal plate region identical to the DPM that has been described in infants with the prenatal 
form of BA [Desmet, 1992a].  Furthermore, there is functional obstruction to bile flow as 
demonstrated by biliary scintographic and Trypan blue cholangiographic analyses [Mazziotti 
et al., 1999].  However, the feasibility of using the inv transgenic mouse as an experimental 
model to elucidate the pathophysiology of BA is still questionable. 
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FIGURE 1.19 Sections of inv mouse liver tissue stained with DBA histochemistry.  This 
method results in a brown reaction product exclusively in biliary epithelial cells.  The stained 
sections show intense proliferation of biliary epithelial cells around (A) portal vein radicles, 
and (B) portal vein mesenchyme, but no lumina are formed and thus there are no ducts or 
ductules.  There is no evidence of hepatocellular injury or inflammation.  DBA = Dolicus 
biflorus agglutinin.  Taken from [Perlmutter and Shepherd, 2002]. 
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The use of other animal models displaying biliary abnormalities similar to those characteristic 
to BA may still provide clues to its pathogenesis.  Such animal models include the pck rat 
[Lager et al., 2001; T. V. Masyuk et al., 2004a], the cpk mouse [Hou et al., 2002], the HNF-6-
KO mouse [Clotman et al., 2003], the HNF-1β-KO mouse, the Pkhd1ex40 mouse [Moser et 
al., 2005], and the Pkhd1del2/del2 mouse [Woollard et al., 2007].  Despite the diversity between 
these models, they are all able to aid in understanding the genetic modulation of bile duct 
pathology. 
 
The Pkhd1ex40 mouse developed by Moser et al [2005] represents a model of cystic biliary 
dysgenesis in ARPKD.  Generated by targeted mutation of Pkhd1, exon-skipping results in 
expression of a modified Pkhd1 transcript, resulting in severe malformations of the IHBDs.  
Detailed histological study of the liver of these mice revealed that they display a severe 
malformation of the ductal plate with mild duct ecstasia.  Deterioration in the condition of 
Pkhd1ex40 mice occurs soon after birth with progressive bile duct proliferation, and ecstasia 
accompanied by fibrosis of the portal tracts.  Further detailed examination of the 
cholangiocellular ultrastructure revealed that cholangiocytes retained their normal 
appearance, with no ciliary abnormalities.  Interestingly, in contrast to human ARPKD 
individuals, Pkhd1ex40 mice develop morphologically and functionally normal kidneys.  
Thus, the Pkhd1ex40 mutation mouse highlights the complexity of the role fibrocystin and 
primary cilia play on biliary tubulomorphogenesis, proving to be a valuable source of 
information to investigate biliary pathogenesis.  Finally, the Del2 mouse developed by 
Woollard et al [2007] as a model of ARPKD with biliary duct and PT dilatation, presents yet 
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another valuable resource in understanding the role of fibrocystin in the development of the 
renal and biliary tubular system.   
 
1.6.1 THE PKHD1DEL2/DEL2 ARPKD MOUSE MODEL 
Due to the generosity of our collaborators Dr. Peter Harris, and Dr Christopher Ward at the 
Mayo Clinic (MN, USA), the model studied in this project is the Pkhd1del2/del2 (Del2) mouse, 
developed by the Harris group to study the disorder ARPKD. 
 
The Del2 mouse was produced by targeted deletion of the murine Pkhd1 gene using a LoxP 
flanked phosphoglycerate kinase (PGK) neomycin cassette system [Wagner et al., 2001] (Fig. 
1.20).  By targeting the first coding exon of Pkhd1, exon 2 which contains the start 
methionine and the signal peptide of fibrocystin, the resulting homozygous Del2 mice were 
viable, fertile, and exhibited hepatic, pancreatic, and renal abnormalities. 
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FIGURE 1.20  A schematic diagram of the knockout construct used to produce the 
Pkhd1del2/del2 mouse model of ARPKD.  (a) The neomycin cassette was positioned in an 
orientation opposite to the Pkhd1 promoter, replacing exon2.  Exon 2 contains the start 
methionine and the signal peptide.  Two LoxP sites flank the neomycin cassette so that it can 
be removed by the expression of Cre recombinase.  (b) Southern blot analysis shows the 
expected DNA fragments using the 5’ and 3’ probes.  The left panel shows genomic DNA cut 
with Spe-1 with bands of the expected size 9 and 17 Kb; the middle panel shows genomic 
DNA cut with Hind1II with bands of 17 and 13.6 Kb.  The right hand panel is a 1.5% agarose 
gel with PCR products derived from primers F1 and R1/R2.  The wt is 1028bp, the LoxP 
deleted allele is 900bp and the neomycin allele is 794bp.  (c) Reverse transcription-PCR data 
confirming that exon 2 is skipped in both kidney and liver of homozygous mice.  Taken with 
permission from [Woollard et al., 2007]. 
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1.6.1.1 Hepatic phenotype of Pkhd1del2/del2mice 
Pkhd1del2/del2 mice develop fibrocystic disease of the liver.  Upon gross inspection, livers are 
massively enlarged occupying much of the abdominal cavity and are macroscopically cystic 
(Fig. 1.21a).  The biliary disease starts at one month of age with the development of tortuous 
bile ducts and enlargement of the portal triads.  This progresses with age, at three months (Fig. 
1.21c) and nine months (Fig. 1.21e), but portal fibrosis and cystogenesis become more 
prominent so that by twelve to fifteen months the liver is very cystic and fibrotic (Fig. 1.21f-
g).  At early stages, bile duct proliferation is evident in the portal areas with primitive tortuous 
bile ducts and reactive stroma (Fig. 1.21b-d). 
 
FIGURE 1.21  Gross appearance of Pkhd1del2/del2 liver from Mallory trichrome stained 
sections.  (a) Gross appearance of 11 months outbred Pkhd1del2/del2 liver.  (b-g)  Sections 
stained with Mallory trichrome, (b) 1, (c) 3, (d) 6, (e) 9, (f) 12, (g) 15 months.  The livers 
become more cystic and fibrotic with age.  Original magnification of (b-g) is x10.  Taken with 
permission from [Woollard et al., 2007]. 
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1.6.1.2 Renal phenotype of Pkhd1del2/del2 mice 
The kidneys of Del2 mice appear normal until approximately nine months of age, when 
outbred females begin to develop cystic dilatation of the PTs (Fig. 1.22d-f).  Outbred male 
kidneys remain unaffected up to eighteen months of age (Fig. 1.22a-c).   Interestingly, female 
outbred animals exhibit an increase in PT diameter between nine and twelve months in both 
the wt and Del2 animals.  Woollard et al [2007] also reported that the increase in wt PT 
diameter is small yet significant, whereas the increase in the Del2 PT is much greater.  Inbred 
females display PT dilatation from three months of age on both BALBc/J and C57BL/6J 
backgrounds. 
 
FIGURE 1.22  Phkd1del2/del2 kidney sections stained with H&E.  Kidneys from Pkhd1del2/del2 male mice 
at ages (a) 9, (b) 12, and (c) 15 months, respectively (original magnification x4).  (d, e, and f) Kidneys 
from Pkhd1del2/del2 female mice at ages (d) 9, (e) 12, and (f) 15 months, respectively (original 
magnification x4).  (g, h, and i) are high power views of the same female kidneys (original 
magnification x10).  (j, k and l) Low-power views of wildtype female kidneys at (j) 9, (k) 12, and (l) 15 
months, respectively (original magnification x4).  Taken with permission from [Woollard et al., 2007]. 
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1.6.1.3 Ciliary phenotype of Pkhd1del2/del2 mice 
There are conflicting reports about the ciliary morphology in animal models of ARPKD [T. 
V. Masyuk et al., 2003; Moser et al., 2005].  Using scanning electron microscopy (SEM) and 
fluorescent histochemistry, Woollard et al [2007] were able to show that the primary cilia in 
the affected biliary tree of Del2 mice were significantly shorter versus wt cilia length (Fig. 
1.23).  Cilia were found to be misshapen, and surrounded by multiple small vesicular 
structures (Fig. 1.23f).  In the kidneys of nine-month-old Del2 animals, vesicular structures 
were observed surrounding the primary cilia.  Most interestingly, cilia appeared as branched 
clumps.  In animals with advanced cystic disease, the cilia from cyst lining epithelial cells were 
found to be stunted and highly branched or ‘star-burst’ in form (Fig. 1.23 d and h). 
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FIGURE 1.23  Primary cilia in bile duct and proximal tubule by SEM and fluorescent 
histochemistry.  (a) A normal bile duct with normal cilia from a wt animal 3 months of age.  
(b) Three month biliary tree from a Pkhd1del2/del2 animal showing shorter and malformed cilia, 
see inset.  (c and d) In the PT, brush border is still visible in these early dilatations (9 month 
Pkhd1del2/del2 animals) but appear disorganised.  The cilia at this early stage are ‘starburst’ 
(arrows in c and d).  This implies gross cilial dysfunction in these animals.  Inset shows a 
branched primary cilium.  (e and f ) TEM of wt biliary cilia (e) and Pkhd2del2/del2 biliary cilia (f) 
note the small vesicular structures around the cilium.  (g and h)  Staining of PT cilia by anti-
acetylated α-tubulin (green) and nuclei by DAPI (blue) in the wt (g) and Pkhd1del2/del2 (h).  
Note the ‘starburst’, highly branched cilia in (h) (arrow).  (g-h, Original magnification x40).  
Taken with permission from [Woollard et al., 2007]. 
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In summary, the Del2 mouse model of ARPKD develops both cystic liver and pancreatic 
disease regardless of gender.  The PT dilatation in the kidney is seen in the female mouse 
relatively late in the animals’ life, nine months on an outbred background, and around three 
months in the inbred lines. 
 
An interesting aspect of this animal model is that the renal disease is restricted to the female 
whilst the male appears to be protected [Woollard et al., 2007].  The difference in renal 
disease between the sexes could be due to sexual dimorphism in the S3 segment of the PT, as is 
evident from the restricted PT dilatation in wt females as they age.  This difference in 
morphology is thought to be due to the differential effects of androgens, and more specifically 
could be driven by oestrogen. 
 
The effects of oestrogen on classical endocrine target organs, such as the female reproductive 
tract, mammary gland, ovary, and neuroendocrine system have been thoroughly studied.  
However, knowledge of the effects of oestrogen in non-classical endocrine organ systems such 
as cardiovascular, immune, gastrointestinal, renal, and hepatic, is now starting to become more 
appreciated [Korach and Wintermantel, 2007]. 
 
Knowledge of the renal cortex as an oestrogen-sensitive target organ is long-standing [De 
Vries et al., 1972; J. A. Johnson et al., 1970; Kochakian, 1947], as demonstrated by (i) the 
presence of a specific oestrogen receptor, (ii) the observed increase in oestrogen receptor levels 
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after prolonged oestrogen treatment, (iii) an increased progesterone receptor level following 
oestrogen treatment, and (iv) stimulated growth of proximal tubular cells in vitro [Han et al., 
1999; J. J. Li and Li, 1987; J. J. Li et al., 1974; Oberley et al., 1989]. 
 
Oestrogen receptors (ERs) are expressed in both hepatocytes and cholangiocytes, where 
oestrogen may play a role in the process of growth, regeneration, and proliferation in vitro and 
in vivo [Alvaro et al., 2002a; Alvaro et al., 2002b; Desmet et al., 1998].  After partial 
hepatotectomy, for example, ER expression in hepatocytes increases together with their 
translocation to the nucleus, where they induce DNA synthesis and allow restoration of 
normal liver mass [Blum and Cannon, 1998; Eagon et al., 1996].  The characteristic selective 
proliferation of residual bile ducts to compensate for the disappearance of bile ducts in 
response to damage typical of cholestatic liver disease has also been shown to be associated 
with a marked increase in the expression of ER, and enhanced estradiol serum levels [Alvaro et 
al., 2002a; Alvaro et al., 2002b; Desmet et al., 1998].  In fact, oestrogens have also been proven 
to reduce cholestasis induced cholangiocyte apoptosis [Svegliati-Baroni et al., 2006]. 
 
Oestrogens are also involved in liver growth in the neonate, and long-term administration for 
pharmacological purposes in adults induces enlargement of liver mass [Alvaro et al., 2000a; 
Eagon et al., 1985].  Several studies have addressed the relationship between ER expression, 
oestrogen metabolism, and biliary secretion, and the development and course of chronic liver 
diseases [Eagon et al., 1985].  Currently there is much evidence supporting the role of 
oestrogen in proliferative disorders such as neoplasias and cystogenesis.  Studies in ADPKD 
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patients have reported a female predominance in the risk of developing chronic hepatic 
involvement and cysts, with a reported female prevalence of 58% to 75%, compared to a 42% 
to 62% prevalence in males [Gabow et al., 1990]. 
 
However, the mechanistic involvement of oestrogen in the aetiology and pathogenesis of such 
disorders has only recently started to be investigated.  Chromosomal instability and 
centrosomal anomalies are observed in cystic cells from patients with ADPKD.  Studies by Li 
et al [2004] concluded that oestrogen is causally linked via the ER to overexpression of the 
centrosome kinase Aurora A and γ-tubulin, centrosomal amplification, chromosomal 
instability, and aneuploidy. 
 
To summarise, simulated models enable a greater understanding of the clinical aspects of the 
disease process, and provide insight into the immunological aspects of BA.  However, as these 
models are created by physical/viral manipulation they cannot provide clues towards a 
definitive genetic cause.  However, this does not mean something cannot be gained from the 
study of animal models displaying similar pathologies.  Any insight into the pathogenesis of 
various aspects of BA can only serve to draw research closer to determining the cause(s) of this 
complex disorder. 
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1.7 INTRODUCTION SUMMARY 
BA is an idiopathic disorder of infants in which there is localised progressive obliteration or 
discontinuity of the extrahepatic biliary system at any point between the porta hepatis and the 
duodenum, accompanied by a characteristic intrahepatic lesion.  Incidence figures vary widely, 
with an estimated worldwide incidence of 1 in 8,000 to 12,000 live births [Balistreri et al., 
1996].  At present, there is no specific therapy for BA; restoration of bile flow by HPE within 
the early stages of the disease can prove successful in up to 60% of cases.  However, it is not 
curative and 70-80% of children will still require a liver transplant despite undergoing HPE, 
making BA the main indication for paediatric liver transplantation. 
 
BA occurs in two clinical forms: a) the more common perinatal or non-syndromic type, and 
b) the foetal (embryonic) or syndromic type.  Non-syndromic presentations are characterised 
by late onset cholestasis and absence of congenital anomalies.  In contrast, the embryonic or 
foetal cases of BA are characterised by early onset cholestasis and are often associated with 
congenital anomalies. 
 
The cause of BA is not known at present, however several theories as to the underlying 
pathogenetic mechanisms are under investigation.  These include viral infection, 
immunologic dysregulation, autoimmune mechanisms, vascular lesion/arteriopathy, defective 
morphogenesis (inherited mutations, somatic mutations, modifier genes), and toxin exposure.  
Evidence of a polygenic multifactorial basis is supported by a number of early studies 
describing familial instances of BA [Cunningham and Sybert, 1988], sibships in which two or 
   108 
more siblings were affected [Krauss, 1964], and discordance for the non-syndromic form of 
BA in monozygotic twins [Hyams et al., 1985; Strickland et al., 1985]. 
 
A number of reports in the literature have described disorders that display clinical features 
that resemble BA, which are caused by mutations, or perturbations in the expression of certain 
genes encoding proteins which localise to primary cilia, basal bodies, and/or centrosomes, and 
have also been shown to be important in tubulomorphogenesis.  These notable features 
include renal cysts [Bassett and Murray, 2008], anomalies of situs determination [M. 
Davenport et al., 1993], and evidence of DPM [Low et al., 2001]; underlining a pathogenetic 
mechanism possibly linking left-right axis determination, renal and hepatic 
tubulomorphogenesis, and primary cilia function.  The disorders and diseases that display 
these features in various combinations are those belonging to two large groups, the 
cholangiopathies, and the ciliopathies.  Of the many syndromes and disorders falling within 
these two large groups a subset of disorders stand out.  The hepatorenal fibrocystic syndromes 
are a group of severe monogenic conditions that present in the neonatal and paediatric age, 
with consistent developmental abnormalities involving the liver and kidneys associated with 
other developmental anomalies.  Of the known hepatorenal fibrocystic syndromes, ARPKD 
stands out in relation to BA as it is characterised by significant hepatic involvement in all 
cases.  All cases of ARPKD are caused by mutations in the gene PKHD1, encoding the novel 
protein fibrocystin.   
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Fibrocystin, a large receptor-like protein is a component of primary cilia in kidney epithelial 
cells, and biliary and pancreatic duct epithelia.  Although the precise function of fibrocystin is 
unknown, studies have shown it to be important in ciliary function and epithelial 
tubulomorphogenesis in both the kidney and liver.  Thus, PKHD1 could be a key 
developmental gene that is expressed during the embryonic development of the biliary system.  
Loss of expression due to sporadic or germ-line mutations may lead to BA, either directly or 
via altered susceptibility. 
 
The evident lack of a suitable experimental animal model of BA has hindered understanding 
the pathogenesis of this complex disorder.  However, the existence of mouse models 
displaying phenotypes similar to those in patients with BA will aid understanding of the 
disease process and the molecular pathways involved. 
 
1.8 HYPOTHESIS 
Specific sequence variants and/or altered expression in a key gene of biliary development that 
encodes a protein that is a functional component of primary cilia may be associated with cyst 
development and cellular damage in human liver disease. 
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1.8.1 Project Aims 
The initial aim of this project is to investigate the phenotypic variability of PKHD1 associated 
disease in human and animal models.  Especially in relation to the cholangiopathy biliary 
atresia, which shares a number of phenotypic features with ARPKD.   
 
In order to meet this aim the key objectives of this project are as follows: 
1) Perform an initial mutational screening of PKHD1 in a small cohort of biliary atresia 
patients that develop renal cysts to determine if sequence variants in the PKHD1 gene are 
associated with the pathogenesis of biliary atresia.  The findings of the initial screen will 
help determine whether it is appropriate to extend the screening to a larger, more stratified 
cohort. 
2) Carry out a preliminary series of immunohistochemical and/or immunofluorescence 
studies in tissue samples from patients with early and end-stage liver disease to determine if 
expression of fibrocystin is altered. 
3) Establish an in vitro cell culture system using primary biliary epithelial cells, from a range of 
liver diseases, to determine if there are structural defects in the basal bodies or primary cilia 
of BEC that display altered fibrocystin expression. 
4) Investigate the mechanism driving, PKHD1 associated cyst development in the ARPKD 
mouse model Pkhd1del2/del2, and the phenotypic difference in disease severity and 
progression in male and female animals. 
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These objectives were set out to determine the following: 
1) If sequence variants of PKHD1 are associated with cases of biliary atresia and renal cysts. 
2) If altered expression of fibrocystin is a causative factor of human biliary disease, or a 
consequence of an altered cellular state. 
3) If the biliary epithelia of patients with early or late stage liver disease have structurally or 
functionally defective primary cilia. 
4) If a defect in the sensory function of BEC primary cilia can result in abnormal bile duct 
structure or function, culminating in their subsequent destruction. 
5) Characterise the variable phenotypic features of altered PKHD1 expression. 
6) If altered expression of PKHD1 can result in disorders that share select phenotypic features 
of ARPKD. 
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CHAPTER  2 EXPERIMENTAL APPROACHES 
 
In order to ensure the aims of this project were met, and the results obtained accurate and of 
value, several areas of the experimental work had to be optimised. 
 
2.1 IMMUNOHISTOCHEMISTRY 
One of the main requirements of an experimental approach to immunohistochemistry is to 
ensure any staining observed is specific to the protein under investigation, and is not non-
specific background.  The proteins under investigation in this project, acetylated α-tubulin 
and fibrocystin, are known to co-localise to the primary cilia.  Due to this overlap, it was 
decided to investigate the localisation and expression levels of these two proteins on separate 
tissue samples, as trying to determine the specific signal for each protein would introduce a 
greater margin for error if detection were attempted on a single sample. 
 
The specificity of the antibodies and the recognised epitopes are also of great importance.  
The experimental work, with regards to acetylated α-tubulin, is based on the use of one 
commercially available monoclonal antibody, clone 6-11B-1 (Sigma, UK; Cat #T6793), 
specific to acetylated α-tubulin.  The specificity of the antibody was determined by 
experiments binding antibodies to α-tubulin from various sources that were described by 
Piperno and Fuller [1985].  The antibody 6-11B-1 does not bind to acetylated lysine alone, 
but recognises an epitope present only in acetylated α-tubulin, making it a long-standing, well 
trusted antibody for specific detection of acetylated α-tubulin.   
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With regard to fibrocystin, a total of five monoclonal antibodies were generously provided by 
Dr Christopher Ward (Mayo Clinic, USA, MN).  Ward et al [2003] generated four 
monoclonal antibodies to the cytoplasmic tail of the protein (as published) and four to the 
extracellular N-terminus.  Using western analysis and immunohistochemical staining on a 
panel of normal human, mouse, and rat tissues, as well as tissue from ARPKD patients, this 
group confirmed specificity of the antibodies to fibrocystin.  Of those antibodies tested by the 
group, four directed against N-terminal epitopes, and one directed against a cytoplasmic 
epitope were gifted for use in this project. 
 
Appropriate tissue selection is also an important requirement for any immunohistochemical 
study.  The method of tissue preservation can have numerous effects on different types of 
epitope, whether they are extracellular, cytoplasmic, membrane-bound, cytoskeletal, 
hydrophobic, or hydrophilic etc.  Different fixatives used to preserve different specimen types 
can either conserve or destroy the antigenic epitope to which a monoclonal antibody is raised.  
Another important consideration for immunostaining is the type of section to use.  Sections 
available for use in this study included unfixed (frozen) sections, and formalin-fixed paraffin-
embedded (FFPE) sections.  The choice of section in the project was therefore determined by 
which type would provide optimal results and allow the desired analysis to be carried out. 
 
Taking all these factors into consideration, appropriate experimental conditions for each of 
the variables discussed above had to be determined. This included optimisation of the 
appropriate final working dilutions of the primary antibodies, to ensure they provided 
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optimal specificity and sensitivity. Assessment of the most suitable section type for both 
antigens was important; to ensure staining was acceptable for subsequent analysis.  Finally, the 
most suitable fixative, which is dependent upon the type of section, had to be determined.   
 
2.2 IN VITRO CELL CULTURE 
Studies trying to assess mechanisms of cellular pathophysiology often make use of cell culture 
systems to avoid the complexity of whole organ/animal experiments.  Primary cultures are 
generally preferred above studies on cell lines as the latter often lose important characteristics 
and/or acquire biochemical/functional properties due to clonal selection and 
dedifferentiation [Charlton and Simmons, 1993; Cho et al., 2001; Kastner et al., 1993].  
Thus, the first requirement of an experimental approach to primary cellular culture is an easy 
means of isolating the desired cell type whilst causing minimal stress to the cells, which may 
result in low yields or an altered state of differentiation. 
 
Although the isolation, and culture of primary human cholangiocytes in two-dimensional 
culture systems is well established at the BCLR [Afford et al., 2001; Auth et al., 2001].  The 
expression of primary cilia by BEC in culture had not been established prior to initiation of 
this project.  In order to examine protein isolation in primary cilia in single cells, a culture 
system in which primary BEC uniformly express primary cilia was an obvious requirement. 
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However, as fresh human tissue that will produce viable cells is a scarce resource, especially 
normal tissue, a suitable ciliated human cell line also had to be identified in which 
optimisations could be implemented.  Unfortunately a suitable human cholangiocyte cell line 
is not available commercially, and a suitable cell line that is from tubular epithelium needed to 
be identified and also optimised to ensure uniform ciliary expression.  The human embryonic 
kidney epithelial cell line, HEK293, was also investigated as a possible ciliated human tubular 
epithelial cell line. 
 
In contrast to the relative ease of isolating primary BEC from human liver, the isolation and 
culture of murine primary BEC is very difficult.  Whilst the ideal cells to study in terms of BA 
are BEC, this could not be fulfilled in this case.  The isolation and culture of primary human 
BEC has been a long established practise within the BCLR since first being described by 
Joplin et al [1989].  In contrast however, the isolation and culture of murine primary BEC is 
not routinely practised for many reasons.  While mouse cholangiocyte cell lines exist, the 
routine isolation and culture of primary cholangiocytes is not feasible.  Although it is possible 
to isolate and culture primary BEC from murine liver using techniques such as micro-
dissection or enzymatic dissection of the liver [Cho et al., 2001], these methods are very 
labour intensive and time consuming and yield only a small number of isolated cells.  These 
techniques are less than suitable for routine use, and also expose the cells to oxidative or 
mechanical aggression that leads to diminished viability.  In contrast however, isolation of 
primary proximal tubular cells (PTCs) from murine kidney, the segment most severely 
affected in the Del2 knockout mouse, can be performed routinely.  Terryn et al [2007] 
developed a quick and simple method by which primary cultures of murine PTCs can be 
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established without aggressive manipulation.  Although the method described by Terryn et al 
for the isolation of murine PTCs will be described in greater detail in the following section 
(3.4.2), it did require modification to better meet the requirements of this project.  The goal 
of Terryn’s group was to establish a culture system that enabled study of both the apical and 
basolateral surfaces of the cell to enable electrophysiological characterisation [Terryn et al., 
2007].  In contrast, the main requirement of this project was an easy and quick means of 
detection of primary cilia and centrosomes at a resolution that allowed centrosome numbers 
to be counted.  Solid, impermeable cell growth support was most suitable as both structures 
would be visible without having to resort to confocal microscopy, which is costly and time 
consuming.  Whilst being less than ideal for studying cells in an environment matched as 
closely as possible to an in vivo location, as a conventional long-standing technique it is a 
reasonable system to use in this case.  The quality of immunostaining that can be achieved 
when using inserts is not optimal due to interference of the filter, which can be observed as a 
striped aspect on the image.  Furthermore, the filter is not flat but an uneven surface, making 
it difficult to obtain a good focus on all cells of a monolayer.  These aspects make filters less 
suited for immunohistological purposes compared with glass culture slides [Terryn et al., 
2007].  Thus the ideal growth matrix used in conjunction with the glass culture slides had to 
be determined, one that would allow the cells to grow normally to confluence, remain 
differentiated and polarised, maintain their epithelial organisation, and most importantly 
produce primary cilia. 
 
Of equal importance to the study of primary cell systems in vitro is the constitution of the 
culture medium used.  Despite a detailed description of the medium used by Terryn et al 
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[2007], extra considerations had to be made due to the alterations made to the culture of the 
cells for this study, and the experimental conditions to be tested.  The most significant 
alteration to the protocol described by Terryn and colleagues was the use of impermeable glass 
culture slides rather than permeable collagen-coated polytetrafluoroethylene (PTFE)-filter 
supports.  This drastic change in culture conditions meant it was more than likely slight 
alterations to the basic composition of the culture medium would be required, thus 
optimisations of the most basic additive, FBS were carried out to determine the optimum 
concentration that would support cell growth.  Furthermore, as the basis of this study is to 
determine the effect of oestrogen on centrosome duplication, a number of extra 
considerations were essential.  As a cell culture additive FBS is used because it provides a 
mixture of nutrients, and growth and differentiation factors essential for normal cellular 
growth.  This also includes steroid hormones, such as oestrogen.  Therefore it was important 
to choose serum with reduced hormone levels that had been assayed to assure treatment 
efficacy.  Using dextran/charcoal treated FBS reduces the levels of hormones and growth 
factors. This serum has been shown to be effective in reducing steroid levels for utilisation in 
oestrogen related investigations [Eagon et al., 1996].  Although much attention has been paid 
to the removal of hormones from sera and to the development of serum-free media for studies 
on hormone responsive cells in culture, less consideration is given to the possible hormonal 
activity of other media components [Berthois et al., 1986]. 
 
Phenol red is a pH indicator commonly used as an additive to cell culture medium.  However, 
phenol red was found to be a weak oestrogen mimic.  Berthois et al [1986] determined that at 
the concentrations used in tissue culture medium (15-45µM), phenol red has a significant 
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oestrogenic activity causing partial oestrogenic stimulation in oestrogen-responsive cells in 
culture.  Therefore, as this study utilises oestrogen-responsive cells, and is based upon 
oestrogen-dependent observations all media used for growth of murine PTCs was phenol red 
free. 
 
In terms of the actual levels of E2 used to treat the cells, levels below, equivalent, and excessive 
to physiological were used.  The basal circulating plasma levels of E2 in young and aged mice 
are not a commonly studied area, making retrieval of relevant data on which to base these 
studies difficult.  Levels published in readily available sources varied greatly [Dubal et al., 
2001; Gong et al., 2003; Leng et al., 2005; Parkening et al., 1978].  Based on the data that 
could be found concentrations of 25, 75, and 500 pg/ml were used.  25pg/ml representing 
both lowest physiological levels reported, and also the average concentration found in 
untreated FBS (Invitrogen).  75pg/ml represents a higher physiological level, while 500pg/ml 
is excessive for any age of mouse at any stage within the oestrous cycle [Parkening et al., 1978].  
The exact treatment of the cells with E2 is detailed in materials and methods section 3.4.2.2. 
 
The development and normal functioning of cells depends on interactions with molecules in 
their microenvironment.  The major classes of molecules that regulate cellular development 
and function, that need to be considered when performing in vitro studies include growth and 
differentiation factors, cell adhesion molecules, and the components of the extracellular 
matrix (ECM).  The ECM is composed of a number of different macromolecules whose 
structural integrity and functional composition are important in maintaining normal tissue 
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architecture.  The ECM exerts influences on behaviour (adherence, spreading, differentiation, 
and migration) and the pattern of gene expression of the cells in contact with it, and is 
intimately involved in both normal biological function and response to injury [Alberts et al., 
1994]. 
 
To create a physiologically relevant in vitro system that would support normal cell growth and 
function, the components of the in vitro environment had to be considered.  The use of ECM 
components as tissue culture surface matrices permits the development of model systems that 
closely mimic in vivo conditions.  Thus, the choice of ECM was an important component to 
consider when optimising the in vitro culture system in this study.  The ECM components 
readily available as pre-coated cellware or for coating culture vessels were gelatine, poly-lysine, 
collagen type I, and collagen type IV.  Collagen, found in most tissues and organs is most 
plentiful in dermis, tendon and bone, it is an integral part of the framework that holds cells 
and tissues together, and has been recognised as a useful matrix for improving cell culture.  In 
vitro use of collagen can exert effects on the adherence, morphology, growth, migration, and 
differentiation of a variety of cell types [Kleinman et al., 1987].  Collagen coated cell culture 
vessels are used not only to promote cell attachment and spreading, but also improves the 
survival of primary cells in culture [BDBiosciences].  Poly-D-lysine (PDL) and Poly-L-lysine 
(PLL) are synthetic components that enhance adhesion and protein absorption by altering 
surface charges on the culture substratum.  In addition to promoting cell adhesion, poly-lysine 
surface treatments support the outgrowth, and improves survival of many types of primary 
cells in culture.  As PDL and PLL are synthetic molecules, they do not stimulate biological 
activity in the cells cultured on them, and they do not introduce impurities carried by natural 
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polymers.  Used in the culture of a variety of primary cell types poly-lysine applications 
include: attachment and spreading of a variety of cell types, attachment, support and survival 
of fastidious cells, and reduced serum culture [BDBiosciences].  Gelatine is a heterogeneous 
mixture of water-soluble proteins derived from the hydrolysis of collagen.  Gelatine is 
commonly used in the culture of vascular endothelial cells, muscle, embryonic stem cells, and 
F9 teratocarcinoma cells as an attachment and growth-promoting substrate.  Human 
fibronectin (HFN) is a widely distributed glycoprotein that is used as a substrate to promote 
attachment of cells through its central-binding domain RGD sequence.  HFN is a product of 
most mesenchymal and epithelial cells, and is present in both the ECM and plasma.  The 
principal function of HFN appears to be in cellular migration during wound healing and 
development, regulation of cell growth and differentiation and haemostasis/thrombosis.  In 
vitro use of fibronectin as a cell support matrix shows that it promotes cell attachment and 
spreading, rapid expansion of cell populations and improved survival of primary cells in 
culture [BDBiosciences].  The variety of cell support matrices available meant optimisations 
were required to determine the ideal support matrix for all of the cell types included within 
this study. 
 
The temperamental nature of primary BEC to grow well and maintain their differentiated 
state when in culture meant optimisation was required to determine the best possible support 
matrix for culture and manipulation of the cells.  Of equal importance to the study was the 
suitability of the culture vessel material, not only for suitability for culture, but also optimal 
visual clarity for subsequent image analysis.  The substrata under consideration were plastic 
culture slides (Permanox®, nunc), plastic coverslips (Thermanox®, nunc), acid washed glass 
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coverslips, and untreated glass coverslips.  Culture substrata affect the adhesion, morphology, 
differentiation, and behaviour of various cell types.  Glass is often used as a growth surface for 
cells that will undergo subsequent fluorescent staining since it has superior optical qualities 
and is naturally charged.  Washing of glass coverslips with acid can further improve cell 
growth by helping cells and matrix molecules adhere more efficiently to the glass.  Plastic 
culture vessels are also of acceptable optical quality.  However, as most plastics are 
hydrophobic, and unsuitable for cell growth they are often treated to generate a charged, 
hydrophilic surface.  Permanox™ plastic slides, and Thermanox™ coverslips are treated for 
optimal cell culture performance, and are also acceptable for fluorescent applications. 
 
A vital requirement of an experimental approach to primary cilia is an easy means of 
detection.  The tubulin based axoneme of primary cilia means they can be visualised using 
anti-tubulin antibodies.  However, general tubulin staining reveals the whole microtubular 
cytoskeleton, which is especially dense around the centrosome region in which primary cilia 
occur, and would obscure visualisation of this organelle.  This was of little value until confocal 
microscopy allowed greatly improved resolution on the narrow optical sections within which 
a primary cilium would nestle, along with many other positive structures.  However, this is a 
costly and time-consuming method.  Thus, this study makes use of the fact that primary cilia 
in cultured cells can be seen despite the high background of general tubulin staining without 
resorting to confocal microscopy [P. T. C. Ho and Tucker, 1989; Tucker et al., 1979b], a 
method which also allows analysis of primary ciliary expression through the cell cycle.  The 
anti-acetylated α-tubulin antibody 6-11B-1 specific for the ε-amino group of acetylated lysine 
residues within α-tubulin stains primary cilia, centrioles, mitotic spindles, midbodies, and 
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small subsets of cytoplasmic MTs in mammalian cells with little general staining of the 
cytoplasmic network [Piperno et al., 1987].  This has been corroborated by many other 
laboratories working on primary cilia, and is now routinely employed for visualisation of this 
organelle [Wheatley et al., 1996]. It was also vital to ensure cells were at a state where 
expression of primary cilia was maximal.  Within in vitro systems the degree of ciliary 
expression depends on several factors, including the state of cell division, confluency, and 
differentiation [A. C. M. Ong and Wheatley, 2003].  Therefore it was also important to 
determine the optimal number of days to maintain the cells in culture to allow for maximal 
cilial expression without loss of cells due to competition for nutrients. 
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CHAPTER  3 MATERIALS AND METHODS 
 
3.1 MUTATIONAL SCREENING 
Work carried out in this chapter was done so in collaboration with the Birmingham 
Children’s Hospital Liver Unit (BCHLU), and the Nephrology and Hypertension Group at 
the Mayo Clinic, MN, USA.  Any work done by the collaborators will be highlighted in the 
appropriate sections.  Mutational analysis study design, subjects, samples, sample preparation, 
sample analysis, and data retrieval was initiated and carried out prior to initiation of this thesis 
project, and therefore not carried out by myself.  Subsequent analysis of data in relation to 
biliary atresia was carried out independently. 
 
3.1.1 Subjects 
Ten children with BA developed renal cysts at a median age of 9.5 years (range 0.25 - 14 
years).  Nine underwent liver transplantation, with eight presenting cysts post-
transplantation.  One developed renal cysts and has not required a liver transplant, and 
another had renal cysts detected prior to transplantation, Table 3.1.  The screening of these 
ten samples was carried out alongside a panel of ARPKD patients, which therefore acted as 
the control samples.  Details of the control samples were not made available for use in this 
project, except that none presented with BA like features. 
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TABLE 3.1  Table showing the clinical relationship between transplant status, renal cyst natural history, and changes in renal function.  The results highlight that development and change in the size and number of renal cysts 
are independent of the transplant process, calcineurin inhibitor use, and renal dysfunction, in these cases. 
 
Patient number Type of biliary atresia Age at diagnosis of biliary atresia (days) Age at liver transplant (years) 
Age at detection of 
renal cysts (years) Natural history of cysts 
IS at time of renal 
dysfunction 
cGFR at conversion to 
MMF 
cGFR after 1 
year on MMF 
Renal cyst relation to 
dysfunction conversion 
MMF 
1 Perinatal 26 Not transplanted 0.83 0.83 year – multiple cysts 
bilaterally 
5 years – no cysts detected 
8 years – single cyst left kidney 
lower pole 
No changes to date 
    
2 Perinatal 28 0.66 14 14 years – 2.3cm cyst left kidney 
mid pole 
15 years – 2 cysts in left kidney 
and 1.3cm cyst in right kidney 
16 years – right increased to 
2.1cm, left now septated 
Cyclosporin 68 130 Cysts identified after 
conversion to MMF and 
increased in size and number 
since 
3 Perinatal 63 4 10 10 years – 4.9cm cyst in left 
kidney mid pole 
15 years – cyst increased to 
5.4cm.  New cysts in left kidney 
in upper pole 
Cyclosporin 74 92 Cysts identified prior to the 
conversion to MMF.  
Number of cysts increased 
since conversion. 
4 Perinatal 49 5 10 10 years – 1.2cm right kidney 
mid-pole. 
No changes to date 
Cyclosporin Remains on cyclosporin N/A No renal dysfunction and no 
changes in cyst morphology or 
number 
5 Perinatal 42 0.83 8 8 years – 2 cysts in right upper 
pole and 1 left upper pole. 
No changes to date 
Tacrolimus 29 14 Cysts identified at time of 
dysfunction and have not 
changed since conversion to 
MMF 
6 Perinatal 67 0.66 3 3 years – 1cm cyst left upper 
pole. 
No changes to date 
Cyclosporin Remains on cyclosporin  No renal dysfunction, no 
change in cyst morphology or 
number 
7 Perinatal 21 2.2 0.25 0.25 years – 3mm mid-pole left 
kidney on CT scan. 
Undetectable on US scan 
Tacrolimus Remains on tacrolimus   
8 Perinatal 133 0.83 12 12 years – 1cm upper pole right 
kidney 
16 years – cyst not detected 
since 
Tacrolimus 41 71 Cysts detected at time of 
dysfunction and have not 
changed since 
9 Perinatal 49 0.75 12 12 years – 2 small cysts lower 
pole left kidney 
15 years – several cysts 
bilaterally in all poles 
Tacrolimus 59 81 Cysts detected following 
conversion to MMF 
10 Perinatal 56 1.33 9 9years – multiple cysts 
bilaterally 
13 years – many more cysts all 
larger in size 
15 years – all cysts developed 
irregular walls 
Tacrolimus 7 41 Cysts detected at the time of 
dysfunction and have 
increased in size and number 
since conversion to MMF 
IS – Immunosuppression; cGFR - calculated glomerular filtration rate, calculated using the Schwartz formula (height(cm) x 40/creatinine (µmol/l); MMF – Mycophenolate mofetil 
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3.1.2 Methods 
All children attending the BCHLU undergo examination of liver and kidneys.  Retrospective 
reviews of all patient records from children diagnosed with BA at this unit, between 1984 to 
present day were investigated for the presence of renal cysts.  The diagnosis of BA was 
confirmed by histological examination of the obliterated biliary tract at the time of Kasai 
HPE.  Renal cysts were identified during routine patient care with abdominal imaging (either 
ultrasound or CT scan).  Blood samples for DNA extraction were obtained by clinical staff at 
the BCH liver unit with the full consent of the patients and/or their families, with ethical 
approval from The South Birmingham Ethics Committee.  DNA was extracted from samples 
at the regional genetics laboratories at Birmingham Women’s Hospital prior to initiation of 
this thesis project. 
 
Once purified, DNA for mutational analysis was sent to the Nephrology and Hypertension 
labs at the Mayo Clinic, MN, USA, where samples were processed by members of the Harris 
group.  Mutational analysis of the gene PKHD1 was undertaken using both denaturing high-
performance liquid chromatography (DHPLC) and direct sequencing.  Possible mutations 
detected by DHPLC were characterised by direct sequencing and changes compared to 
previously described mutations and polymorphisms in the ARPKD Mutation Database 
(www.humgen.rwth-aachen.de).   DNA was amplified by standard PCR techniques using 
exon flanking primers covering the exon and splice sites [Rossetti et al., 2003].  The ABI 3.0 
BigDye™ system was used to sequence the exonic and flanking intronic regions and analysed 
using an ABI3730 DNA analyser.  Sequences were screened for variants using the Mutation 
Surveyor program, and any pedigrees drawn up.  Any polymorphisms or mutations found by 
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the group were then forwarded on to myself for further interpretation in relation to this 
project.  The likely pathogenicity of any changes found was based upon the chemical 
differences of the substitution [R. Grantham, 1974]; the degree of conservation in mouse, rat 
and chicken orthologs [Hogan et al., 2003]; and whether the change had previously been 
described as pathogenic (or as a polymorphism).  The conservation of residues was tested by 
BLAST using the NCBI website (www.ncbi.nlm.nih.gov/BLAST/), and sequences were 
aligned with the online COBOLT Constraint-based multiple alignment tool 
(http://www.ncbi.nlm.nih.gov/tools/cobalt/). 
 
3.1.3 Statistical analysis 
A 2X2 contingency table was used to determine if there was a significant difference in the 
number of patients with BA that presented with cysts, and the number of patients 
transplanted for other liver diseases that also presented with cysts.  Although the total number 
of samples was not small, there were however only two groups, and one factor with two 
outcomes.  The Fisher’s exact test, and the chi-squared test of association were used to 
determine if the association between the two groups (patients with BA, and patients without 
BA), and the two outcomes (cysts and no cysts) was statistically significant. 
 
3.2 IMMUNOHISTOCHEMISTRY IN HUMAN TISSUE 
Independent contributors to the analysis conducted in this chapter were: Dr G. M. Reynolds 
(GMR), Professor S. Hubscher (SH), and Dr S. C. Afford (SCA).  All other work conducted 
in this chapter was done so unaided. 
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3.2.1 Cohort 
The cohort of patients used within this study were chosen to represent a range of disease 
aetiologies and histological properties in order to determine the effect of multiple disease 
processes on fibrocystin expression and α-tubulin acetylation.  To clarify the classification of 
these diseases in terms of inflammatory, malignant, cystic etc, a table summarising the 
characteristic features of each disease can be found in appendix 2, table 2.2. 
 
3.2.2 Cases 
Cases were selected from the pathology archive at the University of Birmingham, and the 
BCH.  Age and gender information was available for most patients, however all patient 
information and identifiers were removed for subsequent analysis. 
 
In total, liver tissue from sixty patients was available for the present study from an array of 
diseases falling into the following groups; inflammatory, malignant, and cholangiopathic.  
This included adult polycystic liver disease (PCLD), n=6; primary biliary cirrhosis (PBC), 
n=5; primary sclerosing cholangitis (PSC), n=5; autoimmune hepatitis (AIH), n=5; hepatitis 
C virus infection (HCV), n=5; chronic alcoholic liver disease (ALD), n=5; α-1-antitrypsin 
deficiency (α1ATdef.), n=5; biliary atresia (BA), n=11, biopsies taken at Kasai HPE (early-
stage) and end-stage; and hepatocellular carcinoma (HCC), n=5.  Normal liver (NL) tissue 
surplus to transplantation requirements was used as a control, n=5.  All end-stage tissue was 
obtained from donors who had consented to the research use of explants. 
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3.2.3 Methods 
3.2.3.1 Paraffin-embedded section preparation: Agitated low-temperature epitope retrieval 
Archival haematoxylin and eosin (H&E)-stained slides were examined by an independent 
pathologist (GMR) to determine suitability of the specimen for inclusion within the study. 
 
Prior to the immunohistochemical assay, 4µm tissue sections were prepared onto commercial, 
charged microscope slides (SurgiPath, UK) and heated for 1 hour at 65oC before use.  Sections 
were then subjected to agitated low-temperature epitope retrieval (ALTER) using a modified 
method that has been previously described [Reynolds et al., 2002].  In brief, sections were 
routinely dewaxed and dehydrated, followed by a wash in tap water.  Slides were incubated in 
1mmol/l ethylenediaminetetraacetic acid (EDTA), pH8.0 with 0.01% Tween20 on a hot-
plate stirrer at 60oC for 16 hours (overnight).  Agitation was achieved using a 30x5mm 
magnetic bar, with the stirrer set at 600rpm. 
 
Sections were washed in tap water and mounted onto a Sequenzer (Shandon, UK).  The 
Sequenzer is a semi-automated staining station, where sections are mounted onto cover plates 
(as per manufacturers instructions) and all washes and incubations are performed by applying 
the solutions to the reservoir at the top of the cover plate for ease of processing.  As the 
detection system used was peroxidase based, the sections were incubated with Dako 
peroxidase blocking reagent (Dako, Cat# S2001) for 10 minutes at room temperature, to 
suppress non-specific staining due to endogenous peroxidase and pseudoperoxidase activity.  
After a tris buffered saline (TBS) wash pH7.6, sections were probed with optimally diluted 
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primary antibody (as indicated in later sections) for 1 hour at room temperature.  Slides were 
washed in TBS, pH7.6 containing 0.01% Tween20. 
 
The detection system used was a universal peroxidase/DAB kit, the DAKO ChemMate™ 
Envision detection system (DAKO, UK, Cat #K5007).  Briefly, this involved a 30-minute 
incubation with the rabbit/mouse ENV detection reagent; which consists of a dextran 
backbone to which a large number of horseradish peroxidase (HRP) molecules and goat anti-
mouse and goat anti-rabbit secondary antibody molecules have been coupled.  Following the 
final TBS/Tween wash, sections were removed from the Sequenzer and incubated for 5 
minutes with the tertiary substrate: a two-component DAB+ chromogen solution, and 
substrate buffer containing hydrogen peroxide.  This produces a crisp brown end product at 
the site of the target antigen that can easily be visualised using light microscopy.  Following a 
final wash in tap water, sections were counterstained in Mayer’s Haematoxylin (SurgiPath, 
UK), dehydrated, cleared, and mounted with a glass cover-slip in a permanent resin based 
mounting medium, DPX (SurgiPath, UK). 
 
3.2.3.2 Frozen tissue section preparation 
Snap frozen tissue blocks were mounted into ‘OCT’ cryo-embedding media (Sakura, Japan) 
before sectioning on a cryostatic microtome.  Prior to immunohistochemical assay, 5µm 
cryostat sections were cut and mounted onto gelatine coated glass microscope slides and 
allowed to air-dry for 30 minutes.  The slides were then placed in fixative for 10 minutes (as in 
section 3.2.4.1) and air dried before being foil wrapped and stored at -20oC, until needed. 
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Before staining was carried out, slides were warmed to room temperature in the foil wraps 
before being removed and post-fixed in acetone for 10 minutes.  Once fixed slides were 
mounted on a Sequenzer (Shandon, UK) and washed in TBS, pH7.6.  Endogenous peroxidase 
activity was then blocked by incubating the sections with Dako ready-to-use peroxidase 
blocking reagent (Dako, UK, Cat# S2001), for 10 minutes.  After washing with TBS, pH7.6, 
sections were incubated with primary antibody, optimally diluted in TBS for 1 hour, followed 
by a TBS/Tween wash.  Secondary detection was carried out using the Dako ChemMate 
Envision system as previously described (Section 3.2.3.1).  Following a final wash in tap water, 
sections were counterstained with Mayer’s Haematoxylin (SurgiPath, UK), dehydrated in 
alcohol, cleared in xylene, and finally mounted with a cover-glass in DPX (SurgiPath, UK). 
 
3.2.4 Optimisations 
3.2.4.1 Frozen tissue section fixative panel 
The following panel of liquid fixatives were used to fix frozen sections after cutting, in an 
attempt to determine which best maintains tissue morphology whilst having the least 
detrimental affect on epitope availability.  A combination of both crosslinking and coagulant 
fixatives were included (Table 3.2). 
 
TABLE 3.2 Frozen tissue section fixative panel 
Coagulant Fixatives  Crosslinking Fixatives 
Iced methanol 
Ice cold methanol:acetone (1:1) 
Iced ethanol (absolute) 
Acetone 
4% Paraformaldehyde in PBS 
Formal saline (formaldehyde, formalin) 
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Each fixative was applied for 10 minutes, before sections were air dried and stored at -20oC.  
Once required for use, sections from 5 cases of normal human liver were stained using the 
section preparation method described in section 3.2.3.2.  The primary antibodies included 
within these optimisations were two of the fibrocystin monoclonal antibodies raised to the 
extracellular region of the protein: clones 11 and 19.  Antibody dilutions were also titrated at 
1:25, 1:50, 1:100, and 1:200 in order to determine the optimal titre for each antibody if 
frozen tissue were to be used for the full study.  Controls included monoclonal antibody raised 
against the BEC marker human epithelium antigen (HEA) 125 at a dilution of 1:100; the 
negative control lacked a primary antibody and was incubated with TBS alone. 
 
3.2.4.2 Primary antibody titrations on paraffin-embedded tissue sections 
All antibodies under consideration for use, were titrated to determine which provided the 
highest levels of specificity and sensitivity on FFPE tissue.  The details of each antibody and 
the titrations used are detailed in table 3.3.  The titrations were carried out on normal liver 
tissue only for fibrocystin, and normal and PBC for acetylated α-tubulin. 
 
TABLE 3.3  Primary antibody titrations 
Target antigen Clone Stock concentration (mg/ml) Titration dilutions 
Acetylated α-tubulin 6-11B-1 1.6 1:25, 1:50, 1:100, 1:200 
Fibrocystin (C-term) 5a 0.5 1:50, 1:100, 1:200, 1:400, 1:800 
Fibrocystin  (N-term) 11 0.38 1:50, 1:100, 1:200, 1:400, 1:800 
Fibrocystin (N-term) 14a 0.57 1:50, 1:100, 1:200, 1:400, 1:800 
Fibrocystin (N-term) 18 0.27 1:50, 1:100, 1:200, 1:400, 1:800 
Fibrocystin (N-term) 19 0.59 1:50, 1:100, 1:200, 1:400, 1:800 
Key: C-term = Carboxyl-terminus; N-term = Amino-terminus 
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Positive and negative controls consisted of a monoclonal antibody directed against the BEC 
marker HEA125, and exclusion of primary antibody, respectively.  Immunohistochemical 
staining was carried out as described in section 3.2.3.1. 
 
3.2.5 Analysis 
All optimisation immunostaining was evaluated microscopically by a pathologist (GMR) to 
determine the experimental conditions that produced the cleanest, most specific staining. 
 
3.2.6 Liver disease cohort studies 
Once optimal experimental conditions had been determined, the full cohort study was 
conducted using archival, FFPE tissue.  Immunohistochemical staining was carried out as 
described in section 3.2.3.1.  The optimal primary antibody dilutions used were: anti-
acetylated α-tubulin (6-11B-1) at 1:200, and anti-fibrocystin (5a) at 1:100.  All other 
conditions, as described in section 3.2.3.1, remained unaltered.  Normal human tissue was 
used as a reference point to assess disease altered expression levels and protein localisation.  
Negative controls consisted of randomly selected samples from within the study cohort, in 
which primary antibody was substituted with a mouse monoclonal immunoglobulin G (IgG) 
antibody for comparison. 
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3.2.6.1 Immunohistochemical analysis 
Three independent investigators evaluated immunostaining microscopically using the 
Axioskop 40 (Zeiss, UK).  Specificity of staining was assessed by a pathologist (GMR), to 
ensure accurate results.  Standard of staining, and quality of specimen morphology was 
evaluated by a pathologist (SH), who was unaware of the expected pattern of staining.  
Histologic scoring was performed by one investigator (SCA), and verified by two pathologists 
independently (GMR and SH).  Images were captured using the Axiocam MRc5, and edited 
using AxioVision software (Zeiss, UK). 
 
The peroxidase immunostaining was analysed at various magnifications using an upright 
transmission light microscope.  A semiquantitative method was used to assess fibrocystin 
expression in whole ducts, based on the extent and intensity of staining.  This included patent 
ducts, as well as ductules and reactive ductules, based upon all ductular epithelial cells staining 
consistently.  The intensity of staining was graded as follows: -, no visible staining; +, faint 
staining on cells; ++, moderate staining on most cells; +++ intense staining on cells.  A grade 
of ± was used to represent questionably weak positive cells in tissue sections.  An overall 
analysis of staining for both fibrocystin and acetylated α-tubulin within the tissue was also 
performed, taking into account the general histopathology of the specimen and any 
inflammatory infiltrates. 
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3.2.6.2 Statistical analysis 
Data for fibrocystin was expressed as a percentage of positive ‘ducts’ from all ducts counted 
per specimen.  Samples with no visible ductal structures detectable at low magnification (x10) 
received a count of 0%.  For statistical analysis, data were expressed both as total percentage 
positive for each disease group, and mean percentage positive within each specimen type, 
comparison between groups was calculated using a 1-tailed t-test, with the assumption of 
unequal variances.  Statistical analysis was performed using SPSS software (SPSS Inc., 
Bologna, Italy).  All quoted p-values are one sided and statistical significance relates to results 
in which the p-value is <0.05.  
 
3.3 HUMAN IN VITRO CELL CULTURE 
3.3.1 Culture and optimisation of the human embryonic kidney (HEK 293) cell line 
3.3.1.1 Chemicals and plasticware 
Tissue culture plasticware was obtained from corning.  GlutaMAX™ high glucose Dulbecco’s 
modified Eagle’s media (DMEM) with phenol red (1x liquid), non-essential amino acids 
(x100 liquid), foetal calf serum (FCS), penicillin/streptomycin liquid, Trypsin-EDTA 
solution, 1x phosphate buffered saline (PBS), bovine serum antigen (BSA), and normal goat 
serum (NGS) were purchased from Invitrogen (Paisley, UK).  All other chemicals were 
purchased from Sigma (Dorset, UK), unless stated otherwise. 
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3.3.1.2 Cell lines 
Human embryonic kidney cell line HEK293 was purchased from ATCC via LGC 
Promochem (Middlesex, UK).  Cells were resuscitated as recommended by the manufacturers 
instructions. 
 
3.3.1.3 Growth conditions 
HEK 293 cells were maintained in GlutaMAX™ DMEM supplemented with 10% FCS, and 
penicillin (50 Units/ml), streptomycin sulphate (50µg/ml) until 100% confluent. 
 
For plating out, media was aspirated from the cell monolayer and the cells washed with warm 
PBS.  Cells were trypsinised to release them from the flask by a 5-minute trypsin digestion at 
37oC.  Trypsin was inactivated by the additions of the aspirated media made up with warm 
PBS.  Cells were pelleted by centrifugation at 1000rpm for 5 minutes, and resuspended in the 
appropriate amount of media needed.  Cells to be used for subsequent immunostaining were 
seeded at high density onto gelatine coated glass coverslips placed in 6-well plates.  Once 
plated, cells were left for 3 days to settle and grow to confluency before immunostaining. 
 
3.3.1.4 Assessment of ciliary expression by immunostaining 
Once confluency was reached cells were maintained at 100% confluency for 1, 3, or 5 days, 
media was changed every 24 hours.  After removal of old culture medium, 100% confluent 
monolayers of HEK293 were washed with PBS before fixation in 4% paraformaldehyde.  
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After permeabilising with Triton X-100, and quenching with 0.01M glycine in PBS.  Cells 
were blocked in 10% NGS in buffer (1% BSA in 1x PBS) for 30 minutes.  After washing in 
buffer, monolayers were incubated with primary antibody diluted in buffer for 1 hour.  After 
washing monolayers were incubated for 1 hour in the dark with the appropriate fluorophore-
conjugated secondaries, optimally diluted in buffer.  Monolayers were then washed in PBS 
before mounting onto a microscope slide using Vectashield® anti-fade mountant with DAPI. 
 
3.3.1.5 Antibodies 
Immunostaining for cilial analysis was performed using mouse monoclonal antibodies against 
acetylated α-tubulin (6-11B-1) (Sigma, UK), and fibrocystin (clone 5a).  Fluorophore-
conjugated subclass specific secondary immunoglobulin combinations to achieve dual 
labelling included: fluorescein isothiocyanate (FITC), and sulphorhodamine 101 acid 
chloride (Texas red/TxRed) conjugated goat anti-mouse antibodies.  Negative controls were 
treated identically to test samples, except with exclusion of primary antibody, secondary 
antibody, or both primary and secondary. 
 
3.3.1.6 Image capture and analysis 
Stained cells were analysed for the presence of primary cilia using the Axioskop upright epi-
fluorescence microscope (Zeiss, UK).  Images were captured using the AxioCam MRc5 and 
AxioVision software (Zeiss, UK). 
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3.3.2 Biliary epithelial cell isolation and culture 
All tissue was obtained with the consent of the patients or their relatives, and approved by the 
South Birmingham Research Ethics Committee. 
 
3.3.2.1 Chemicals 
Collagenase type IA, RPMI-1640 medium, DMEM, Ham’s F12 nutrient medium, L-
Glutamine-Penicillin-Streptomycin (GPS), hydrocortisone, cholera toxin, and triiodo-l-
thyronine (T3) were purchased from Sigma (Dorset, UK).  Percoll™ was purchased from GE 
Healthcare (UK).  Mouse anti-human anti-EpCAM (HEA125) antibody was purchased from 
Progen Biotechnik (Germany).  Recombinant human hepatocyte growth factor (HGF), and 
epithelial growth factor (EGF) were purchased from Peprotech (London, UK).  Insulin was 
acquired from the Queen Elizabeth Hospital pharmacy (Birmingham, UK).  Human serum 
was purchased from HD Supplies (Buckingham, UK).  Dynabeads® and TrypLE™ cell 
dissociation enzyme were purchased from Invitrogen (Paisley, UK).  Nylon mesh was 
purchased from John Stanier & Co. (Manchester, UK).  Collagen was made in-house from 
rat-tails. 
 
3.3.2.2 Primary cell culture 
Primary BECs were cultured under sterile conditions from collagenase-digested liver tissue 
from normal livers, and a number of liver diseases using methods modified slightly from that 
described by [Joplin, 1994]. 
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Briefly, 80-100g of liver tissue was minced with scalpels on a chopping board.  Minced liver 
was digested in 20ml PBS and 5ml sterile filtered collagenase type IA incubated at 37oC for 30 
minutes with intermittent agitation.  After digestion, the digested liver was sieved through 
fine nylon mesh (pore size 63 microns), and washed through with PBS to make the final 
volume up to 160-200ml.  The cell suspension was then aliquoted into 8 universals and 
centrifuged at 2000rpm for 10 minutes.  The supernatant was discarded, and the 8 pellets 
pooled into 4 universals were washed once more with PBS by centrifugation at 2000rpm for a 
further 10 minutes.  This washing procedure was repeated twice more until only one universal 
remained containing the cell suspension.  The cell suspension was then carefully layered onto 
a 33% and 77% iso-osmotic Percoll™ gradient in 8 conical tubes and centrifuged at 2000rpm 
for 30 minutes.  The interface layer was collected into 4 universals, made up with PBS and 
washed by centrifugation at 2000rpm for 5 minutes.  Washing was repeated twice more, 
pooling the pellets until a single universal remained.  The supernatant was discarded, and the 
remaining pellet resuspended in 500µl ice-cold RPMI, and incubated with BEC-specific 
mouse monoclonal antibody to HEA125 for 30 minutes at 37oC with intermittent agitation. 
Cells were washed once more with 10ml PBS by centrifugation at 2000rpm for 10 minutes.  
The supernatant was discarded, and the remaining pellet resuspended in 500µl RPMI, with 
the addition of 10µl sheep anti-mouse IgG1-coated Dynabeads®.  The cell and Dynabead 
suspension was incubated on ice for 30 minutes with constant agitation.  BEC were then 
positively selected by magnetic separation.  The cell and Dynabead suspension was placed on a 
Dynamag™ magnet for 5 minutes.  With the tube remaining in the magnet, the supernatant 
was removed and discarded.  The magnetic separation step was repeated once more to wash 
away non-specific cells and cellular debris.  Cells and attached beads were resuspended in 5ml 
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of BEC culturing media: Ham’s F12:DMEM (1:1), heat-inactivated human serum (10% v/v), 
GPS (1% v/v), EGF (100µg/ml), hydrocortisone (2µg/ml), cholera toxin (1µg/ml), HGF 
(100µg/ml), T3 (2nM), and insulin (0.125µg/ml).  Cells were left undisturbed for two days to 
allow the cells to settle and adhere to the flask. After 2 days the medium was removed, and the 
cells gently washed with warmed PBS to remove detached Dynabeads®.  Cells were expanded 
in 25cm3 tissue culture flasks with regular medium changes until they became a confluent 
monolayer.  For passage and plating out, cells were subjected to a gentle trypsinisation, 5 
minutes in TrypLE, followed by neutralisation with PBS containing 10% FCS.  In all 
subsequent experiments cells were used between passages two and four depending on the 
initial yield of the primary isolate. 
 
3.3.2.3 Ciliary optimisations in cultured BEC 
For the ciliary optimisations cells were seeded onto plastic chamber slides, plastic coverslips, 
acid-washed glass coverslips, or untreated glass coverslips.  Each culture substratum was either 
left uncoated, or coated with gelatine, poly-lysine, or collagen.  Cells were cultured in BEC 
medium with regular media exchanges until 100% confluent.  Once cells had reached 100% 
confluency cells were stained at 1, 3, or 5 days post-confluency. 
 
3.3.2.4 Assessment of ciliary expression by immunostaining 
Carried out as previously described in section 3.3.1.4. 
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3.3.2.5 Antibodies 
Details of antibodies used are the same as those in section 3.3.1.5. 
 
3.3.2.6 Image capture and analysis 
Carried out as previously described in section 3.3.1.6. 
 
 
3.4 MURINE EXPERIMENTATION AND IN VITRO CELL CULTURE 
 
All animal experiments were conducted under protocols approved by the Mayo Institutional 
Animal Care and Use Committee (IACUC). 
 
3.4.1 Immunofluorescent immunohistochemistry 
Archival tissue from Del2 mice was available as either snap-frozen tissue blocks or FFPE tissue 
blocks.  In order to cover the desired age range, tissue of both types was used as visualisation of 
primary cilia in both section types is comparable at a level satisfactory for the initial 
investigations. 
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3.4.1.1 Paraffin-embedded section preparation: Citrate buffer antigenic retrieval 
Prior to immunostaining, 5µm tissue sections of murine kidney and liver were prepared onto 
commercial charged microscope slides by the Tissue and Cell Molecular Analysis (TACMA) 
shared resource group at Mayo Clinic (MN, USA).  Upon receipt, sections were heated for 1 
hour at 65oC before use, to ensure sections would not float free of the slides during processing.  
Sections were then subjected to antigenic retrieval in citrate buffer.  Briefly, slides were 
deparaffinised in Histo-Clear (National diagnostics, USA; Cat# HS-200) for 10 minutes 
before rehydration through a series of ethanol washes, 1-2 minutes each at 100%, 90%, 80%, 
70%, and 50% ethanol in double distilled water (ddH2O), before a final wash in PBS.  A 
10mM solution of unbuffered sodium tricitrate was heated to near boiling in a steamer, and 
the slides were immersed in this buffer and placed back into the steamer for 40 minutes.  Once 
removed and the liquid allowed to cool to near room temperature, any free aldehydes that 
might cause autofluorescence were quenched by washing the slides in 0.1M glycine in PBS for 
10 minutes.  Slides were then washed twice in PBS and incubated with 10mg/ml sodium 
borohydride in ice-cold Hank’s buffered salt solution (HBSS) for 40 minutes to reduce shift 
bases that can cause autofluorescence.  After further washes in PBS, sections were delineated 
with a hydrophobic barrier pen (DAKO, Cat# S2002) to contain any liquids added to the 
section, thereby reducing the amount of reagent required.  Sections were then subjected to 
immunofluorescent staining with the desired antibodies (Refer to section 3.4.1.3). 
 
3.4.1.2 Frozen tissue section preparation  
Snap frozen tissue blocks of murine liver and kidney were mounted into OCT embedding 
media (Sakura, Japan) before sectioning on a cryostatic microtome.  Prior to 
   142 
immunohistochemical assay, 5µm cryostatic sections were cut and mounted onto 
commercially available charged glass microscope slides and dried at 60oC for 20 minutes.  
Once dry, sections were permeabilised by submerging in either PBS or TBS with 0.1% Triton 
X-100 for 10 minutes.  Sections were delineated with a hydrophobic barrier pen (DAKO, 
Cat# S2002) before immunofluorescent staining with the desired antibodies (Refer to section 
3.4.1.3). 
 
3.4.1.3 Immunostaining 
Dependent upon the detection molecules used, different buffer systems had to be adopted 
when staining was conducted.  In order to bind to their ligand, lectins require free metal ions 
such as Mn2+, Ca2+, and Mg2+.  However, with PBS this can result in the formation of a 
calcium phosphate precipitation, therefore TBS was used in place of PBS whenever lectins 
were used. 
 
Delineated and rehydrated sections were blocked with Image-iT® FZ signal enhancer 
(Invitrogen, Cat# I36933) for 30 minutes to improve the fluorescence signal-to-noise ratio.  
After a 5-minute wash in PBS or TBS, pH7.4, sections were blocked for a further 30 minutes.  
Sections to be probed with biotinylated-lectin were blocked in lectin buffer (1mM Mn2+, 
1mM Ca2+, and 1mM Mg2+ in TBS, Ph7.4) with 0.2% BSA.  Sections to be probed with 
antibodies were blocked in PBS with 0.2% BSA and 10% NGS.  After washing with 0.2% BSA 
in PBS/lectin buffer, sections were incubated for one hour with primary antibody or 
biotinylated lectin optimally diluted in buffer (PBS/lectin buffer with 0.2% BSA).  After 
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washing in buffer, sections were then incubated for 30 minutes with optimally diluted Alexa 
Fluor (AF) conjugated secondary antibodies in the dark.  Sections were then washed several 
times in buffer, then PBS or TBS to wash away any serum proteins before a 1-2 minute 
incubation with 1µg/ml DAPI in PBS or TBS.  Following one last wash in PBS or TBS, 
sections were mounted in Vectashield® anti-fade mountant (Vector labs, Cat# H-1000), and 
sealed with clear nail polish to prevent evaporation of the mounting media. 
 
3.4.1.4 Antibodies 
Immunostaining analyses were performed using well-characterised mouse monoclonal 
antibodies against acetylated α-tubulin (6-11B-1), and γ-tubulin (GTU-88) (Sigma, MO, 
USA).  Biotinylated, PT specific lotus tetragonolobus lectin (LTA), and BEC specific lectin 
dolichos biflorus (DBA) were used as markers for the target tubular structures.  Isotype 
specific goat anti-mouse secondary antibodies used in various combinations included AF-488 
(green), and AF-594 (red) conjugated immunoglobulins, and AF-594, and AF-488 
conjugated streptavidin, used in the appropriate combinations to allow for dual staining.  
Negative controls were included with exclusion of either the primary or secondary antibodies, 
or exclusion of both to determine basal levels of tissue autofluorescence. 
 
3.4.2 Isolation and culture of primary mouse proximal tubular cells 
3.4.2.1 Chemicals 
Dulbecco’s modified Eagle’s/Ham’s F12 (DMEM-F12) without phenol red, Hank’s balanced 
salt solution (HBSS) without phenol red (liquid 1x), non-essential amino acids (liquid, 100x), 
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sodium pyruvate, L-glutamine, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
and charcoal-stripped FBS were purchased from Invitrogen (USA).  Nylon mesh was 
obtained from Small Parts Inc. (FL, USA).  All other enzymes, hormones, and chemicals were 
purchased from Sigma (MO, USA).  Chamber slides were 8-well (0.72cm2) collagen I coated 
glass cultureslides (BD Biosciences, USA). 
 
3.4.2.2 Primary cell culture 
Primary PTCs were cultured under sterile conditions from collagenase-digested cortical 
fragments of kidneys isolated from male and female Del2 and wildtype mice of the C57BL/6 
background.  Although mice of both the C57BL/6 and BALB/c background were available, 
there were no significant phenotypic differences between mice from either background.  The 
C57BL/6 background was chosen, as these animals were more abundant and readily available 
for study. 
 
Renal cortices were micro-dissected visually in ice-cold dissection solution (DS) (HBSS with 
in mmol/l: 10 glucose, 5 glycine, 1 alanine, 15 HEPES, pH7.4) and sliced into ~1mm wide 
pieces.  The fragments were transferred to sterile filtered collagenase solution (DS with 0.1% 
wt/vol type-IV collagenase) at 37oC and digested for 30 minutes with intermittent agitation.  
After digestion, the supernatant was sieved through two nylon sieves (pore size 250µm and 
80µm).  The long PT fragments (about 100µm in length) remaining on the 80µm sieve were 
resuspended by flushing the sieve in the reverse direction with warm DS (37oC containing 
BSA 1% (wt/vol).  The PT fragments present in the BSA solution were centrifuged for 5 
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minutes at ~170g, washed, and then resuspended into the appropriate amount of culture 
medium: 1:1 DMEM/F12 without phenol red supplemented with heat inactivated charcoal 
stripped FBS 10%, HEPES 15mmol/l, L-glutamine 2mmol/l, insulin 5µg/ml, transferrin 
5µg/ml, selenium 50nmol/l, sodium pyruvate 0.55mmol/l, 100x nonessential amino acids 
10ml/l, dexamethasone 50nmol/l, and Nystatin 10,000 units/l.  Different concentrations of 
FBS ranging from 1% to 10% were trialled.  Only at 10% FBS, did cells proliferate readily and 
maintain an unchanged epithelial morphology.  The PT fragments were seeded onto collagen 
I coated 8-well chamber slides at a density of one mouse (two kidneys) to 12 wells. 
 
Fragments were also seeded onto poly-lysine and fibronectin coated chamber slides, however 
optimal cell growth and adhesion were achieved only on collagen coated chamber slides.  
Once seeded, the PT fragments were left unstirred for 48 hours at 37oC, and 95% air, ~5% 
CO2 in a standard humidified incubator. After which, culture medium was changed for the 
first time.  For wells to be treated with oestrogen, this first media change included the 
appropriate concentration of E2 in duplicate (Fig. 3.1).  The medium was then replaced every 
two days.  After seven days, cellular outgrowth from the fragments was sub-confluent in 
control wells (0pg/ml E2), while confluency increased at higher levels of E2.  Cilia were 
expressed across the panel. 
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Well 1: 
Control 
0pg/ml E2 
Well 2: 
Sub-physiological 
25pg/ml E2 
Well 3: 
Physiological 
75pg/ml E2 
Well 4: 
Excess to physiological  
500pg/ml 
Well 5: 
Control 
0pg/ml E2 
Well 6: 
Sub-physiological 
25pg/ml E2 
Well 7: 
Physiological 
75pg/ml E2 
Well 8: 
Excess to physiological  
500pg/ml 
 
Well 9: 
Control 
0pg/ml E2 
Well 10: 
Control 
0pg/ml E2 
  
Well 11: 
Control  
0pg/ml E2 
Well 12: 
Control 
0pg/ml E2 
  
 
FIGURE 3.1 Experimental layout of culture slides.  Schematic diagram of the experimental layout used for 17 β-
estradiol  (E2) experiments on the primary PTCs.  The top slide layout enabled all conditions to be performed in 
duplicate for each animal, ensuring enough cells were available to count.  The lower slide with 4 control (0pg/ml 
E2) wells were used for antibody controls for each animal, and each time staining was carried out.  
 
3.4.2.3 Immunostaining 
Subsequent to removal of old culture medium, 7-day-old monolayers of primary cultured 
PTCs were washed in PBS before fixation in ice-cold methanol.  Following permeabilisation 
with Triton, cells were blocked with 10% NGS in buffer (0.2% BSA in PBS) for 30 minutes.  
After washing in buffer, cultures were incubated with primary antibodies optimally diluted in 
buffer for 1 hour.  After washing, cultures were incubated with the appropriate AF-conjugated 
secondaries, optimally diluted in buffer, for 30 minutes in the dark.  Cultures were then 
washed in successive changes of; buffer, PBS, 1µg/ml DAPI in PBS, and finally PBS.  Finally, 
cultures were mounted with a coverglass using Vectashield® anti-fade mountant, and sealed 
with clear nail polish to prevent specimens from drying out. 
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3.4.2.4 Antibodies 
Immunostaining analyses were performed using well-characterised mouse monoclonal 
antibodies against acetylated α-tubulin (6-11B-1), and γ-tubulin (GTU-88) (Sigma, MO, 
USA).  PTC specific cell adhesion molecule N-cadherin [Nurnberger et al., 2002; Prozialeck 
et al., 2004] was used as a marker to confirm that the cells being observed were indeed PTCs.  
Secondary immunoglobulin subclass specific combinations to achieve dual staining included: 
AF-594, and AF-488 conjugated goat anti-mouse antibodies.  Negative controls were treated 
identically to test samples, except with exclusion of primary antibody, secondary antibody, or 
both primary and secondary. 
 
3.4.3 Data analysis 
All immunostaining of tissue and primary PTCs was analysed using the Nikon Eclipse E600 
upright epi-fluorescence microscope, and images were captured using the Nikon DXM1200 
digital camera (Nikon, IL, USA).  Confocal images were also captured using the Zeiss 
LSM510 laser-scanning microscope.  Data on centrosomal overduplication was collected by 
counting cells with the normal compliment of centrosomes (≤2), versus those with 
centrosomal overduplication (>2).  An average of over 100 cells were counted for every sample 
and treatment.  Values are expressed as the percentage of cells with more than 2 centrosomes 
from the total number of cells counted.  For each experimental condition, counts were taken 
in multiples (n=3/4 animals) and values expressed as the mean±SD.  Significance of 
difference between two means was calculated using a 1-tailed, unpaired t-test, with 
assumption of unequal variance.  Statistical analysis was performed using SPSS software (SPSS 
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Inc., Bologna, Italy).  All quoted p-values are one-sided, and statistical significance related to 
results for which the p-value is <0.05. 
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CHAPTER  4 MUTATIONAL SCREENING OF PKHD1 IN A 
COHORT OF BILIARY ATRESIA PATIENTS WITH ASSOCIATED 
RENAL CYST FORMATION 
 
4.1 INTRODUCTION 
Renal cysts are a common feature of the ciliopathies, syndromes characterised by both renal 
cyst formation and liver disease.  The underlying pathogenesis of these conditions is an 
abnormality of primary ciliary structure and function.  ARPKD is a classic ciliopathy 
characterised by the development of renal and hepatic cysts, and CHF as a result of DPM 
[Desmet, 1992b], features also of BA [C.E. Tan et al., 1994b].  Mutations in the gene 
PKHD1 result in the ciliopathy ARPKD [Rossetti et al., 2003].  The shared clinical features 
of BA and ARPKD, along with the knowledge that ARPKD is the result of an abnormality in 
primary cilia, prompted investigation to determine if sequence variants of PKHD1 could 
provide a clue to the pathogenesis of BA, or even play a role in the development or 
susceptibility of BA in patients who also develop renal cysts. 
 
4.2 AIM 
Perform an initial mutational screen of PKHD1 in a small cohort of biliary atresia patients 
that develop renal cysts, to determine if mutations in this key ciliary gene could contribute to 
the above phenotype. 
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4.3 RESULTS 
4.3.1 Association of renal cysts in transplant patients with BA 
Nine of the 206 (4%) patients with BA who were transplanted at the BCHLU had renal cysts 
as compared with cyst identification in 9 of 463 (2%) of children with other forms of liver 
disease.  However, statistical analysis using a 2-tailed Fisher’s test for a 2X2 contingency table, 
with the alternative hypothesis that the incidence of cysts will be higher in patients with BA 
than in other liver diseases, returned a p-value of 0.1188.  The same data examined using a χ2 
test of association returned the same conclusion with a value of χ2 = 3.008, d.f. = 1, p = 
0.0829.  With the critical figure of statistical significance being represented with a p-value of 
p<0.05, this signifies that it is unlikely that cysts occur more frequently in patients with BA 
when compared to patients with other liver diseases.  Thus the association of renal cysts in 
transplant patients with BA is not significantly higher than renal cysts associated with other 
causes of paediatric liver transplantation.   
 
4.3.2 Clinical evaluation 
Histological examination of the biliary remnants at the time of Kasai HPE confirmed the 
diagnosis of BA in 355 patients (Fig. 4.1).  No child had renal cysts identified at the time BA 
was confirmed as the diagnosis (Table 3.1).  206 patients diagnosed with BA subsequently 
required liver transplantation (58%). 
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FIGURE 4.1  Patient 10 liver biopsy H&E immunohistochemistry, original magnification 
x200.  Liver biopsy from patient 10 showing ductular transformation at the margin of an 
expanded portal tract.  Some ductules contained bile plugs (arrow).  Note that the pattern of 
biliary fibrosis; it does not resemble a ductal plate malformation. 
 
 
Ten of the 355 patients were verified as having developed renal cysts either by abdominal 
ultrasound scan (nine of the children) or abdominal CT (one child) (Fig. 4.2).  All ten 
patients had the perinatal (non-syndromic) form of BA.  There was no reported family history 
of liver or renal disease and no children developed hepatic cysts.  Nine of the ten children have 
undergone liver transplantation. 
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FIGURE 4.2  Renal cyst ultrasound.  This renal ultrasound scan demonstrates a large cyst in 
the upper pole of the right kidney in child 10 (Arrow indicates cyst). 
 
 
Patient 1 has had long-term success from the Kasai HPE and has not required a liver 
transplant, and has not yet developed renal dysfunction, and patient 7 developed renal cysts 
prior to transplantation.  (Table 3.1).  The median age at detection of renal cysts was 9.5 years 
(range 0.25 to 14 years).  The natural history of the cysts was variable, ranging from a single 
cyst, which did not change with time, to a rapid increase in size and number of cysts (Table 
3.1).  Nine of the ten children had received a liver transplant at a median age of 0.83 years 
(range 0.66 to 5 years). 
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PKHD1 was analysed by DHPLC in genomic DNA from six children with BA and renal 
cysts.  A further three cases (2, 7, and 8) along with further analysis of patient 10, were 
analysed by direct sequencing of PKHD1.  Patient 10 was found to be a compound 
heterozygote with a frameshifting change in exon 34, c.5476delG (A1826fsX147) (Fig. 4.3).  
This frameshift results in an early termination product 147 amino acids after the occurrence 
of the deletion, in exon 37.  The frameshift in exon 34 is not conserved in mouse, rat or 
chicken (Fig. 4.3c).  The site of the premature stop in exon 37 is conserved in the mouse, rat, 
and chicken orthologues of Pkhd1 (Fig. 4.3c).   
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FIGURE 4.3  Mutational analysis of PKHD1.  (a) Direct sequencing of the PKHD1 gene in patient 10 and 
normal control shows the deletion c.5476delG that results in a frameshift in exon 34.  (b) Segregation analysis 
shows co-segregation of the deletion mutation and the two missense changes E2124G and F283L in the father 
(I1), the affected child (II1) and the unaffected sibling (II2). (c) cDNA and protein sequences of PKHD1 at the 
site the frameshift deletion in exon 34, and the resulting premature stop codon in exon 37.  The deletion at exon 
34 shifts the entire coding sequence by one base changing the following 147 amino acids downstream, finally 
resulting in the STOP codon TGA at exon 37, which sits within a region conserved in the mouse, rat, and 
chicken orthologues of Pkhd1.  This is highlighted in the sequence alignment of the three species with the 
human PKHD1 sequence. 
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In addition, two novel non-synonymous missense changes were detected F283L (847 T→C) 
and E2124G (6371 A→G).  F283L (phenylalanine to leucine) is a conservative change, from 
one hydrophobic amino acid to another, at a site conserved in the mouse, rat, and chicken 
orthologs (Fig. 4.4a). E2124G (glutamic acid to glycine) is a non-conservative change, from a 
negatively charged amino acid to a small neutral, non-polar amino acid, but at a poorly 
conserved site (Fig. 4.4b).  Extended analysis of patient 10’s family, who are phenotypically 
normal (including normal ultrasound scan imaging of the kidneys), revealed a sibling and the 
father to have the deletion mutation and both missense changes.  This indicates that the 
missense changes are unlikely to be pathogenic (Fig. 4.3b), making the deletion the only 
change likely to be pathogenic.  No other likely pathogenic changes to PKHD1 were found in 
any of the other cases, or controls.  
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FIGURE 4.4  Mutational analysis of PKHD1.  Direct sequencing of the PKHD1 gene in 
patient 10 and normal control shows the missense mutations in exons 12 and 39.  (A) The 
mutation in exon 12 results in a conservative change at a site conserved in the mouse, rat, and 
chicken orthologues of Pkhd1.  (B) The mutation in exon 39 results in a non-conservative 
change at a site conserved only in the murine ortholog of Pkhd1. 
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4.4 CONCLUSIONS 
The observation of renal cysts in paediatric liver disease is an established clinical association.  
However, in this project the aim was to determine if this association is greater in patients with 
BA than other liver diseases, which would suggest that BA is associated with renal cyst 
development. 
 
Of 659 children who received a liver transplant at BCHLU, 206 were transplanted for BA; 
further to this the BCHLU identified the development of renal cysts in 10 of 355 (2.8%) 
patients with BA.  Nine of the 206 (4%) patients with BA who were transplanted had renal 
cysts as compared with cyst identification in 9 of 463 (2%) children with other forms of liver 
disease.  However, the observed differences are not significant, and give no indication of an 
increased association of renal cysts with BA relative to other paediatric liver diseases. 
 
The identification of a compound heterozygote BA patient with renal cysts does not support 
a role for PKHD1 in the pathogenesis of BA alone.  This is further supported by the fact these 
changes were also carried by other family members. 
 
In light of the findings, it was decided to suspend mutational screening of PKHD1 in a larger 
more stratified cohort of BA patients until a second, more convincing mutation was identified 
in BA patients with associated renal cysts.  Unfortunately this could not be achieved before 
the completion of this project.  Thus from these particular findings it can be concluded that 
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PKHD1 does not appear to contribute to the pathogenesis of BA, or the occurrence of renal 
cysts in BA. 
 
The apparent lack of an increased association of renal cysts and BA does not however mean 
that there is no association between hepatic disorders and renal cystic disease caused by 
mutations in PKHD1.  Thus the main aim of this work moved away from investigating the 
pathogenetic role of PKHD1 in BA specifically, becoming a study of the phenotypic 
variability of PKHD1 associated disease in human liver disorders and animal models of 
ARPKD. 
 
4.5 DISCUSSION 
Simple renal cysts in childhood are a rare finding, occurring in 0.1% of children [Mir et al., 
1983].  Renal cyst formation may be secondary to renal dysplasia as an isolated developmental 
abnormality or they may be a clinical feature of a syndrome.  Renal cysts may also be acquired 
and develop in long term renal dialysis patients [Thomsen et al., 1997].  The development of 
renal cysts is also a common feature of ciliopathies.  This was taken into careful consideration 
during this study and renal function was calculated for all patients in the cohort using the 
Schwartz formula (height (cm) x40/creatinine (µmol/l) as an approximation for glomerular 
filtration rate (GFR) with a normal calculated GFR being greater then 60ml/minute/1.73cm2 
[Hogg et al., 2003].  No patient within the cohort studies displayed renal dysfunction prior to 
liver transplantation (Table 3.1).  Thus, the presence of cysts suggests an underlying 
pathological process.  
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Interestingly, Calvo-Garcia [Calvo-Garcia et al., 2008] compared cyst association between BA 
and other paediatric liver diseases in a cohort of post-transplanted patients.  They also found 
there was no increased association of renal cysts in cases of BA when compared to other 
paediatric liver diseases.  None of their cohort developed renal cysts prior to transplantation, 
and the development of cysts was attributed to renal dysfunction due to the transplant 
process, in particular the use of calcineurin inhibitors (CNI).  In the cohort of patients with 
BA and renal cysts included within the current study, renal dysfunction was identified in five 
children post-transplantation, while renal function improved significantly upon 
discontinuation of CNI in four (Table 3.1).  The onset of renal dysfunction was not found to 
correlate with the identification of renal cysts, indeed in several patients the number and size 
of cysts increased despite an improvement in renal function subsequent to discontinuing 
CNIs.  This suggests that in cases such as these the development and progression of renal cysts 
can be independent to renal dysfunction and CNIs.  Two individuals from the cohort 
developed renal cysts following HPE and prior to liver transplantation, providing reasonable 
doubt of whether the transplantation process is the sole cause of cyst formation in these cases.  
The findings of this investigation suggests renal cyst formation in paediatric liver disease can 
be independent of the transplant process or renal function, and therefore cannot be the sole 
aetiology for the development of renal cysts in such cases.  The development of cysts prior to 
transplantation, and the association of renal cysts in BA does indicate that they may have 
formed as part of the primary aetiology. 
 
However, it is the very nature of these cysts that argues against an association with PKHD1 
mutations.  Phenotypically the renal cysts of ARPKD patients are small, and great in number, 
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resulting in bilateral sponge-like enlarged echogenic kidneys.  In contrast, the renal cysts 
observed in this cohort were isolated single cysts in the majority of cases (Table 3.1).  Only 
patent 10 presented with renal cystic disease that resembled typical ARPKD [Menezes and 
Onuchic, 2006; Rossetti et al., 2003; Ward et al., 2002].  However, the slight difference 
between the renal cystic phenotype observed in this cohort, and that typically in patients with 
ARPKD cannot lead to a complete dismissal of this observation as chance.  A retrospective 
review of cases of ARPKD and CHF patients at the Mayo clinic by Adeva et al [2006] 
concluded that although ARPKD typically presents with greatly enlarged echogenic kidneys, 
mutations in PKHD1 can result in CHF with minimal kidney involvement [Adeva et al., 
2006], including cases with only 1 or 2 isolated renal cysts.  Whilst previous studies have 
identified the existence of genotype/phenotype correlations in ARPKD [Bergmann et al., 
2005a; Bergmann et al., 2003; Furu et al., 2003; Rossetti et al., 2003], patients with two 
truncating mutations typically have a severe renal presentation that results in neonatal death.  
Patients with at least one mutation typically have a milder renal presentation, suggesting that 
some missense changes may be hypomorphic alleles [Furu et al., 2003; Rossetti et al., 2003]. 
 
In this series, sequencing the PKHD1 gene revealed three novel changes in a single family.  
The affected child, and both the unaffected father and brother carried the same alleles at the 
three sites.  These changes were not found in the control samples, which included both 
normal and diagnosed ARPKD patients.  Thus, no population frequency data for these 
changes is available.  Given a carrier frequency of approximately 1:70 for disease causing 
PKHD1 mutations in non-isolated populations, and the vast number of private alleles, the 
prevalence of any individual mutation would be expected to be low in the normal population 
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[Bergmann et al., 2004; Zerres et al., 1998a; Zerres et al., 1998b].  However, the small number 
of cases in this study renders these findings meaningless.  Making it unclear at this stage 
whether mutations in PKHD1 are associated with the BA with renal cysts phenotype, thus no 
clear conclusion could be drawn. 
 
What is clear however is that the variability of the disease presentation and course of ARPKD 
and BA most likely reflects the importance of susceptibility and modifier genes in such 
diseases as well as environmental influences, making this a complex case to solve. 
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CHAPTER  5 INCREASED ACETYLATION OF α-TUBULIN AND 
DECREASED EXPRESSION OF FIBROCYSTIN ARE SENSITIVE 
MARKERS OF CELLULAR DAMAGE AND ACTIVATION IN 
INFLAMMATORY LIVER DISEASE 
 
5.1 INTRODUCTION 
Preliminary immunohistochemical studies, using a mouse monoclonal antibody specific for 
the intracellular domain of the wildtype fibrocystin protein [Ward et al., 2003], showed that 
in liver tissue from end-stage BA patients, bile ducts were consistently negative.  The very 
nature of the pathology of BA may cause an alteration in cell function and protein expression 
over time as the disease progresses.  Thus the absence of fibrocystin staining in end-stage 
diseased liver does not indicate if expression is lacking at the initiation of the disease, 
diminishes as a result of the disease process, or was never expressed in these tissues to begin 
with.  This is something that must be clarified not only in BA, but other human liver diseases, 
in order to determine the role of fibrocystin in the pathogenesis of BA. 
 
Alpha-tubulin is a constitutively expressed component of MTs, the basal body, and the 
axoneme of primary cilia.   Formation of these ordered structures requires MT stability, a 
feature that has also been correlated with acetylation [LeDizet and Piperno, 1986].  Hyper-
acetylation of α-tubulin in the hepatocytes of ethanol-fed rats was found to result in impaired 
tubulin polymerisation, and possible altered MT integrity and dynamics [Kannarket et al., 
2006].  Because MTs are central to many cellular processes including mitosis, vesicular 
transport, organelle placement and transport, and primary ciliary formation, it is proposed 
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that altered microtubular dynamics could have far reaching effects on numerous cellular 
functions. 
 
5.2 AIMS 
 Determine if altered expression of fibrocystin and/or acetylated α-tubulin are specific or 
non-specific markers of biliary damage in human liver disease, using a cohort of adult 
patient samples, and paediatric BA patient samples. 
 Determine if the primary cilia of biliary epithelial cells from a cohort of liver disease 
patients have structural defects. 
 
5.3 RESULTS 
5.3.1 Evaluation of fibrocystin immunostaining achieved with different fixatives on 
frozen tissue 
 
Comparison of antigen preservation for immunohistochemical detectability between a panel 
of cross-linking and coagulant fixatives on frozen tissue sections indicated that detection of 
the antigen, depended very much upon the prior treatment of the tissue (Fig. 5.2).  There was 
no obvious difference in the level of staining achieved with each of the different fixatives, 
except with acetone used alone.  No staining above that of non-specific background was 
observed for methanol, methanol:acetone, ethanol, or formalin, when compared to the 
negative control (Figs. 5.1a and 5.2).  A slightly elevated level of background staining was 
observed in paraformaldehyde fixed tissue, but no specific staining of the biliary epithelium 
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could be detected (Fig. 5.2).  In contrast, samples fixed in acetone displayed high levels of 
positive staining, both within the bile ducts, as expected, but also within the sinusoids (Fig. 
5.3).  These results were consistent for both antibodies (clones 11 and 19) at all dilutions 
tested (all dilutions not shown).  The absence of any specific fibrocystin staining with any of 
the fixatives used meant evaluation had to move to FFPE tissue. 
   
165 
 
FIGURE 5.1 Sections of snap frozen normal human liver tissue stained using DAB immunohistochemistry.  This method results in a brown 
reaction product exclusively where the target antibody is bound.  (A) Negative control, no primary antibody.  Block arrows indicate negative bile 
ducts within portal tract.  (B)  Positive control, human epithelial antigen 125 (HEA125), also known as  epithelial cell adhesion molecule (EpCAM).  
Block arrow indicates positive bile duct located within a portal tact.  * Indicates hepatic artery branch.  PV = portal vein. 
 
 
   
166 
 
FIGURE 5.2  Immunohistochemical fixative panel performed on sections of snap frozen normal human liver tissue.  Frozen tissue sections were stained for 
fibrocystin using DAB.  This method results in a brown reaction product exclusively where fibrocystin is expressed.  Each panel clearly shows at least one bile duct 
located within a portal tract (block arrows).  In none of the sections can positive staining be seen.  Note the absence of any non-specific staining within any of the 
tissue, indicating the staining to be highly specific. (A) Methanol fixed, (B) Methanol: Acetone (1:1) fixed, (C) Absolute ethanol fixed, (D) 4% w/v 
paraformaldehyde fixed, (E) formaldehyde fixed.  Original magnification: x200.  Scale bar = 100µm. PV = portal vein.  * = Hepatic artery branch. 
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FIGURE 5.3  Acetone fixed sections of snap frozen normal human liver tissue.  Frozen tissue sections were stained for fibrocystin using DAB 
immunohistochemistry.  This method results in a brown reaction product exclusively where fibrocystin is expressed.  Each panel clearly shows at least 
one bile duct located within a portal tract.  The sections show bile ducts stain positively for fibrocystin (block arrows).  Line arrows indicate the 
location of background sinusoidal staining.  (A) Fibrocystin dilution 1:25.  (B)  Fibrocystin dilution 1:200.  Original magnification: x200.  Scale bar 
= 100µm.  PV = portal vein.  *  = hepatic artery branch. 
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5.3.2 Optimisation of monoclonal antibodies for immunohistochemical study 
In order to perform a full immunohistochemical screen of fibrocystin and acetylated α-
tubulin expression in the cohort of liver diseases, the appropriate final working dilutions of 
the antibodies to be used had to be determined.  Not only this, but the most appropriate of 
five fibrocystin clones available had to be determined.  A serial titration was carried out for 
each antibody on normal liver for fibrocystin, and normal liver and liver from a PBC patient 
for acetylated α-tubulin. 
 
The results of the titrations indicted that the optimum working dilution for the acetylated α-
tubulin antibody (6-11B-1) on FFPE was 1:200, for the specific detection within biliary 
epithelia with minimum background (Fig. 5.4).  At higher concentrations, the level of 
background became unacceptable, making it difficult to determine a true positive result (Fig. 
5.4). 
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FIGURE 5.4 Acetylated α -tubulin antibody titrations on sections of formalin-fixed paraffin embedded human liver stained using DAB 
immunohistochemistry.  The anti-acetylated α-tubulin antibody (6-11B-1) was serially titrated to determine the dilution at which optimal specific staining 
would be achieved, with minimal non-specific staining.  Positive bile ducts are stained brown where acetylated α-tubulin can be detected (block arrows).  Both 
normal and PBC tissue was used, as the levels of expression in either states was not known.  While staining was strongest in tissue taken from PBC liver, the 
dilution at which the antibody performed best for both tissue types was determined to be 1:200 (D and H).  In both types of tissue high levels of background was 
evident at lower dilutions (A-C, and E-G).  Note the evidence of bile ductular proliferation in panel G (line arrows).   Evidence of steatosis in the normal liver 
sections is highlighted by the rectangle in the top right corner of panel D.   Original magnifications: panels A, C-H: x200; panel B: x100. 
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Immunostaining with the five fibrocystin antibodies directed against various epitopes within 
the protein structure was assessed by a pathologist (GMR) using three points of reference; 
non-specific background, kupffer cell, and BEC staining (Table 5.1).  Specific staining was 
classed as maximal signal within bile ducts with minimal detectable in other structures.  All 
five clones exhibited high levels of non-specific staining at very high concentrations (Figs. 5.5 
a-e).  Clone 14 failed to detect fibrocystin within biliary epithelia at all, while clone 19 was 
only able to detect fibrocystin within bile ducts at very high concentrations (Fig. 5.5 c and e).  
Both clone 11 and 18 were able to detect fibrocystin within biliary epithelia at a number of 
dilutions (Figs. 5.5 b and d), however the level of non-specific staining was unacceptable, as it 
would increase the probability of declaring a false positive when assessing specific staining.  
Finally, clone 5a proved optimal, detecting fibrocystin within bile ducts at a range of 
concentrations with very little non-specific staining (Fig. 5.5a).  Thus the optimal working 
dilution for clone 5a, and that used in the full study was 1:100. 
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FIGURE 5.5a  Fibrocystin antibody (clone 5a) titration on sections of formalin-fixed 
paraffin embedded human liver tissue stained using DAB immunohistochemistry.  Anti-
fibrocystin monoclonal antibody clone 5a was serially diluted, and tested on normal human 
liver tissue to determine the optimal dilution that would produce maximal specific staining of 
the biliary epithelium with minimal non-specific staining.  A brown stain is evident in bile 
ducts positive for fibrocystin (block arrows).  Optimal staining was achieved at a dilution of 
1:100 (See table 5.1).  PV = portal vein; * = hepatic artery branch; scale bar = 100µm.  
Original magnification: x200. 
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FIGURE 5.5b  Fibrocystin antibody (clone 11) titration on sections of formalin-fixed 
paraffin embedded human liver tissue stained using DAB immunohistochemistry.  Anti-
fibrocystin monoclonal antibody clone 11 was serially diluted, and tested on normal human 
liver tissue to determine the optimal dilution that would produce maximal specific staining of 
the biliary epithelium with minimal non-specific staining.  A brown stain is evident in bile 
ducts positive for fibrocystin (block arrows).  Optimal staining was not achieved at any 
dilution for this clone (See table 5.1).  PV = portal vein; * = hepatic artery branch.  Original 
magnification of 1:50, 1:100, 1:200, and 1:400: x200; Scale bar = 100µm.  Original 
magnification for 1:800: x400; Scale bar = 50µm. 
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FIGURE 5.5c  Fibrocystin antibody (clone 14) titration on sections of formalin-fixed 
paraffin embedded human liver tissue stained using DAB immunohistochemistry.  Anti-
fibrocystin monoclonal antibody clone 14 was serially diluted, and tested on normal human 
liver tissue to determine the optimal dilution that would produce maximal specific staining of 
the biliary epithelium with minimal non-specific staining.  A brown stain is evident in bile 
ducts positive for fibrocystin (block arrows).  Optimal staining was not achieved at any 
dilution for this clone (See table 5.1).  PV = portal vein; * = hepatic artery branch.  Scale bar = 
100µm.  Original magnification x200. 
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FIGURE 5.5d  Fibrocystin antibody (clone 18) titration on sections of formalin-fixed 
paraffin embedded human liver tissue stained using DAB immunohistochemistry.  Anti-
fibrocystin monoclonal antibody clone 18 was serially diluted, and tested on normal human 
liver tissue to determine the optimal dilution that would produce maximal specific staining of 
the biliary epithelium with minimal non-specific staining.  A brown stain is evident in bile 
ducts positive for fibrocystin (block arrows).  Optimal staining was not achieved at any 
dilution for this clone (See table 5.1).  PV = portal vein; * = hepatic artery branch.  Scale bar = 
100µm.  Original magnification x200. 
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FIGURE 5.5e  Fibrocystin antibody (clone 19) titration on sections of formalin-fixed 
paraffin embedded human liver tissue stained using DAB immunohistochemistry.  Anti-
fibrocystin monoclonal antibody clone 19 was serially diluted, and tested on normal human 
liver to determine the optimal dilution that would produce maximal specific staining of the 
biliary epithelium with minimal non-specific staining.  A brown stain is evident in bile ducts 
positive for fibrocystin (block arrows).  Optimal staining was not achieved at any dilution for 
this clone (See table 5.1).  PV = portal vein; * = hepatic artery branch.  Original magnification 
of 1:50, 1:100, 1:200, and 1:400: x200; Scale bar = 100µm.  Original magnification at 1:800: 
x400; Scale bar = 50µm. 
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TABLE 5.1  Fibrocystin antibody titration on FFPE human liver tissue sections 
  Antibody Dilution 
Clone (epitope location) 
(Stock concentration) Structure 1:50 1:100 1:200 1:400 1:800 
BD +++ ++ + - - 
KC - - - - - 
5a (C-terminal) 
(0.50 mg/ml) 
b/g + - - - - 
BD ++ + - - - 
KC +++ ++ + - - 
11 (N-terminal) 
(0.30 mg/ml) 
b/g - - - - - 
BD - - - - - 
KC +++ +++ +++ ++ + 
14 (N-terminal) 
(0.57 mg/ml) 
b/g - - - - - 
BD +++ +++ ++ + - 
KC +++ +++ +++ ++ ++ 
18 (N-terminal) 
(0.27 mg/ml) 
b/g +++ ++ + - - 
BD + - - - - 
KC ++ + + - - 
19 (N-terminal) 
(0.59 mg/ml) 
b/g - - - - - 
Key: -, no visible staining; +, faint staining on cells; ++, moderate staining on most cells; +++ intense staining on 
cells; BD, bile ducts; KC, kupffer cells; b/g, background (non-specific).  Optimal staining was judged as the 
antibody giving maximal optimal signal, with minimal background, and nonspecific staining.  This was obtained 
with clone 5a at a dilution of 1:100, as it provided strong specific staining, with no background or non-specific 
staining. 
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5.3.3 Increased levels of acetylated α-tubulin and decreased levels of fibrocystin 
expression are detected in a cohort of various adult liver diseases 
 
Fibrocystin expression in BEC within tissue specimens taken from a variety of end-stage 
inflammatory and non-inflammatory liver diseases was variable within different structures for 
each disease type included (Table 5.4).  Fibrocystin expression was also documented in nerve 
bundles, inflammatory cells, and portal vessels within tissue sections for most cases studied, 
but was not always evident in these structures (not shown).  In normal tissue, bile ducts were 
consistently positive for fibrocystin, whereas staining was frequently low or absent in all end-
stage liver disease tissue including end-stage BA (Figs. 5.6 and 5.7).  Kasai wedge biopsies, 
taken at the time of HPE surgery during the earlier stages of BA, showed ductules strongly 
expressing fibrocystin (Fig. 5.7). 
 
The count data analyses for the number of positive ducts per section, and per case are shown 
in table 5.3 and figures 5.8 and 5.9.  Raw count data can be found in appendix 2, table 2.1.  
The overall intensity of staining for each disease group shows staining intensity was 
diminished overall in all end-stage tissue, if staining was at all present.  For all end-stage 
diseases, the reduction in the number of positive cells relative to normal tissue is statistically 
significant, at p<0.05 (Table 5.3). 
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FIGURE 5.6  Fibrocystin expression on sections of formalin-fixed paraffin-embedded adult human end-stage liver disease tissue stained using 
DAB immunohistochemistry.  This method results in a brown reaction product where fibrocystin is expressed.  Expression of fibrocystin was 
frequently low or absent in bile ducts from all end stage liver disease tissue (block arrows).  In contrast, most bile ducts in normal liver tissue were 
strongly positive (block arrow in bottom, right panel).  Evidence of ductular proliferation is also evident in the section of AIH liver tissue (black 
oval).  Note also the characteristic concentric obliterative fibrosis of PSC surrounding the bile duct (curved black arrow).  α1AT Def. - α1-antitryisin 
deficiency (n=5); AIH – autoimmune hepatitis (n=5); ALD – alcoholic liver disease (n=5); PCLD – polycystic liver disease (n=6); HCC – 
hepatocellular carcinoma (n=5); HCV – hepatitis C viral infection (n=5); PBC – primary biliary cirrhosis (n=5); PSC – primary sclerosing 
cholangitis (n=5).  Original magnification of normal liver section: x400.  Original magnification of all other sections: x200. 
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FIGURE 5.7  Fibrocystin expression on sections of formalin-fixed paraffin embedded human biliary atresia liver tissue. Sections were stained 
using DAB histochemistry, which produces a brown stain exclusively where fibrocystin is present.  In normal tissue bile ducts were consistently 
positive for fibrocystin (block arrows).  Kasai wedge biopsies taken at the time of hepatobiliary surgery during the earlier stages of biliary atresia show 
intense proliferation of biliary epithelial cells.  Ductules retain positivity for fibrocystin in the early stages of biliary atresia (ductular structures within 
oval).  Staining of fibrocystin in bile ducts and ductules in end-stage biliary atresia is absent (ductular structures within oval); indicating that 
expression of fibrocystin is eventually lost at the point of end stage disease.  Normal Liver: original magnification x200.  BA (Kasai wedge): original 
magnification x100, scale bar = 100µm.  BA (end-stage): original magnification x200, scale bar =100µm.  PV – portal vein; BA – biliary atresia.   
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TABLE 5.2  Expression levels of fibrocystin in various structures within human liver tissue 
sections.  Table shows qualitative representation of the overall staining intensity observed 
within all cases of the cohort.  Staining was carried out on FFPE tissue sections using the anti-
fibrocystin antibody 5a. 
Specimen type Ducts Hepatocytes Vessels Infiltrate Stroma Other 
NL (n=5) ++ - - - - Nerve bundles +++ 
PCLD (n=6) + - - - - Occasional cyst + 
PBC (n=5) + - - - - Nerve bundles +++ 
PSC (n=5) - - - - - Nerve bundles +++ 
AIH (n=5) +/- - - - - Nerve bundles +++ 
ALD (n=5) - - - - - Nerve bundles +++ 
α 1AT Def. (n=5) - - - - -  
HCC (n=5) +/- - - +++ -  
HCV (n=5) +/- - ++ + -  
BA (HPE) (n=5) ++ - ++ - -  
BA (End-stage) (n=6) - - + - -  
Key: -, no visible staining; +, faint staining on cells; ++, moderate staining on most cells; +++, intense staining on cells; NL, normal liver; 
PCLD, polycystic liver disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; ALD, 
alcoholic liver disease; α1AT Def, α1-antitrypsin deficiency; HCC, hepatocellular carcinoma; HCV, hepatitis C viral infection; BA, 
biliary atresia; HPE, hepatoportoenterostomy. 
 
 
TABLE 5.3  Fibrocystin immunohistochemical staining data analysis 
Specimen 
type 
Number 
of cases 
Total 
positively 
staining bile 
ducts 
Total % 
positive 
Mean % 
positive 
Standard 
deviation Intensity Cysts 
p-
value* 
NL 5 144/204 71 67 24.496 ++ N/A - 
PCLD 6 54/281 19 24 34.349 + Occ. 
+ 
0.020 
PBC 5 10/130 8 8 8.373 + N/A 0.002 
PSC 5 13/188 7 4.26 9.526 - N/A 0.002 
AIH 5 21/108 19 11 11.563 +/- N/A 0.002 
ALD 5 13/52 25 5 11.180 - N/A 0.001 
α 1AT 
Def. 
5 20/60 33 7 14.892 - N/A 0.001 
HCC 5 29/99 29 24 34.866 +/- N/A 0.031 
HCV 5 8/270 3 6 10.654 +/- N/A 0.002 
BA  11 0/418 0 0 0 - N/A 0.002 
Key: -, no visible staining; +, faint staining on cells; ++, moderate staining on most cells; +++ intense staining on cells; NL, normal liver; 
PCLD, polycystic liver disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; ALD, 
alcoholic liver disease; α1AT Def, α1-antitrypsin deficiency; HCC, hepatocellular carcinoma; HCV, hepatitis C viral infection; BA, biliary 
atresia; Occ., occasional.  P-value relative to normal liver for a 1-tailed unpaired t-test with assumption of unequal variance, significance 
p<0.05. 
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FIGURE 5.8  Fibrocystin cohort staining count data: total percentage of positive ducts.  All 
visible bile ducts, and ductules on stained sections were counted, and analysed.  The number 
of positively staining bile ducts, for each disease group, is expressed as a percentage of the total 
ducts counted, for that group.  The total number of positive ducts, from normal liver is 71%.  
The percentage of positive ducts is significantly decreased in all end-stage liver diseases, when 
compared to levels of staining in normal tissue. PCLD, polycystic liver disease; PBC, primary 
biliary cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; ALD, 
alcoholic liver disease; α1AT, α1-antitrypsin deficiency; HCC, hepatocellular carcinoma; 
HCV, hepatitis C viral infection; BA, biliary atresia. 
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FIGURE 5.9  Fibrocystin cohort staining count data: intra-specimen mean percentage of 
positive ducts.  Chart representing the mean percentage of bile ducts that stained positive for 
fibrocystin within each disease group.  All visible bile ducts, and ductules on stained sections 
were counted, and analysed.  The number of positively staining bile ducts, for each specimen, 
within each disease group, is expressed as a percentage of the total ducts counted.  The mean 
number of positive ducts, from normal liver is 67%.  On average, the mean percentage of 
positive bile ducts within each specimen of end-stage liver disease tissue is significantly lower, 
when compared to normal tissue.  PCLD, polycystic liver disease; PBC, primary biliary 
cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; ALD, alcoholic 
liver disease; α1AT, α1-antitrypsin deficiency; HCC, hepatocellular carcinoma; HCV, 
hepatitis C viral infection; BA, biliary atresia.  Error bars represent standard deviation for each 
disease. 
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Expression of acetylated α-tubulin by BEC within the tissue sections studied juxtaposes that 
of fibrocystin.  Expression was consistently negative in normal liver.  However, one out of the 
five normal specimens presented with mild/moderate steatosis and contained weakly positive 
bile ducts, hepatocytes, and stellate cells (not shown).  All disease groups showed very strong 
acetylated α-tubulin staining of bile ducts, particularly in periseptal regions of ductular 
reactivity (Fig. 5.11).  Periseptal/periportal hepatocytes and bile ducts were strongly positive 
in ALD, HCC, and HCV (not shown).  Staining for acetylated α-tubulin in BA biopsies 
taken at Kasai HPE was identical to that seen in all end-stage livers (Fig. 5.12).  Strong 
acetylated α-tubulin staining was present in both the early and late stages of BA in ductules 
and hepatocytes, consistent with the observations made in other cohorts of end-stage adult 
liver disease (Fig. 5.13). 
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FIGURE 5.10  Section of end-stage autoimmune hepatitis human liver tissue displaying 
periseptal ductular reactivity.  Formalin-fixed paraffin-embedded section stained with 
acetylated α-tubulin histochemistry.  The stained section shows positively staining, periseptal 
ductular proliferation in response to inflammation and fibrosis (highlighted area).   Original 
magnification: x200.        
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FIGURE 5.11  Acetylated α-tubulin expression on sections of formalin-fixed paraffin-embedded human end-stage liver disease tissue stained 
using DAB immunohistochemistry.  This method results in a brown reaction product where acetylated α-tubulin is expressed.  Expression of 
acetylated α-tubulin was completely absent from bile ducts in normal donor liver (bottom, far left panel, block arrows).  In contrast, most disease 
groups showed strong positive staining in bile ducts and reactive ductules (block arrows).  Strong expression of acetylated α-tubulin was seen in 
periseptal hepatocytes in HCV and ALD.  Inflammatory cells were generally negative.  Malignant cells of HCC were strongly positive whereas cystic 
epithelium in adult PCLD was generally negative (block arrow).  Nerve bundles were also stained strongly for acetylated α-tubulin in several of the 
disease groups (line arrows).  α1AT Def. - α1-antitryisin deficiency; AIH – autoimmune hepatitis; ALD – alcoholic liver disease; PCLD – polycystic 
liver disease; HCC – hepatocellular carcinoma; HCV – hepatitis C viral infection; PBC – primary biliary cirrhosis; PSC – primary sclerosing 
cholangitis.  Original magnification: x200. 
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FIGURE 5.12  Acetylated α-tubulin expression on sections of formalin-fixed paraffin-embedded human biliary atresia liver tissue. Sections were 
stained using DAB histochemistry, which produces a brown stain where acetylated α-tubulin is present.  In normal tissue bile ducts were consistently 
negative for acetylated α-tubulin (far left panel, line arrows).  Kasai wedge biopsies taken at the time of hepatobiliary surgery during the earlier stages 
of biliary atresia show intense proliferation of biliary epithelial cells.  Strong acetylated α-tubulin staining was present in both the early (middle 
panel, oval), and late stages of biliary atresia (far right panel, oval), in ductules and hepatocytes, consistent with the observations made in other 
cohorts of end stage adult liver disease.   BA – biliary atresia.  Original magnification: Normal liver, and BA Kasai wedge, x200; BA end-stage x100. 
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TABLE 5.4  Expression levels of acetylated α-tubulin in a number of structures within 
human liver tissue sections.  Table shows qualitative representation of the overall staining 
intensity observed within all cases of the cohort.  Staining was carried out on FFPE tissue 
sections using the anti-acetylated α-tubulin antibody 6-11B-1. 
Specimen type Ducts Hepatocytes Vessels Infiltrate Stroma Other 
NL - - - - -  
PCLD ++ - - - - Cysts + 
PBC ++ - - - -  
PSC ++ - - - -  
AIH ++ + - - -  
ALD ++ ++ - - +  
α 1AT def. ++ + - - -  
HCC ++ + - - - Tumour cells+ 
HCV ++ + - - -  
BA (HPE) ++ +/- - - -  
BA (end-stage) ++ + - - -  
Key: -, no visible staining; +, faint staining on cells; ++, moderate staining on most cells; +++ intense staining on cells; NL, normal liver; 
PCLD, polycystic liver disease; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; AIH, autoimmune hepatitis; ALD, 
alcoholic liver disease; α1AT Def, α1-antitrypsin deficiency; HCC, hepatocellular carcinoma; HCV, hepatitis C viral infection; BA, biliary 
atresia. 
 
To summarise, normal tissue bile ducts were consistently positive for fibrocystin, and negative 
for acetylated α-tubulin.  In all end-stage liver disease tissue studied, bile ducts were 
consistently negative for fibrocystin, and positive for acetylated α-tubulin.  Kasai wedge 
biopsies taken at the earlier stages of BA, showed that ductules retain positivity for fibrocystin, 
but that it is eventually lost at the point of end-stage disease, whilst retaining expression of 
acetylated α-tubulin. 
 
5.3.4 Immunofluorescence analysis of primary ciliary expression in HEK293 cells: time-
course evaluation 
 
Cells were evaluated for the expression of primary cilia 1, 3, or 5 days post-confluency, by 
staining with the ciliary marker acetylated α-tubulin, and the ciliary protein fibrocystin as an 
additional confirmation.  At none of the above time points were cilia uniformly expressed by 
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HEK293 cells under the culture conditions used.  Ciliary like structures were however 
observed in isolated cells, see figure 5.13. 
 
5.3.5 Immunofluorescence analysis of primary ciliary expression in primary BEC: 
substratum, ECM, and time-course evaluation 
 
Primary BEC were evaluated for ciliary expression after culture on a variety of substrata 
coated with different matrix components, using the ciliary marker acetylated α-tubulin, and 
the ciliary protein fibrocystin as additional confirmation that the structure observed was a 
primary cilium.  Cells did not always achieve 100% confluency on all the substrates 
investigated and so a time-course of 1, 3, or 5 days post-confluence could not always be strictly 
adhered to.  Where cells did reach 100% confluency the time-course was followed.  Cells that 
could not maintain 100% confluency due to cells washing off during feeding were examined 
the same number of days post-plating as cells that were able to maintain 100% confluency.    
Primary BEC, isolated from liver tissue taken from patients suffering end-stage liver disease 
where cholangiocyte damage is not the primary pathology e.g. Non-alcoholic steatohepatitis, 
did not uniformly express primary cilia under any of the culture conditions used.  However, 
cilia were found on isolated cells under certain conditions.  Where observed, both acetylated 
α-tubulin and fibrocystin co-localised to the structure, providing confirmatory evidence 
(Figure 5.14).  In summary, none of the cell types used were able to uniformly express primary 
cilia under any of the conditions tested, and therefore were unsuitable for any further studies 
into ciliary expression, structure, or function in vitro.  All results are also summarised in table 
5.5. 
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FIGURE 5.13  Representative images of a primary cilium observed on an isolated cell from 
100% confluent HEK293 cells grown on gelatine coated glass coverslips.  HEK293 cells in 
culture did not uniformly express primary cilia, but cilia were observed on isolated cells within 
monolayers.  Top left panel shows control where the primary antibody has been excluded in 
order to determine the levels of nonspecific secondary staining. Levels of non-specific staining 
were extremely low and very acceptable.  Top right panel shows only the TxRed channel 
representing acetylated α-tubulin staining.  Acetylated α-tubulin is localised to what appears 
to be the axoneme of a primary cilium (block arrow).  Bottom left panel shows only the FITC 
channel representing fibrocystin staining.  Fibrocystin localises to the axoneme of the primary 
cilium, confirming the structure to be a primary cilium (block arrow).  Fibrocystin also 
appears to be speckled throughout the cytoplasm, as observed by [Nagano et al., 2005] (white 
circle).  Bottom right panel shows the TxRed and FITC channels merged confirming the co-
localisation of acetylated α-tubulin and fibrocystin to the primary cilia of HEK293 cells when 
present.  Key: Red, acetylated α-tubulin; Green, fibrocystin; Blue, DNA. 
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FIGURE 5.14  Representative images of a primary cilium observed on an isolated cell from 
sub-confluent BEC grown on gelatine coated glass coverslips.  BEC in culture did not 
uniformly express primary cilia, but cilia were observed on isolated cells within monolayers.  
Top left panel shows control where the primary antibody has been excluded in order to 
determine the levels of non-specific secondary staining. Levels of non-specific staining were 
extremely low and acceptable.  Top right panel shows only the TxRed channel representing 
acetylated α-tubulin staining.  Acetylated α-tubulin is localised to what appears to be the 
axoneme of a primary cilium (block arrow).  Bottom left panel shows only the FITC channel 
representing fibrocystin staining.  Fibrocystin localises to the axoneme of the primary cilium, 
confirming the structure to be a primary cilium (block arrow).  Bottom right panel shows the 
TxRed and FITC channels merged confirming the co-localisation of acetylated α-tubulin and 
fibrocystin to the primary cilia of BEC cells when expressed.  Key: Red, acetylated α-tubulin; 
Green, fibrocystin; Blue, DNA. 
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TABLE 5.5  Summary of BEC substratum and ECM ciliary expression optimisations 
MATRIX 
 
 
SUBSTRATE 
Uncoated Gelatine coated 
Collagen 
coated 
Poly-lysine 
coated 
Permanox® 
chamber slides 
Cells did not attached adequately to allow cells to grow to confluency.  
Transmission microscopy showed cellular morphology was also poor. 
Thermanox® 
coverslips 
High levels of background autofluorescence in all channels from the 
coverslips prevented accurate assessment of ciliary expression.  
Transmission microscopy showed good epithelial morphology 
Glass 
coverslips 
Cells grew well. No 
cilia observed. 
Cells grew well.  
Cilia observed 
on isolated 
cells. 
Cells grew 
well.  No cilia 
observed. 
Cells grew well.  
No cilia observed. 
Acid-washed 
glass coverslips 
Good cellular 
growth, but cells 
tended to wash 
away upon feeding. 
Good cellular 
growth.  No 
cilia observed. 
Cells grew 
well.  No cilia 
observed. 
Good cellular 
growth.  Primary 
cilia observed on 
isolated cells. 
 
 
 
5.4 CONCLUSIONS 
The main finding of this chapter is the novel observation that decreased expression of 
fibrocystin in biliary epithelium is associated with elevated levels of α-tubulin acetylation in 
both inflammatory and non-inflammatory adult end-stage liver diseases.  This observation is 
also true in end-stage BA with and without cysts.  In contrast, in the early stages of BA 
fibrocystin expression is still evident, despite elevated levels of α-tubulin acetylation.  The 
consequences of this are not obvious, however, as they are not limited to one disease it does 
suggest that these events occur secondary to the primary disease process and are not causative.  
What can be concluded from this immunohistochemical work is that decreased expression of 
fibrocystin and increased α-tubulin acetylation in biliary epithelial cells could be a non-
specific marker of an ongoing assault to the biliary tree in a multitude of hepatic disorders. 
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Secondary to the immunohistochemical characterisation of fibrocystin expression in patient 
samples, the next aim of this chapter was to examine the structure and/or function of BEC 
primary cilia in vitro.  Unfortunately the failure of the cells used to produce uniform ciliary 
expression meant this section of the project completely failed to meet the aims set-out. 
 
The findings of the work carried out to try to obtain uniform ciliary expression in the human 
embryonic kidney epithelial cell line HEK293 were that, although HEK293 cells are capable 
of expressing primary cilia in culture, uniform expression cannot be obtained in 2-dimensioanl 
culture on an impermeable substratum.  The findings for primary BEC is identical to that of 
HEK293 cells.  As a result of this all aims based upon the visualisation and characterisation of 
primary cilia on cells in vitro were abandoned, however they will be discussed later. 
 
5.5 DISCUSSION 
The absence of fibrocystin staining in the liver sections from children with biliary atresia and 
renal cyst may be due to lack of expression by PKHD1 due to a molecular defect within the 
gene.  This would support the overall project hypothesis of abnormal ciliary development in 
the aetiology of BA.  Alternatively, as the observation was also made in liver sections from a 
mixed cohort of adult end-stage liver diseases, the absence of fibrocystin may be related to loss 
of expression secondary to advanced biliary disease, and could be a non-specific marker of liver 
damage, along with elevated levels of α-tubulin acetylation.  If this is indeed the case, this 
raises the following questions; what causes this change in fibrocystin expression and α-tubulin 
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acetylation, and what are the resultant effects?  At this point the answers to these questions 
can only be speculated upon. 
 
In terms of fibrocystin expression, the reasons for a decrease in expression are difficult to 
speculate as the basic function of this protein is yet to be fully understood.  However, with the 
knowledge that mutations in the gene encoding fibrocystin, PKHD1, are responsible for 
ARPKD, clues as to its function are beginning to be elucidated.  ARPKD is characterised by 
the cystic dilatation of the PTs of the kidneys, and bile ducts with CHF.  Characterisation of 
cystic BEC by multiple groups has determined that fibrocystin is absent from the primary cilia 
of these cells, which in some cases also display an abnormal axonemal architecture [Haycraft et 
al., 2001; T. V. Masyuk et al., 2003; Pazour et al., 2000].  Upon further characterisation of the 
cystic epithelia it was discovered that the epithelial cells surrounding the cysts are usually less 
well differentiated [Lin and Satlin, 2004], suggesting fibrocystin expression is tied into the 
differentiation state of tubular epithelia.  Although it does not appear that tubular epithelia 
differentiation is dependent upon fibrocystin expression, when it is lost, cells either fail to 
become fully differentiated, or become dedifferentiated.  Despite the fact that not all of the 
diseases included in the present cohort display a cystic phenotype, the loss of fibrocystin 
expression could indeed indicate that an altered cellular state occurs as a result of bile ductal 
damage.  Abnormalities in cell polarity have also been described in ARPKD [Calvet, 1994; J. J. 
Grantham, 1993; 2001; Murcia et al., 1999; P. D. Wilson, 1997].  Thus, the primary cilium is 
also thought to contribute to the maintenance of cellular polarity within tubular structures 
and that loss of this organelle can result in/contribute to loss of PCP.  Again, although only 
one of the diseases included in the cohort displays cysts as a main phenotypic characteristic, 
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loss of BEC polarity is reported in HCV infection [Delladetsima et al., 1996; Goldin et al., 
1996; Mihm et al., 1997], PBC [Nakanuma et al., 2001], and AIH [Zen et al., 2005].  
Therefore the loss/decrease of fibrocystin expression may also correlate with a loss of epithelia 
polarity as a result of ductular damage.  Unfortunately, the clear visualisation of primary cilia 
and/or centrosomes in tissue is very difficult due to the many layers of cells present, thus it was 
not possible to determine if the BECs which lacked fibrocystin staining had altered polarity. 
 
Upon initiation of this project it was not predicted that levels of α-tubulin acetylation would 
correlate with ductular damage.  Immunohistochemical staining for acetylated α-tubulin was 
included because it was a known marker of primary cilia, and because hyperacetylation of α-
tubulin had been associated with hepatocyte damage in ethanol-fed rats.  Speculation as to 
why the acetylation of α-tubulin increases during ductular damage is perhaps a little less 
extraneous than for the observed decrease in fibrocystin.  For instance, protein acetylation is 
thought to regulate a diverse set of functions [Kouzarides, 2000].  Interestingly, several 
environmental stresses; ageing, diet, and disease all affect the regulation of the protein 
acetylation status in cells [Chang and Min, 2002; Deckert and Struhl, 2001; Timmermann et 
al., 2001].  Recent studies indicate that histone/protein acetylation also regulates the extent of 
inflammatory responses [Blanchard et al., 2002; Ito et al., 2002; Rahman, 2002].  For 
example, in allergic diseases such as asthma, enhanced histone acetylation is associated with 
inflammation, and reduced acetylation with decreased inflammation [Bhavsar et al., 2008].  
The relevance of this to α-tubulin acetylation, is that a number of the histone deacetylases 
(HDACs) and histone acetylases (HATs), are also able to acetylate a variety of non-histone 
proteins, including α-tubulin [Polevoda and Sherman, 2002].  Therefore, the increase in α-
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tubulin acetylation observed in this study could simply be a reflection of an inflammatory 
response.  Or in the case of those disorders not characterised by overt inflammation, the 
acetylation could reflect an ongoing cellular response to epithelial damage.  Interestingly, such 
functions have also been implicated in cellular polarity [Boyault et al., 2007]. 
 
Acetylation of α-tubulin at lysine 40 is an established marker of MT stability [Piperno et al., 
1987].  Thus, the amount of acetylated α-tubulin is though to be proportional to the stability 
of the MTs.  However, it has been reported by several groups that although MT stability is 
correlated with α-tubulin acetylation, stabilisation is not promoted by α-tubulin acetylation 
[Palazzo et al., 2003].  In fact, it has recently been shown that increased α-tubulin acetylation 
does not increase levels of stable MTs; rather MTs must be stabilised by other mechanisms 
(such as capping [Infante et al., 2000; Piperno et al., 1987]), and then these stable MTs 
accumulate acetylated α-tubulin [Palazzo et al., 2003].  This is consistent with results showing 
that tubulin acetylation has no effect on in vitro MT assembly [Maruta et al., 1986] and that 
acetylated tubulin is only detectable in long-lived stable MTs in vivo [Webster and Borisy, 
1989].  This is further supported by the finding that tubacin, an inhibitor of α-tubulin 
deacetylation in mammalian cells, causes an increase in α-tubulin acetylation without directly 
stabilising MTs [Haggarty et al., 2003].  It is also hypothesised that because α-tubulin 
acetylation alone does not appear to drastically change MT stability, it may instead affect the 
activity of MT associated proteins (MAPs) or MT motors [Palazzo et al., 2003], enabling the 
binding of specific MAPs to MTs within specialised domains [Maruta et al., 1986; Mizuno 
and Singer, 1994]. 
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While it could be argued, that the increased levels of α-tubulin acetylation goes against the 
proliferative response to ductular damage observed in some of the diseases studied.  There are 
studies that suggest α-tubulin acetylation per se does not play an essential role in some of the 
functions of MTs such as mitosis in the cell cycle [Gaertig et al., 1995].  Indeed, acetylated α-
tubulin is present within the mitotic spindle of several cell types [Piperno et al., 1987].  It is 
clear however, that the exact functions of α-tubulin acetylation are still to be fully understood.  
What is clear from this study and many others is that alterations in basal levels of MT 
acetylation are an indication of an altered cell state. 
 
In summary, the immunohistochemical study of fibrocystin expression in samples of patient 
tissue has revealed the novel observation that decreased expression of fibrocystin and 
increased α-tubulin acetylation are non-specific markers of biliary damage in adult end-stage 
liver disease, and end-stage BA.  It also reveals that the observed changes in protein expression 
are a secondary consequence of the primary disease process rather than a causative event.  The 
study has also shown that α-tubulin acetylation is markedly increased in most common 
inflammatory liver diseases, highlighting a state of increased cellular activation during the 
inflammatory process.  Thus, on the basis of these findings, it can be concluded that 
acetylation of α-tubulin is a highly sensitive marker of cellular activation in most common 
inflammatory liver diseases and the absence of fibrocystin staining reflects ongoing damage to 
the intrahepatic biliary tree, rather than a phenomenon specific to ciliopathies. 
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The in vitro cell culture work carried out in this chapter, although incomplete, highlights the 
many requirements that must be met to form a solid foundation to support the aims of any 
research project that relies upon such a technique.  To recapitulate, these include, but are not 
limited to, identifying a cell line that is suitable to the needs of the investigation, and 
optimising the isolation and growth conditions of the chosen cells.  All of the above factors 
should have been considered and set-in place before a full study of primary cilia in the chosen 
cells began.  The inability to optimise the most basic complementary techniques required to 
support this section of the study resulted in the deferral of this part of the project. 
 
The selection of a ciliated human epithelial cell line for the optimisation was challenging.  The 
obvious choice for a project studying bile duct damage would be a BEC line.  Unfortunately, 
the human cholangiocyte cell lines have lost a number of the specialised characteristics of 
BEC, and none are reported to be ciliated in the literature.  The human cell line HEK293 was 
selected as a candidate, as a tubular epithelial cell.  However, many cell lines derived from cells 
that were originally ciliated in vivo do not assemble cilia in culture [Pazour and Witman, 
2003], HEK293 cells are no exception to this.  HEK293 cells were selected to be studied 
before the realisation they were entirely unsuitable.  HEK293 cells do not fully polarise in 
culture, explaining the lack of primary ciliary expression [M-Z Zhang et al., 2004b].  Many of 
the non-human ciliated cell lines are fully polarised in culture, enabling them to produce 
primary cilia.  As the work in this project demonstrates, HEK293 cells may be capable of 
primary cilial expression in culture under the right conditions.  Culture techniques such as 
collagen-gels and semi-permeable culture inserts, which promote polarisation of the cells, may 
therefore induce a more uniform expression of primary cilia.  Another method that could have 
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been used to induce ciliary expression in this study is serum starvation, a technique used to 
induce ciliary expression in cells grown in vitro.  It is thought this method “aligns” cells for 
particular properties, such as ciliary expression, a property influenced by the cell-cycle 
[Cooper and Gonzalez-Hernandez, 2009; Pan and Snell, 2007].  Additionally, a study to 
identify or generate an alternative human ciliated cholangiocyte cell line would be 
advantageous to the continuation of this project. 
 
The relevance of primary cultures of isolated BEC for the functional study of fibrocystin in 
relation to BA is obvious.  However, the availability of viable human liver tissue is a limiting 
factor when conducting an investigation that is dependent upon such a scarce resource.  A 
further limitation is the need to consider the disease affecting the tissue.  As this project 
required viable BEC, diseases characterised by severe cholangiopathy may not produce viable 
cells, further narrowing the selection of tissue available for the study.  
 
Primary cultures of isolated BEC are also temperamental, with high levels of inter- and intra-
sample variability in viability, and yield.  Thus, to establish a model system of uniform ciliary 
expression in primary BEC is challenging.  The measures used to develop a system in this 
project focused around maintaining ease of manipulation, analysis, and image capture.  
However, it is clear from this work that a culture system more akin to the in vivo environment 
of these cells utilising three-dimensional culture systems such as collagen-gels or semi-
permeable cell culture inserts, might have proven more successful.  Such systems would 
however introduce further complications in terms of ease of manipulation, and subsequent 
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analyses.  Although less complex alternative options were available for consideration, again the 
very nature of primary BEC in culture needed to be carefully considered.  Whist serum 
starvation has been shown to induce ciliary expression in a number of cell lines [Pan and Snell, 
2007], the effect of serum starvation on such a temperamental cell type could be catastrophic.  
Alternative methods considered also included the culture of the primary isolated BEC in a 
flow chamber.  The constant flow of media over the apical surface of the cells may aid 
polarisation, inducing ciliary expression.  Again, such a system would also introduce 
complications in terms of subsequent manipulation and image capture, although this could be 
overcome. 
 
In summary, the main initial project aims that relied upon the establishment of an in vitro 
ciliated cell population could not be met, resulting in a change of focus which led to the novel 
observation of fibrocystin and α-tubulin acetylation as markers of non-specific BEC damage. 
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CHAPTER  6 KNOCKDOWN OF PKHD1 DOES NOT INCREASE 
OESTROGEN DRIVEN CENTROSOMAL AMPLIFICATION IN 
PRIMARY MURINE PROXIMAL TUBULE EPITHELIAL CELLS 
 
6.1 INTRODUCTION 
Knockdown of Pkhd1 in the Del2 mouse model results in what appears to be a gender specific 
renal cystic disease, with a ‘star-burst’ ciliary phenotype in the cystic renal epithelia of both 
sexes.  The cause of the gender difference is speculated to be due to differences in the 
expression of androgenic hormones in the two sexes.  The reported association of oestrogen 
with increased levels of cystic disease in ADPKD prompted the hypothesis that the observed 
difference of renal cystic phenotype in this mouse model is possibly due to the actions of 
oestrogen in the proximal tubular epithelium, resulting in centrosomal amplification and 
‘star-burst’ cilia, leading to accelerated cystogenesis.  This theory was further supported by 
studies that shed light on the mechanism of centrosomal amplification, by which, oestrogen 
may drive an abnormal proliferative response in epithelial tissues that may result not only in 
cysts alone, but may be characteristic of any tissue displaying abnormal proliferative 
behaviour, such as tumours or the reactive cholangiocytes observed in a number of cholestatic 
liver diseases, such as BA. 
 
The observation of significant centrosomal amplification in the epithelia lining cysts in the 
Pkd1 knockout, and PKD1 transgenic mouse models, as well as human ADPKD patients 
provided evidence that centrosomal amplification does indeed play a role in cystic 
development.  Furthermore, these observations indicate that cystoproteins may also play a role 
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in centrosomal amplification.  Taken together, this evidence forms the basis of the following 
hypothesis: 
Knockdown of fibrocystin results in centrosomal amplification, resulting in cystic disease of 
the renal tubules and bile ducts.  The mitogenic effects of oestrogen on receptive tissues, and 
implication in centrosomal amplification means it may act in synergy to promote a more 
severe cystic phenotype. 
 
6.2 AIMS 
In order to investigate this hypothesis, the following aims were set out: 
• Investigate if Pkhd1 knockdown and/or oestrogen drives centrosomal amplification in 
primary murine PTCs. 
• Determine the age at which the proximal tubules begin to dilate in Del2 mice. 
• Determine the age at which ‘star-burst’ cilia and centrosomal amplification first appear in 
the proximal tubules of both male and female Del2 mice. 
• Determine if centrosomal amplification precedes cystogenesis or occurs as a result of 
cystogenesis when fibrocystin is knocked down. 
These aims were set out in order to determine if the lack of fibrocystin expression in the 
presence of oestrogen act in synergy to further boost centrosomal amplification in proximal 
tubular epithelial cells, possibly accounting for the gender specific renal cystic phenotype 
observed in the Del2 mice.  Providing further insight into the functional roles of fibrocystin in 
tubular epithelium. 
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6.3 RESULTS AND ANALYSIS 
6.3.1 Treatment of primary murine proximal tubular epithelial cells in vitro drives 
centrosomal overduplication 
 
In order to determine if exposing primary PTCs to E2 in culture resulted in an increase in 
centrosomal overduplication, statistical analysis of the mean percentages of cells displaying 
more than 2 centrosomes from control samples was compared to samples treated with E2.  
This analysis was performed for age-matched animals, one, three, six, and nine months, in 
order to examine if there is a gender dependent difference in the observed level of centrosomal 
amplification.  Comparison of wt male versus wt female, and Del2 male versus Del2 female 
was also carried out to determine if a gender dependent effect was more evident in wt or Del2 
mice. 
 
A total of 52 mice were used in this study, 26 wt and 26 Del2 animals, with an average cell 
count of ≥100 cells counted for each animal and all treatments, detailed in appendix 3.  The 
number of cells displaying centrosomal overduplication (>2 centrosomes) is expressed as a 
percentage of the total number of cells counted. 
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6.3.1.1 One-month-old wt animals 
Counts of at least 100 cells were performed at all four treatments of β-estradiol: 0pg/ml, 
25pg/ml, 75pg/ml, and 500pg/ml.  For one-month-old wt animals counts were collected from 
4 male and 4 female mice.  For wt male mice the mean number of cells displaying centrosomal 
overduplication does not show a linear increase with increasing levels of E2 (Fig. 6.1).  In 
comparison, levels of centrosomal overduplication in proximal tubular epithelial cells derived 
from one-month-old wt females exhibit a clear linear increase with increasing levels of E2 (Fig. 
6.1).  For males, when the mean number of cells displaying centrosomal overduplication at 
25pg/ml, 75pg/ml, and 500pg/ml E2 are compared with the control sample, there is a 
significant increase in the number of cells displaying centrosomal amplification at all three 
treatment levels, relative to the control (Table 6.1).  In comparison, when the mean number 
of treated cells displaying centrosomal amplification from female mice are compared to the 
control cells (0pg/ml), a significant increase in the number of cells with centrosomal 
overduplication is evident at only high physiological and excess levels of E2 (75pg/ml, and 
500pg/ml E2 respectively), table 6.2. 
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FIGURE 6.1  One-month-old wt: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars) show a positive correlation 
with levels of abnormal cells (>2 centrosome) increasing with increasing levels of E2.  In contrast, 
those cells isolated from male mice (blue bars) show an ‘all-or-nothing’ type increase in abnormal cells 
when treated with E2, with no gradual increase with higher levels of E2.  The increase in the levels of 
abnormal cells upon addition of E2 relative to the control sample are statistically significant at all levels 
of E2 for male mice (Table 6.1).  For cells isolated from female animals the observed increase only 
becomes significant compared to the control at 75pg/ml and 500pg/ml E2 (Table 6.2).   
 
TABLE 6.1  Cell count data analysis for one-month-old wt males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 15 5.749  
25 32 11.488 0.026 
75 28 5.382 0.008 
500 29 11.847 0.047 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 6.2  Cell count data analysis for one-month-old wt females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 18 6.295  
25 22 7.956 0.241 
75 30 4.884 0.014 
500 38 6.800 0.003 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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Comparison of the level of centrosomal amplification at matched levels of E2 treatment for 
male and female mice showed that there is no significant difference between the levels of 
centrosomal overduplication observed in primary proximal tubular epithelial cells isolated 
from males and females (Table 6.3), further illustrated in Appendix 3, Fig. 3.1. 
TABLE 6.3 Cell count data analysis for one-month-old wt males Vs. females 
Sample: E2 
(pg/ml) 
Mean % of cells with >2 centrosomes 
(male) 
 
Mean % of cells with >2 centrosomes 
(female) 
p-
value* 
0 15 18 0.210 
25 32 22 0.113 
75 28 30 0.263 
500 29 38 0.125 
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
 
 
 
 
 
 
 
 
   206 
6.3.1.2 One-month-old Del2 animals 
100 or more cells were counted at all four levels of β-estradiol treatment for one-month-old 
Del2 male mice (n of 3).  Those cells with more than 2 centrosomes were expressed as a 
percentage of total cells counted.  The mean number of cells displaying centrosomal 
amplification did not show a linear increase in abnormal cells with increasing levels of E2 (Fig. 
6.2).  When the mean percentage of abnormal cells at 25pg/ml, 75pg/ml, and 500pg/ml E2 
were compared to the mean percentage of abnormal cells in the control sample (0pg/ml E2), 
cells treated with 75pg/ml, and 500pg/ml E2 had a significantly higher percentage of 
abnormal cells (Table 6.4). 
 
Similar counts for cells isolated from four one-month-old female Del2 mice revealed a linear 
increase in the mean number of abnormal cells with increasing levels of E2 (Fig 6.2).  When 
the mean percentage of abnormal cells in the control sample (0pg/ml E2) was compared with 
the mean percentage of abnormal cells in treated samples, samples treated with 75pg/ml and 
500pg/ml E2 displayed a significantly higher mean percentage of abnormal cells (Table 6.5). 
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FIGURE 6.2  One-month-old Del2: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars) display a linear increase in 
the number of abnormal cells (>2 centrosomes) in correlation with increasing levels of E2.   In 
contrast, those cells isolated from male mice (blue bars) show a maximal response upon administration 
of E2 at all levels.  The increase in the levels of abnormal cells upon addition of E2 relative to the 
control samples are statistically significant at 75pg/ml, ad 500pg/ml E2 for male and female mice 
(Table 6.4 and 6.5).  
 
TABLE 6.4  Cell count data analysis for one-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 14.7 7.986  
25 25.6 8.121 0.068 
75 25.3 7.398 0.048 
500 25.3 5.752 0.040 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 6.5  Cell count data analysis for one-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 13 7.054  
25 20 13.095 0.199 
75 28 7.233 0.011 
500 33 9.703 0.010 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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Comparison of the level of centrosomal amplification at matched levels of E2 treatment for 
one-month-old Del2 male and female mice showed that there is no significant difference 
between the levels of centrosomal overduplication observed in primary proximal tubular 
epithelial cells isolated from males and females (Table 6.6), further illustrated in Appendix 3 
Fig. 3.2. 
 
TABLE 6.6  Cell count data analysis for one-month-old Del2 males Vs. females 
Sample: E2 
(pg/ml) 
Mean % cells with >2 centrosomes 
(male) 
Mean % cells with >2 centrosomes 
(female) 
p-
value* 
0 14.7 13 0.385 
25 25.6 20 0.291 
75 25.5 28 0.294 
500 25.3 33 0.133 
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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6.3.1.3 Three-month-old wt animals 
Counts of 100 or more cells were performed at all four levels of β-estradiol treatment: 0pg/ml, 
25pg/ml, 75pg/ml, and 500pg/ml.  For three-month-old wt animals counts were collected 
from 3 male and 3 female mice, the mean percentage of abnormal cells was used for the 
following analysis.  Levels of centrosomal overduplication in primary PTCs from wt male and 
female animals show an almost linear increase with increasing levels of E2 (Fig. 6.3).  For both 
sexes the number of cells displaying centrosomal amplification when compared to the control 
show a significant increase at high physiological and excess to physiological levels of E2, 
75pg/ml and 500pg/ml, respectively (Tables 6.7 and 6.8).   
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FIGURE 6.3  Three-month-old wt: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars) show a linear increase in the 
number of abnormal cells (those expressing >2 centrosomes) with respect to increasing levels of E2.  
Whilst cells isolated from male mice (blue bars) show an initial linear increase in the mean number of 
abnormal cells, a maximal level appears to be reached at 75pg/ml E2.  The increase in the levels of 
abnormal cells upon addition of E2 relative to the control sample are statistically significant at 
75pg/ml and 500pg/ml E2 for both male and female mice (Tables 6.7 and 6.8).  
 
 
TABLE 6.7  Cell count data analysis for three-month-old wt males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 18.2 9.543  
25 36.1 14.938 0.084 
75 46.1 5.823 0.013 
500 43.3 5.296 0.015 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 6.8  Cell count data analysis for three-month-old wt females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 20.2 8.133  
25 23.6 2.043 0.276 
75 34.6 3.444 0.038 
500 44.2 7.092 0.010 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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Comparison of the level of centrosomal amplification at matched levels of E2 treatment for 
male and female mice showed that there is no significant difference between the levels of 
centrosomal overduplication observed in primary proximal tubular epithelial cells isolated 
from males and females (Table 6.9), further illustrated in Appendix 3 Fig. 3.3. 
TABLE 6.9  Cell count data analysis for three-month-old wt males Vs. females 
Sample: E2 
(pg/ml) 
Mean % cells with >2 centrosomes 
(male) 
Mean % cells >2 centrosomes 
(female) 
p-
value* 
0 18.2 20.2 0.397 
25 36.1 23.6 0.142 
75 46.1 34.6 0.089 
500 43.3 44.2 0.453 
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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6.3.1.4 Three-month-old Del2 animals 
Counts of 100 or more cells were performed at all four levels of E2 treatment: 0pg/ml, 
25pg/ml, 75pg/ml, and 500pg/ml.  For three-month-old Del2 animals counts were collected 
for 3 male and 3 female mice, and the mean percentage of abnormal cells used for the 
following analysis.  The mean percentage of cells displaying an abnormal centrosomal 
complement from male mice does not display a linear increase at higher doses of E2.  Reaching 
an almost maximal response at 25pg/ml E2, comparable to low physiological levels, increasing 
very little at 75pg/ml E2 (Fig.6.4).  When compared to levels of abnormal cells from the 
control sample (0pg/ml E2) the mean percentage of abnormal cells treated with 25pg/ml, and 
500pg/ml E2 are significantly higher (Table 6.10).  This is the same for proximal tubular 
epithelial cells isolated from three-month-old Del2 female mice (Fig 6.4, Table 6.11). 
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FIGURE 6.4  Three-month-old Del2: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars) and male mice (blue bars) 
both show a maximal response to treatment with E2 at low physiological levels (25pg/ml E2), with 
little increase with increasing levels of E2.  The increase in the levels of abnormal cells upon addition of 
E2 relative to the control sample are statistically significant at 25pg/ml and 500pg/ml E2 for both 
male and female mice.   
 
 
TABLE 6.10  Cell count data analysis for three-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 18.3 5.755  
25 37.9 5.858 0.007 
75 41.5 16.232 0.060 
500 37.3 1.778 0.010 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 6.11  Cell count data analysis for three-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 15.5 5.818  
25 31.2 5.824 0.015 
75 30.3 10.795 0.063 
500 38.7 12.225 0.031 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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Comparison of the levels of centrosomal amplification at matched levels of E2 treatment for 
male and female mice showed that there is no significant difference in the level of centrosomal 
overduplication observed in primary proximal tubular epithelial cells between the two genders 
in vitro (Table 6.12), further illustrated in Appendix 3, Fig. 3.4. 
 
TABLE 6.12  Cell count data analysis for three-month-old Del2 males Vs. females 
Sample: E2 
(pg/ml) 
Mean % cells >2 centrosomes 
(male) 
Mean % cells >2 centrosomes 
(female) 
p-
value* 
0 18.3 15.5 0.293 
25 37.9 31.2 0.115 
75 41.5 30.3 0.193 
500 37.3 38.7 0.433 
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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6.3.1.5 Six-month-old wt animals 
100 plus cells were counted at all four levels of β-estradiol treatment (0pg/ml, 25pg/ml, 
75pg/ml, and 500pg/ml E2) for six-month-old wt mice.  Counts were collected, and the mean 
percentage of abnormal cells from total cells calculated and analysed, with an n of 3 for male 
and female mice.  The mean percentage of cells displaying centrosomal overduplication from 
male wt animals shows no significant increase with increasing levels of E2 treatment (Fig. 6.5).  
Basal levels of centrosomal amplification are high in the control sample, with a mean of 30% 
abnormal cells (n of 3) (Fig. 6.5).  In contrast, identical counts and analysis for female wt mice 
show a positive linear correlation with increasing E2 levels (Fig. 6.5).  On comparison of the 
mean number of abnormal cells between control and treated samples for male animals, there is 
no significant difference between the treatments (Table 6.13).  When the same comparison is 
made for the female data, the level of centrosomal overduplication at only 500pg/ml E2 
(excessive to physiological) is significantly higher compared to the control (0pg/ml) (Table 
6.14). 
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FIGURE 6.5  Six-month-old wt: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars), and male mice (blue bars) 
both show a linear increase in the number of abnormal cells with respect to increasing levels of E2, 
albeit more pronounced in the female samples).  The increase in the levels of abnormal cells upon 
addition of E2 relative to the control sample is only statistically significant at 500pg/ml E2 for cells 
isolated from female mice. 
 
TABLE 6.13 Cell count data analysis for six-month-old wt males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 35.8 8.539  
25 38.8 0.742 0.301 
75 39.8 1.599 0.523 
500 43.5 4.932 0.132 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 6.14  Cell count data analysis for six-month-old wt females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 18.1 3.729  
25 25.2 6.121 0.088 
75 31.1 15.224 0.136 
500 36.1 7.213 0.016 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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In order to determine if there is a gender difference in the level of centrosomal amplification 
upon administration of E2, comparison of the mean percentage of abnormal cells at matched 
levels of E2 treatment for males versus females was carried out.  When comparing the mean 
percentage of abnormal cells between male and female samples, levels of abnormal cells were 
significantly higher in cells derived from male mice than female mice at 0pg/ml E2 (control), 
and 25pg/ml E2 (low physiological) (Table 6.15), further illustrated in Appendix 3, Fig. 3.5. 
 
TABLE 6.15  Cell count data analysis for six-month-old wt males Vs. females 
Sample: E2 
(pg/ml) 
Mean % cells >2 centrosomes 
(male) 
Mean % cells >2 centrosomes 
(female) 
p-
value* 
0 35.8 18.1 0.026 
25 38.8 25.2 0.030 
75 39.8 31.1 0.215 
500 43.5 36.1 0.112 
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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6.3.1.6 Six-month-old Del2 animals 
Counts of 100 or more cells were performed at all four levels of E2 treatment: 0pg/ml, 
25pg/ml, 75pg/ml, and 500pg/ml.  For six-month-old Del2 animals, counts were collected for 
3 male and 3 female mice, and the mean percentage of abnormal cells used for the following 
analysis.  Analysis of the mean percentage of cells displaying an abnormal centrosomal 
complement from male and female mice reveals a linear increase that correlates positively with 
E2 dose (Fig. 6.6).  Comparison of the mean percentage of abnormal cells between control 
and treated samples taken from male mice shows there is a significantly higher level of 
abnormal cells in treated samples at all doses, table 6.16.  When the same analysis is performed 
for female samples there is also a statistically significant increase in the number of abnormal 
cells in treated samples compared to the control (Table 6.17). 
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FIGURE 6.6  Six-month-old Del2: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars) and male mice (blue bars) 
both show a linear increase in the number of abnormal cells (those expressing >2 centrosomes) with 
respect to increasing levels of E2.  The increase in the levels of abnormal cells upon addition of E2 
relative to the control sample are statistically significant at all levels of E2 for cells isolated from both 
male and female mice (Table 6.16 and 6.17).  
 
TABLE 6.16  Cell count data analysis for six-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 14.0 1.706  
25 30.7 3.211 0.002 
75 34.0 2.224 0.0002 
500 40.1 7.217 0.010 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
TABLE 6.17  Cell count data analysis for six-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 6.3 2.517  
25 18.3 5.508 0.023 
75 24.3 0.577 0.002 
500 29.7 9.018 0.019 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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Upon further analysis, comparison of centrosomal amplification between the genders at 
matched levels of β-estradiol treatment (0pg/ml, 25pg/ml, 75pg/ml, and 500pg/ml) reveals 
that levels of centrosomal amplification are significantly higher in cells derived from male 
animals at 0pg/ml E2, 25pg/ml E2, and 75pg/ml E2.  Although this difference is not 
statistically significant at 500pg/ml E2 it is still evident (Table 6.18), further illustrated in 
Appendix3, Fig. 3.6. 
 
TABLE 6.18  Cell count data analysis for six-month-old Del2 males Vs. females 
Sample: E2 
(pg/ml) 
Mean % cells >2 centrosomes 
(male) 
Mean % cells >2 centrosomes 
(female) 
p-
value* 
0 14.0 6.3 0.008 
25 30.7 18.3 0.020 
75 34.0 24.3 0.006 
500 40.1 29.7 0.098 
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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6.3.1.7 Nine-month-old wt animals 
Counts of at least 100 cells were performed at all four doses of β-estradiol: 0pg/ml, 25pg/ml, 
75pg/ml, and 500pg/ml.  For nine-month-old wt animals counts were collected for 3 male 
and 3 female mice.  For both the male and female samples the mean percentage of abnormal 
cells revealed no real trend with increasing levels of E2 treatment (Fig. 6.7).  Levels of 
centrosomal amplification were consistently high across all experimental conditions.  
Comparison of the mean percentage of abnormal cells between treated and control samples 
reveals that for cells derived from male mice there is only a significantly increase in the level of 
abnormal cells at 500pg/ml E2 (Table 6.19).  Similar analysis for cells derived from female 
mice reveals there is no significant difference in the level of centrosomal amplification 
between treated and control cells (Table 6.20). 
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FIGURE 6.7  Nine-month-old wt: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars) and male mice (blue bars) 
both show no particular pattern in the number of increasing abnormal cells (those expressing >2 
centrosomes) with increasing levels of E2.  The increase in the levels of abnormal cells upon addition 
of E2 relative to the control sample are statistically significant only at 500pg/ml E2 for cells isolated 
from male mice.   
 
TABLE 6.19  Cell count data analysis for nine-month-old wt males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 26.5 10.079  
25 37.3 15.035 0.183 
75 35.7 14.145 0.208 
500 45.0 9.612 0.041 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 6.20  Cell count data analysis for nine-month-old wt females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 27.4 15.618  
25 38.5 24.679 0.276 
75 33.2 8.878 0.308 
500 46.4 12.963 0.092 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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Further analysis, comparing the mean percentage of abnormal cells at matched levels of E2 for 
male versus female samples revealed there is no significant difference between samples derived 
from the difference genders (Table 6.21), further illustrated in Appendix 3, Fig. 3.7. 
TABLE 6.21  Cell count data analysis for nine-month-old wt males Vs. females 
Sample: E2 
(pg/ml) 
Mean % cells >2 centrosomes 
(male) 
Mean % cells >2 centrosomes 
(female) 
p-
value* 
0 26.5 27.4 0.467 
25 37.3 38.5 0.473 
75 35.7 33.2 0.405 
500 45.0 46.4 0.447 
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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6.3.1.8 Nine-month-old Del2 animals 
Counts of at least 100 cells were performed at all four doses of β-estradiol: 0pg/ml, 25pg/ml, 
75pg/ml, and 500pg/ml.  For nine-month-old Del2 animals, counts were collected from 3 
male, and 3 female mice.  The mean percentage of abnormal cells was consistently high in all 
doses of E2 for both male and female samples (Fig. 6.8).  Statistical comparison of the mean 
number of abnormal cells in control and treated cells isolated from male animals revealed 
there was no significant difference in the level of centrosomal amplification (Table 6.22).  The 
same analysis performed for female samples revealed that at 75pg/ml and 500pg/ml E2 treated 
cells had significantly higher levels of centrosomal overduplication when compared to the 
control (Table 6.23). 
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FIGURE 6.8  Nine-month-old Del2: Mean percentage of primary proximal tubular cells displaying 
centrosomal overduplication.  Cells isolated from female mice (red bars) show a subtle linear increase 
in the number of abnormal cells (those expressing >2 centrosomes) with respect to increasing levels of 
E2.  In contrast, those cells isolated from male mice (blue bars) show no real pattern of increasing levels 
of abnormal cells upon administration of E2. The increase in the level of abnormal cells upon addition 
of E2 relative to the control sample are statistically significant at 75pg/ml and 500pg/ml E2 for only 
female primary proximal tubular epithelial cells. 
 
TABLE 6.22  Cell count data analysis for nine-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 42.7 5.367  
25 36.9 6.860 0.155 
75 46.8 2.533 0.163 
500 50.5 6.753 0.099 
. 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 6.23  Cell count data analysis for nine-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 centrosomes Standard deviation p-value* 
0 28.3 7.546  
25 37.7 9.970 0.135 
75 43.6 4.320 0.026 
500 49.8 13.722 0.047 
*p-values relative to control (0pg/ml).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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Comparison of the level of centrosomal amplification at matched levels of E2 treatment for 
male and female mice showed that in the control samples cells derived from male mice had 
significantly higher levels of abnormal cells (>2 centrosome).  However, there is no difference 
between male and female samples treated with E2 (Table 6.24), further illustrated by 
Appendix 3, Fig. 3.8. 
 
TABLE 6.24  Cell count data analysis for nine-month-old Del2 males Vs. females 
Sample: E2 
(pg/ml) 
Mean % cells >2 centrosomes 
(male) 
Mean % cells >2 centrosomes 
(female) 
p-
value* 
0 42.7 28.3 0.030 
25 36.9 37.7 0.457 
75 46.8 43.6 0.175 
500 50.5 49.8 0.472  
*t-test: mean of male Vs. female.  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
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6.3.1.9 Primary murine proximal tubular epithelial cells display abnormal cellular 
morphology upon treatment with 17 β-estradiol in vitro 
 
The severity of centrosomal amplification, and the associated morphological implications 
were not formally documented or measured in this study.  Cellular morphology was generally 
assessed by immunofluorescent immunohistochemistry in order to further understand the 
possible mechanism by which E2 may drive abnormal epithelial proliferation.  An overall 
assessment of nuclear morphology, centrosome number per cell, and cilial expression was 
carried out whilst cell counts were performed. 
 
Proximal tubular epithelial cells isolated from wt and Del2 animals showed little evidence of 
centrosomal amplification in control samples.  Where centrosomal overduplication was 
evident the number of centrosomes present rarely exceeded more than four per cell.  An 
associated increase in the number of primary cilia expressed was also evident in control 
samples, rarely exceeding more than 2 primary cilia per cell.  Nuclear morphology, a good 
representation of any significant chromosomal instability present, was also rarely abnormal in 
control samples from both wt and Del2 animals (Fig. 6.9 and 6.10).   
 
Severity of centrosomal overduplication, and the associated anomalies of primary cilial 
expression and abnormal nuclear morphology increased in correlation with increasing levels of 
E2 treatment.  This occurred in cells isolated from both wt and Del2 animals (Fig. 6.9 and 
6.10 
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Overall, the severity of centrosomal overduplication observed was greater in cells isolated from 
Del2 mice, when compared to wt samples at matched levels of E2 treatment, including control 
samples (Fig. 6.9 and 6.10).  Cells in which multiple centrosomes were present in large 
numbers (>5 centrosomes per cell) generally displayed an abnormal nuclear morphology, with 
multiple nuclei, or small micronuclear fragments.  Such cells were observed in PTC samples 
derived from wt and Del2 animals at all levels of E2 treatment.  However, the degree of 
nuclear dysmorphia observed increased in severity with increasing levels of E2 treatment (Fig. 
6.9 and 6.10).  The degree of nuclear dysmorphia also appeared to be more severe in cells 
isolated from Del2 mice when compared to cells isolated from wt mice matched for age, and 
E2 treatment (Fig.6.9 and 6.10). 
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FIGURE 6.9  Immunofluorescence staining of 17 β-estradiol treated primary proximal tubular epithelial cells isolated from wildtype mice.  Images show increasing complexity of centrosomal amplification and 
consequent ciliary and nuclear abnormalities in correlation with increasing levels of E2.  Cells treated with E2 in which multiple centrosomes are present also express multiple primary cilia, much like the starburst phenotype 
seen in the cystic epithelium of Del2 animals (G).  Control samples (A, and E), for both female and male animals respectively, show a number of cells with the expected complement of centrosomes (≤2 centrosomes per cell), 
with a single primary cilium.  Upon treatment with E2, cells begin to display a number of abnormal characteristics, including: abnormal numbers of centrosomes (>2 per cell), evident in panels B-D, and F-H, representing  
cells treated with E2.  Multiple primary cilia are evident in panel G, with a single PTC from a male animal treated with 75pg/ml E2.  Dysmorphic nuclei, an increase in the number of nuclei proper, and micronuclei, all of 
which are especially evident in panel B, with a single large dysmorphic PTC from a female animals treated with 25pg/ml E2. This cell (B), displays 4 large nuclei with at least 3 micronuclei, with a cluster of centrosomes and 
associated multiple primary cilia lying above the nuclei.  The presence of multiple centrosomes also results in abnormal mitoses, where the nuclear material is pulled in multiple directions, as opposed to two well-defined 
poles.  This is evident in panel D, a single PTC from a female animal treated with 500pg/ml E2, 8 centrosomes can be visualised clearly, the nuclear material is being pulled to four separate poles.  Key: Red, acetylated α-
tubulin; Green, γ-tubulin; Blue, DAPI stained DNA. 
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FIGURE 6.10  Immunofluorescence staining of 17 β-estradiol treated primary proximal tubular epithelial cells isolated from Del2 mice.  Images illustrating the increasing complexity of the 
centrosomal anomalies, and consequent ciliary and nuclear abnormalities, present in primary PTCs when cultured with increasing levels of E2 in vitro.  Cells in which multiple centrosomes are 
present also express multiple cilia, much like the star-burst phenotype seen in the cystic epithelium of Del2 animals.  Often these primary cilia are seen as a nest of acetylated α-tubulin positive 
structures surrounding a cluster of centrosomes panels C and G.  Control samples for both female, and male animals (A and E, respectively), show a number of cells with the expected complement of 
centrosomes (≤2 centrosomes per cell), with a single primary cilium, and a small fraction of the cells displaying between 3 and 4 centrosomes with 2 primary cilia.  Upon treatment with 17 β-
estradiol, cells begin to display a number of abnormal characteristics, including: abnormal numbers of centrosomes (>2 centrosome per cell), evident in panels B-D and F-H.  Multiple primary cilia, 
evident in panel G, with a single PTC from a male animal treated with 75pg/ml E2.  Dysmorphic nuclei, an increase in the number of nuclei proper, and micronuclei, all of which are especially 
evident in panel B, with a single large dysmorphic PTC from a female animal treated with 25pg/ml E2.  This cell (B) displays 4 large nuclei with at least 8 micronuclei, with a cluster of centrosomes 
and associated primary cilia lying above the nuclei.  The presence of multiple centrosomes also results in abnormal mitoses, where the nuclear material is pulled in multiple directions, as opposed to 
two well-defined poles.  This is evident in panel H, a single PTC from a male mouse treated with 500pg/ml E2, at least 3 centrosomes can be visualised clearly, with the nuclear material being pulled 
to 3 separate poles.  Key: Red, acetylated α-tubulin; Green, γ-tubulin; Blue, DAPI stained DNA. 
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6.3.2 Susceptibility of primary murine proximal tubular epithelial cells to E2 driven 
centrosomal overduplication is age dependent 
 
To determine if age alone is a significant factor in susceptibility to centrosomal 
overduplication in primary proximal tubular epithelial cells, the mean percentage of cells 
displaying an abnormal complement of centrosomes from one-month-old wt and Del2 mice 
were compared with cells isolated from older wt and Del2 animals, respectively.  This was 
done to examine the effect of age alone on centrosomal amplification by matching all other 
variables.  Comparing young and old wt animals excludes any effect of fibrocystin knockdown 
on centrosomal overduplication.  But comparing young and old Del2 animals this allows 
comparison of cells derived from proximal tubules that are only just beginning to dilate with 
those that are fully cystic. 
 
6.3.2.1 Three-month-old wt animals 
Comparison of the mean percentage of abnormal cells observed in PTCs derived from wt 
male and wt female animals at the ages of one month (n of 4 for both males and females), and 
three months (n of 3 for both males and females), reveals levels of abnormal cells are 
consistently higher in samples derived from three-month-old wt animals (Fig. 6.11).  
Statistically, this observation is only significant for cells isolated from male mice, treated with 
75pg/ml E2 (Table 6.25).  In all other samples this general increase is not significantly 
different (Table 6.25 and 6.26). 
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FIGURE 6.11  One-month-old Vs three-month-old wt: comparison of centrosomal 
amplification in 17 β-estradiol treated primary proximal tubular epithelial cells.  The 
number of cells displaying centrosomal overduplication, represented as the mean percentage 
of cells with more than 2 centrosomes, from one-month-old (blue bars), and three-month-old 
(red bars) mice were compared to determine if levels were significantly higher in cells isolated 
from older animals.  Levels were found to be consistently higher in both male (upper chart), 
and female (lower chart) three-month-old animals. 
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TABLE 6.25  Cell count data analysis for one-month-old versus three-month-old  wt males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 15 18.2 0.300 
25 32 36.1 0.347 
75 28 46.1 0.033 
500 29 43.3 0.062 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
TABLE 6.26  Cell count data analysis for one-month-old versus three-month-old wt females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 18 20.2 0.374 
25 22 23.6 0.372 
75 30 34.6 0.103 
500 38 44.2 0.139 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.2.2 Three-month-old Del2 animals 
Comparison of the mean percentage of abnormal cells observed in PTCs derived from Del2 
male, and Del2 female animals at the ages of one month (n of 4 for both males and females), 
and three months (n of 3 for both males and females) reveals the number of cells displaying 
centrosomal overduplication to be higher in samples derived from three-month-old mice (Fig. 
6.12).  Statistically this increase is only significant in PTCs derived from male Del2 mice 
treated with 25pg/ml E2 (comparable to low physiological levels), and 500pg.ml E2 (levels 
excess to physiological) (Tables 6.27 and 6.28). 
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FIGURE 6.12  One-month-old Vs three-month-old Del2: comparison of centrosomal 
amplification in 17 β-estradiol treated primary proximal tubular epithelial cells.  The 
number of cells displaying centrosomal overduplication, represented as the mean percentage 
of cells with more than 2 centrosomes, from one-month-old (blue bars), and three-month-old 
(red bars) mice were compared to determine if levels were significantly higher in cells isolated 
from older animals.  Levels were found to be consistently higher in both male (upper chart), 
and female (lower chart) three-month-old animals. 
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TABLE 6.27  Cell count data analysis for one-month-old versus three-month-old  Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 14.7 18.3 0.261 
25 25.6 37.9 0.026 
75 25.5 41.5 0.111 
500 25.3 37.3 0.010 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
TABLE 6.28  Cell count data analysis for one-month-old versus three-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 13 15.5 0.321 
25 20 31.2 0.099 
75 28 30.3 0.405 
500 33 38.7 0.252 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.2.3 Six-month-old wt animals 
Comparing the mean number of cells displaying centrosomal amplification between one-
month-old (n of 4 for both males and females), and six-month-old (n of 3 for both males and 
females) wt animals reveals, samples isolated from the older animals generally display higher 
numbers of abnormal cells (Fig. 6.13).  Statistically, there is very little difference between the 
levels of abnormal cells in samples derived from female mice (Table 6.30).  In contrast cells 
derived from six-moth-old male mice show a significant increase in the number of cells 
displaying centrosomal amplification when compared to cells isolated form one-month-old 
males (Table 6.29). 
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FIGURE 6.13  One-month-old Vs six-month-old wt: comparison of centrosomal 
amplification in 17 β-estradiol treated primary proximal tubular epithelial cells.  The 
number of cells displaying centrosomal overduplication, represented as the mean percentage 
of cells with more than 2 centrosomes, from one-month-old (blue bars), and six-month-old 
(red bars) mice were compared to determine if levels were significantly higher in cells isolated 
from older animals.  Levels were found to be consistently higher in samples isolated from six-
month-old male mice (upper chart).  In contrast, levels were variable in cells isolated from 
female mice. 
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TABLE 6.29  Cell count data analysis for one-month-old versus six-month-old  wt males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 15 35.8 0.048 
25 32 38.8 0.151 
75 28 39.8 0.008 
500 29 43.5 0.042 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
TABLE 6.30  Cell count data analysis for one-month-old versus six-month-old wt females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 18 18.1 0.476 
25 22 25.2 0.295 
75 30 31.1 0.457 
500 38 36.1 0.395 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.2.4 Six-month-old Del2 animals 
Comparing the mean number of cells displaying centrosomal amplification between one-
month-old (n of 4 for both males and females), and six-month-old (n of 3 for both males and 
females) Del2 animals reveals, samples isolated form six-month-old male animals generally 
display higher levels of centrosomal overduplication when treated with E2 (Fig. 6.14).  
However, only at 500pg/ml E2 does this become statistically significant (Table 6.31).  With 
the mean percentage of cells displaying centrosomal overduplication in one-month-old and 
six-month-old male control samples being relatively equal (Fig. 6.31).  In contrast, cells 
isolated from female mice display higher levels of centrosomal amplification in cells isolated 
from one-month-old animals at all levels of E2 treatment (Fig.6.14).  None of which is 
statistically significant (Table 6.32). 
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FIGURE 6.14  One-month-old Vs six-month-old Del2: comparison of centrosomal 
amplification in 17 β-estradiol treated primary proximal tubular epithelial cells.  The 
number of cells displaying centrosomal overduplication, represented as the mean percentage 
of cells with more than 2 centrosomes, from one-month-old (blue bars), and six-month-old 
(red bars) mice were compared to determine if levels were significantly higher in cells isolated 
from older animals.  Levels were found to be consistently higher in E2 treated samples isolated 
from six-month-old male mice (upper chart).  In contrast, levels were found to be consistently 
higher in cells isolated from one-month-old female mice. 
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TABLE 6.31  Cell count data analysis for one-month-old versus six-month-old  Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 14.7 14.0 0.432 
25 25.6 30.7 0.118 
75 25.5 34.0 0.05 
500 25.3 40.1 0.023 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
TABLE 6.32  Cell count data analysis for one-month-old versus six-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 13 6.3 0.076 
25 20 18.3 0.413 
75 28 24.3 0.168 
500 33 29.7 0.360 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.2.5 Nine-month-old wt animals 
Analysis of the mean percentage of cells displaying centrosomal overduplication from nine-
month-old (n of 3) and one-month-old (n of 4) wt male and female mice shows that overall, 
levels are consistently higher in cells derived from nine-month-old animals (Fig. 6.15).  
However, this observation is not significant at any level of E2 treatment for either gender 
(Tables 6.33 and 6.34). 
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FIGURE 6.15  One-month-old Vs nine-month-old wt: comparison of centrosomal 
amplification in 17 β-estradiol treated primary proximal tubular epithelial cells.  The 
number of cells displaying centrosomal overduplication, represented as the mean percentage 
of cells with more than 2 centrosomes, from one-month-old (blue bars), and nine-month-old 
(red bars) mice were compared to determine if levels were significantly higher in cells isolated 
from older animals.  Levels were found to be consistently higher in E2 treated samples isolated 
from nine-month-old male mice (upper chart), and female mice (lower chart). 
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TABLE 6.33  Cell count data analysis for one-month-old versus nine-month-old  wt males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 15 26.5 0.083 
25 32 37.3 0.309 
75 28 35.7 0.215 
500 29 45.0 0.050 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
TABLE 6.34  Cell count data analysis for one-month-old versus nine-month-old wt females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 18 27.4 0.211 
25 22 38.5 0.185 
75 30 33.2 0.308 
500 38 46.4 0.184 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.2.6 Nine-month-old Del2 animals 
Analysis of the mean percentage of cells displaying centrosomal amplification from one-
month-old (n of 4), and nine-month-old (n of 3) Del2 male and female mice show that the 
number of abnormal cells is consistently higher in cells derived from nine-month-old animals 
(Fig. 6.16).  In samples isolated from male mice the observed increase is statistically significant 
at all levels of E2 treatment, also true for the control (Table 6.35).  For female mice, the 
increase in levels of centrosome overduplication was significant at 0pg/ml, 25pg/ml, and 
75pg/ml E2 (Table 6.36). 
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FIGURE 6.16  One-month-old Vs nine-month-old Del2: comparison of centrosomal 
amplification in 17 β-estradiol treated primary proximal tubular epithelial cells.  The 
number of cells displaying centrosomal overduplication, represented as the mean percentage 
of cells with more than 2 centrosomes, from one-month-old (blue bars), and nine-month-old 
(red bars) mice were compared to determine if levels were significantly higher in cells isolated 
from older animals.  Levels were found to be consistently higher in all samples isolated from 
nine-month-old male mice (upper chart), and female mice (lower chart). 
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TABLE 6.35  Cell count data analysis for one-month-old versus nine-month-old  Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 14.7 42.7 0.001 
25 25.6 36.9 0.041 
75 25.5 46.8 0.003 
500 25.3 50.5 0.003 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
TABLE 6.36  Cell count data analysis for one-month-old versus nine-month-old Del2  females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (one month) 
Mean % of cells with >2 
centrosomes (three months) 
p-value * 
0 13 28.3 0.025 
25 20 37.7 0.050 
75 28 43.6 0.009 
500 33 49.8 0.072 
*p-value calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
6.3.3 Knockdown of fibrocystin in primary proximal tubular epithelial cells has no effect 
on 17 β-estradiol driven centrosomal overduplication 
 
Statistical analysis to compare the mean number of cells displaying centrosomal 
overduplication in age-matched wt and Del2 animals was carried out to determine if 
knockdown of fibrocystin resulted in a significant increase in the incidence of centrosomal 
amplification in primary PTCs.  Age-matched analysis for the four age-points was performed 
to examine whether levels in cells derived from cystic versus non-cystic tubules would differ. 
6.3.3.1 One month old animals 
Comparing the mean percentage of abnormal proximal tubular epithelial cells derived from 
counts of 100 or more cell for one-month-old wt (n of 4) and one-month-old Del2 (n of 4) 
male and female mice revealed, the number of abnormal cells is higher in samples isolated 
from wt mice (Fig. 6.17).  The difference in the levels of centrosomal overduplication between 
wt and Del2 mice when compared is not statistically significant at any level of E2 treatment 
(Tables 6.37 and 6.38). 
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FIGURE 6.17  Age-matched comparison of the mean percentage of primary proximal 
tubular epithelial cells displaying centrosomal amplification from one-month-old wt and 
Del2 animals.  Levels of centrosomal amplification, represented as the mean number of cells 
with more than two centrosomes per sample, from wt (blue bars) and Del2 (red bars) mice 
were compared to determine if levels were significantly higher in cells isolated from Del2 
animals.  Levels were found to be consistently higher in both male (top chart) and female 
(lower chart) wt animals. 
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TABLE 6.37 Cell count data analysis for one-month-old wt versus one-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 15 14.7 0.491 
25 32 25.6 0.177 
75 28 25.5 0.334 
500 29 25.3 0.317 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
TABLE 6.38 Cell count data analysis for one-month-old wt versus one-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 18 13 0.157 
25 22 20 0.398 
75 30 28 0.368 
500 38 33 0.208 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.3.2 Three-month-old animals 
Analysis comparing the mean percentage of abnormal proximal tubular epithelial cells isolated 
from three-month-old wt (n of 3), and three-month-old Del2 (n of 3) male and female mice 
revealed, differences between wt and Del2 samples to be inconsistent (Fig. 6.18).  Although 
cells from both wt and Del2 animals show a similar response to increasing levels of E2, cells 
isolated from neither genotype show a consistently higher level of centrosomal amplification 
compared to the other (Fig. 6.18). 
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FIGURE 6.18  Age-matched comparison of the mean percentage of primary proximal 
tubular epithelial cells displaying centrosomal amplification from three-month-old wt and 
Del2 animals.  Levels of centrosomal amplification, represented as the mean number of cells 
with more than two centrosomes per sample, from wt (blue bars) and Del2 (red bars) mice 
were compared to determine if levels were significantly higher in cells isolated from Del2 
animals.  Levels were not found to be consistently higher in either wt or Del2 animals. 
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TABLE 6.39 Cell count data analysis for three-month-old wt versus three-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 18.2 18.3 0.495 
25 36.1 37.9 0.427 
75 46.1 41.5 0.350 
500 43.3 37.3 0.187 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
TABLE 6.40 Cell count data analysis for three-month-old wt versus three-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 20.2 15.5 0.231 
25 23.6 31.2 0.070 
75 34.6 30.3 0.286 
500 44.2 38.7 0.273 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.3.3 Six-month-old animals 
Analysis of the mean percentage of cells displaying centrosomal overduplication from six-
month-old wt (n of 3), and six-month-old Del2 (n of 3) male and female mice reveals that 
upon comparison, levels of abnormal cells are consistently higher in samples isolated from wt 
animals (Fig. 6.19).  This difference is statistically significant at 25pg/ml and 75pg/ml E2 in 
male samples (Table 6.41), and notably in control samples for both male and female isolates 
(Table 6.41 and 6.42). 
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FIGURE 6.19  Age-matched comparison of the mean percentage of primary proximal 
tubular epithelial cells displaying centrosomal amplification from six-month-old wt and 
Del2 animals.  Levels of centrosomal amplification, represented as the mean number of cells 
with more than two centrosomes per sample, from wt (blue bars) and Del2 (red bars) mice 
were compared to determine if levels were significantly higher in cells isolated from Del2 
animals.  Levels were found to be consistently higher in both male (top chart) and female 
(lower chart) wt animals. 
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TABLE 6.41 Cell count data analysis for six-month-old wt versus six-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 35.8 14.0 0.050 
25 38.8 30.7 0.021 
75 39.8 34.0 0.013 
500 43.5 40.1 0.273 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
TABLE 6.42 Cell count data analysis for six-month-old wt versus six-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 18.8 6.3 0.007 
25 25.2 18.3 0.112 
75 31.1 24.3 0.260 
500 36.1 29.7 0.197 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.3.4 Nine-month-old animals 
Age-matched comparison of the mean percentage of proximal tubular cells displaying an 
abnormal centrosomal complement between wt and Del2 mice reveals that, although levels of 
abnormal cells increase with higher doses of 17 β-estradiol, the incidence of centrosomal 
overduplication is higher in samples derived from Del2 animals (Fig. 6.20).  However, 
statistical analysis shows that the higher incidence of centrosomal overduplication in Del2 
samples is not statistically significant (Table 6.43 and 6.44). 
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FIGURE 6.20  Age-matched comparison of the mean percentage of primary proximal 
tubular epithelial cells displaying centrosomal amplification from nine-month-old wt and 
Del2 animals.  Levels of centrosomal amplification, represented as the mean number of cells 
with more than two centrosomes per sample, from wt (blue bars) and Del2 (red bars) mice 
were compared to determine if levels were significantly higher in cells isolated from Del2 
animals.  Levels varied between wt and Del2 PTCs, but were found to be generally higher in 
Del2 samples. 
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TABLE 6.43 Cell count data analysis for nine-month-old wt versus nine-month-old Del2 males 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 26.5 42.7 0.044 
25 37.3 36.9 0.482 
75 35.7 46.8 0.153 
500 45.0 50.5 0.235 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
TABLE 6.44 Cell count data analysis for nine-month-old wt versus nine-month-old Del2 females 
Sample: E2 (pg/ml) Mean % of cells with >2 
centrosomes (wt) 
Mean percentage of cells with >2 
centrosomes (Del2) 
p-value* 
0 27.4 28.3 0.468 
25 38.5 37.7 0.480 
75 33.2 43.6 0.084 
500 46.4 49.8 0.383 
*p-values calculated from 1-sided t-test with unequal variance assumed, p<0.05 significance 
 
 
6.3.4 At what age do ‘star-burst’ primary cilia occur in Pkhd2Del2/Del2 animals? 
Fluorescent immunohistochemical staining of kidney and liver tissue from a number of one 
and four-month-old Del2 animals was carried out in order to determine the approximate age 
at which ‘star-burst’ cilia and associated centrosomal overduplication may begin to occur.  In 
order to confirm that the tubular segments under observation were indeed the proximal 
tubules or bile ducts, kidneys were stained with the proximal tubule specific marker, LTA, and 
liver with the bile duct specific marker, DBA. 
 
In one-month-old fully inbred (past 10th generation inbred) male Del2 mice, no evidence of 
dilation of the proximal tubules was found (Fig. 6.21b).  At four months, tubules appeared 
slightly dilated (Fig. 6.21c).  Primary cilia were visible within the tubule lumen of proximal 
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tubules in sections taken from male Del2 mice (Fig. 6.21).  In contrast, proximal tubules 
examined from one-month-old inbred Del2 female mice displayed evidence of dilation, 
especially when compared to tubules within wt kidneys (Fig. 6.21e).  By four-months of age 
the proximal tubules of female Del2 mice were significantly dilated (Fig. 6.21e), with sparse 
stunted primary cilia visible (not shown). 
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FIGURE 6.21  Fluorescent immunohistochemistry of wt and Pkhd1Del2/Del2 kidney tissue sections.  These representative images show the general morphology of the proximal 
tubules in wt and Del2 mice.  The proximal tubule specific marker lotus tetragonolobus agglutinin (LTA) can be seen in red, highlighting the luminal surface of the epithelial cells 
lining the tubules.  Nuclei of cells are stained blue with DAPI.  Primary cilia stained with the marker acetylated α-tubulin, if present, are seen in green.  In wild type kidney (Panels 
A and D) normal proximal tubular morphology of a small continuously labelled lumen is shown, with patent primary cilia.  At one month of age proximal tubules of male Del2 
animals (Panel B) are undilated, with a few primary cilia visible.  In contrast, proximal tubules from one-month-old female Del2 mice (Panel E) have begun to dilate, however 
primary cilia remain present.  At four month of age the proximal tubules of male Del2 mice have begun to dilate slightly with fewer primary cilia present in the tubule lumen 
(Panel C).  In contrast, the proximal tubules of female Del2 animals at four month of age (Panel F) are highly dilated with no primary cilia visible. 
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FIGURE 6.22  Fluorescent immunohistochemistry of wt and Pkhd1Del2/Del2 liver tissue 
sections.  These representative images show the general morphology of the bile ducts in wt 
and Del2 mice.  The bile duct specific marker Dolicus biflorus agglutinin (DBA) can be seen 
in green in the sections taken from wt animals (Panels A and C), and in red in the sections 
taken from Del2 mice (Panels B and D), highlighting the surface of the biliary epithelial cells 
lining the tubules (block arrows).  Nuclei of cells are stained blue with DAPI.  Primary cilia, 
stained with the marker acetylated α-tubulin, if present are seen in red in wt sections (Panels 
A and C), and green in Del2 sections (Panels B and D).  In wile-type liver, panels A and C, 
normal bile duct morphology of a small continuously labelled lumen is evident, with patent 
primary cilia.  At one-month of age, bile ducts from both male and female Del2 animals are 
cystic. Very few stunted primary cilia visible in Del2 sections, (Panels B and D). 
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6.4 CONCLUSIONS AND DISCUSSION 
6.4.1 Centrosomal amplification in primary murine proximal tubule epithelial cells 
shows positive correlation to increasing levels of 17 β-estradiol in vitro 
 
The study has shown that the culture of primary murine proximal tubular epithelial cells with 
increasing levels of 17 β-estradiol drives a mitogenic response that results in the 
overduplication of centrosomes.  In summary the main findings of this chapter are that 
primary proximal tubular epithelial cells derived from younger (one and three month old) 
male and female, wt and Del2 mice display a significant susceptibility to E2 induced 
centrosomal overduplication in vitro.  This is evident by the significant increase in the number 
of abnormal cells in samples cultured with E2 when compared to levels displayed in control 
samples.  PTCs from older animals (six and nine months) also display an increased level of 
centrosomal amplification with increasing doses of E2 in vitro, however the increase in the 
number of abnormal cells in treated samples compared to control samples is less significant 
than in cells isolated from younger animals.  The resulting increase in the number of 
centrosomes per cell is also associated with multiple primary cilia, and nuclear dysmorphia.  
So, although these findings are of little relevance to biliary atresia, or the functional study of 
fibrocystin, it does provide insight into the mechanism driving cystic development in tubular 
structures. 
 
Analysis of the levels of centrosomal amplification induced in primary murine PTCs, when 
cultured with increasing doses in E2 shows there is a general positive correlation in cells 
derived from both wt and Del2 animals.  Although the trend was not always linear, there was a 
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definite overall increase in the incidence and severity of centrosomal amplification as levels of 
E2 increased.  Comparison of the mean percentage of cells displaying centrosomal 
amplification in untreated control and treated samples were on the whole significantly 
different, with those wells treated with E2 displaying a higher incidence of abnormal cells.  
Abnormal cells being those with more than two centrosomes.  Levels of abnormal PTCs 
derived from female animals did display a linear increase in the mean number of cell displaying 
more than two centrosomes in correlation with E2 doses.  In contrast male cells displayed a 
more random response, despite the increasing levels of E2 used in culture.  Once there was an 
initial increase in the level of abnormal cells upon introduction of the lowest dose of E2, levels 
remained relatively steady with little increase in the number of abnormal cells, despite 
increasing levels of E2.  This could be due to difference in the in vitro environment from 
which these cells originated, as levels of circulating hormone such as E2 are innately different 
in male and female animals. 
 
The expression profiles of the oestrogen receptor isoforms may also be responsible for the 
observed gender difference, if they do vary between male and female mice.  Or it may be 
possible that differential expression of oestrogen receptor modulators may also contribute to 
this effect.  Unfortunately, oestrogen receptor expression was not included in this study, and 
thus the above is only speculative. 
 
In order to examine if there was a significant difference in the incidence of centrosomal 
amplification in primary PTCs, from male and female animals, age-matched comparison of 
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the mean number of abnormal cells observed was carried out.  In order to determine if there 
was a significant difference in E2 responsiveness in primary PTCs isolated from male and 
female animals, E2 dose-matched comparison of the mean number of abnormal cells observed 
was also carried out. This analysis revealed there is very little difference in the severity of 
centrosomal amplification at matched levels of E2 treatment.  Levels from neither sex were 
consistency greater than the other. 
As primary PTCs isolated from both male and female mice displayed similar levels of 
centrosomal overduplication, these results provide no further clue towards the increased 
severity of cystic disease in female mice.  However, what it does provide is evidence supporting 
a stimulatory role for E2 in the progression of renal cystic disease.  This evidence also suggests 
it is the stimulatory effect of E2 in female Del2 mice as opposed to a protective role of 
testosterone in male Del2 animals that results in the more severe cystic phenotype in female 
mice.  Similar to the cystogenic stimulatory effect of E2, that is also seen in polycystic liver 
disease in females receiving oestrogen therapy, or in those who are pregnant [Sherstha et al., 
1997]. 
 
6.4.2 Severity of centrosomal amplification and the associated nuclear dysmorphia 
increases with increasing levels of 17 β-estradiol 
 
The positive correlation between the number of abnormal cells, and E2 levels, is also 
associated with increasing severity of the type of centrosomal abnormalities observed.  
However, as this was not formally measured, its effects can only be speculated upon.  It 
remains unclear how this would result in a more severe cystic phenotype in female Del2 mice, 
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or how it could relate to an abnormal proliferative response, such as ductal proliferation in 
diseases such as BA, without leading to cancer, or cellular crisis.  In order to better understand 
the functional relevance of centrosomal aberrations, and hence their biological significance, it 
is critical to consider the cellular context in which they occur [Duensing and Munger, 2002a; 
b; Nigg, 2002].  Centrosome anomalies are an astonishingly frequent finding in malignant 
tumours [Salisbury et al., 1999], with the degree of centrosomal aberrations often correlating 
with malignant progression [D'Assoro et al., 2002].  The frequent coincidence of centrosome 
aberrations, and cytogenetic changes, in primary tumours and tumour cell lines, has led to the 
conclusion that centrosomal abnormalities are a universal cause of genomic instability 
[Ghadimi et al., 2000; Pihan et al., 1998].  Despite the correlations between centrosome 
aberrations and clinical disease, a cause and effect relationship between centrosome 
aberrations, and tumour aggression has yet to be clearly proven.  Indeed, centrosome 
aberrations have been detected in non-cancerous, inflammatory tissue [Battini et al., 2008; 
Lothschütz et al., 2002].  Malignant tumours have been observed to display centrosome 
anomalies in the presence of a diploid genome or a limited set of genetic alterations [Duensing 
and Munger, 2003].  Furthermore, genomically unstable neoplasms can possess a normal set 
of centrosomes [Martin-Subero et al., 2003], indicating that centrosome abnormalities may 
neither be sufficient nor necessary in cancer development.  It is also acknowledged, that 
additional centrosomal changes are frequently detected in cancerous cells including; excess 
pericentriolar material, defects of centrosome maturation and microtubule-nucleating 
capacity, or misorientation of centrosomes within cells [Salisbury et al., 1999].  These findings 
not only question the significance of centrosome aberrations in chromosomal instability, they 
also underscore that centrosome anomalies are likely to represent a uniform cellular response 
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to a variety of cellular insults that do not necessarily result in cancer, but other proliferative 
disorders [Duensing, 2005]. 
 
Centrosome aberrations can be classified into subgroups, with presumably distinct biological 
impact [Duensing, 2005].  While strict categorisation of the centrosomal and genomic 
anomalies observed in these PTC studies was not implemented at the time cells were being 
counted, overall observations did detect noticeable differences in the kind of anomalies 
present.  A tentative classification of the types of centrosomal abnormalities, observed in 
cancer cells by Duensing [2005], places centrosome overduplication into three basic 
categories: primary centrosome overduplication, transient accumulation, and permanent 
centrosome accumulation (Table 6.45).  Whereas the first two categories of centrosome 
anomalies may lead to chromosomal instability if counter-regulatory cellular mechanisms fail, 
the latter category is unlikely to cause genomic instability.  The first two categories are also 
able to generate multipolar anaphases that result in competent daughter cells, which also 
possess an abnormal centrosomal, and chromosomal complement.  In this study, all three 
categories of centrosomal abnormalities were observed in PTCs from wt and Del2 animals 
(Figs. 6.9 and 6.10).  The predicted ability of those with primary centrosome overduplication 
and transient centrosome accumulation to produce viable daughter cells would explain how 
cells with an abnormal centrosome and chromosome complement are able to grow in culture. 
This ability may also result in abnormal proliferative behaviour in tubular epithelial cells, 
causing the phenotypes observed in PKD and hepatobiliary diseases such as BA.  The 
difference between cystic ductular, and proliferative ductular responses, may be due to 
differences in the ratio of cells displaying permanent centrosomal accumulation, that are 
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unable to produce viable daughter cells, and cells that are able to produce viable daughter cells.  
It is possible that the lack of the additional centrosomal changes frequently detected in 
cancerous cells may provide the balance between the proliferative nature of ductular 
proliferation, cyst growth, and cancer. 
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TABLE 6.45  Proposed classification of centrosome abnormalities in tumour cells.   
Taken from [Duensing, 2005] 
Type of 
centrosome 
aberration 
Primary 
centrosome 
overduplication 
Transient centrosome 
accumulation 
Permanent centrosome 
accumulation 
Definition Abnormal numbers 
of centrosomes in 
cells competent to 
generate daughter 
cells 
 
Abnormal numbers of 
centrosomes together with 
altered ploidy in cells 
competent to generate 
daughter cells 
Abnormal number of 
centrosomes in cells that are 
unable to generate viable 
daughter cells 
Nuclear 
morphology 
Normal 
 
 
Enlarged, binucleated Frequently multinucleated, 
micronuclei, nuclear 
enlargement 
Chromosomal 
content 
Normal Tetraploid/polyploid 
 
Polyploid/aneuploid ± 
structural chromosomal 
aberrations 
 
Persistent cell 
division defect 
No 
 
 
No Frequent 
Multipolar 
anaphases 
 
Possible Possible Unlikely 
Centrosome-
mediated 
chromosomal 
instability 
 
Possible Possible Unlikely 
Examples of 
oncogenic 
mechanisms 
 
HPV-16 E7 Aurora-A, Plk1 ± p53 
deficiency 
HPV-16 E6; p21Cip1 or p53 
deficiency after DNA 
damage 
Cell morphology 
(gray, nuclei; 
black dots, 
centrosomes) 
 
  
 Normal nuclear 
morphology, diploid 
DNA content, 
multiple 
centrosomes 
Binucleation and/or 
nuclear enlargement, tetra-
/polyploidy, multiple 
centrosomes 
Nuclear atypia, 
multinucleation, 
micronuclei, nuclear 
enlargement, poly-
/aneuploidy, multiple 
centrosomes 
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6.4.3 PTC from older mice display increased susceptibility to E2 induced centrosomal 
overduplication 
 
Analysis of the mean percentages of cells with centrosomal overduplication, from both male 
and female mice, at the ages of one, three, six, and nine months, shows that there is an almost 
consistent rise in the number of abnormal cells derived from older animals.  This observation 
also holds true whether cells were isolated from wt or Del2 animals.  Overall, many differences 
observed were not statistically significant, making these observations meaningless. 
 
Although not always statistically significant, the overall increase in the number of abnormal 
cells in samples isolated from older Del2 animals correlates with the increasing severity of 
cytogenesis in Del2 animals as they age.  This observation could be attributed to the natural 
progression of the disease.  It is reasonable to speculate, that cells isolated from tubules that 
have either begun to dilate, or are already very dilated/cystic may have already reached a steady 
state of centrosomal accumulation, whilst maintaining the ability to produce viable daughter 
cells.  This may result in a higher proportion of those cells that are isolated possessing an 
abnormal centrosomal complement, whilst maintaining the ability to be cultured in vitro.  
However, this hypothesis cannot be applied to the increase seen in cells isolated from older wt 
animals.  Woollard et al [2007] reported a significant increase in the PT diameter of female wt 
mice, this provides evidence that the age-related increase in tubule diameter is a physiological 
phenomenon.  This suggests that as the animals age, tubular epithelial cells either lose their 
ability to maintain the optimal tubule diameter or a physiologically relevant mechanism 
results in this widening.  Either way, it is not known whether the widening of the PT in wt 
mice is the result of abnormal cellular activity in response to the aging process, or an 
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important process related to homeostasis.  Irrespective of this, it appears that whatever 
mechanism is driving this dilatation; it results in an increase in the number of cells with 
centrosomal overduplication, resulting in a higher proportion of isolated cells that possess an 
abnormal centrosomal complement. 
 
6.4.4 Fibrocystin knockdown does not result in increased frequency or severity of 
centrosomal amplification in primary murine PTCs 
 
Statistical comparisons of the mean number of PTCs displaying centrosomal overduplication, 
in cells derived from age-matched wt and Del2 animals, shows knockdown of fibrocystin has 
no significant effect on the incidence of centrosomal amplification in primary PTCs.  Indeed, 
in younger animals (one to six months), cells derived from wt animals displayed higher levels 
of centrosomal amplification at all levels of E2 treatment, when compared to levels observed 
in Del2 samples.  In contrast, cells derived from older Del2 animals (9 months), displayed 
higher levels of centrosomal amplification when compared to cells derived from wt animals.  
Despite very few of these observations being statistically significant, these results can be 
interpreted in a number of ways.  Firstly, it could simply be interpreted that the knockdown of 
fibrocystin simply has no effect on centrosomal amplification.  However, although the exact 
functions of fibrocystin are not known, the chances of this are unlikely.  Fibrocystin is a cilial 
protein, shown in many studies to localise to the centrosome derived ciliary axoneme.  
Therefore, the likelihood of it having absolutely nothing to do with the structure, or function 
of the centrosome is improbable.  Furthermore, the ciliary proteins PC-1 and PC-2, have both 
been found to play a role in centrosomal duplication despite not having any obvious direct 
link to centrosome structure, or function [Burtey et al., 2008; Fukasawa, 2005]. 
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It is unknown whether a small functional fragment of the Pkhd1 gene is still transcribed, and 
translated, in Del2 animals.  Targeted removal of exon 2, the first coding exon of the Pkhd1 
gene, removes the start codon, and the signal peptide from the ORF of the cDNA [Woollard 
et al., 2007].  Rapid amplification of 5’ complementary DNA ends (5’ RACE), and directed 
PCR analysis, confirms skipping of exon 2, and no possible alternative start site, indicate that 
Del2 animals cannot make full-length fibrocystin.  Western analysis with both rabbit anti-
mouse fibrocystin and chicken anti-mouse fibrocystin, affinity purified antibodies, failed to 
detect fibrocystin in wt kidney membrane preparations, for reasons which remain unknown.  
Therefore, total loss of fibrocystin in Del2 knockdown mice has yet to be verified [Woollard 
et al., 2007], but is being worked upon by the group who developed the Del2 mouse (personal 
communication).  If an alternative start codon is present within the ORF of the Pkhd1 
cDNA, an alternative smaller partially functional fragment may still be transcribed in Del2 
animals.  Although this fragment may not be fully functional, it may still possess functions 
related to centrosome regulation. 
 
Another explanation for the higher incidence of centrosomal amplification in wt cells, may be 
‘culture-shock.’  Cells derived from a cystic environment, with accompanying fibrosis, 
inflammation, and the associated alterations in cytokine, and chemokine levels, would have 
altered expression of key homeostatic proteins enabling the cell to adapt to the changes within 
its immediate environment. However, this is entirely speculative. 
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6.4.5 The age at which ‘star-burst’ cilia and associated centrosomal amplification occurs 
in the PTs of Del2 animals is not apparent upon examination of tissue from one 
and four month old animals 
 
Although it is evident the PTs of female Del2 mice begin to dilate from one month of age, 
there is no evidence of ‘star-burst’ cilia in the samples examined.  By four months, the PTs of 
female Del2 animals had very few stunted cilia, with most areas having no primary cilia.  
Expression of the PT marker, LTA, was also less defined, and appeared to be less restricted to 
the apical membrane, although this may be an artefact of staining.  In contrast, male Del2 
kidney did not exhibit any tubular expansion at one month of age, although tubules did 
appear to have begun to dilate out by four months of age.  Primary cilia were visible in PTs of 
male Del2 animals, at one, and four months of age. 
 
In comparison, the bile ducts of both male and female Del2 animals were significantly dilated 
by one month of age, suggesting expansion is initiated very early in life.  Expression of the bile 
duct marker DBA is discontinuous along the wall of the cysts, suggesting those cells lining the 
cyst have dedifferentiated.  Primary cilia were sparse along the wall of the cyst, and where 
present were stunted in appearance, however no starburst cilia were observed. 
 
The lack of evidence of ‘star-burst’ cilia in the PTs and bile ducts of one and four month old 
Del2 animals resulted from, the timescale used in this study being inadequate to provide the 
resolution needed to accurately pinpoint the age at which ‘star-burst’ cilia may appear.  The 
ages used did not cover an adequate age-range for the accurate determination of the age at 
which dilatation begins.  The reasons for such an inadequate timescale, and age-range were 
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poor timing for the initiation of such a study, and the invaluable nature of the resource under 
investigation.  The high cost and time-consuming nature of, aging-out animals, processing 
animals, and specimen preparation, all had to be taken into consideration.  This meant, that in 
conjunction with the use of animals for the E2 primary culture studies, a limited supply of 
suitable archival tissue was available for this section of the study.  However, despite these 
limitations this study highlights the pathogenetic role of Pkhd1 knockdown in the liver.  
Providing more evidence supporting the importance of fibrocystin in hepatic 
tubulomorphogenesis.  Although no definite evidence of Pkhd1 knockdown driving 
centrosomal amplification was uncovered, this work has provided more data towards the 
investigation of the nature of tubular dilatation in Del2 animals, and the levels of cilial 
expression, an ongoing investigation by Dr C. Ward (Mayo Clinic, MN, USA). 
 
In conclusion, the results obtained from this section of the current study indicate that, E2 
drives centrosomal overduplication within murine primary proximal tubular cells in a dose 
dependent manner.  As a consequence, nuclear dysmorphia and overexpression of primary 
cilia also display E2 sensitivity.   These results also indicate that this response is age dependent.  
However, no evidence that this response is further promoted by knockdown of fibrocystin 
was obtained.  Overall, the work contained within this chapter provides no direct answers to 
uncovering the aetiology of BA, or the function of fibrocystin.  What it does provide is further 
insight into the process that drives fibrosis and cystogenesis in renal and hepatic tubules. 
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CHAPTER  7 DISCUSSION AND CONCLUSIONS 
 
Overall, this project is a general investigation of PKHD1 and fibrocystin in biliary duct injury, 
and the cellular phenotype of the Pkhd1Del2/Del2 mutant mouse.  Although the main aims for 
this project initially set out to investigate a possible role of PKHD1 sequence variants in cases 
of BA with renal cysts, inconclusive preliminary data meant the investigation had to broaden 
to include a wider range of diseases. 
 
Despite the broadening of the investigation to encompass disorders not specifically related to 
BA, but becoming a more general study of fibrocystin and liver diseases this project did reveal 
a few interesting observation. These findings include the identification of three novel PKHD1 
sequence variants in a patient with BA and cysts.  The identification of a non-specific marker 
of ongoing biliary duct damage in both cholangiopathic and non-cholangiopathic liver 
diseases.  The functional investigation of the Pkhd1 gene in the knockout mouse model, the 
Del2 mouse revealed that although knockdown of Pkhd1 does not result in any BA like 
hepatic morphological phenotype, the resulting altered epithelial cell behaviour and hepatic 
changes are shared by a number of cholangiopathies.  Further investigation of the mechanisms 
related to altered epithelial behaviour uncovered cells that exhibit altered proliferative 
behaviour, common to a number of the cholangiopathies, including BA. 
 
In conclusion, this thesis was unable to provide enough evidence to conclusively prove or 
disprove the hypotheses that “sequence variants and/or altered expression in the key gene 
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PKHD1 may be associated with cyst development and cellular damage in human liver 
disease.”  The initial aim of this project was to investigate the phenotypic variability of 
PKHD1 associated disease in human and animal models by meeting a number of key 
objectives that set out to fully characterise the role of fibrocystin iv vivo and in vitro.  The 
main finding of the investigations carried out to meet this aim is that altered expression of 
fibrocystin is a non-specific marker of biliary damage that is consequential of the disease 
process.  An unexpected, and novel finding was that increased levels of α-tubulin acetylation is 
also another non-specific marker of biliary duct injury. 
 
Investigations into the mechanism driving cystogenesis in the Pkhd1del2\del2 knockout mouse 
model were able to uncover that abnormalities in centrosomal duplication may play a role in 
abnormal tubulomorphogenesis, a feature common to all ciliopathies. 
 
Questions that were not answered in this investigation include those that were reliant upon 
the establishment of a robust in vitro cell culture system.  Thus, the structural and functional 
integrity of primary cilia in relation to BA, and PKHD1 expression remains to be investigated.  
However, the main question this thesis was unable to answer was whether sequence variants 
of the gene PKHD1 play a role in the acquired form of BA with or without renal cysts. 
 
The main aim of the mutational screening was to determine if mutations in the PKHD1 gene 
were associated with BA patients who displayed renal cysts, in order to establish a possible 
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genetic clue to the pathogenesis of this complex trait disorder particularly as most of these 
patients would not have lived long enough to develop cysts without transplantation.  The 
reasoning behind this aim was that as the gene mutated in the nephropathy ARPKD, which 
presents with hepatic involvement in ~45% of cases, PKHD1 is a candidate as a possible 
genetic link between non-syndromic and syndromic BA.  Furthermore, the syndromic form of 
BA displays anomalies of situs determination, a feature common to the ciliopathies.  Epithelial 
cells taken from the biliary tract of ARPKD patients lack fibrocystin staining, and primary 
cilia appear stunted.  The identification of renal cysts in isolated BA led to the hypothesis that 
as a ciliary protein, fibrocystin and its encoding gene, PKHD1, are feasible candidates in the 
pathogenesis of BA. 
 
As previously discussed, PKHD1 is a large gene comprised of a minimum of 86 exons, with 
the longest open reading frame of fibrocystin containing a 67 exon transcript.  It is mainly for 
this reason the mutational screening for this project was carried out by the Harris group.  The 
primer design and optimisation necessary to screen a gene of this size is a considerable 
undertaking, and would be costly and time-consuming.  Recruitment of a suitable pool of 
control samples would also have been extremely difficult to obtain. 
 
Mutations in PKHD1 associated with ARPKD have a carrier frequency of 1:70 [Bergmann et 
al., 2004; Zerres et al., 1998a; Zerres et al., 1998b], with ten case subjects in this project, a pool 
of at least 700 control samples would be needed in order to ensure any findings within a case 
sample was not coincidental.  As project collaborators, the Harris group (Mayo Clinic, MN, 
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USA) have a long-standing PKHD1 screening protocol in place with designed and optimised 
primers, access to a large pool of control DNA from both normal and ARPKD patients, and 
are collaborators in the Mutation Database Autosomal Recessive Polycystic Kidney Disease 
(http://www.humgen.rwth-aachen.de/).  This allowed for quicker, and more accurate 
screening of the ten patients included in the initial screen, fully analysed data was received 
back from the Harris group for interpretation. 
 
The identification of three sequence variants in patient 10 and two of their unaffected family 
members cannot be dismissed as purely coincidental, especially as none of these variants were 
found in any of the other controls.  Furthermore, PKHD1 displays complex patterns of 
splicing, which may contribute to the observed allelic heterogeneity observed in both animal 
models and patients with ARPKD.  As described by Bergmann et al [2005b], who observed 
ARPKD patients with one or no detectable mutations in the longest ORF of PKHD1.  In 
such cases mutations were found in alternatively spliced exons.  Interestingly, the changes 
found in the alternatively spliced regions of the PKHD1 gene are also observed in normal 
control samples [Bergmann et al., 2005b].  Therefore, before the changes observed in patient 
10 of this study can be classed as pathogenic mutations, or non-pathogenic polymorphisms, all 
86 exons of the PKHD1 gene would need to be screened to determine if any pathogenic 
mutations are present.  Furthermore, the potential impact of these sequence variants would 
have to await the definition of transcripts containing alternative exons and their predicted 
reading frames. 
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As PKHD1 is such a large gene the occurrence of pleiotropy is a possibility, such that 
mutations within different regions of the gene could result in similar or completely different 
phenotypic traits, a characteristic shared by a number of the genes involved in the ciliopathies 
[Hildebrandt and Zhou, 2007].  Features of BA such as hepatic cysts, fibrosis, ductular 
proliferation, and/or ductal plate malformation are all pleiotropic phenotypes common to the 
ciliopathies.  Evidence of such a phenomenon in relation to PKHD1 comes from the ex40 
mouse model [Moser et al., 2005], which expresses a modified Pkhd1 transcript in which exon 
40 is skipped.  The ex40 mouse develops severe malformations of the IHBDs, with progressive 
portal fibrosis and portal hypertension.  However, in contrast to ARPKD patients, the ex40 
mouse develops morphologically and functionally normal kidneys [Moser et al., 2005].  The 
authors of this paper put this unexpected result down to a functionally divergent role for 
fibrocystin in the kidneys and liver, thus genetic pleiotropy could account for the observed 
phenotype.  Therefore, such a phenomenon should also be considered for PKHD1 in relation 
to BA. 
 
Alternatively, the “second-hit” that may differentiate patient 10 from their unaffected family 
members may be located within another gene.  While some diseases such as cystic fibrosis, α1-
antitrypsin deficiency, and phenylketonuria, are caused by mutations in a single gene loci 
inherited in a Mendelian fashion [Stickel and Osterreicher, 2006], a number of the 
ciliopathies and other liver diseases are polygenic, and could be classified as a “complex trait” 
[Beales, 2005; Czaja and Donaldson, 2000; Invernizzi and Mackay, 2008; Knisely, 2003; 
Zaghloul and Katsanis, 2009].  Indeed, studies suggest that ciliopathy associated genes have 
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the capacity to contribute pathogenic alleles to multiple ciliopathies [Zaghloul and Katsanis, 
2009]. 
 
In genetics “complex traits” are defined as those where the mode of inheritance is unknown, 
that is: where a Mendelian autosomal dominant, autosomal recessive, or sex-linked pattern of 
inheritance attributable to a single gene locus does not apply [Donaldson, 2004].  Indeed, if 
“complex traits” were also defined as a disorder in which: “one or more genes acting alone or 
in concert increase or reduce the risk of that trait” [Haines and Pericak-Vance, 1998], such a 
definition would allow for all the possibilities (oligogenic, polygenic, and multifactorial) and 
covers two essential details.  Firstly, genetic variation (mutations or polymorphisms) result in 
differences in the risk of disease, the mutations themselves do not confer disease.  Secondly, 
the term ‘trait’ may refer to either the disease itself, a group of related diseases (syndrome), or 
to a particular clinical sub-group within a disease, such disease causing mutations may not 
only determine which diseases individuals develop, but also the clinical severity of the 
resulting disease [Donaldson, 2004]. 
 
As BA appears in several clinical forms, acquired, embryonic, and syndromic, this does suggest 
the disease is a common end-point to a number of primary diseases/disorders.  If this is indeed 
the case, mutations in a number of genes that result in BA as a disease trait, or a BA type 
phenotype must be considered as candidates for mutational screening to identify genes that 
contribute to the phenotype.  Considerable efforts would be required to determine the role of 
a single gene or group of genes, since their effect on disease manifestations are usually smaller 
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than crucial gene defects in monogenic disorders, but may also be masked/modified by other 
variants within the genome.  In such cases, genetically modified animals are valuable tools in 
the analysis of disease-specific gene loci, by using knockout animal models, deficient for the 
gene of interest.  In humans the detection of disease modulating genes is more difficult and 
challenging, as proven in this case.  Currently, three different approaches can be applied to the 
identification of the genes responsible for ‘complex trait’ disorders: family-based linkage 
analysis, candidate gene association case-control studies, and genome-wide polymorphism 
studies.  Family-based analysis, which requires large multiplex families, and genome-wide 
polymorphism studies are both time-consuming and expensive to undertake.  In the absence 
of the appropriate families in which to use linkage-based approaches to study the genetic basis 
of complex disorders such as BA, the candidate gene approach is more commonly used.  
Therefore a multistage candidate gene association study was deemed more appropriate for this 
project as sample sizes were severely restricted, and it would uncover any possible associations 
between BA with cysts and PKHD1 mutations relatively quickly [Hirschhorn and Daly, 
2005].  Case-control association analysis has the advantage of taking into account sporadic 
(non-familial) cases and can provided the study groups are large enough, produce very 
powerful results.  It is also a viable and informative option for the study of genes in diseases 
with a small heritable component.  The major disadvantage of this approach compared with 
linkage analysis is that an association does not necessarily imply a primary relationship 
between the polymorphism and disease, but may be due to linkage disequilibrium between the 
polymorphism and disease causing mutation elsewhere in the same gene or a neighbouring 
gene [Donaldson, 2004].  In order to carry out a successful genetic case-control association 
study several important design points must be adhered to stringently, these are: careful 
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selection of the candidate gene, consideration of functional implications of genetic or splice 
variants, careful selection and stratification of cases and controls, and careful data analysis 
both before and after the study [Stickel and Osterreicher, 2006].  As the majority of these vital 
design points were not even considered during the design and application of this project, the 
reliability of the data produced by this study is non-existent.  All that can be solidly concluded 
is that sequence variants were identified. 
 
The selection of a candidate gene for an association study is usually based on biological 
plausibility, in that the gene chosen could play a putative role in the pathogenesis of the 
studied disease [Day, 2003].  The selection of a single candidate gene in terms of BA is 
challenging, especially when the possibility of the disorder being a ciliopathy is considered.  
The ciliopathies show a high degree of phenotypic pleiotropy, with many disorders sharing 
identical or similar phenotypes.  In the case of BA with renal cysts, a number of disorders 
display significant hepatic involvement in association with renal cysts, however as previously 
explained the significant level of hepatic involvement in cases of the monogenic disease 
ARPKD made PKHD1 an ideal first candidate for screening. 
 
Another important task in genotype-phenotype association studies is the selection of 
appropriate cases and controls, another area where this project fails.  A suitable recruitment 
strategy is required, and should control for potential confounders of an association such as age 
and gender.  Specifically in the case of BA, an important confounder that had to be considered 
was if the patients selected had acquired, or syndromic BA. This approach is required to avoid 
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a confounding effect by population stratification due to a marked variation of the allele 
frequency of certain genes among subgroups with a different baseline risk for the disease 
[Cardon and Palmer, 2003].  Thus, both cases and controls need to be well characterised.  In 
terms of the cases selected for the first stage of the mutational analysis of this project, the 
observation of renal cysts in patients with BA in a single transplantation centre could be 
argued to have been caused by selective bias.  However, the observation of renal cysts in BA 
patients at independent centres suggests the association is feasible [Calvo-Garcia et al., 2008; 
Franchi-Abella et al., 2007].  The inclusion of a proportionate number of control subjects is 
equally important.  This was not carefully factored into this study.  Control subjects were not 
matched carefully for age or gender.  Control subjects that were included in this study were 
from an extensive database maintained by the Harris group.  Therefore the details of the 
control subjects were not made available.  Control subjects did include normal individuals and 
ARPKD patients.  Only data from the two unaffected family members of patient 10 was 
supplied.  Upon finding the three changes in both family members, extension of the study was 
deemed inappropriate, as these results were not informative.  Although none of the sequence 
variants detected were found in the control samples, with a carrier frequency of 1 in 70 
[Bergmann et al., 2004; Zerres et al., 1998a; Zerres et al., 1998b], it is unlikely these findings 
are purely coincidental, nonetheless significantly more work would need to be done to prove 
this.  However, limited subject samples also meant continuation of PKHD1 mutational 
analysis had to be suspended. 
 
Statistical issues have become increasingly complex in genetic studies, particularly statistical 
power.  This is important as it reflects the probability that a statistically significant effect is 
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demonstrated when it really exists.  In “under-powered” studies both a type I, or a type II error 
may occur.  Type I errors refer to false-positive associations frequently seen in studies with low 
sample sizes, whereas type II errors represent false negative findings that may result from 
insufficient patient characterisation or population stratification [Stickel and Osterreicher, 
2006].  Recently, a sample size of ≥150 has been defined as a critical threshold for the 
replication validity of genetic association studies [Ioannidis et al., 2001].  If taken into 
account, large numbers of carefully selected and stratified patients, and age and gender 
matched controls are necessary to give a study sufficient power to detect a significant effect 
[Cardon and Palmer, 2003].  Thus, the greatest shortcoming of this project was the woefully 
small sample size, an unavoidable hindrance of a retrospective study.  Despite BA being the 
most common cause of hepatic transplantation in children, the disease is relatively rare within 
the general population [Chardot et al., 1999; Fischler et al., 2002; McKiernan et al., 2000; 
Yoon et al., 1997].  Therefore, when cases are stratified into groups of specific associated 
anomalies, numbers become even more restricted.  Furthermore, when patient selection is 
limited to a single institution, restricted resources further compounded this problem.  
Consequently, a true association could have been missed due to insufficient sample size.  The 
advantage of the multi-stage approach however, is that upon detection of an allelic variant 
associated with the phenotype of BA with renal cysts in the initial screen, an extended 
association study targeting the identified allelic variant would be cheaper and easier than 
complete resequencing of the entire PKHD1 gene in all samples [Hirschhorn and Daly, 
2005]. 
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The immunohistochemical aspect of this project has demonstrated a statistically significant 
alteration in the expression levels of both acetylated α-tubulin and fibrocystin in bile ducts 
from a cohort of inflammatory and non-inflammatory liver diseases.  Although most of the 
cases studied were those of adult end-stage liver diseases at the point of orthotopic 
transplantation, examination of biopsy specimens from early stage BA determined this 
alteration to be a consequence of disease progression rather than causative.  This suggests that 
BA could not be caused by mutations in PKHD1 alone.  However, what must be considered is 
that it is difficult to draw any solid conclusion with the small number of Kasai biopsy samples 
examined.  The reason for this is quite simply that such samples are very scarce, and therefore 
a limited resource.  Human tissue is in general a precious resource, making it difficult to 
obtain a high number of cases, but when parameters such as early-stage BA Kasai biopsy 
samples with identifiable portal tracts are also applied, the supply becomes even more 
restricted.  Often such biopsy samples are needle biopsies, or very small wedge biopsies taken 
for diagnostic purposes, therefore priority for use in studies such as this is not high.  This 
being said, despite the small number of Kasai specimens examined it is clear that absence of 
fibrocystin in end-stage BA is due to a gradual loss of expression.  The exact reason for this is 
not clear at this point, and can only be speculated upon.  The most feasible explanation, which 
encompasses the decrease in fibrocystin in all end-stage diseases studied, is that stressed cells 
have an altered protein expression, with the levels of proteins that are not vital to cellular 
survival being reduced.  Therefore, disease process that results in an altered cellular state 
appear to result in a loss of fibrocystin expression.  Although the positive biliary epithelial cell 
marker, human epithelial antigen 125 (HEA125), was not used throughout the study, 
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inclusion of a more extensive panel of BEC markers, such as cytokeratin 19 (CK19) would 
have aided further identification of cells that had altered protein expression profiles. 
 
Whilst using an expanded panel of BEC specific markers would have helped further 
characterise the exact state these cells were in, extensive study of BEC from the diseases in the 
cohort by the BCLR had revealed these cells do maintain their basic differentiated biliary 
epithelial cell phenotype (personal communication).  Furthermore, work by the BCLR has 
also shown that BEC isolated from livers in this cohort of diseases are fully differentiated, 
displaying the BEC specific markers HEA125, CK18, and CK19, which allow for the 
immunological isolation and in vitro primary culture of these cells using the BEC specific 
marker HEA125.  These HEA125 positive BEC have also been shown to only lose their 
specific epithelial cell markers after several passages in vitro (personal communication). 
 
It is unfortunate that the resolution the tissue was examined at did not allow for the 
visualisation of primary cilia.  The expression of primary cilia is indicative to the state a cell is 
in, if the cell expresses one under normal conditions, especially in regards to mitosis and 
polarity, and therefore would have provided yet another useful indicator of the state the cells 
that have lost fibrocystin expression are in.  This would also help identify exactly where 
fibrocystin was being expressed in positive cells if not on the ciliary axoneme.  Unfortunately, 
despite several attempts, the ability to clearly visualise primary cilia or centrosomes in tissue is 
extremely difficult within the 5µm tissue sections.  Despite the use of confocal microscopy, 
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images were not clear enough to allow for cilia or centrosomes to be accurately characterised 
or counted. 
 
The observed increase in α-tubulin acetylation in this project is also a significant observation.  
The exact cause of which can only be speculated upon at this point.  All of the liver diseases 
included in the cohort display some degree of cholangiocyte activation, the exact nature of this 
cellular activation is not apparent when taking only the increased levels of α-tubulin 
acetylation into account.  As with the observed decrease in fibrocystin, to uncover the 
mechanisms resulting in these alterations a more extensive panel of characterised markers 
would have been valuable.  Markers such as proliferation cell nuclear antigen (PCNA), active 
caspase-3, and single-stranded DNA.  Cholangiocytes may proliferate in response to liver 
injury [M. J. Phillips et al., 1989; Thung, 1990], however, such a response does not 
immediately correlate with increased levels of α-tubulin acetylation, which is though to be a 
marker of stable MT populations.  Thus, the inclusion of a marker that could identify cells 
that are actively proliferating, or undergoing apoptosis would help clarify exactly what state 
cells with increased levels of α-tubulin acetylation are in.  This would help determine how cell 
state correlates to the changes in fibrocystin and acetylated α-tubulin expression. 
 
As with all retrospective studies, there are limitations.  As human tissue is a scarce resource, 
normal tissue especially, for each disease group included in the cohort there was no 
comparison with an age and gender matched group of normal samples, although the normal 
samples used did cover a range of ages.  Another limitation is the samples of some diseases are 
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more abundant than others, due to incidence within the population.  Thus, a set number of 
samples had to be decided upon for each disease group before commencement of the study 
that would ensure equal numbers of specimens to be examined for each disease group 
included.  The difficulty in this was that in certain disorders or specimen types the number of 
identifiable portal tracts, ducts, and ductular structures varied widely.  It is generally accepted 
that it is necessary to have an aggregate of twenty portal tracts to assess the number of bile 
ducts adequately in an individual patient [Ludwig et al., 1987].  Unfortunately, as some 
samples were needle biopsies, or displaying significant levels of ductopenia and portal fibrosis, 
not all specimens from individual patients had enough portal tracts to apply this criterion.  In 
order to ensure a more uniform number of ducts had been counted for each disease group, the 
level of duct loss and the size of specimen should have been taken into account, allowing for a 
more uniform comparison between the groups.  To overcome this, data was expressed and 
analysed as a percentage of the total number of ducts observed per disease group. 
 
Another area the scarcity of human tissue impacted was the inclusion of a larger panel of 
paediatric tissue, which is very difficult to gain access to for research.  Comparison of BA to a 
cohort of adult end-stage liver diseases is not an accurate way to observe alterations in protein 
expression in paediatric disease.  At different stages of development, the adult and paediatric 
liver will inevitably react differently to identical insults.  Thus, in order to better understand 
how expression of fibrocystin is altered in paediatric liver diseases such as BA a larger cohort of 
paediatric liver tissue should have also been included in this study.  Tissue from patients with 
diseases such as Wilson’s disease, autoimmune hepatitis, cystic fibrosis liver disease, and 
Tyrosinaemia has been shown to retain fibrocystin expression (personal communication).  
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Although this does suggest fibrocystin is expressed in these conditions, and is not a general 
marker of bile duct damage, the samples were taken from livers that were not at such an 
advanced stage of liver damage compared to the BA cohort.  Furthermore, the number of 
samples examined was extremely limited.  Therefore the examination of fibrocystin in 
paediatric liver disease requires further investigation with expansion of sample numbers and 
aetiology. 
 
Studies carried out in the Pkhd1del2/del2 mouse model of ARPKD were designed specifically for 
functional characterisation of fibrocystin in relation to tubular epithelial cell differentiation 
and injury.  The ideal way to do this, in relation to liver disease, would be to use RNAi 
technology in human cell lines or primary cultures.  Unfortunately, despite several attempts to 
set-up and optimise such a system this proved unfeasible for a number of reasons.  Thus, the 
direction of the investigation was altered slightly to focus on the Pkhd1 knockdown model, 
the Pkhd1del2/del2 mouse [Woollard et al., 2007].  However, by moving into the mouse the 
technical difficulties and high variability of yield when isolating murine BEC made working 
with primary BEC from this model impractical.  It was more feasible to work with a cell type 
equally affected in the mouse model that was easier to obtain.  As the isolation and culture of 
murine PTCs is published, and the proximal tubular segment of the nephron is the most 
significantly affected in the Del2 model, primary PTCs were the most practical cells to use for 
the investigation.  Although BEC and PTCs are derived from different embryonic origins, 
endoderm and mesoderm respectively, they are comparable as epithelial cells that are required 
to form and maintain a tubular structure that is vital to the function of the organ.  Despite 
originating from different embryonic origins, both the endoderm and mesoderm give rise to 
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epithelial cells with similar characteristics, for example the multiciliated cells of the 
reproductive tract arise from the mesoderm, while the multiciliated cells of the respiratory 
tract originate from the endoderm, both of which are completely affected in disorders such as 
primary ciliary dyskinesia, or cystic fibrosis.  Thus, the use of PTCs should be relatively 
comparable to BEC in terms of the basic functional roles of fibrocystin, in a monociliated 
tubular epithelial cell. 
 
However, a major drawback of the Del2 model is that the actual level of fibrocystin 
knockdown could not be assayed for at the protein level.  As this is a mouse model the 
production of highly specific monoclonal antibodies raised against fibrocystin is extremely 
difficult, as those raised in mice would cross-react at an unacceptable level.  Although 
monoclonal antibodies raised in rabbits are starting to become widely available, there are none 
readily available to murine fibrocystin.  Attempts to detect fibrocystin in control samples 
using several polyclonal antibodies were unsuccessful [Woollard et al., 2007].  Therefore it is 
uncertain if fibrocystin is completely knocked out in this animal model.  It is clear in this 
model that the removal of the first coding exon has resulted in altered expression of 
fibrocystin as the model displays the hepatic and renal cystic disease of ARPKD.  However, 
the fact the renal disease remains limited to the proximal tubules, and does not evolve to 
include the collecting ducts, as is evident in patients with ARPKD [Torres and Harris, 2005], 
does suggest the effect of removing exon 2 from the murine transcript is different to the 
effects caused by the mutations affecting PKHD1 in human ARPKD patients. However this 
does not make the Del2 model any less valuable as a tool to help unravel the mechanisms 
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underlying abnormal tubular morphology.  Indeed, this was another reason the Del2 model 
was used for this study. 
 
The results obtained from investigations carried out in the Del2 mouse model demonstrated 
not only that centrosomal overduplication is one of the mechanisms involved in tubular 
dilatation, but also that this mechanism displays a sensitivity to E2.  The methodology used to 
obtain these findings did have several limitations.  One very obvious problem was that the 
basal level of centrosomal amplification observed in control samples from both wt and Del2 
animals were very high, much higher than normally accepted.  However, because addition of 
E2 resulted in a statistically significant increase in the levels of centrosomal amplification in a 
large number of samples this can be taken as a true result.  Clearly such a high level of basal 
centrosomal amplification is not desirable and would need to be improved upon to make the 
data much stronger.  The high basal levels of centrosomal overduplication could also mask any 
subtle differences in the level of centrosomal amplification caused by other factors, especially 
the knockdown of PKHD1.  A number of factors could have resulted in this raised basal level 
of cells displaying more than two centrosomes in control samples, such as ‘culture shock’ as 
previously discussed in chapter 6.  There are a number of ways in which this could be 
addressed, and are currently under investigation by the Harris group.  A way to avoid culture 
shock induced centrosomal amplification would be to introduce E2 in vivo.  This method is 
already being trialled at the Mayo Clinic by Dr Ward.  The numbers of centrosomes within 
epithelial cells from both the liver and kidneys could then be examined using electron 
microscopy of tissue sections, or fluorescence microscopy of isolated tubular units, removing 
the need to culture the cells at all.  Such methods are of course expensive and time consuming, 
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and would require specific ethical approval.  Another method would be to simply count a 
higher number of cells in each sample, and include a higher number of animals in the study.  
This would increase statistical power, decreasing the possibility of type I or type II errors, and 
would also increase the likelihood of more subtle differences becoming more significant.  The 
use of cell lines or RNAi would not be a suitable solution to the effect of culture shock.  Cell 
lines, as previously described, are derived by colonial expansion of cells that have 
dedifferentiated or become altered in order to survive in vitro culture, thus they often display 
genomic abnormalities, and may also have altered numbers of centrosomes.  The use of RNAi 
to abrogate Pkhd1 expression in either a murine cell line or primary cells would also introduce 
yet another traumatic factor to the experiment.  Although any such detrimental effects could 
be controlled for, there is always the selective pressure of in vitro culture. 
 
Despite these obvious drawbacks it is clear from this work, and many other studies looking at 
the role of centrosomal overduplication in cancer and other proliferative disorders, that 
centrosomal amplification is a complex pathologic mechanism.  Not only does it appear to 
link cytogenesis and tumorigenesis, but it may also play a role in more subtle epithelial 
hyperproliferative pathologies, such as the ductular proliferation observed in a number of 
cholangiopathies, or the pseudotumors associated with long-standing BA patients [Liu et al., 
2007].  Furthermore, the observation of renal cysts in the small subset of BA patients included 
in this project provides further support for a possible link to centrosomal amplification.  
What differentiates these pathologies and results in the differences in severity is most likely 
disease specific and also governed by the gene or genes mutated in the disorder.  Before such 
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factors can be determined, the exact point at which centrosomal overduplication occurs in the 
disease process would need to be clarified. 
 
The relevance of the Del2 studies to BA can also be found in the slight female predominance 
of the disorder [Lipsett et al., 1997].  This preponderance has been attributed to a 
dysregulation in autoimmunity, however it could also be the result of the mitogenic effects of 
E2 on epithelial proliferation.  Of course this would have to be further investigated in specific 
relation to BA.  Although true mouse models of BA do not exist as yet, the effect of E2 on 
disease progression in even the infectious models of BA or the inv mouse could provide 
further insight into the possible mechanisms that result in the complex pathology of BA and 
its many sub-types.   
 
Despite the difficulties of visualising primary cilia and centrosomes in tissue sections it is not 
impossible, but would require the use of electron microscopy.  Difficulties in getting primary 
BEC to express primary cilia in vitro would not necessarily prevent the study of centrosome 
numbers and nuclear morphology in these cells.  Comparison of age and gender grouped tissue 
may also uncover interesting morphological differences, all of which would unravel the 
complex aetiopathology of BA. 
 
To summarise, mutational screening of PKHD1 in a cohort of BA with renal cysts has 
revealed PKHD1 is unlikely to be directly involved in the pathogenesis of BA.  A genetic 
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susceptibility may be identified in all children with BA, although a specific genetic mutation is 
more likely in those with the embryonal type BA.  Absence of fibrocystin in end-stage BA was 
determined to not be specific to BA, but a non-specific marker of bile duct damage in a cohort 
of adult end-stage liver diseases.  This coupled with increased acetylation of α-tubulin 
indicates the biliary epithelium may respond to insults in a similar way across a spectrum of 
disorders.  Finally, investigation of the mechanism that drives abnormal tubular epithelial 
proliferation in the ciliopathies indicates centrosomal amplification with ciliary involvement 
may play a role in abnormal tubular development. 
 
In conclusion, the ciliary protein fibrocystin and its encoding gene PKHD1 do not appear to 
be directly involved in the pathogenesis of BA with or without cysts.  However, the novel 
hypothesis that primary cilia are implicated in the pathogenesis of BA will enable further 
exploration of those genes involved in ciliary development and laterality [Fliegauf et al., 2007]. 
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CHAPTER  8 FUTURE DIRECTIONS 
 
The individual investigations that make up this project all aim towards further understanding 
the pathogenesis of BA, looking at PKHD1 and its encoding protein fibrocystin for clues.  
However, in doing so this work has raised more questions than it has answered.  In terms of 
meeting the main aim of this project, it is clear PKHD1 is associated with a variety of 
phenotypic features in both man and mouse, all of which appear to be related to primary 
ciliary function, cellular polarity, and cellular proliferation.  However, many questions remain 
to be answered in order to gain a full understanding of the role of PKHD1 and fibrocystin in 
hepatic and renal disease. 
 
In terms of a genetic basis for BA, mutational analysis of PKHD1 was unable to uncover 
categorical evidence of pathological mutations leaving a key question remaining: which or 
what gene(s) are mutated in cases of BA?  Although this project has no evidence of a link 
between BA and PKHD1, it does not provide enough evidence to inevitably rule it out as a 
susceptibility gene, and so more work would be required to do this. 
 
In order to expand further upon the findings of the mutational analysis carried out in this 
project. A number of approaches can be used.  To increase the power of a case-control 
association study, mutation screening could be extended to a larger cohort of patients, 
carefully stratified on the basis of a number of criteria (principally, the disease classification, 
presence of associated congenital malformations, and histology of the biliary remnant).  By 
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carefully subdividing a large cohort into smaller groups with shared features, it may increase 
the chances of finding a positive association.  To further increase the chances of a positive 
association the whole PKHD1 gene would need to be sequenced covering all splice 
alternatives, the promoter region, and the 3’ untranslated region.  As with the ARPKD cases 
described by Bergmann et al [Bergmann et al., 2005b], sequence variants associated with BA 
may be located within alternatively spliced or untranslated regions.  Increasing the size of the 
cohort substantially would of course require multicentre co-operation in order to obtain a 
large number of samples.  By increasing the number of cases in a single investigation 
unexpected patterns of association could arise, providing further support for a genetic link.  
Familial cases may become apparent as more case data is complied, which may allow for the 
use of linkage analysis. 
 
Once any sequence variants had been identified their exact impact on gene expression or 
protein function would help determine the significance of the variant.  A large number of 
novel missense mutations and a significant level of polymorphisms have been found in 
PKHD1 [Harris and Rossetti, 2004], differentiating pathogenic mutations from neutral 
changes can be difficult [Rossetti et al., 2003].  Variants described as mutations in one study 
can be described as polymorphisms in others [Furu et al., 2003; Onuchic et al., 2002; Rossetti 
et al., 2003].  Segregation analysis in larger (especially multiplex) families, the nature of the 
substitution (and conservation of the base in other species), plus prevalence in the normal 
population can be used to try to differentiate mutations and polymorphisms.  However, these 
methods cannot prove the significance of a change, in recessive disease mutations will be 
found in the normal population, although given the number of different mutations and 
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prevalence of carriers (~ 1:70 individuals [Zerres et al., 1998a]), each change would be 
expected to be rare.  Indeed, it is possible that some rare “polymorphisms” may be mutagenic 
when found in combination with other sequence variants [Harris and Rossetti, 2004].  To 
further characterise how individual sequence variants alter protein expression, and/or 
localisation, techniques such as site-directed mutagenesis could be used to create mRNA 
containing the introduced changes, which could then be cloned into cells, and the expression 
patterns observed. 
Another area that would need to be investigated to further the work carried out here would be 
to screen several other genes that encode cystoproteins involved in disorders that share 
features with BA.  Suitable candidates would include INVS, NPHP3, and JAG1, genes 
mutated in nephronophthisis 2, nephronophthisis 3, and Alagille syndrome, respectively.  To 
expand even further on this, as BA with anomalies of laterality may be a more suitable 
candidate for a major gene mutation than the nonsyndromic form [Carmi et al., 1993; D-Y. 
Zhang et al., 2004a], stringent categorisation of BA sub-types may allow for a comparative 
genome-wide scan, much like that carried out by Zhang et al [2004a], who performed a 
comparative genome-wide expression analysis comparing expression of regulatory genes in 
embryonic and perinatal forms of BA.  A similar approach using a SNP chip may identify 
marker clusters in certain subgroups, providing clues to possible genotype-phenotype 
associations.  If actual sequence variants could not be identified, haplotype association may 
provide a rudimentary screening protocol to aid early diagnosis of BA [Guay-Woodford et al., 
1995; Sharp et al., 2008]. 
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As the investigative field of primary human BEC is still very much in its infancy a lot of basic 
experimental techniques need to be established in order to address the many questions that 
need to be answered in terms of liver diseases such as BA.  Especially as no suitable human 
cholangiocyte cell lines exist to perform such work in.  The establishment of RNAi in primary 
BEC would be an invaluable tool in future investigations of BA and other liver diseases.  
There are however many areas that can be further investigated without the use of RNAi that 
could still provide a huge amount of valuable information about the pathological mechanisms 
that cause the phenotype observed.  Unfortunately there are a number of other obstacles that 
would need to be overcome.  One of the main factors affecting this area of study is the 
expression of primary cilia in vitro.  If a culture system could be established in which isolated 
BEC expressed primary cilia there are a number of ways this could be exploited.  At the most 
basic level cells could be isolated from a variety of liver diseases and their morphology directly 
compared to that of normal cells, to determine if any gross abnormalities in cilial morphology 
or centrosome numbers could provide clues to the pathological mechanisms underlying the 
disease.  Techniques such as the isolation of enriched ciliary fractions, as described by Huang 
et al [2006], could also be utilised to compare the proteomes of cilia isolated from BEC taken 
from normal and affected livers.  Such a comparison may reveal dysregulation in the 
expression of proteins key to cilial structure, development, and/or function, providing strong 
candidates for mutational screening. 
 
Establishment of a 3D culture system using primary BEC would also be a valuable tool in the 
investigation of biliary tubulogenesis.  Cells isolated from the livers of patients with BA and 
other liver diseases could be compared to BEC from normal livers to determine if the cells 
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from affected livers display altered growth characteristics, or if they are able to form tubules in 
culture.  BEC would also be more likely to express primary cilia if grown in a 3D culture 
system, where they would be able to better maintain an apical-basolateral orientation more 
akin to the in vivo environment.  This would provide another system in which the primary 
cilia of these cells could be characterised, to determine if they are abnormal in the different 
sub-groups of BA. 
 
The effect of mechanical bending of BEC primary cilia should also be investigated, by 
subjecting isolated cells or isolated ductular units to fluid sheer stress in a perfusion chamber.  
Measurement of changes to intracellular calcium levels would provide evidence of any 
response to mechanical stimulation.  This system could be employed to compare the 
mechanosensory response of cilia from normal and affected livers.  RNAi methodology could 
also be combined with this system to determine the effect knockdown of PKHD1 might have 
on mechanosensation in primary cells. 
 
Another basic experimental technique that would need to be established in primary BEC 
would be the introduction of inhibitory RNAs, and other molecules into the cells.  As primary 
BEC are highly sensitive to culture conditions, and can easily dedifferentiate under stress, a 
method to transfect cells whilst causing minimal trauma would be of great value to future 
research in this area.  Once such a method was established, the development of more reliable 
BEC cell lines for use in investigations such as this would be easier to establish.  Current BEC 
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lines have lost some of the essential features of fully differentiated BEC (investigations carried 
out at BCLR). 
 
The ability to assay BEC using fluorescent-activated cell sorting (FACS) is also limited.  
However if a protocol for BEC could be optimised, it would add another valuable tool to help 
unravel the pathophysiological mechanisms affecting BEC in diseases such as BA. 
 
Once a suitable assortment of basic experimental techniques specific to BEC have been 
established research in terms of BA could progress more rapidly.  As the dysregulation of 
epithelial cell growth appears to be a key feature in the process of cyst formation and ductular 
proliferation, with such experimental techniques in place it would be possible to test if the 
abrogation of fibrocystin expression can cause a defect in cell-cycle regulation.  For example, 
the effect of PKHD1 knockdown on cell cycle progression could be assayed using FACS 
analysis to determine if cells become arrested at certain phases of the cell cycle, or if they are 
able to by-pass any checkpoints that should be activated by the disease process. 
 
The JAK-STAT signalling pathway has been implicated in the function of the polycystins 
[Boucher and Sandford, 2004], it could therefore be determined if this pathway also mediates 
signalling by fibrocystin. STATS are latent cytoplasmic transcription factors that translocate 
to the nucleus after activation by direct phosphorylation by receptor tyrosine kinases.  To 
investigate the involvement of the STAT pathway in any putative signalling by fibrocystin, 
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decreased levels of tyrosyl- and serine-phosphorylated STATs in cells subjected to RNAi 
could be assayed.  Since fibrocystin lacks a kinase domain, it would most likely be unable to 
phosphorylate STATs directly, but may do so indirectly by activation of a member of the 
Janus kinase family of tyrosine kinases (JAKs), thus activation of JAK family members (JAK 1 
to 3 or TyK2) could also be tested for. 
Progressive bile duct destruction and portal tract fibrosis are hallmark features of BA.  This 
suggests that, in common with many other liver diseases, an inappropriate inflammatory 
response is perpetuated in BA that may exacerbate the tissue damage caused by the underlying 
defect.  During inflammation it is thought that cholangiocytes can promote an inflammatory 
response and contribute to their own destruction in a number of ways including: i) promotion 
of apoptosis via autocrine and paracrine mechanisms; ii) increasing expression of chemokines 
and adhesion molecules which in turn regulate leukocyte infiltration and activation; iii) 
during fibrogenesis it is also possible that activated cholangiocytes could modulate fibroblast 
activity via similar mechanisms resulting in excessive fibrogenic responses that lead to fibrosis 
and cirrhosis [Adams and Afford, 2005; Ahmed-Choudhury et al., 2003].  The development 
of primary co-culture systems with cholangiocytes, fibroblasts, macrophages, and cytolytic T 
cells would provide insight into the exact role cholangiocytes play in this response.  
Furthermore, by combining RNAi with this system it could be determined whether 
fibrocystin plays any role in cholangiocyte fibroblast interactions including: i) fibroblast 
survival and activation modulated via TNF receptor p75 [Oakley et al., 2003]; ii) fibroblast 
activation including chemokine secretion, adhesion molecule expression and extracellular 
matrix synthesis; iii) the effects of fibrocystin expression on cholangiocyte survival; these 
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parameters could be assessed using enzyme-linked immunosorbent assays, cytokine multiplex 
arrays, and cell survival assays for proliferation and apoptosis. 
 
The most obvious way to expand upon the immunohistochemical studies carried out in this 
project would be to increase the number of early and late-stage paediatric, and early stage BA 
samples included.  The inclusion of more paediatric cases at various stages of disease would 
enable a more detailed study of the exact stage of the disease that fibrocystin expression begins 
to decrease.  To fully characterise the exact state of the cholangiocytes throughout the disease 
process.  To examine how the altered hepatic environment affects them, an expanded panel of 
markers could be used.  Markers to determine if the cells maintain their epithelial phenotype 
or if they are dedifferentiated, such as the epithelial markers cytokeratins 18 and 19, the 
fibroblast markers smooth muscle actin and T-cell antigen (Thy1), and the endothelial 
marker platelet-endothelial cell adhesion molecule (CD31).  Markers of apoptosis or 
proliferation would also help identify areas where cell death, or activation are present.  By 
comparing staining between normal and various affected livers, an expression profile 
characterising the levels of marker expression for different disorders may reveal similarities 
between disorders thought to be very dissimilar in their aetiology, and provide clues to the 
disease mechanisms active in diverse disorders that are less well characterised.  Utilisation of 
more sensitive and powerful visualisation techniques such as electron, and confocal 
microscopy would also enable further characterisation of cellular morphology within tissue 
from patients, including high-resolution characterisation of ciliary ultrastructure and 
centrosome numbers. 
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The mechanisms responsible for the increased levels of α-tubulin acetylation in the different 
liver diseases included in the cohort remains undetermined at this point.  In order to 
determine what causes this increase a study of the proteins known to be involved in α-tubulin 
acetylation may shed light in the pathways involved in this increase, and how they relate to the 
disease process.  The levels and localisation of proteins such as the histone deacetylase 
HDAC6 may provide an explanation of the observed increase in MT acetylation. 
 
The Del2 mouse model, despite displaying few of the phenotypic characteristics of BA, will 
remain a valuable resource for the functional study of Pkhd1 and fibrocystin.  Further work to 
determine the exact levels or domains of fibrocystin still translated, if at all, will enable a more 
accurate assessment of any genotype-phenotype correlations.  Further primary epithelial 
culture of other cell types, such as BEC may provide a more relevant understanding of the 
pathological mechanisms underlying liver disease in relation to Pkhd1 knockdown.  
Exploration of techniques such as air/liquid interface culture may promote the expression of 
multi-ciliate cells and enable a more accurate evaluation of the severity of centrosomal 
overduplication in relation to Pkhd1 knockdown.  By combining such techniques with more 
sensitive visualisation techniques, such as electron microscopy, would allow for a more 
comprehensive study of cilia and centrosomal abnormalities in non-cancerous proliferative 
epithelial disorders that effect tubular structures.  Once a greater understanding of such 
abnormalities is gained this knowledge can be applied to similar disorders to help determine 
the underlying pathological mechanisms resulting in altered tubule formation. 
 
  296 
As BA does appear to present with a slight female preponderance, more in-depth study of the 
roles of E2, and the oestrogen receptors in BEC under both normal physiological and 
pathological conditions may provide further understanding of the increased female 
susceptibility to certain liver disorders.  While the addition of E2 to cells in culture was an 
option explored in the current project, the complication of high basal readings in control 
samples may have masked more subtle effects on centrosomal overduplication.  Thus, the 
development of a system that introduces high levels of E2 to mice in vivo would provide a 
useful tool to aid understanding of how E2 acts in less obvious target organs. 
 
The aetiology of BA remains an enigma.  While this complex disorder provides many clues to 
the mechanisms underlying its certain characteristic features, there is still no unifying factor to 
draw upon. The multiple clinical subtypes, lack of any informative familial cases, and lack of 
any spontaneous or genetic animal models displaying all the clinical features of BA impedes 
the rate at which progress can be made.  In this regard, the more research done to pick apart 
the mechanisms that cause the characteristics shared between BA and other disorders with 
known genetic causes may help shed light on the pathogenesis of BA.   
 
In short, it is the very complex nature of this disorder that makes it so difficult to determine 
its exact cause, but if the approach used to tackle this formidable task broke the disorder down 
into more stringently categorised subgroups it may just be that the cause of this apparent 
complexity is because BA is being approached as a single disease entity, not an end-stage 
phenotype common to multiple disorders. 
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APPENDIX 1  
 
TABLE 1.1 Disorders associated with the ductal plate malformation.  Modified from [Knisely, 2003] 
DISORDER OMIM 
GENE OR 
LOCUS  
(GENES OR 
LOCI) 
HEPATIC FEATURES OTHER SIGNIFICANT CLINICAL 
FEATURES 
Jeune 
asphyxiating 
thoracic 
dystrophy 
208500 
611263 
Unknown 
(15q13) 
IFT80 
(3q24-q26) 
May have neonatal 
cholestasis; Caroli’s 
disease; and 
congenital hepatic 
fibrosis 
Short stature, narrow, long thorax 
with short ribs; micromelia; skeletal 
malformations; pulmonary 
hypoplasia; retinal degeneration; 
pancreatic cysts and insufficiency; 
cystic renal tubular dysplasia 
Autosomal 
dominant 
polycystic kidney 
disease (ADPKD) 
601313 
173910 
600666 
PKD1 
(16p13.3-
p13.12) 
PKD2 
(4q21-q23) 
PKD3 
(Unknown) 
Biliary 
microhamartomas 
and cysts; preserved 
hepatic function; 
severe hepatic cystic 
disease with 
pregnancy and 
oestrogen therapy 
Renal cysts; renal failure; cyst 
complications (mass effect, 
haemorrhage, infection, rupture); 
intracranial aneurysm; hypertension; 
cardiac abnormalities 
Autosomal 
recessive 
polycystic kidney 
disease (ARPKD) 
606702 PKHD1 
(6p21.1-
p12) 
Biliary 
microhamartomas 
and cysts; recurrent 
cholangitis; 
congenital hepatic 
fibrosis; Caroli’s 
disease, and biliary 
dysgenesis; cirrhosis; 
portal hypertension 
Renal cysts; renal fibrosis; 
glomerulosclerosis; renal failure; 
pulmonary hypoplasia 
Autosomal 
dominant 
polycystic liver 
disease (ADPLD) 
174050 
(PCLD) 
177060 
608648 
 
 
PRKCSH 
(19p13.2-
p13.1) 
SEC63 
(6q21) 
Biliary 
microhamartomas 
and cysts; severe 
hepatic cystic disease 
with pregnancy and 
oestrogen therapy; 
cyst complications 
(mass effect, 
haemorrhage, 
infection, rupture), 
preserved liver 
function; portal 
hypertension; portal 
vein thrombosis; 
jaundice 
Pancreatic cysts; mitral valve prolapse 
and other mitral valve leaflet 
abnormalities; cachexia; abdominal 
distension; abdominal pain; early 
satiety; fatigue; 
anorexia/malnutrition; persistent 
nausea; vomiting; supine dyspnoea; 
severe ascites; lower body oedema; 
uterine prolapse due to displacement. 
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DISORDER OMIM 
GENE OR 
LOCUS  
(GENES OR 
LOCI) 
HEPATIC FEATURES OTHER SIGNIFICANT CLINICAL 
FEATURES 
Caroli’s syndrome 600643 Subsumed 
in PKHD1 
Polycystic segmental 
dilatation of the 
intrahepatic bile 
ducts; cyst 
complications; 
recurrent 
cholangitis; liver 
abscess; 
hepatomegaly; 
portal hypertension; 
cholangiocarcinoma 
Associated with polycystic kidney 
disease 
Congenital 
hepatic fibrosis 
(CHF) 
263200 Subsumed 
in PKHD1 
MPI 
(15q22-
qter)  
Biliary 
microhamartomas 
surrounded by a 
dense fibrous 
stroma; portal 
hypertension; 
recurrent 
cholangitis; 
cholangiocarcinoma;  
 
Biliary atresia 
(early severe, 10-
20%) 
210500 Unknown Progressive 
obliteration of the 
extrahepatic and 
intrahepatic biliary 
system; biliary 
obstruction; 
cholestasis; 
conjugated 
progressive 
hyperbilirubinemia; 
hepatic failure 
Renal, cardiac, and gastrointestinal 
malformations (ventricular 
hypertrophy, intestinal malrotation, 
preduodenal portal vein); laterality 
abnormalities 
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DISORDER OMIM 
GENE OR 
LOCUS  
(GENES OR 
LOCI) 
HEPATIC FEATURES OTHER SIGNIFICANT CLINICAL 
FEATURES 
Bardet-Biedl 
syndrome 
209901 
(BBS1) 
606151 
(BBS2) 
608845 
(BBS3) 
600374 
(BBS4) 
603650 
(BBS5) 
604896 
(BBS6) 
607590 
(BBS7) 
608132 
(BBS8) 
607968 
(BBS9) 
610148 
(BBS10) 
602290 
(BBS11) 
610683 
(BBS12) 
609883 
(BBS13) 
610142 
(BBS14) 
BBS1 
(11q13) 
BBS2 
(16q21) 
ARL6 
(3p12-q13) 
BBS4 
(15q22.3) 
BBS5 
(2q31) 
MKKS 
(20p12) 
BBS7 
(4q27) 
TTC8 
(14q32.11) 
PTHB1 
(7p14) 
BBS10 
(12q) 
TRIM32 
(9q33.1) 
BBS12 
(4q27) 
MKS1  
(17q23) 
CEP290 
(12q21.3) 
Congenital hepatic 
fibrosis; 
Retinal dystrophy; retinitis 
pigmentosa; obesity; polydactyly; 
dysmorphic extremities; 
hypogenitalism; renal cystic dysplasia; 
renal structural abnormalities; mental 
retardation; cardiac abnormalities; 
anosmia; situs inversus 
Joubert syndrome 213300 
(JBTS1) 
608091 
(JBTS2) 
608629 
(JBTS3) 
609583 
(JBTS4) 
610188 
(JBTS5) 
610688 
(JBTS6) 
611560 
(JBTS7) 
612291 
(JBTS8) 
612285 
(JBTS9) 
JBTS1 
(9q34) 
JBTS2 
(11p12-
q13) 
AIH1 
(6q23.3) 
NPHP1 
(2q13) 
CEP290 
(12q21.3) 
MKS3 
(8q21.13-
q22.1) 
RPGRIP1L 
(16q12.2) 
ARL13B 
(3q11.2) 
CC2D2A 
(4p15.3) 
Congenital hepatic 
fibrosis 
Retinal dystrophy; renal anomalies 
(multicystic dysplastic kidneys); 
dysmorphic extremities; cerebellar 
vermis hypoplasia and associated 
neurologic anomalies (hypotonia, 
developmental delay, 
hyperpnoea/apnoea); cardiac 
malformations; dysmorphic facial 
features 
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DISORDER OMIM 
GENE OR 
LOCUS  
(GENES OR 
LOCI) 
HEPATIC FEATURES OTHER SIGNIFICANT CLINICAL 
FEATURES 
Meckel-Gruber 
syndrome 
609883 
(MKS1) 
603194 
(MKS2) 
607361 
(MKS3) 
611134 
(MKS4) 
611561 
(MKS5) 
612284 
(MKS6) 
MKS1 
(17q23) 
MKS2 
(11q13) 
TMEM67 
(8q21.13-
q22.1) 
CEP290 
(12q21.3) 
RPGRIP1L 
(16q12.2) 
CC2D2A 
(4p15.3) 
Reactive bile duct 
proliferation; bile 
duct dilatation; 
periportal fibrosis; 
portal vascular 
obliteration; biliary 
dysgenesis 
Occipital encephalocele; central 
nervous system abnormalities (e.g. 
dandy-walker malformation); 
postaxial polydactyly; polycystic 
kidneys; gross renal enlargement; 
cardiac malformations 
Nephronophthisis 256100 
(NPHP1) 
602088 
(NPHP2) 
604387 
(NPHP3) 
606966 
(NPHP4) 
609237 
(NPHP5) 
610142 
(NPHP6) 
611498 
(NPHP7) 
610937 
(NPHP8) 
609799 
(NPHP9) 
NPHP1 
(2q13) 
INVS 
(9q31) 
NPHP3 
(3q22) 
NPHP4 
(1p36) 
IQCB1 
(3q21.1) 
CEP290 
(12q21.3) 
GLIS2 
(16p13.3) 
RPGRIP1L 
(16q12.2) 
NEK8 
(17q11.1) 
Congenital hepatic 
fibrosis; cholestasis; 
portal fibrosis; 
hepatomegaly; 
ductal proliferation 
Small kidneys; corticomedullary cystic 
disease; glomerulosclerosis; retinal 
degeneration and ocular 
complications; cortical microcysts; 
cone shaped epiphyses 
 
  301 
APPENDIX 2  
 
TABLE 2.1 Raw data table. Fibrocystin staining in human liver tissue cohort. 
Sample 
Total 
positive 
ducts 
Percentage of 
positive cells (%) Intensity Cysts Comments 
NL 1 21/33 63.6 ++ N/A Severe steatosis? VMb 
complex -, nerve bundles 
+++ 
NL 2 50/55 90.9 + N/A Nerve bundles +++ 
NL 3 12/34 35.3 ++ N/A  
NL 4 16/32 50 ++ N/A  
NL 5 45/50 90 ++ N/A  
PCLD 1 1/50 2 + Occ+  
PCLD 2 3/30 10 + ++ Moderate steatosis 
PCLD 3 4/45 8.9 + Occ+  
PCLD 4 10/40 25 + Occ+  
PCLD 5 33/36 91.7 ++ + VMb complex - 
PCLD 6 3/80 3.8 + +  
PBC 1 3/38 7.9 + N/A Nerve bundles +++ 
PBC 2 1/30 3.3 + N/A Nerve bundles +++ 
PBC 3 1/19 5.3 + N/A  
PBC 4 0/20 0 - N/A  
PBC 5 5/23 21.7 + N/A  
PSC 1 13/61 21.3 + N/A Nerve bundles +++ 
PSC 2 0/41 0 - N/A Nerve bundles +++ 
PSC 3 0/0 0 - N/A Very sclerotic ducts 
PSC 4 0/38 0 - N/A  
PSC 5 0/48 0 - N/A  
AIH 1 3/32 9.4 + N/A Nerve bundles +++ 
AIH 2 8/40 20 + N/A Nerve bundles +++ 
AIH 3 10/36 27.8 + N/A  
AIH 4 0/0 0 - N/A  
AIH 5 0/0 0 - N/A  
ALD 1 13/52 25 + N/A Nerve bundles +++ 
ALD 2 0/0 0 - N/A Moderate steatosis 
ALD 3 0/0 0 - N/A  
ALD 4 0/0 0 - N/A  
ALD 5 0/0 0 - N/A  
α1ATdef.1 0/0 0 - N/A Moderate steatosis 
α1ATdef.2 0/0 0 - N/A  
α1ATdef.3 20/60 33.3 + N/A  
α1ATdef.4 0/0 0 - N/A  
α1ATdef.5 0/0 0 - N/A  
HCC 1 0/0 0 - N/A No positive structures 
HCC 2 0/30 0 - N/A  
HCC 3 0/25 0 - N/A Very strong inflammatory 
cells 
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Sample 
Total 
positive 
ducts 
Percentage of 
positive cells (%) Intensity Cysts Comments 
HCC 4 23/30 76.7 +/++ N/A Very strong inflammatory 
cells 
HCC 5 6/14 42.9 + N/A  
HCV 1 5/20 25 + N/A Portal vessels very strong 
HCV 2 1/50 2 + N/A Portal vessels very strong in 
places 
HCV 3 1/100 1 +/- N/A Portal vessels very strong in 
places 
HCV 4 1/50 2 + N/A Strong inflammatory cells 
and vessels in places 
HCV 5 0/50 0 - N/A Strong inflammatory cells 
and vessels in places 
BA 1 0/50 0 - N/A Portal vessels strong on 
places 
BA 2 0/50 0 - N/A Portal vessels strong on 
places 
BA 3 0/50 0 - N/A Portal vessels strong on 
places 
BA 4 0/50 0 - N/A Portal vessels strong on 
places 
BA 5 0/50 0 - N/A Portal vessels strong on 
places 
BA 6 0/47 0 - N/A  
BA 7 0/50 0 - N/A  
BA 8 0/50 0 - N/A  
BA 9 0/16 0 - N/A  
BA 10 0/5 0 - N/A  
BA 11 0/0 0 - N/A  
Key: -, no visible staining; +, faint staining on cells; ++, moderate staining on most cells; +++, intense 
staining on cells; NL, normal liver; PCLD, polycystic liver disease; PBC, primary biliary cirrhosis; PSC, 
primary sclerosing cholangitis; AIH, autoimmune hepatitis; ALD, alcoholic liver disease; α1ATdef, α1-
antitrypsin deficiency; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; BA, biliary atresia; VMb 
complex, von Meyenburg complex. 
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TABLE 2.2  Details of liver diseases included in cohort study 
Disease Disease characteristics and features Treatment Reasons for inclusion in the current cohort 
Hepatitis C viral 
infection (HCV) 
−  Mechanisms by which HCV causes chronic and progressive liver 
disease are not fully understood 
−  HCV-associated liver damage thought to be immune mediated 
−  Disease severity ranges from asymptomatic chronic infection, to 
cirrhosis and HCC 
−  Morphological features: steatosis, intraportal lymphoid aggregates 
or follicles, and bile duct lesions 
−  Liver transplantation in patients with life 
threatening liver complications of portal 
hypertension, cirrhosis, HCC, and liver failure 
−  Epithelial involvement characterised by; lymphocytic 
infiltration, and epithelial changes (vacuolisation, 
eosinophilia of the cytoplasm, nuclear hyperchromasia, 
multilayering, and loss of cellular polarity 
Hepatocellular 
carcinoma (HCC) 
−  Median survival after diagnosis: 6 to 9 months 
−  Major risk factors: hepatitis B viral infection, chronic HCV 
infection, prolonged dietary aflatoxin exposure, and cirrhosis 
−  Genetic predisposition underlies both familial and sporadic 
(acquired) cases 
−  Histological variant forms: combined hepato-
cholangiocarcinoma, fibromellar carcinoma, and cholangiocellular 
carcinoma 
−  Partial hepatic resection 
−  Total hepatotectomy with liver transplantation 
in patients with poor underlying liver function 
−  Biliary tract involvement includes: tumour thrombi, 
hemobilia, tumour compression, diffuse tumour 
infiltration, jaundice, metastatic lymphoadenopathy at 
the porta hepatis 
−  Association with a number of inflammatory and fibrotic 
liver diseases 
−  HCC arising from malignant transformation of biliary 
hamartomas, hepatic lesions related to DPM 
Polycystic liver 
disease (PCLD) 
−  Cyst number and size is often greater in women than in men 
−  An asymptomatic course in common 
−  Liver pathology is indistinguishable between PCLD and ADPKD 
−  Genetically heterogeneous, with only two identified causative loci 
−  Characterised by progressive multiple diffuse cysts forming in the 
liver parenchyma 
−  Cystic dilatation arises from cellular proliferation and fluid 
secretion into the cysts 
−  Surgical intervention for symptomatic PCLD 
includes: cyst unroofing, extensive fenestration, 
and fenestration combined with resection 
−  For highly symptomatic patients with diffuse 
involvement of the liver or those with significant 
co-morbid condition treatment is limited to 
transplantation 
−  Classic cholangiopathy 
−  Distinct form of liver disease without concomitant 
ADPKD 
−  Histological display of von Meyenburg complexes, and 
bile duct proliferation 
−  Cystic dilatations known as biliary microhamartomas or 
von Meyenburg complexes are caused by ductular 
overgrowth after embryogenesis 
α1-antitrypsin 
deficiency (α1AT 
Def.) 
−  Inherited metabolic disorder affecting about 1 in 2000 to 1 in 
5000 individuals 
−  Most common genetic cause of neonatal liver disease 
−  α1AT is a serine protease inhibitor produced in the liver 
−  α1AT protects lungs against proteolytic damage from neutrophil 
elastase 
−  Mutations in the coding sequence of α1AT prevent its export 
from hepatocytes, where it polymerises into large aggregates, 
resulting in cell injury and death 
−  In infants there is no approved treatment for liver 
disease except transplantation 
−  Rare indication for liver transplantation amongst 
adults 
−  Inflammatory cholangiopathy characterised by biliary 
epithelia cell destruction, inflammatory cell infiltration, 
and periportal fibrosis 
−  Severe biliary epithelial cell damage, and paucity of 
intrahepatic bile ducts detected in some infants 
−  Cholestatic presentation is hard to distinguish from 
other neonatal liver diseases, especially biliary atresia 
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Disease Disease characteristics and features Treatment Reasons for inclusion in the current cohort 
Autoimmune 
hepatitis (AIH) 
−  Poorly defined necroinflammatory liver disease of unknown 
aetiology 
−  Major pathological mechanism is thought to be loss of tolerance 
against host hepatic tissue 
−  Histological hallmarks: dense portal mononuclear cell infiltrate, 
emperipolesis, piecemeal necrosis, bridging necrosis, panlobular 
and multilobular necrosis, and cirrhosis 
−  Immunosuppressive therapy 
−  For cases that progress to cirrhosis and end-stage 
liver disease, treatment is liver transplantation 
with concurrent immunosuppression 
−  Inflammatory biliary involvement found in 30-40% of 
cases 
−  Biliary lesions consist of, epithelial necrosis, nuclear 
pyknosis and infiltration by lymphocytes 
Alcoholic liver 
disease (ALD) 
−  Well known aetiology, exact pathogenesis remains unclear 
−  Hepatic injury thought to be immune mediated, combined with 
free radical hepatic injury 
−  Three recognised forms of ALD: alcoholic fatty liver disease 
(steatosis), acute alcoholic hepatitis, and alcoholic cirrhosis 
−  Histological features: steatosis, fibrosis, cirrhosis, micronodular 
cirrhosis, cholestasis, Mallory’s hyaline bodies, hepatocellular 
necrosis, macroregenerative nodules, chronic inflammation, bile 
duct proliferation, liver cell dysplasia, and HCC 
−  Liver transplantation for end-stage ALD −  Inflammatory liver disease with ductular involvement 
−  Characterised by well established cirrhosis with 
abundant ductular proliferation 
Primary biliary 
cirrhosis (PBC) 
−  Organ-specific autoimmune disease of unknown aetiology 
−  Predominantly affects women 
−  Characterised by slow progressive destruction of small 
intrahepatic bile ducts with portal inflammation, and fibrosis, 
leading to liver failure 
−  Triad of diagnosis: elevated alkaline phosphatase, 
antimitochondrial antibodies, and characteristic histological 
changes 
−  Characteristic histological features are granulomatous cholangitis, 
or nonsuppurative destructive cholangitis that progresses to 
cirrhosis 
−  End-stage liver disease: liver transplantation −  Established immune-mediated cholangiopathy 
−  Characterised by: inflammatory destruction of the 
intrahepatic bile ducts, lymphocytic portal infiltration, 
periportal inflammation, ductular proliferation, 
ductopenia, biliary cirrhosis, and cholestasis 
Primary sclerosing 
cholangitis (PSC) 
−  Rare cholestatic liver disease 
−  Characteristics: chronic inflammation and fibrotic obliteration of 
the hepatic biliary tree, bile stasis, hepatic fibrosis 
−  Aetiology and pathogenesis is little understood, although immune 
dysregulation thought to play a key role 
−  Nonspecific histopathology, rarely diagnostic 
−  No effective pharmacotherapy 
−  End-stage liver disease: resection or 
transplantation 
−  Histological involvement of the intrahepatic and 
extrahepatic bile ducts 
−  Characteristic periductular fibrosis with concentric 
fibrosis of intrahepatic bile ducts, with stricturing and 
dilation of the biliary tree 
Key: DPM – ductal plate malformation; ADPKD – autosomal dominant polycystic kidney disease. 
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ONE MONTH OLD WILDTYPE B6 MICE: RAW DATA 
 
TABLE 3.1 Centrosomal count data analysis for one-month-old wt males 
Sample: 
E2 
(pg/ml) 
% cells with >2 
centrosomes: 
animal 1 
% cells with >2 
centrosomes: 
animal 2 
% cells with >2 
centrosomes: 
animal 3 
% cells with >2 
centrosomes: 
animal 4 
Mean % of cells 
with >2 
centrosomes 
Standard 
deviation 
p-
value* 
0 12 17 8 22 15 5.749  
25 33 46 19 29 32 11.488 0.026 
75 26 33 21 30 28 5.382 0.008 
500 40 35 13 26 29 11.847 0.047 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 3.2 Centrosomal count data analysis for one-month-old wt females 
Sample: 
E2 
(pg/ml) 
% cells with >2 
centrosomes: 
animal 1 
% cells with >2 
centrosomes: 
animal 2 
% cells with >2 
centrosomes: 
animal 3 
% cells with >2 
centrosomes: 
animal 4 
Mean % of cells 
with >2 
centrosomes 
Standard 
deviation 
p-
value* 
0 22 9 23 19 18 6.295  
25 14 33 20 22 22 7.956 0.241 
75 35 29 33 23 30 4.884 0.014 
500 31 34 46 39 38 6.800 0.003 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
FIGURE 3.1 One-month-old wt: Scatter plot of mean percentage of cells with >2 centrosomes.  Chart representation of the lack of 
significance between centrosomal overduplication between the sexes when treated with the same level of E2.  This is illustrated by the fact 
the points representing each gender overlap at more than one data point at a single level of E2. 
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ONE MONTH OLD DEL2 B6 MICE: RAW DATA 
 
TABLE 3.4 Centrosomal count data analysis for one-month-old Del2 males 
Sample: 
E2 
(pg/ml) 
% cells with >2 
centrosomes: 
animal 1 
% cells with >2 
centrosomes: 
animal 2 
% cells with >2 
centrosomes: 
animal 3 
% cells with >2 
centrosomes: 
animal 4 
Mean % of cells 
with >2 
centrosomes 
Standard 
deviation 
p-
value* 
0 28 18 8 8 14.7 7.986  
25 18 29 18 34 25.6 8.121 0.068 
75 20 36 22 24 25.5 7.398 0.048 
500 23 26 33 19 25.3 5.752 0.040 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 3.5 Centrosomal count data analysis for one-month-old Del2 females 
Sample: 
E2 
(pg/ml) 
% cells with >2 
centrosomes: 
animal 1 
% cells with >2 
centrosomes: 
animal 2 
% cells with >2 
centrosomes: 
animal 3 
% cells with >2 
centrosomes: 
animal 4 
Mean % of cells 
with >2 
centrosomes 
Standard 
deviation 
p-
value* 
0 4 18 19 12 13 7.054  
25 5 36 16 23 20 13.095 0.199 
75 20 25 33 36 28 7.233 0.011 
500 20 35 44 31 33 9.703 0.010 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
 
FIGURE 3.2 One-month-old Del2: Scatter plot of mean percentage of cells with >2 centrosomes.  Chart representation of the lack of 
significance between centrosomal overduplication between the sexes when treated with the same level of E2.  This is illustrated by the fact 
the points representing each gender overlap at more than one data point at any given level of E2. 
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THREE MONTH OLD WILDTYPE B6 MICE: RAW DATA 
 
TABLE 3.7 Centrosomal count data analysis for three-month-old wt males 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 12 29 13 18.2 9.543  
25 39 49 20 36.1 14.938 0.084 
75 44 57 37 46.1 5.823 0.013 
500 46 53 35 43.3 5.296 0.015 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
TABLE 3.8 Centrosomal count data analysis for three-month-old wt females 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 14 29 17 20.2 8.133  
25 23 22 26 23.6 2.043 0.276 
75 32 34 38 34.6 3.444 0.038 
500 48 49 36 44.2 7.092 0.010 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
FIGURE 3.3 Three-month-old wt: Scatter plot of mean percentage of cells with >2 centrosomes.  Chart representation of the lack of 
significance between centrosomal overduplication between the sexes when treated with the same level of E2.  This is illustrated by the fact 
the points representing each gender overlap at more than one data point at a single level of E2. 
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THREE MONTH OLD DEL2 B6 MICE: RAW DATA 
 
TABLE 3.10 Centrosomal count data analysis for three-month-old Del2 males 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 25 13 17 18.3 5.755  
25 42 40 31 37.9 5.858 0.007 
75 56 45 24 41.5 16.232 0.060 
500 38 39 35 37.3 1.778 0.010 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 3.11 Centrosomal count data analysis for three-month-old Del2 females 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 12 22 12 15.5 5.818  
25 37 30 26 31.2 5.824 0.015 
75 42 29 20 30.3 10.795 0.063 
500 47 44 25 38.7 12.225 0.031 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
 
FIGURE 3.4 Three-month-old Del2: Scatter plot of mean percentage of cells with >2 centrosomes.  Chart representation of the lack of 
significance between centrosomal overduplication between the sexes when treated with the same level of E2.  This is illustrated by the fact 
the points representing each gender overlap at more than one data point at any given concentration of E2 
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SIX MONTH OLD WILDTYPE B6 MICE: RAW DATA 
 
TABLE 3.13 Centrosomal count data analysis for six-month-old wt males 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 43 26 38 35.8 8.539  
25 40 39 38 38.8 0.742 0.301 
75 39 42 39 39.8 1.599 0.253 
500 44 38 48 43.5 4.932 0.132 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 3.14 Centrosomal count data analysis for six-month-old wt females 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 17 15 22 18.1 3.729  
25 26 19 31 25.2 6.121 0.088 
75 38 14 41 31.1 15.224 0.136 
500 36 29 43 36.1 7.213 0.016 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
 
FIGURE 3.5 Six-month-old wt: Scatter plot of mean percentage of cells with >2 centrosomes.  The significant difference between the 
mean percentage of cells with centrosomal overduplication between male and female mice at 0pg/ml and 25pg/ml is represented by no 
overlap between the data points representing each set.  The lack of a significant difference at 75pg/ml and 500pg/ml is illustrated by the 
fact the data points representing each gender overlap at more than one data point. 
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SIX MONTH OLD DEL2 B6 MICE: RAW DATA 
 
TABLE 3.16 Centrosomal count data analysis for six-month-old Del2 males 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 12 14 16 14.0 1.706  
25 28 34 31 30.7 3.211 0.002 
75 34 36 32 34.0 2.224 0.0002 
500 42 47 32 40.1 7.217 0.010 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
TABLE 3.17 Centrosomal count data analysis for six-month-old Del2 females 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 4 9 6 6.3 2.517  
25 22 12 21 18.3 5.508 0.023 
75 25 24 24 24.3 0.577 0.002 
500 39 21 29 29.7 9.018 0.019 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
 
FIGURE 3.6 Six-month-old Del2: Scatter plot of mean percentage of cells with >2 centrosomes.  The significant difference between the 
mean percentage of cells with centrosomal overduplication between male and female mice at 0pg/ml, 25pg/ml, and 75pg/ml is 
represented by no overlap between the data points representing each level of E2.  The lack of a significant difference at 500pg/ml is 
illustrated by the fact the data points representing each gender overlap. 
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NINE MONTH OLD WILDTYPE B6 MICE: RAW DATA 
 
TABLE 3.19 Centrosomal count data analysis for nine-month-old wt males 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 38 22 19 26.5 10.079  
25 55 27 30 37.3 15.035 0.183 
75 52 30 25 35.7 14.145 0.208 
500 56 39 40 45.0 9.612 0.041 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 3.20 Centrosomal count data analysis for nine-month-old wt females 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 43 28 11 27.4 15.618  
25 56 49 10 38.5 24.679 0.276 
75 43 27 29 33.2 8.878 0.308 
500 50 57 32 46.4 12.963 0.092 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
FIGURE 3.7 Nine-month-old wt: Scatter plot of mean percentage of cells with >2 centrosomes.  Chart representation of the lack of 
significance between centrosomal overduplication between the sexes when treated with the same level of E2.  This is illustrated by the fact 
the points representing each gender overlap at more than one data point at a single level of E2. 
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NINE MONTH OLD DEL2 B6 MICE: RAW DATA 
 
TABLE 3.22 Centrosomal count data analysis for nine-month-old Del2 males 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 40 39 49 42.7 5.367  
25 37 30 44 36.9 6.860 0.155 
75 50 46 45 46.8 2.533 0.163 
500 49 45 58 50.5 6.753 0.099 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
TABLE 3.23 Centrosomal count data analysis for nine-month-old Del2 females 
Sample: E2 
(pg/ml) 
% cells with >2 
centrosomes: animal 
1 
% cells with >2 
centrosomes: animal 
2 
% cells with >2 
centrosomes: animal 
3 
Mean % of cells with 
>2 centrosomes 
Standard 
deviation 
p-
value* 
0 28 21 36 28.3 7.546  
25 33 31 49 37.7 9.970 0.135 
75 39 45 47 43.6 4.320 0.026 
500 47 38 65 49.8 13.722 0.047 
*p-values relative to control (0pg/ml E2).  t-test: 1-sided, unequal variance assumed, p<0.05 significance. 
 
 
 
 
FIGURE 3.8 Nine-month-old Del2: Scatter plot of mean percentage of cells with >2 centrosomes.  The significant difference between 
the mean percentage of cells with centrosomal overduplication between control cells from male and female mice represented by no overlap 
between the data points representing 0pg/ml of E2.  The lack of a significant difference at 25pg/ml, 75pg/ml, and 500pg/ml is illustrated 
by the fact the data points representing each gender overlap.
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